



Universiteit
Leiden
The Netherlands

On the pathogenesis and clinical outcome of ANCA-associated vasculitis

Rahmattulla, C.

Citation

Rahmattulla, C. (2018, October 11). *On the pathogenesis and clinical outcome of ANCA-associated vasculitis*. Retrieved from <https://hdl.handle.net/1887/72515>

Version: Not Applicable (or Unknown)

License: [Leiden University Non-exclusive license](#)

Downloaded from: <https://hdl.handle.net/1887/72515>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/72515> holds various files of this Leiden University dissertation.

Author: Rahmattulla, C.

Title: On the pathogenesis and clinical outcome of ANCA-associated vasculitis

Issue Date: 2018-10-11

On the pathogenesis and clinical outcome of ANCA-associated vasculitis

Chinar Rahmattulla

*On the pathogenesis and clinical outcome of
ANCA-associated vasculitis*

Chinar Rahmattulla

Colophon

On the pathogenesis and clinical outcome of ANCA-associated vasculitis /
C. Rahmattulla

Ph.D. thesis, University of Leiden, Leiden, the Netherlands

ISBN: 978-94-028-1169-8

Printing: Ispkamp Printing

Layout: Matthijs Ariëns, persoonlijkproefschrift.nl

The publication of this thesis was financially supported by: the Dutch vasculitis foundation and the department of Pathology of the Leiden University Medical Center

Copyright © C. Rahmattulla. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means without permission of the author and corresponding journal.

*On the pathogenesis and clinical outcome of
ANCA-associated vasculitis*

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties
te verdedigen op donderdag 11 oktober 2018
klokke 11:15 uur

door

Chinar Rahmattulla
geboren te Tuz, Kirkuk (Irak) in 1989

Promotor: Prof. dr. J.A. Bruijn

Co-promotores: Dr. I.M. Bajema

Dr. A.E. Berden

Promotiecommissie: Prof. dr. V.T.H.B.M. Smit

Prof. dr. M.E.J. Reinders

Prof. dr. F.R. Rosendaal

Dr. S. Wilhelmus (Pathan, Rotterdam, Nederland)

Dr. A. Kronbichler (Academisch Ziekenhuis Innsbruck,
Oostenrijk)

“Plus j’ai avancé en âge, mieux j’ai compris ton amitié et la supériorité de ta raison.”
(“The longer I live, the better I understand the kindness of thy heart
and the high quality of thy mind.”)

L. Pasteur (Dedication to his father in *Fermentation of Dextro-Tartrate of Lime*, 1879)

To my parents and grandparents

Table of contents


I	General introduction and outline of this thesis	11
II	Genetic variants in ANCA-associated vasculitis: a meta-analysis <i>Rahmattulla C, Mooyaart AL, van Hooven D, Schoones JW, Bruijn JA, Dekkers OM; European Vasculitis Genetics Consortium, Bajema IM. Ann Rheum Dis. 2016;75:1687-92.</i>	37
III	Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials <i>Rahmattulla C, de Lind van Wijngaarden RA, Berden AE, Hauer HA, Floßmann O, Jayne DR, Gaskin G, Rasmussen N, Noël LH, Ferrario F, Waldherr R, Wolterbeek R, Göçeroğlu A, Pusey CD, Hagen EC, Bruijn JA, Bajema IM; European Vasculitis Study Group (EUVAS). Rheumatology (Oxford). 2015;54:899-907.</i>	55
IV	Histopathological classification of antineutrophil cytoplasmic antibody-associated glomerulonephritis: an update <i>Rahmattulla C, Bruijn JA, Bajema IM. Curr Opin Nephrol Hypertens. 2014;23:224-31.</i>	75
V	Incidence of malignancies in patients diagnosed with ANCA-associated vasculitis between 1991 and 2013 <i>Rahmattulla C, Berden AE, Wakker SC, Reinders ME, Hagen EC, Wolterbeek R, Bruijn JA, Bajema IM. Arthritis Rheumatol. 2015;67:3270-8.</i>	91
VI	Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis <i>Van Daalen EE, Rizzo R, Kronbichler A, Wolterbeek R, Bruijn JA, Jayne DR, Bajema IM, Rahmattulla C. Ann Rheum Dis. 2017;76:1064-1069.</i>	109
VII	Summary and general discussion	125
VIII	Summary in Dutch (samenvatting in het Nederlands)	141
Appendices		151
	Supplementary data	153
	Authors and affiliations	318
	Curriculum vitae	323
	List of publications	325
	Acknowledgements (woord van dank)	327

Chapter I

General introduction and outline of this thesis

Vasculitis means inflammation of blood vessels. The International Chapel Hill Consensus Conference Nomenclature of Vasculitides (CHCC) provides definitions for the different vasculitides and subcategorises them into three major categories: large-vessel vasculitis, medium-vessel vasculitis, and small-vessel vasculitis (**figure 1**).^{1, 2}

Figure 1. The International Chapel Hill Consensus Conference Nomenclature of Vasculitides (CHCC)



The International Chapel Hill Consensus Conference Nomenclature of Vasculitides (CHCC) subcategorises the different vasculitides into three major categories: large-vessel vasculitis, medium-vessel vasculitis, and small-vessel vasculitis. The figure depicts (from left to right) aorta, large artery, medium artery, small artery/arteriole, capillary, venule, and vein. Anti-GBM = anti-glomerular basement membrane; ANCA = antineutrophil cytoplasmic antibody. Reproduced from Jennette et al.² with permission.

Large-vessel vasculitis predominantly affects the aorta and its major branches. Two important vasculitides within this category are Takayasu arteritis and giant cell arteritis. Medium-vessel vasculitis predominantly affects medium sized arteries. Kawasaki disease is an example of a medium-vessel vasculitis. Small-vessel vasculitis is further subcategorised into immune complex small-vessel vasculitis and antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. Immune complex small-vessel vasculitis shows immunoglobulin (Ig) and complement deposits in the blood vessel walls. Two important vasculitides within this category are IgA vasculitis and anti-glomerular basement membrane

(anti-GBM) disease. ANCA-associated vasculitis is a necrotizing vasculitis with few or no immune deposits that is typically associated with ANCA-seropositivity by indirect immunofluorescence or enzyme-linked immunosorbent assay (ELISA).³

ANCA-associated vasculitis

This thesis focuses on different aspects of ANCA-associated vasculitis. ANCA first became widely recognized after a key publication in *The Lancet* in 1985 in which van der Woude *et al.* described circulating antibodies in patients with vasculitis that were in several ways similar to the granulocyte-specific antinuclear antibodies (GS-ANA) described in rheumatoid arthritis.⁴ It should however be mentioned that Davies *et al.* had already described the presence of this class of antibodies in patients with pauci-immune glomerulonephritis in 1982.⁵ Van der Woude *et al.* first named these antibodies ACPA (anticytoplasmic antibodies). This term was later replaced by ANCA, as the antibodies were found to be directed against neutrophil (and monocyte) constituents. The two most important ANCA antigens are proteinase 3 (PR3)⁶⁻⁸ and myeloperoxidase (MPO)⁹.

ANCA-associated vasculitis comprises the clinical diagnoses granulomatosis with polyangiitis (GPA, formerly Wegener's granulomatosis¹⁰⁻¹²), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss Syndrome).²

GPA is a necrotizing granulomatous inflammation usually involving the upper and lower respiratory tract.¹³ Approximately 90-95% of patients with active, generalized GPA are ANCA-positive; a small subset of GPA patients is ANCA-negative.¹⁴⁻¹⁷ Thus, the absence of ANCA does not exclude the diagnosis of GPA. About 70% of the ANCA-positive GPA patients are PR3-ANCA positive; the remainder are MPO-ANCA positive.¹⁸

MPA is characterized by a non-granulomatous necrotizing systemic vasculitis. Nearly 90% of patients with MPA are ANCA-positive.¹⁴⁻¹⁷ About 60% of the ANCA-positive MPA patients are MPO-ANCA positive; the remainder are PR3-ANCA positive.^{9, 18} Because PR3-ANCA and MPO-ANCA may occur in both GPA and MPA, these conditions cannot be distinguished on the basis of ANCA-serotype.

EGPA is an eosinophil-rich and necrotizing granulomatous inflammation often involving the respiratory tract. In contrast to GPA and MPA, EGPA is associated with asthma and eosinophilia. Although variable from study to study, approximately 50% of patients with EGPA are ANCA-positive.^{19, 20} About 70-90% of the ANCA-positive EGPA patients are MPO-ANCA positive.^{20, 21}

The clinical diagnoses GPA and MPA are often grouped together on the grounds of striking similarities in clinical presentation and comparable histologic

findings.^{18, 22} Nevertheless, there are marked differences between these disease entities, fuelling an ongoing debate as to whether GPA and MPA are different entities within the same disease spectrum or represent distinct auto-immune diseases.²³⁻²⁵ Although there are overlaps, a clinical diagnosis of GPA usually involves PR3-ANCA positivity whereas a clinical diagnosis of MPA usually involves MPO-ANCA positivity. In this respect, data from a large genome-wide association study (GWAS) are interesting.²⁶ These data indicate that within the spectrum of ANCA-associated vasculitis distinct subtypes may be recognized. ANCA-serotype was demonstrated to be the main indicator of these subtypes.²⁶

To date, the concept of a single disease spectrum has led to the inclusion of GPA and MPA patients in the same clinical trials and the development of similar treatment strategies for these patients.^{14-17, 27, 28} Evidence that the different entities in ANCA-associated vasculitis actually represent distinct auto-immune diseases may in the future lead to the development of more specific therapeutic strategies. The existence of different subtypes within the spectrum of ANCA-associated vasculitis and their clinical implications are further investigated in **Chapter 2** and **Chapter 3** of this thesis.

Aetiology and pathogenesis of ANCA-associated vasculitis

The pathogenesis of ANCA-associated vasculitis has not been completely elucidated. However, over the past decades, significant progress has been made in the understanding of this complex disease. Environmental exposures, genetic factors, influences of the immune system, and the intensity and duration of the injury are all hypothesized to be involved in the pathogenesis of ANCA-associated vasculitis. Interestingly, the variability in aetiological and synergistic factors that may lead to the development of ANCA-associated vasculitis is hypothesized to contribute to the clinicopathologic differences between patients.²⁹

Onset and exacerbation of ANCA-associated vasculitis occur more often during winter and spring. This points towards the existence of pathogenic, infectious or other environmental, factors that are typically present during these seasons.³⁰ Numerous studies demonstrated that pro-inflammatory factors, for example induced by infections, act synergistically in ANCA-associated vasculitis onset and exacerbation.^{31, 32} In particular, *Staphylococcus aureus* infection was linked to ANCA-associated vasculitis onset.³³⁻³⁵ Moreover, nasal carriage of *Staphylococcus aureus* was demonstrated to be an important risk factor for relapse in patients with GPA,³⁶ and treatment with trimethoprim-sulfamethoxazole was shown to aid in the induction of remission³⁷⁻⁴⁶ and the prevention of relapses³⁷. These treatment effects could be ascribed to the immunosuppressant and/or anti-staphylococcal properties of trimethoprim-sulfamethoxazole.

Evidence that genetic factors contribute to the pathogenesis of ANCA-associated vasculitis comes from familial association studies,⁴⁷⁻⁵¹ differences in the prevalence of ANCA-associated vasculitis between ethnic groups,⁵² and numerous candidate gene associations studies⁵³. Quite recently, two GWAS performed by the Vasculitis Clinical Research Consortium and the European Vasculitis Genetic Consortium also identified genetic associations in ANCA-associated vasculitis.^{26, 54} Both GWAS found a strong association with a single nucleotide polymorphism (SNP) in human leukocyte antigen (*HLA*)-*DPB1*. The European Vasculitis Genetic Consortium GWAS also found a strong association between PR3-ANCA vasculitis and *PRTN3* (the gene encoding PR3) and *SERPINA1* (the gene encoding α 1-antitrypsin; a major inhibitor of PR3), and between MPO-ANCA vasculitis and *HLA-DQ*. Moreover, this GWAS demonstrated genetic distinctions between GPA and MPA patients and between PR3-ANCA positive and MPO-ANCA positive patients. The numerous candidate gene association studies and two GWAS have revealed a great number of genetic variants that possibly contribute to the pathogenesis of ANCA-associated vasculitis. In **Chapter 2** of this thesis, we conducted a meta-analysis to investigate the genetic variants that are most likely associated with ANCA-associated vasculitis. We included raw data from the European Vasculitis Genetic Consortium GWAS to increase the validity of the meta-analysis.

Are ANCA pathogenic?

In vitro and *in vivo* evidence support a pathogenic role for ANCA in the pathogenesis of ANCA-associated vasculitis.^{55, 56} *In vitro* data include experiments demonstrating that ANCA IgG activates cytokine-primed neutrophils,⁵⁷⁻⁵⁹ that ANCA-activated neutrophils induce endothelial cell injury,^{60, 61} and that ANCA-activated neutrophils activate the alternative complement pathway⁶².

The most convincing evidence that ANCA are pathogenic comes from animal models. Xiao *et al.* demonstrated that intravenous injection of purified murine anti-MPO IgG into wild type mice or immunodeficient Rag2-/- mice (these mice fail to generate mature T and B lymphocytes) induces proteinuria and haematuria in these mice. Moreover, the histopathologic lesions found in the kidneys of these mice were comparable to those in renal biopsies of patients with ANCA-associated glomerulonephritis.⁵⁶ Furthermore, Little *et al.* demonstrated that rats immunised with human MPO develop anti-human MPO-ANCA that binds these rats' neutrophils and induces pauci-immune crescentic glomerulonephritis and pulmonary haemorrhage with histologic evidence of lung vasculitis in these rats.⁶³ Thus far, it has not been possible to successfully reproduce these findings in a PR3-ANCA vasculitis animal model.^{29, 64}

Clinical evidence for the pathogenicity of ANCA includes the occurrence of pulmonary-renal syndrome in a neonate shortly after birth from a mother with MPO-ANCA positive MPA, most likely caused by transplacental transfer of maternal MPO-ANCA.^{65, 66} This clinical evidence is limited, however, in that it comprises only one case-report and until today no sequelae have been reported. Further clinical evidence for the pathogenicity of ANCA includes the induction of ANCA, particularly high titres of MPO-ANCA, by certain drugs (e.g. propylthiouracil and hydralazine⁶⁷) and the subsequent onset of disease manifestations in humans. More clinical evidence is found in the beneficial effect of plasma exchange in the treatment of ANCA-associated vasculitis.¹⁷

One observation plaguing the contention that ANCA are pathogenic was the presence of ANCA in only 90-95% of ANCA-associated vasculitis patients.¹⁴⁻¹⁷ However, the remaining 5-10% of patients that have long been assumed to be ANCA-negative based on the results of conventional clinical assays might be classified as ANCA-positive after all. Roth *et al.* demonstrated that, when using a highly sensitive epitope-excision method, ANCA-negative patients' purified IgG reacts with a specific MPO-epitope.⁶⁸ This MPO-ANCA epitope was blocked from reacting with ANCA IgG in serum because of competitive binding by ceruloplasmin, which is a natural inhibitor of MPO that is naturally present in serum.


The pathogenicity of ANCA was also questioned since healthy individuals were also demonstrated to have ANCA.⁶⁹⁻⁷² Interestingly, Roth *et al.* demonstrated that compared with MPO-ANCA occurring in vasculitis, natural MPO-ANCA are present in lower titres, have lower avidity, have less subclass diversity, and are less capable of activating neutrophils *in vitro*.⁶⁸ Moreover, the epitope specificity of the repertoire of MPO-ANCA occurring in vasculitis patients was shown to differ from the epitope specificity of MPO-ANCA occurring in healthy individuals.⁶⁸ Thus, not all ANCA seem to be equal.⁷³

Presumed pathogenic sequence for acute vascular injury in ANCA-associated vasculitis

The putative pathogenic sequence inducing acute vascular inflammation in ANCA-associated vasculitis is depicted in **figure 2**.²⁹ Starting from the upper left, resting neutrophils have ANCA autoantigens (e.g. PR3 and MPO) sequestered in their cytoplasmic granules. Exposure to priming factors, e.g. cytokines induced by infection or pathogenic factors released by complement activation, leads to the exposure of ANCA-antigens on the neutrophil's surface and in the microenvironment. Circulating ANCA bind to these antigens and activate them by Fc γ receptor engagement and F(ab')₂ binding. ANCA-activated neutrophils penetrate vessel walls and release factors that initiate necrosis and

apoptosis of the neutrophils and the environment. Meanwhile, the alternative complement pathway is activated and generates C5a, a chemoattractant for neutrophils that also primes the arriving neutrophils for activation by ANCA, generating a positive feedback effect.

Figure 2. The putative pathogenic sequence inducing acute vascular inflammation in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis.




Starting from the upper left, resting neutrophils have ANCA-antigens (e.g. proteinase 3 (PR3) and myeloperoxidase (MPO)) in their cytoplasmic granules. Exposure to priming factors, e.g. cytokines induced by infection or pathogenic factors released by complement activation, leads to the exposure of the ANCA-antigens on the neutrophil's surface and in the microenvironment. Circulating ANCA bind to these antigens and activate the neutrophils. ANCA-activated neutrophils penetrate vessel walls and release factors that initiate necrosis and apoptosis of the neutrophils and the environment. Meanwhile, the alternative complement pathway is activated and generates C5a, a chemoattractant for neutrophils that also primes the arriving neutrophils for activation by ANCA, generating a positive feedback effect. Reproduced from Xiao et al.²⁹ with permission.

Disease manifestations

The peak age of ANCA-associated vasculitis onset is 65-74 years.⁷⁴ Men are more often affected than women, but when women are affected, they tend to have a younger age at disease onset than men.⁷⁵ Patients typically present with prodromal 'flu-like' symptoms that have been present for several weeks to months.³ These symptoms include malaise, fever, headache, polyarthralgia, polymyalgia, and unintended weight loss.^{13, 76} Presenting symptoms can be very similar to symptoms of non-vasculitic diseases such as infections, post-viral syndrome, and malignancies. It can therefore be challenging for clinicians to pinpoint the diagnosis early in the diagnostic process. A survey including 701 patients with ANCA-associated vasculitis demonstrated a lag of three to 12 months between disease onset and diagnosis, suggesting that diagnostic delay is a problem.⁷⁵ Correct diagnosis on the first visit to a physician was accomplished in only 7% of patients and 50% of patients had to visit at least four physicians before the correct diagnosis was made.

Figure 3 depicts the various manifestations of ANCA-associated vasculitis. Although disease symptoms in GPA and MPA overlap, the incidences of these symptoms can differ significantly between the two conditions. For instance, ear, nose, and throat (ENT) symptoms occur in 90% of GPA patients and in only 35% of MPA patients.^{13, 76} Large observational studies demonstrated that the airways and lung parenchyma are commonly affected, as are the kidneys, although renal involvement can be asymptomatic until renal failure occurs.⁷⁶⁻⁷⁸ Approximately half of patients develop skin manifestations.⁷⁶⁻⁷⁸ Clearly, ANCA-associated vasculitis can become manifest in virtually all organs. Therefore, thorough physical examination is important to determine the full extent of the disease.³

Figure 3. The various manifestations of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis.




*These lesions can be seen on chest radiography and computed tomography. Reproduced from Berden et al.³ with permission.

Chapters 3 and 4 of this thesis focus on renal involvement in ANCA-associated vasculitis. Renal involvement is common and is important with respect to patient morbidity and mortality.²² The kidneys become involved in approximately 80% of GPA patients and 90% of MPA patients.¹³ A key study published in 1958 demonstrated that the main cause of death in untreated ANCA-associated vasculitis patients is uraemia due to rapidly progressive renal failure.⁷⁹

Rapidly progressive renal failure with an active sediment (i.e. red cell casts and/or proteinuria) in patients who are seropositive for ANCA is suggestive of ANCA-associated glomerulonephritis. The morphologic changes in the renal biopsy are the gold standard for establishing the diagnosis of ANCA-associated glomerulonephritis.^{80, 81} In these biopsies, light microscopy shows necrotizing and crescentic glomerulonephritis.⁸² Immunofluorescence microscopy shows little or no immunoglobulin or complement staining (the so-called pauci-immune staining pattern). By electron microscopy, subendothelial edema, microthrombosis, and degranulation of neutrophils are present, but immune deposits are absent.⁸³


Several studies have demonstrated strong associations between histopathological parameters in the renal biopsy and renal outcome. The most consistent findings were associations between the percentage of normal glomeruli and favorable renal outcome and between the percentage of sclerotic glomeruli and poor renal outcome.⁸⁴⁻⁸⁷ Moreover, the presence of active lesions such as cellular crescents was found to be positively associated with renal recovery under immunosuppressive treatment.^{84, 85} In 2010, the histopathological classification of ANCA-associated glomerulonephritis was devised within the collaboration of the European Vasculitis Society (EUVAS) with the aim of further adding to the prognostication of patients with ANCA-associated glomerulonephritis.⁸⁸ This classification system is built around glomerular pathology and distinguishes four classes: focal class biopsies contain $\geq 50\%$ normal glomeruli; crescentic class biopsies contain $\geq 50\%$ glomeruli with cellular crescents; sclerotic class biopsies contain $\geq 50\%$ sclerotic glomeruli; and biopsies without predominant lesions are assigned to the mixed class. Examples of glomerular lesions typically for each of the four classes are depicted in **figure 4**. The classification flowchart is depicted in **figure 5**.

Figure 4. Examples of glomerular lesions that can be observed in the four classes of the histopathological classification of antineutrophil cytoplasmic antibodies (ANCA)-associated glomerulonephritis.



A-C show examples of normal glomeruli; D-G show examples of cellular crescents; H-J show examples of fibrous crescents; and K shows an example of global glomerulosclerosis. Reproduced from Berden et al.⁸⁸ with permission.

Figure 5. The classification flowchart for the histopathological classification of ANCA-associated glomerulonephritis.



Reproduced from Berden *et al.*⁸⁸ with permission.

The study by Berden *et al.* wherein the classification system was proposed incorporated a validation study including 100 patients.⁸⁸ Multiple regression analysis showed that baseline renal function and the histopathological classification were the only independent predictors of renal outcome. The histopathological classification of ANCA-associated glomerulonephritis has been validated in various cohorts.⁸⁹⁻¹⁰⁹ The outcomes of these validation studies, points of consideration, and future perspectives are discussed in **Chapter 4** of this thesis.

Treatment of ANCA-associated vasculitis

Early diagnosis of ANCA-associated vasculitis is of major importance as prompt instigation of treatment is essential to prevent progressive organ damage, particularly end-stage renal disease, and death.⁷⁹ In the last 20 years, a significant number of large, international trials were performed with the aim of improving the treatment modalities in ANCA-associated vasculitis.^{14-17, 27, 28, 110-112}

Treatment of ANCA-associated vasculitis traditionally consists of two phases.¹¹³ Phase I consists of aggressive remission-inducing immunosuppression classically consisting of cyclophosphamide and corticosteroids for the duration of three to six months. Phase II consists of remission maintenance treatment with,

amongst others, azathioprine or methotrexate while corticosteroids are tapered and if possible stopped.¹¹⁴ The choice of treatment depends on disease severity and organ manifestations. Recently, rituximab was introduced for both induction and remission maintenance treatment in ANCA-associated vasculitis.^{27, 28, 115}

Induction treatment

Induction treatment of ANCA-associated vasculitis consists of cyclophosphamide treatment until complete clinical remission is achieved, which is often after three to six months. The CYCLOPS trial demonstrated that, while achieving similar remission rates, intravenous pulsed cyclophosphamide treatment results in a lower cumulative cyclophosphamide dose than oral cyclophosphamide treatment.¹⁵ However, long-term analysis of this cohort demonstrated a higher relapse risk in the intravenous group than in the oral group.¹¹⁶ The increased frequency of relapses in the intravenous group was not associated with increased mortality or renal damage.

Two randomised controlled trials, RITUXVAS²⁷ and RAVE²⁸, investigated rituximab – a chimeric monoclonal antibody directed against pre-B cells and mature B lymphocytes – in the treatment of ANCA-associated vasculitis. RITUXVAS included only newly diagnosed patients, whereas in RAVE both new and relapsing patients were included. In both trials, rituximab was non-inferior to cyclophosphamide for remission induction. Moreover, both trials demonstrated no significant difference between the number of adverse events in the rituximab group and the cyclophosphamide group. However, concerns were raised about a possible higher malignancy rate in patients treated with rituximab.^{117, 118} **Chapter 5** of this thesis reports the first 10-year follow-up study investigating malignancy risk in patients with ANCA-associated vasculitis treated with cyclophosphamide according to current treatment regimens. **Chapter 6** reports the first study to compare the long-term malignancy risks between rituximab-based treatment and cyclophosphamide-based treatment in ANCA-associated vasculitis.

The NORAM trial investigated methotrexate induction treatment in patients with ANCA-associated vasculitis with early systemic disease without significant renal involvement.¹⁴ Methotrexate was demonstrated to have similar efficacy to cyclophosphamide for remission induction, but was associated with a higher relapse rate. Long-term follow-up of these patients demonstrated that methotrexate treatment is associated with less effective disease control and prolonged use of steroids.¹¹⁹

Evidence from a retrospective study¹²⁰ and a prospective pilot trial¹²¹ indicates that mycophenolate mofetil is effective in the induction treatment of ANCA-associated vasculitis. An advantage of mycophenolate mofetil over cyclophosphamide includes a more favourable safety profile in terms of toxicity. The MYCYC trial compares mycophenolate mofetil to cyclophosphamide

for induction treatment in ANCA-associated vasculitis (ClinicalTrials.gov NCT00414128). The MYCYC trial results are expected in 2018.

Maintenance treatment

Maintenance treatment aims at the prevention of relapses. The landmark EUVAS trial CYCAZAREM demonstrated that cyclophosphamide exposure in patients with ANCA-associated vasculitis can be safely reduced by the substitution of cyclophosphamide by azathioprine shortly after remission achievement.¹⁶ Relapse risk and severe adverse event occurrence were similar between the cyclophosphamide group and the azathioprine group. Currently, azathioprine, alongside with methotrexate, is the first choice for maintenance treatment in ANCA-associated vasculitis.¹²²

Methotrexate can be used as an alternative to azathioprine for remission maintenance in patients with ANCA-associated vasculitis in whom renal function is not severely impaired. The WEGENT trial demonstrated similar remission maintenance and adverse events rates between methotrexate and azathioprine maintenance treatment.¹¹⁴

Rituximab was recently introduced for remission maintenance treatment in ANCA-associated vasculitis patients who relapsed on other maintenance therapies or who are at high risk of relapse. The MAINRITSAN trial demonstrated a superiority of rituximab over azathioprine as maintenance treatment after cyclophosphamide induction treatment.¹¹⁵ Adverse events rates were similar in the rituximab group and the azathioprine group. The ongoing RITAZERAM trial compares rituximab to azathioprine as maintenance treatment in relapsing patients who achieved remission following rituximab induction treatment (ClinicalTrials.gov NCT01697267).

The IMPROVE trial demonstrated that mycophenolate mofetil is less effective than azathioprine in remission maintenance after remission induction with cyclophosphamide.¹¹¹ Therefore, mycophenolate mofetil maintenance treatment is only considered in ANCA-associated vasculitis patients in whom azathioprine and methotrexate are contraindicated.

Prognosis of patients with ANCA-associated vasculitis

As stated previously, the natural history of untreated ANCA-associated vasculitis is that of a rapidly progressive, usually fatal disease.⁷⁹ The introduction of immunosuppressive therapy in the 1960s has dramatically reduced the 1-year mortality rate of patients with ANCA-associated vasculitis from 82% to 10%.^{32, 79, 123} Nevertheless, patients continue to have an increased mortality risk compared to the general population.¹²³

A large, prospective 5-year follow-up study that included 535 patients demonstrated that ANCA-associated vasculitis patients have a 2.6 times increased mortality risk compared to the general population.¹²³ Infection (48%) and active vasculitis (19%) were the main causes of death during the first year after diagnosis. This finding emphasizes the importance of finding the right balance between disease control and immunosuppressive treatment. After the first year of diagnosis, patients continued to have a 1.3 times increased mortality risk.¹²³ Cardiovascular disease (26%), malignancy (22%), and infection (20%) accounted for the majority of these deaths.

About 14% of patients will experience at least one major cardiovascular event within 5 years after ANCA-associated vasculitis diagnosis.¹²⁴ Patients with GPA are reported to have a 3.6 times increased myocardial infarction risk compared to the general population.¹²⁵ In addition, when matched for renal function and other traditional risk factors, cardiovascular risk is still doubled in patients with ANCA-associated vasculitis.¹²⁶ PR3-ANCA positivity, older age, and diastolic hypertension were shown to be independent determinants of poor cardiovascular outcome.¹²⁴ Factors contributing to the increased cardiovascular risk in vasculitis include the chronic inflammatory state, endothelial dysfunction, renal dysfunction, and the use of corticosteroids, which accelerates the development of hypertension, dyslipidaemia, and diabetes.^{127, 128}

Malignancies were demonstrated to be the second leading cause of death after the first year of ANCA-associated vasculitis diagnosis.¹²³ A number of studies, using data from retrospective monocentre cohorts,^{76, 129-131} prospective multicentre clinical trials,^{132, 133} and nationwide registry linkage,¹³⁴ demonstrated that patients with ANCA-associated vasculitis have an increased malignancy risk compared to the general population.¹³⁵ In particular, the risks of leukaemia, lymphoma, bladder cancer, and non-melanoma skin cancer (NMSC) were increased. Except for one 7-year follow-up study published in 1992,⁷⁶ average follow-up in these studies was at most five years¹²⁹⁻¹³². Moreover, the observation period in most studies was 1960-1990. Thus, the patients included in these studies were treated with treatment regimens that are outdated and, consequently, the findings of these studies do not represent current malignancy risks.^{76, 129, 131, 134}

As explained previously, treatment regimens in ANCA-associated vasculitis have changed significantly in recent years based on efforts to reduce cumulative cyclophosphamide exposure.¹⁴⁻¹⁷ Moreover, rituximab has emerged as a promising substitute for cyclophosphamide in the treatment of ANCA-associated vasculitis.^{27,}

^{28, 136, 137} **Chapter 5** of this thesis reports the first 10-year follow-up study that investigates malignancy risk in ANCA-associated vasculitis patients treated with cyclophosphamide according to current treatment regimens. **Chapter 6** reports the first study to compare the long-term malignancy risks between rituximab-based treatment and cyclophosphamide-based treatment in ANCA-associated vasculitis.

Several factors have been hypothesized to contribute to the increased malignancy risk in patients with ANCA-associated vasculitis. Firstly, immunosuppressive treatment may decrease the immune system's ability to recognize and eradicate malignant cells. The importance of a well-functioning immune system in the prevention of malignancies is well-demonstrated by the increased malignancy risk observed in HIV-positive patients.¹³⁸ Moreover, immunosuppressive therapy itself may have direct mutagenic properties, as, for example, demonstrated in cyclophosphamide-induced bladder cancer.¹³⁹⁻¹⁴³ Furthermore, long-standing immune activation per se may be oncogenic; for example, long-standing immune activation is hypothesized to contribute to the increased lymphoma risk seen in a number of chronic autoimmune rheumatic conditions.¹⁴⁴

The European Vasculitis Society and the European Vasculitis Genetics Consortium

Research in ANCA-associated vasculitis is hindered by the low incidence of this complex disease. Therefore, in 1994 the EUVAS was founded with the objective of uniting vasculitis researchers and clinicians and promoting the study of vasculitis. The apparent need for clinical trials was demonstrated by the wide heterogeneity in treatment, poor patient outcomes, and high levels of treatment-related toxicity.¹²² Thus far, the EUVAS has conducted a significant number of clinical trials with the aim of optimizing the treatment of ANCA-associated vasculitis.^{14-17, 27, 110, 111, 145} Long-term follow-up studies of the first four EUVAS trials (CYCAZAREM,¹⁶ NORAM,¹⁴ MEPEX,¹⁷ and CYCLOPS¹⁵) have been published and longer follow-up is pending. The aim of these studies was to investigate several long-term outcomes in ANCA-associated vasculitis, including long-term patient survival,¹²³ disease relapse,¹⁴⁶ cardiovascular events,¹²⁴ malignancies,¹³² disease-related damage,¹⁴⁷⁻¹⁴⁹ and severe adverse events¹⁵⁰. To harmonize the clinical trials, scoring systems were created for both presenting clinical manifestations¹⁵¹⁻¹⁵³ and renal histology¹⁵⁴. Other studies conducted by the EUVAS include ANCA assay standardization studies^{18, 155, 156} and renal histopathological studies^{84, 85, 88, 157-162}. The study presented in **Chapter 3** of this thesis was performed within the collaboration of the EUVAS. The European Vasculitis Genetics Consortium has grown out of EUVAS activity and focuses on the genetics of ANCA-associated vasculitis. In 2010, the European Vasculitis Genetic Consortium published the first GWAS in ANCA-associated vasculitis.²⁶ The study presented in **Chapter 2** of this thesis was performed within the collaboration of the European Vasculitis Genetic Consortium.

Outline of this thesis

The role of genetic variants in ANCA-associated vasculitis is explored in **Chapter 2** of this thesis. The numerous candidate gene association studies and two GWAS have revealed a great number of genetic variants that could contribute to the pathogenesis of ANCA-associated vasculitis. In **Chapter 2** we report the results of a meta-analysis investigating the genetic variants that are most likely associated with ANCA-associated vasculitis. We included raw data from the European Vasculitis Genetic Consortium GWAS to increase the validity of the meta-analysis.²⁶ Moreover, in the light of the ongoing debate as to whether the different subtypes within ANCA-associated vasculitis represent different entities within the same disease spectrum or are distinct auto-immune diseases, we investigated whether these subtypes have distinct genetic backgrounds. In **Chapter 3** we investigated whether ENT involvement represents a separate phenotype in ANCA-associated vasculitis by exploring the relationship between ENT manifestations and renal outcome.

As discussed previously, renal disease is a common and severe manifestation of ANCA-associated vasculitis that can lead to end-stage renal disease and death. **Chapter 4** reviews the outcomes of studies validating the histopathological classification of ANCA-associated glomerulonephritis and discusses points of consideration and future perspectives.

The prognosis of patients with ANCA-associated vasculitis has improved dramatically in recent years, shifting attention towards the long-term complications these patients experience. In **Chapter 5** the malignancy risk in patients with ANCA-associated vasculitis treated with current immunosuppressive regimens was investigated and its relationship with cyclophosphamide treatment was explored. Recently, rituximab was introduced for both induction and remission maintenance treatment in ANCA-associated vasculitis with the promise of, amongst others, further reducing malignancy risk. **Chapter 6** reports the first study to date to compare the long-term malignancy risks between rituximab-based treatment and cyclophosphamide-based treatment in ANCA-associated vasculitis.

The findings of this thesis will be summarized and placed in a more general perspective in **Chapter 7**.

References

- Jennette JC, Falk RJ, Andrassy K, *et al.* Nomenclature of systemic vasculitides. Proposal of an international consensus conference. *Arthritis Rheum* 1994;37:187-92.
- Jennette JC, Falk RJ, Bacon PA, *et al.* 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum* 2013;65:1-11.
- Berden A, Goceroglu A, Jayne D, *et al.* Diagnosis and management of ANCA associated vasculitis. *BMJ* 2012;344:e26.
- van der Woude FJ, Rasmussen N, Lobatto S, *et al.* Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. *Lancet* 1985;1:425-9.
- Davies DJ, Moran JE, Niall JF, *et al.* Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? *Br Med J (Clin Res Ed)* 1982;285:606.
- Goldschmeding R, van der Schoot CE, ten Bokkel Huinink D, *et al.* Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. *J Clin Invest* 1989;84:1577-87.
- Niles JL, McCluskey RT, Ahmad MF, *et al.* Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase. *Blood* 1989;74:1888-93.
- Jennette JC, Hoidal JR, Falk RJ. Specificity of anti-neutrophil cytoplasmic autoantibodies for proteinase 3. *Blood* 1990;75:2263-4.
- Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. *N Engl J Med* 1988;318:1651-7.
- Falk RJ, Gross WL, Guillevin L, *et al.* Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. *J Am Soc Nephrol* 2011;22:587-8.
- Falk RJ, Gross WL, Guillevin L, *et al.* Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. *Ann Rheum Dis* 2011;70:704.
- Falk RJ, Gross WL, Guillevin L, *et al.* Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. *Arthritis Rheum* 2011;63:863-4.
- Jennette JC, Falk RJ. Small-vessel vasculitis. *N Engl J Med* 1997;337:1512-23.
- De Groot K, Rasmussen N, Bacon PA, *et al.* Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum* 2005;52:2461-9.
- de Groot K, Harper L, Jayne DR, *et al.* Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. *Ann Intern Med* 2009;150:670-80.
- Jayne D, Rasmussen N, Andrassy K, *et al.* A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. *N Engl J Med* 2003;349:36-44.
- Jayne DR, Gaskin G, Rasmussen N, *et al.* Randomized trial of plasma exchange or high-dose methylprednisolone as adjunctive therapy for severe renal vasculitis. *J Am Soc Nephrol* 2007;18:2180-8.
- Hagen EC, Daha MR, Hermans J, *et al.* Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. *Kidney Int* 1998;53:743-53.

19. Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. *Am J Med* 2003;115:284-90.
20. Sable-Fourtassou R, Cohen P, Mahr A, *et al.* Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. *Ann Intern Med* 2005;143:632-8.
21. Sinico RA, Di Toma L, Maggiore U, *et al.* Renal involvement in Churg-Strauss syndrome. *Am J Kidney Dis* 2006;47:770-9.
22. Mukhtyar C, Flossmann O, Hellmich B, *et al.* Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. *Ann Rheum Dis* 2008;67:1004-10.
23. Hogan SL, Falk RJ, Nachman PH, *et al.* Various forms of life in antineutrophil cytoplasmic antibody-associated vasculitis. *Ann Intern Med* 2006;144:377-8; author reply 8-9.
24. Hoffman GS, Langford CA. Are there different forms of life in the antineutrophil cytoplasmic antibody universe? *Ann Intern Med* 2005;143:683-5.
25. Linder R, Orth I, Hagen EC, *et al.* Differentiation between Wegener's granulomatosis and microscopic polyangiitis by an artificial neural network and by traditional methods. *J Rheumatol* 2011;38:1039-47.
26. Lyons PA, Rayner TF, Trivedi S, *et al.* Genetically distinct subsets within ANCA-associated vasculitis. *N Engl J Med* 2012;367:214-23.
27. Jones RB, Tervaert JW, Hauser T, *et al.* Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. *N Engl J Med* 2010;363:211-20.
28. Stone JH, Merkel PA, Spiera R, *et al.* Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med* 2010;363:221-32.
29. Xiao H, Hu P, Falk RJ, *et al.* Overview of the Pathogenesis of ANCA-Associated Vasculitis. *Kidney Dis (Basel)* 2016;1:205-15.
30. de Lind van Wijngaarden RA, van Rijn L, Hagen EC, *et al.* Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known. *Clin J Am Soc Nephrol* 2008;3:237-52.
31. Pinching AJ, Rees AJ, Pussell BA, *et al.* Relapses in Wegener's granulomatosis: the role of infection. *Br Med J* 1980;281:836-8.
32. Fauci AS, Haynes BF, Katz P, *et al.* Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. *Ann Intern Med* 1983;98:76-85.
33. Boudewyns A, Verbelen J, Koekelkoren E, *et al.* Wegener's granulomatosis triggered by infection? *Acta Otorhinolaryngol Belg* 2001;55:57-63.
34. Subra JF, Michelet C, Laporte J, *et al.* The presence of cytoplasmic antineutrophil cytoplasmic antibodies (C-ANCA) in the course of subacute bacterial endocarditis with glomerular involvement, coincidence or association? *Clin Nephrol* 1998;49:15-8.
35. Hellmich B, Ehren M, Lindstaedt M, *et al.* Anti-MPO-ANCA-positive microscopic polyangiitis following subacute bacterial endocarditis. *Clin Rheumatol* 2001;20:441-3.
36. Stegeman CA, Tervaert JW, Sluiter WJ, *et al.* Association of chronic nasal carriage of *Staphylococcus aureus* and higher relapse rates in Wegener granulomatosis. *Ann Intern Med* 1994;120:12-7.
37. Stegeman CA, Tervaert JW, de Jong PE, *et al.* Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. *N Engl J Med* 1996;335:16-20.
38. Axelson JA, Clark RH, Ancerewicz S. Wegener granulomatosis and trimethoprim-sulfamethoxazole. *Ann Intern Med* 1987;107:600.

39. DeRemee RA. The treatment of Wegener's granulomatosis with trimethoprim/sulfamethoxazole: illusion or vision? *Arthritis Rheum* 1988;31:1068-74.
40. DeRemee RA, McDonald TJ, Weiland LH. Wegener's granulomatosis: observations on treatment with antimicrobial agents. *Mayo Clin Proc* 1985;60:27-32.
41. George J, Levy Y, Kallenberg CG, *et al*. Infections and Wegener's granulomatosis--a cause and effect relationship? *QJM* 1997;90:367-73.
42. Valeriano-Marcet J, Spiera H. Treatment of Wegener's granulomatosis with sulfamethoxazole-trimethoprim. *Arch Intern Med* 1991;151:1649-52.
43. West BC, Todd JR, King JW. Wegener granulomatosis and trimethoprim-sulfamethoxazole. Complete remission after a twenty-year course. *Ann Intern Med* 1987;106:840-2.
44. Yuasa K, Tokitsu M, Goto H, *et al*. Wegener's granulomatosis: diagnosis by transbronchial lung biopsy, evaluation by gallium scintigraphy and treatment with sulfamethoxazole/trimethoprim. *Am J Med* 1988;84:371-2.
45. Zycinska K, Wardyn KA, Zielonka TM, *et al*. Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement. *Eur J Med Res* 2009;14 Suppl 4:265-7.
46. Ohtake T, Kobayashi S, Honjou Y, *et al*. Generalized Wegener's granulomatosis responding to sulfamethoxazole-trimethoprim monotherapy. *Intern Med* 2001;40:666-70.
47. Franssen CF, ter Maaten JC, Hoorntje SJ. Brother and sister with myeloperoxidase associated autoimmune disease. *Ann Rheum Dis* 1994;53:213.
48. Hay EM, Beaman M, Ralston AJ, *et al*. Wegener's granulomatosis occurring in siblings. *Br J Rheumatol* 1991;30:144-5.
49. Hull CM, Couser WG, Knostman JD. A familial case of P-ANCA glomerulonephritis presenting in a father and daughter. *Am J Kidney Dis* 2000;35:E23.
50. Muniain MA, Moreno JC, Gonzalez Campora R. Wegener's granulomatosis in two sisters. *Ann Rheum Dis* 1986;45:417-21.
51. Nowack R, Lehmann H, Flores-Suarez LF, *et al*. Familial occurrence of systemic vasculitis and rapidly progressive glomerulonephritis. *Am J Kidney Dis* 1999;34:364-73.
52. Piram M, Maldini C, Mahr A. Effect of race/ethnicity on risk, presentation and course of connective tissue diseases and primary systemic vasculitides. *Curr Opin Rheumatol* 2012;24:193-200.
53. Bonatti F, Reina M, Neri TM, *et al*. Genetic Susceptibility to ANCA-Associated Vasculitis: State of the Art. *Front Immunol* 2014;5:577.
54. Xie G, Roshandel D, Sherva R, *et al*. Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. *Arthritis Rheum* 2013;65:2457-68.
55. Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. *Nat Rev Rheumatol* 2014;10:463-73.
56. Xiao H, Heeringa P, Hu P, *et al*. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. *J Clin Invest* 2002;110:955-63.
57. Falk RJ, Terrell RS, Charles LA, *et al*. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. *Proc Natl Acad Sci U S A* 1990;87:4115-9.
58. Huugen D, Xiao H, van Esch A, *et al*. Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. *Am J Pathol* 2005;167:47-58.
59. Schreiber A, Xiao H, Jennette JC, *et al*. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. *J Am Soc Nephrol* 2009;20:289-98.

60. Ewert BH, Jennette JC, Falk RJ. Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. *Kidney Int* 1992;41:375-83.
61. Savage CO, Gaskin G, Pusey CD, *et al.* Myeloperoxidase binds to vascular endothelial cells, is recognized by ANCA and can enhance complement dependent cytotoxicity. *Adv Exp Med Biol* 1993;336:121-3.
62. Xiao H, Schreiber A, Heeringa P, *et al.* Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. *Am J Pathol* 2007;170:52-64.
63. Little MA, Smyth CL, Yadav R, *et al.* Anti-neutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. *Blood* 2005;106:2050-8.
64. Little MA. L7. Animal models of PR3-ANCA vasculitis: approaches and controversies. *Presse Med* 2013;42:512-5.
65. Bansal PJ, Tobin MC. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. *Ann Allergy Asthma Immunol* 2004;93:398-401.
66. Schlieben DJ, Korbet SM, Kimura RE, *et al.* Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. *Am J Kidney Dis* 2005;45:758-61.
67. Choi HK, Merkel PA, Walker AM, *et al.* Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. *Arthritis Rheum* 2000;43:405-13.
68. Roth AJ, Ooi JD, Hess JJ, *et al.* Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. *J Clin Invest* 2013;123:1773-83.
69. Olson SW, Owshalimpur D, Yuan CM, *et al.* Relation between asymptomatic proteinase 3 antibodies and future granulomatosis with polyangiitis. *Clin J Am Soc Nephrol* 2013;8:1312-8.
70. Cui Z, Zhao MH, Segelmark M, *et al.* Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals. *Kidney Int* 2010;78:590-7.
71. Olson SW, Arbogast CB, Baker TP, *et al.* Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. *J Am Soc Nephrol* 2011;22:1946-52.
72. Xu PC, Cui Z, Chen M, *et al.* Comparison of characteristics of natural autoantibodies against myeloperoxidase and anti-myeloperoxidase autoantibodies from patients with microscopic polyangiitis. *Rheumatology (Oxford)* 2011;50:1236-43.
73. Jennette JC, Falk RJ. L1. Pathogenesis of ANCA-associated vasculitis: observations, theories and speculations. *Presse Med* 2013;42:493-8.
74. Watts RA, Lane SE, Bentham G, *et al.* Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. *Arthritis Rheum* 2000;43:414-9.
75. Abdou NI, Kullman GJ, Hoffman GS, *et al.* Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. *J Rheumatol* 2002;29:309-16.
76. Hoffman GS, Kerr GS, Leavitt RY, *et al.* Wegener granulomatosis: an analysis of 158 patients. *Ann Intern Med* 1992;116:488-98.
77. Reinhold-Keller E, Beuge N, Latza U, *et al.* An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. *Arthritis Rheum* 2000;43:1021-32.
78. Stone JH, Wegener's Granulomatosis Etanercept Trial Research Group. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granu-

- lomatosis etanercept trial. *Arthritis Rheum* 2003;48:2299-309.
79. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). *Br Med J* 1958;2:265-70.
80. Jayne DR, Marshall PD, Jones SJ, *et al.* Auto-antibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. *Kidney Int* 1990;37:965-70.
81. Jennette JC. Rapidly progressive crescentic glomerulonephritis. *Kidney Int* 2003;63:1164-77.
82. Bajema IM, Hagen EC, Ferrario F, *et al.* Immunopathological aspects of systemic vasculitis. *Springer Semin Immunopathol* 2001;23:253-65.
83. Joh K, Muso E, Shigematsu H, *et al.* Renal pathology of ANCA-related vasculitis: proposal for standardization of pathological diagnosis in Japan. *Clin Exp Nephrol* 2008;12:277-91.
84. Bajema IM, Hagen EC, Hermans J, *et al.* Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. *Kidney Int* 1999;56:1751-8.
85. Hauer HA, Bajema IM, Van Houwelingen HC, *et al.* Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. *Kidney Int* 2002;62:1732-42.
86. Aasarod K, Bostad L, Hammerstrom J, *et al.* Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis. *Nephrol Dial Transplant* 2001;16:953-60.
87. Haroun MK, Stone JH, Nair R, *et al.* Correlation of percentage of normal glomeruli with renal outcome in Wegener's granulomatosis. *Am J Nephrol* 2002;22:497-503.
88. Berden AE, Ferrario F, Hagen EC, *et al.* Histopathologic classification of ANCA-associated glomerulonephritis. *J Am Soc Nephrol* 2010;21:1628-36.
89. Noone DG, Twilt M, Hayes WN, *et al.* The new histopathologic classification of ANCA-associated GN and its association with renal outcomes in childhood. *Clin J Am Soc Nephrol* 2014;9:1684-91.
90. Khalighi MA, Wang S, Henriksen KJ, *et al.* Pauci-immune glomerulonephritis in children: a clinicopathologic study of 21 patients. *Pediatr Nephrol* 2015;30:953-9.
91. Bjornekleit R, Sriskandarajah S, Bostad L. Prognostic Value of Histologic Classification of ANCA-Associated Glomerulonephritis. *Clin J Am Soc Nephrol* 2016;11:2159-67.
92. Kristensen T, Gregersen JW, Krag SR, *et al.* The relation between histopathological classification and renal outcome, ANCA subtype and treatment regimens in ANCA-associated vasculitis. *Clin Exp Rheumatol* 2016;34:S105-10.
93. Diaz-Crespo F, Villacorta J, Acevedo M, *et al.* The predictive value of kidney biopsy in renal vasculitis: a multicenter cohort study. *Hum Pathol* 2016;52:119-27.
94. Tanna A, Guarino L, Tam FW, *et al.* Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. *Nephrol Dial Transplant* 2015;30:1185-92.
95. Quintana LF, Perez NS, De Sousa E, *et al.* ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis. *Nephrol Dial Transplant* 2014;29:1764-9.
96. Cordova-Sanchez BM, Mejia-Vilet JM, Morales-Buenrostro LE, *et al.* Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement. *Clin Rheumatol* 2016;35:1805-16.
97. Chen YX, Xu J, Pan XX, *et al.* Histopathological Classification and Renal Outcome in Patients with Antineutrophil Cytoplasmic Antibodies-associated Renal Vasculitis: A Study

- of 186 Patients and Metaanalysis. *J Rheumatol* 2017;44:304-13.
98. Nohr E, Girard L, James M, *et al.* Validation of a histopathologic classification scheme for antineutrophil cytoplasmic antibody-associated glomerulonephritis. *Hum Pathol* 2014;45:1423-9.
99. Unlu M, Kiremitci S, Ensari A, *et al.* Pauci-immune necrotizing crescentic glomerulonephritis with crescentic and full moon extracapillary proliferation: clinico-pathologic correlation and follow-up study. *Pathol Res Pract* 2013;209:75-82.
100. Ford SL, Polkinghorne KR, Longano A, *et al.* Histopathologic and clinical predictors of kidney outcomes in ANCA-associated vasculitis. *Am J Kidney Dis* 2014;63:227-35.
101. Togashi M, Komatsuda A, Nara M, *et al.* Validation of the 2010 histopathological classification of ANCA-associated glomerulonephritis in a Japanese single-center cohort. *Mod Rheumatol* 2014;24:300-3.
102. Ellis CL, Manno RL, Havill JP, *et al.* Validation of the new classification of pauci-immune glomerulonephritis in a United States cohort and its correlation with renal outcome. *BMC Nephrol* 2013;14:210.
103. Chang DY, Wu LH, Liu G, *et al.* Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. *Nephrol Dial Transplant* 2012;27:2343-9.
104. Muso E, Endo T, Itabashi M, *et al.* Evaluation of the newly proposed simplified histological classification in Japanese cohorts of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in comparison with other Asian and European cohorts. *Clin Exp Nephrol* 2013;17:659-62.
105. Iwakiri T, Fujimoto S, Kitagawa K, *et al.* Validation of a newly proposed histopathological classification in Japanese patients with anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. *BMC Nephrol* 2013;14:125.
106. Hilhorst M, Wilde B, van Breda Vriesman P, *et al.* Estimating renal survival using the ANCA-associated GN classification. *J Am Soc Nephrol* 2013;24:1371-5.
107. Naidu GS, Sharma A, Nada R, *et al.* Histopathological classification of pauci-immune glomerulonephritis and its impact on outcome. *Rheumatol Int* 2014;34:1721-7.
108. Moroni G, Binda V, Leoni A, *et al.* Predictors of renal survival in ANCA-associated vasculitis. Validation of a histopathological classification schema and review of the literature. *Clin Exp Rheumatol* 2015;33:S-56-63.
109. Li X, Liang S, Zheng C, *et al.* Clinicopathological characteristics and outcomes of pediatric patients with systemic small blood vessel vasculitis. *Pediatr Nephrol* 2014;29:2365-71.
110. Schmitt WH, Hagen EC, Neumann I, *et al.* Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. *Kidney Int* 2004;65:1440-8.
111. Hiemstra TF, Walsh M, Mahr A, *et al.* Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. *JAMA* 2010;304:2381-8.
112. Specks U, Merkel PA, Seo P, *et al.* Efficacy of remission-induction regimens for ANCA-associated vasculitis. *N Engl J Med* 2013;369:417-27.
113. Hellmich B, Lamprecht P, Gross WL. Advances in the therapy of Wegener's granulomatosis. *Curr Opin Rheumatol* 2006;18:25-32.
114. Pagnoux C, Mahr A, Hamidou MA, *et al.* Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. *N Engl J Med* 2008;359:2790-803.
115. Guillevin L, Pagnoux C, Karras A, *et al.* Rituximab versus azathioprine for maintenance

- in ANCA-associated vasculitis. *N Engl J Med* 2014;371:1771-80.
116. Harper L, Morgan MD, Walsh M, *et al.* Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. *Ann Rheum Dis* 2012;71:955-60.
117. Karassa FB. Rituximab or cyclophosphamide in ANCA-associated renal vasculitis. *N Engl J Med* 2010;363:2073; author reply -4.
118. Falk RJ, Jennette JC. Rituximab in ANCA-associated disease. *N Engl J Med* 2010;363:285-6.
119. Faurschou M, Westman K, Rasmussen N, *et al.* Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum* 2012;64:3472-7.
120. Draibe J, Poveda R, Fulladosa X, *et al.* Use of mycophenolate in ANCA-associated renal vasculitis: 13 years of experience at a university hospital. *Nephrol Dial Transplant* 2015;30 Suppl 1:i132-7.
121. Silva F, Specks U, Kalra S, *et al.* Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement--a prospective, open-label pilot trial. *Clin J Am Soc Nephrol* 2010;5:445-53.
122. Gopaluni S, Jayne D. Clinical Trials in Vasculitis. *Curr Treatm Opt Rheumatol* 2016;2:161-77.
123. Flossmann O, Berden A, de Groot K, *et al.* Long-term patient survival in ANCA-associated vasculitis. *Ann Rheum Dis* 2011;70:488-94.
124. Suppiah R, Judge A, Batra R, *et al.* A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. *Arthritis Care Res (Hoboken)* 2011;63:588-96.
125. Faurschou M, Mellemkjaer L, Sorensen IJ, *et al.* Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. *Arthritis Rheum* 2009;60:1187-92.
126. Morgan MD, Turnbull J, Selamet U, *et al.* Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. *Arthritis Rheum* 2009;60:3493-500.
127. Raza K, Thambyrajah J, Townend JN, *et al.* Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lessons for atherosclerotic disease? *Circulation* 2000;102:1470-2.
128. Booth AD, Jayne DR, Kharbanda RK, *et al.* Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. *Circulation* 2004;109:1718-23.
129. Westman KW, Bygren PG, Olsson H, *et al.* Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. *J Am Soc Nephrol* 1998;9:842-52.
130. Faurschou M, Sorensen IJ, Mellemkjaer L, *et al.* Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. *J Rheumatol* 2008;35:100-5.
131. Holle JU, Gross WL, Latza U, *et al.* Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. *Arthritis Rheum* 2011;63:257-66.
132. Heijl C, Harper L, Flossmann O, *et al.* Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. *Ann Rheum Dis* 2011;70:1415-21.
133. Silva F, Seo P, Schroeder DR, *et al.* Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. *Arthritis Rheum* 2011;63:2495-503.

134. Knight A, Askling J, Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. *Int J Cancer* 2002;100:82-5.
135. Mahr A, Heijl C, Le Guenno G, *et al.* ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships. *Best Pract Res Clin Rheumatol* 2013;27:45-56.
136. Specks U, Fervenza FC, McDonald TJ, *et al.* Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. *Arthritis Rheum* 2001;44:2836-40.
137. Keogh KA, Ytterberg SR, Fervenza FC, *et al.* Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. *Am J Respir Crit Care Med* 2006;173:180-7.
138. Grulich AE, van Leeuwen MT, Falster MO, *et al.* Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. *Lancet* 2007;370:59-67.
139. Pedersen-Bjergaard J, Specht L, Larsen SO, *et al.* Risk of therapy-related leukaemia and pre-leukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. *Lancet* 1987;2:83-8.
140. Pedersen-Bjergaard J, Ersboll J, Hansen VL, *et al.* Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. *N Engl J Med* 1988;318:1028-32.
141. Travis LB, Curtis RE, Glimelius B, *et al.* Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. *J Natl Cancer Inst* 1995;87:524-30.
142. Worth PH. Cyclophosphamide and the bladder. *Br Med J* 1971;3:182.
143. Grosse Y, Baan R, Straif K, *et al.* A review of human carcinogens--Part A: pharmaceuticals. *Lancet Oncol* 2009;10:13-4.
144. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. *Arch Intern Med* 2005;165:2337-44.
145. Karras A, Pagnoux C, Haubitz M, *et al.* Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. *Ann Rheum Dis* 2017.
146. Walsh M, Flossmann O, Berden A, *et al.* Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum* 2012;64:542-8.
147. Robson J, Doll H, Suppiah R, *et al.* Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. *Ann Rheum Dis* 2015;74:177-84.
148. Martinez Del Pero M, Walsh M, Luqmani R, *et al.* Long-term damage to the ENT system in Wegener's granulomatosis. *Eur Arch Otorhinolaryngol* 2011;268:733-9.
149. Suppiah R, Hadden RD, Batra R, *et al.* Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials. *Rheumatology (Oxford)* 2011;50:2214-22.
150. Little MA, Nightingale P, Verburgh CA, *et al.* Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. *Ann Rheum Dis* 2010;69:1036-43.
151. Luqmani RA, Bacon PA, Moots RJ, *et al.* Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. *QJM* 1994;87:671-8.
152. Exley AR, Bacon PA, Luqmani RA, *et al.* Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. *Arthritis Rheum* 1997;40:371-80.
153. Stone JH, Hoffman GS, Merkel PA, *et al.* A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vas-

- litides (INSSYS). *Arthritis Rheum* 2001;44:912-20.
154. Bajema IM, Hagen EC, Hansen BE, *et al.* The renal histopathology in systemic vasculitis: an international survey study of inter- and intra-observer agreement. *Nephrol Dial Transplant* 1996;11:1989-95.
155. Hagen EC, Andrassy K, Csernok E, *et al.* Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. *J Immunol Methods* 1996;196:1-15.
156. Hagen EC, Andrassy K, Chernok E, *et al.* The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. EEC/BCR Group for ANCA Assay Standardization. *J Immunol Methods* 1993;159:1-16.
157. Hauer HA, Bajema IM, Hagen EC, *et al.* Long-term renal injury in ANCA-associated vasculitis: an analysis of 31 patients with follow-up biopsies. *Nephrol Dial Transplant* 2002;17:587-96.
158. Hauer HA, Bajema IM, van Houwelingen HC, *et al.* Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. *Kidney Int* 2002;61:80-9.
159. Vergunst CE, van Gurp E, Hagen EC, *et al.* An index for renal outcome in ANCA-associated glomerulonephritis. *Am J Kidney Dis* 2003;41:532-8.
160. de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, *et al.* Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. *J Am Soc Nephrol* 2006;17:2264-74.
161. de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, *et al.* Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. *J Am Soc Nephrol* 2007;18:2189-97.
162. Berden AE, Jones RB, Erasmus DD, *et al.* Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. *J Am Soc Nephrol* 2012;23:313-21.

Chapter II

Genetic variants in ANCA-associated vasculitis: a meta-analysis

*C. Rahmattulla, A.L. Mooyaart, D. van Hooven, J.W. Schoones, J.A. Bruijn, O.M.
Dekkers, European Vasculitis Genetics Consortium & I.M. Bajema*

Annals of the Rheumatic Diseases 2016: 1687-92

Abstract

Background

Genetic factors may influence the pathogenic pathways leading to antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We performed a meta-analysis to determine the genetic variants most likely associated with AAV and investigated whether diagnostic and serological subtypes within AAV have distinct genetic backgrounds.

Methods

Studies investigating the association between genetic variants and AAV in humans were searched in PubMed, EMBASE and Web of Science. All variants investigated in at least two studies were selected. Subsequently, all studies assessing these variants were included in this meta-analysis. Additionally, data on these variants from the largest genome-wide association studies in AAV were included to increase the validity of this meta-analysis.

Results

The literature search yielded 5180 articles. 62 articles investigating 140 genetic variants were included, 33 of which were associated with AAV in a meta-analysis. These genetic variants were in or near the following genes: *CD226*, *CTLA-4*, *FCGR2A*, *HLA-B*, *HLA-DP*, *HLA-DQ*, *HLA-DR*, *HSD17B8*, *IRF5*, *PTPN22*, *RING1/RXR*, *RXR*, *STAT4*, *SERPINA1* and *TLR9*. Moreover, we identified genetic distinctions between granulomatosis with polyangiitis and microscopic polyangiitis and between proteinase 3 ANCA vasculitis and myeloperoxidase ANCA vasculitis. In 76% of the genetic variants, subdivision based on ANCA serotype resulted in higher ORs than subdivision based on clinical diagnosis.

Conclusions

This meta-analysis identified 33 genetic variants associated with AAV, supporting a role for alpha-1-antitrypsin, the major histocompatibility complex system, and several distinct inflammatory processes in AAV pathogenesis. Our results indicate that subdivision of AAV based on ANCA serotype has a stronger genetic basis than subdivision based on clinical diagnosis.

Introduction

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic autoimmune disease in which patients often have circulating proteinase 3 (PR3)-ANCA or myeloperoxidase (MPO)-ANCA.^{1,2} The clinical syndromes within the spectrum of AAV are granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis.

The subtypes within AAV show significant differences in clinical and epidemiological characteristics,^{3,4} leading to debate regarding whether these subtypes are part of a single disease spectrum or represent distinct diseases.⁵⁻⁷ To date, the prevailing concept of a single disease spectrum has resulted in similar treatment strategies in clinical trials⁸⁻¹⁰ and to suggestions that genetic studies should consider the subtypes together.¹¹ Evidence that these subtypes are pathogenically distinct may lead to the development of syndrome-specific therapeutic strategies.

Both environmental and genetic factors are thought to be involved in the pathogenesis of AAV.¹² Evidence for the role of genetic factors comes from differences in the prevalence of AAV between ethnic groups,¹³ familial association studies¹⁴ and genetic associations studies including the two genome-wide association studies (GWAS) performed in AAV.^{15,16}

Attempts to replicate findings of genetic association studies performed in AAV have yielded inconsistent outcomes. Small sample sizes and false-positive results arising from the low prior probabilities of genetic associations may be responsible for these inconsistencies.¹⁷ These factors are especially relevant in complex diseases such as AAV.¹⁸

The aim of this study was to determine the genetic variants associated with AAV. Therefore, we performed a meta-analysis to assess the pooled effect of all genetic variants that have been investigated in AAV in at least two studies. To increase the validity of this meta-analysis, we also included previously unpublished data from the largest GWAS performed in AAV.¹⁵ Moreover, we conducted stratified analyses based on clinical diagnosis and ANCA serotype to investigate whether these different AAV subtypes have distinct genetic backgrounds.

Methods

Literature search and eligibility

A comprehensive search string was carried out in collaboration with a librarian. PubMed, EMBASE and Web of Science were searched until April 2014 for studies investigating genetic variants in patients with AAV. The search strategy consisted of multiple queries combining 'Anti-Neutrophil Cytoplasmic Antibody-Associated

Vasculitis', 'ANCA', 'vasculitis', 'Granulomatosis with Polyangiitis', 'Wegener's Granulomatosis', 'Microscopic polyangiitis', 'Eosinophilic granulomatosis with polyangiitis', 'Churg Strauss Syndrome', 'PR3', 'MPO', 'Polymorphisms' or 'Genes'. To minimise the chance of omitting references, a second broader search was performed for genetic variants in vasculitis in general rather than AAV alone (supplementary table S1). The specific genes and polymorphisms that resulted from the previous searches were added in a next search to minimise the chance of omitting references. To ensure maximum sensitivity, no limits, filters or language restrictions were placed on the searches.

Two observers (CR and DvH) independently reviewed the titles and abstracts of the citations retrieved by the search and read potentially relevant studies independently. Studies that compared genetic variants between patients with AAV and controls without AAV derived from the general population were eligible. Cases had to have an AAV by fulfilling either the Chapel Hill Consensus Conference criteria,¹⁹ American College of Rheumatology criteria,²⁰ European Medicines Agency algorithm,²¹ 1998 Japanese criteria proposed by the Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan,²² or clinical, histological and serological criteria. Definitions of cases and controls in each included study are depicted in supplementary table S2. All genetic variants investigated in at least two studies were included. Genetic variants investigated in multiple cohorts in one publication were also included. This was the case for genetic variants in *GHSR*,²³ *LEPR*²³ and *TLR9*.²⁴ For the included genetic variants, all genetic studies were identified to estimate the pooled effect of the genetic variant in a meta-analysis, irrespective of their p values. To increase the validity of this meta-analysis, we also included unpublished data on these genetic variants from the Lyons *et al*¹⁵ GWAS. This was possible for the genetic variants in this meta-analysis that were not human leucocyte antigen (HLA) serotypes or tandem repeats and that were genotyped in the Lyons *et al* GWAS. Moreover, we included data from the stage 1 analysis including all single-nucleotide polymorphisms (SNPs) with a p value $<10^{-4}$ from the Xie *et al*¹⁶ GWAS.

Data extraction

Minor allele frequencies of the included genetic variants were extracted from included studies. Studies investigating the same genetic variant published by the same author(s) were checked for overlapping patient groups, in which case only the study with the largest patient group was included. Studies that reported insufficient data to calculate an OR were excluded.

Statistical analysis

ORs and 95% CIs were calculated at the allele level. To account for potential heterogeneity, random-effects model was performed in all analyses that included

at least five studies.²⁵ Because the HLA serotypes are not completely independent from the HLA alleles, the following HLA variants were collapsed in the analyses: *HLA-DR1*, *HLA-DRB1*01* and *HLA-DRB1*0101*; *HLA-DR3* and *HLA-DRB1*03*; *HLA-DR7* and *HLA-DRB1*07*; *HLA-DR8* and *HLA-DRB1*08*; and *HLA-DR9*, *HLA-DRB1*09* and *HLA-DRB1*0901*. Collapsing other HLA variants was not possible because some studies investigated multiple, closely related, HLA variants in the same patients. If these HLA variants had been collapsed, the same patients would have been included in the same analysis multiple times, increasing their weight in the analysis and introducing a systematic error. To determine whether the disease subtypes within AAV represent parts of a single disease spectrum or distinct clinical entities, we performed pre-specified subgroup analysis stratifying patients according to clinical diagnosis (GPA/MPA) and ANCA serotype (PR3-ANCA/MPO-ANCA and cytoplasmic (c)-ANCA/perinuclear (p)-ANCA), if enough data were available. Moreover, we performed stratified analyses based on ethnicity for all genetic variants investigated in both Caucasian and Asian patients. We assumed difference in effect estimates likely to be present in case subgroups showed significant effects in opposite directions, that is, having a protective effect in one subgroup but leading to an increased risk of AAV in the other subgroup. Heterogeneity within studies was displayed by I^2 , which reflects the percentage of total variation across studies beyond chance.²⁶ Egger and Harbord tests were used to assess publication bias.²⁷ All of the p values presented are nominal p values and are not corrected for multiple testing. Correction for multiple testing was not performed as the strong linkage disequilibrium between variants tested in the major histocompatibility complex (MHC) region makes calculating an appropriate multiple correction factor impractical. All analyses were performed using STATA V.12 (StataCorp. 2011; Stata Statistical Software: Release 12, College Station, Texas, USA).

Results

Initial search and results

Our literature search yielded 5180 articles, from which we identified 140 genetic variants published in 62 articles. All included studies were case-control studies, two of which were GWAS. These articles were published from 1978 through 2014, and the number of patients with AAV included ranged from 12 to 1445. The characteristics of all included studies are provided in supplementary table S2. Additionally, previously unpublished data from the Lyons *et al*¹⁵ GWAS were available and included in the meta-analysis for 18 genetic variants: *CD226* rs763361, *CTLA-4* rs231775, *CTLA-4* rs3087243, *FCAR* rs16986050, *FCGR2A* rs1801274, *GHSR* rs509035, *HLA-DPB2* rs3130215, *IL1 β* rs1143634, *IL6* rs1800795, *IL10* rs1800896, *IRF5* rs10954213, *PTPN22* rs2476601, *RING1/RXR β*

rs213213, *RXRB* rs6531, *RXRB* rs9277935, *STAT4* rs7574865, *SERPINA1* Z allele and *TNFA* rs1800629.

Thirty-three genetic variants were significantly associated with AAV after meta-analysis (table 1 and supplementary figure S1), and 107 genetic variants were not associated with AAV after meta-analysis (supplementary table S3). The ORs for the significant associations after meta-analysis ranged from 0.35 to 0.81 for protective genetic variants and from 1.13 to 2.94 for the genetic variants associated with an increased risk of AAV.

AAV is associated with the Z and S alleles of SERPINA1

Both the S allele and Z allele of *SERPINA1* were significantly associated with AAV, with pooled ORs of 1.30 (95% CI 1.03 to 1.63) and 2.94 (95% CI 2.22 to 3.88), respectively. Subgroup analysis showed that the association with the *SERPINA1* Z allele was present in both PR3-ANCA (pooled OR 2.58 (95% CI 1.57 to 4.25)) and MPO-ANCA (pooled OR 2.01 (95% CI 1.04 to 3.87)) positive patients and in both c-ANCA (pooled OR 3.53 (95% CI 2.28 to 5.49)) and p-ANCA (pooled OR 3.13 (95% CI 1.21 to 8.13)) positive patients (supplementary table S4 and figure S2).

AAV is associated with genetic variants in the MHC region

Seventeen genetic variants in *HLA-B*, *HLA-DP*, *HLA-DQ* and *HLA-DR* remained significantly associated with AAV after meta-analysis (table 1). *HLA-DPA1* rs9277341 had the strongest protective effect (pooled OR 0.35 (95% CI 0.30 to 0.40)), and *HLA-DPBI*0401* was the strongest contributor to an increased risk of AAV (pooled OR 1.99 (95% CI 1.44 to 2.74)). *RING1/RXRB* rs213213, *RXRB* rs6531 and *RXRB* rs9277935 were also significantly associated with AAV with pooled ORs of 1.71 (95% CI 1.57 to 1.86), 1.63 (95% CI 1.50 to 1.77) and 0.44 (95% CI 0.37 to 0.50), respectively.

AAV is associated with genetic variants involved in inflammatory processes

CTLA-4 rs231775 was associated with an increased risk of AAV (pooled OR of 1.16 (95% CI 1.06 to 1.28)) while *CTLA-4* rs3087243 and *CTLA-4* (AT)₈₆ had a protective effect (pooled ORs of 0.81 (95% CI 0.75 to 0.87) and 0.54 (95% CI 0.43 to 0.67), respectively). *PTPN22* rs2476601, *CD226* rs763361 and *IRF5* rs10954213 were also significantly associated with AAV, with pooled ORs of 1.39 (95% CI 1.24 to 1.56), 1.14 (95% CI 1.07 to 1.21) and 0.77 (95% CI 0.70 to 0.83), respectively. Moreover, *TLR9* rs352162 and rs352140 were significantly associated with AAV with pooled ORs of 1.58 (95% CI 1.43 to 1.75) and 1.13 (95% CI 1.02 to 1.25), respectively.

Table 1. Genetic variants significantly associated with AAV after meta-analysis

Variant by gene (minor allele)	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis	I ² (%)	P value for heterogeneity	P value for funnel plot asymmetry ^a
CD226 rs763361 (T)	3	2422/17898	1.14 (1.07 – 1.21)	<0.001	0	0.444	0.792
CTLA-4 (AT) ₈₆	4	303/543	0.54 (0.43 – 0.67)	<0.001	89	<0.001	0.946
CTLA-4 rs231775 (G)	3	1002/6179	1.16 (1.06 – 1.28)	0.002	60	0.080	0.080
CTLA-4 rs3087243 (A)	3	2015/7855	0.81 (0.75 – 0.87)	<0.001	25	0.262	0.122
FCGR2A rs1801274 (C)	6	1239/6209	0.90 (0.82 – 0.99)	0.028	0	0.834	0.788
HLA-B5	2	335/6573	0.59 (0.38 – 0.92)	0.019	0	0.432	N/A
HLA-B8	6	475/7855	1.48 (1.04 – 2.11)	0.028	47	0.096	0.063
HLA-DPA1 rs9277341 (C)	2	1032/2200	0.35 (0.30 – 0.40)	<0.001	54	0.116	0.215
HLA-DPB1*0301	5	1154/1337	0.38 (0.21 – 0.69)	0.002	78	<0.001	0.938
HLA-DPB1*0401	5	1154/1337	1.99 (1.44 – 2.74)	<0.001	84	<0.001	0.738
HLA-DPB2 rs3130215 (A)	3	1417/7249	1.40 (1.29 – 1.52)	<0.001	99	<0.001	0.446
HLA-DQB1*0303	3	176/218	1.82 (1.09 – 3.03)	0.021	17	0.301	0.916
HLA-DR6	5	487/6222	0.50 (0.27 – 0.95)	0.033	55	0.062	0.997
HLA-DRB1*101	2	268/465	1.89 (1.15 – 3.08)	0.011	0	0.487	N/A
HLA-DRB1*1201	2	216/465	0.37 (0.15 – 0.91)	0.031	0	0.491	N/A
HLA-DRB1*13	4	233/833	0.47 (0.32 – 0.70)	<0.001	0	0.504	0.884
HLA-DRB1*14	4	322/862	1.91 (1.07 – 3.42)	0.029	0	0.728	0.700
HLA-DRB1*15	3	236/633	1.86 (1.39 – 2.50)	<0.001	69	0.021	0.347
HLA-DRB1*1501	2	216/465	1.68 (1.20 – 2.34)	0.002	0	0.925	N/A
HLA-DRB3	4	260/1845	0.62 (0.49 – 0.79)	<0.001	68	0.024	0.689
HLA-DRB4	4	260/1845	1.69 (1.36 – 2.10)	<0.001	61	0.055	0.533

Table 1. Genetic variants significantly associated with AAV after meta-analysis (Continued)

Variant by gene (minor allele)	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis	I ² (%)	P value for heterogeneity	P value for funnel plot asymmetry ^a
<i>HSD17B8</i> rs421446 (C)	2	738/1872	0.40 (0.34 – 0.48)	<0.001	0	0.620	N/A
<i>IRF5</i> rs10954213 (G)	3	1535/6977	0.77 (0.70 – 0.83)	<0.001	99	<0.001	0.948
<i>PTPN22</i> rs2476601 (A)	4	2099/8678	1.39 (1.24 – 1.56)	<0.001	0	0.693	0.500
<i>RING1/RXRB</i> rs213213 (A)	3	1414/7238	1.71 (1.57 – 1.86)	<0.001	73	0.026	0.187
<i>RXRB</i> rs6531 (C)	3	1557/6955	1.63 (1.50 – 1.77)	<0.001	96	<0.001	0.292
<i>RXRB</i> rs9277935 (T)	3	1417/7233	0.44 (0.37 – 0.50)	<0.001	73	0.025	0.393
<i>SERPINA1</i> S allele	5	1474/5762	1.30 (1.03 – 1.63)	0.025	0	0.464	0.547
<i>SERPINA1</i> Z allele	8	3662/8581	2.94 (2.22 – 3.88)	<0.001	41	0.092	0.078
<i>STAT4</i> rs7574865 (T)	3	1520/6956	1.11 (1.01 – 1.22)	0.029	3	0.357	0.590
<i>TLR9</i> rs352162 (T)	1	1289/1898	1.58 (1.43 – 1.75)	<0.001	96	<0.001	N/A
<i>TLR9</i> rs352140 (T)	1	1289/1898	1.13 (1.02 – 1.25)	0.018	0	0.432	N/A
<i>TLR9</i> rs352139 (T)	1	1289/1898	1.11 (1.00 – 1.23)	0.041	0	0.756	N/A

^a Harbord test for funnel plot asymmetry was performed for all genetic variants, except for *CD226* rs763361, *CTLA-4* rs3087243, and *PTPN22* rs2476601. In these cases the Harbord test was not applicable and the Egger test was performed.

Genetic associations differ for the different diagnostic and serological subtypes of AAV

A significant association with GPA and /or MPA was present for 25 genetic variants, and a significant association with both GPA and MPA was present for ten genetic variants (supplementary table S4 and figure S2). In six of these ten genetic variants (60%), the associations were in opposite directions, that is, having a protective effect in one subgroup but leading to an increased risk of AAV in the other subgroup (figure 1). A significant association with PR3-ANCA and/or MPO-ANCA was present for 25 genetic variants, and a genetic association with both PR3-ANCA and MPO-ANCA was present for seven genetic variants. In four of these seven genetic variants (57%), the associations were in opposite directions, that is, having a protective effect in one subgroup but leading to an increased risk of AAV in the other subgroup (figure 1). Moreover, ORs were higher for ANCA serotype than for clinical diagnosis in 76% (16/21) of the genetic variants that were significantly associated with both clinical diagnosis and ANCA serotype.


Genetic associations differ for AAV patients of Caucasian and Asian origin

The results of the stratified analyses performed for 42 variants investigated in both Caucasian and Asian patients are depicted in supplementary table S5. CTLA-4 (AT)₈₆, CTLA-4 (AT)₁₀₆ and HLA-DR6 were significantly associated with AAV in the Caucasian patients but not in the Asian patients. Conversely, HLA-B55 was significantly associated with AAV in the Asian patients but not in the caucasian patients. Of interest, IRF5 rs10954213 (G) was significantly associated with AAV in both the Caucasian and Asian patients; however, it had a protective effect in the Caucasian patients while it increased the risk of AAV in the Asian patients. The results of these analyses should be interpreted with caution, because each analysis included only one study involving Asian patients.

Genetic variants identified by GWAS

To date, two GWAS have been performed in AAV. The first GWAS included patients with GPA and MPA and found HLA-DP rs3117242, COL11A2 rs3130233, COL11A2 rs3117016 and SERPINA1 rs7151526 to be associated with AAV.¹⁵ Moreover, HLA-DP rs3117242, ARHGAP18 rs1705767 and SERPINA1 rs7151526 were associated with PR3-ANCA vasculitis, and HLA-DQ rs5000634 was associated with MPO-ANCA vasculitis. The second GWAS included only patients with GPA and found HLA-DPB1 rs9277554 and HL-DPA1 rs9277341 to be associated with GPA.¹⁶ SEMA6A rs26595 was associated with GPA at a genome-wide significance level when the results of the two cohorts that were included in this GWAS were combined. However, although SEMA6A rs26595 was not genotyped in the first GWAS,¹⁵ data for a large number of proxy SNPs

Figure 1. Subgroup analysis based on clinical diagnosis (A) and antineutrophil cytoplasmic antibody (ANCA) serotype (B), with the clinical diagnosis (A) or ANCA serotype (B) and number of included publications depicted between the parentheses.



(A) In 6 of the 10 genetic variants (60%) in which there was an association with both granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), the associations were in opposite directions. (B) In four of the seven genetic variants (57%) in which there was an association with both proteinase 3 (PR3)-ANCA vasculitis and myeloperoxidase (MPO)-ANCA vasculitis, the associations were in opposite directions.

across this locus were available, and these did not reach statistical significance (data not shown).

Discussion

This meta-analysis identified 33 genetic variants, in or near 15 genes, associated with AAV. Twenty of these 33 genetic variants were present in the MHC region. This study provides the first complete and comprehensive overview including all genetic variants investigated in AAV in at least two studies. Genetic variants in or near *CD226*, *CTLA-4*, *FCGR2A*, *HLA-B*, *HLA-DP*, *HLA-DQ*, *HLA-DR*, *HSD17B8*, *IRF5*, *PTPN22*, *RING1/RXRB*, *RXRB*, *STAT4*, *SERPINA1* and *TLR9* were associated with AAV in this meta-analysis. Of interest, *FCGR2A* and *STAT4* were not associated with AAV in the individual studies, but were significantly associated with AAV after meta-analysis. Moreover, we showed genetic distinctions between the clinical diagnoses GPA and MPA and between the ANCA serotypes PR3-ANCA and MPO-ANCA. Additionally, our results confirm that subdivision of AAV based on ANCA serotype has a stronger genetic basis than subdivision based on clinical diagnosis.

A number of the genetic variants associated with AAV in this meta-analysis have also been associated with other autoimmune diseases, such as *CTLA-4* rs3087243 in rheumatoid arthritis^{28,29} and type 1 diabetes^{30,31} and *PTPN22* rs2476601 in Crohn's disease,³²⁻³⁴ Behçet's disease,³⁵ systemic lupus erythematosus³⁶⁻³⁸ and giant cell arteritis.^{39,40} These findings are in line with the fact that first-degree relatives of patients with AAV have an increased risk of other autoimmune diseases.^{41, 42} Overlapping genetic variants may form the basis of a disturbed immune system, and together with environmental factors and other, more distinct genetic factors, form a 'bad hand of cards' that leads to the development of AAV.

The results of this meta-analysis support a role for the intricate relationship among alpha-1-antitrypsin and ANCA, the MHC system and other inflammatory processes in the pathogenesis of AAV. The association between *SERPINA1* and AAV supports the concept that ANCA are important in AAV pathogenesis. Alpha-1-antitrypsin is coded by *SERPINA1* and is a major inhibitor of PR3. It has been hypothesised that lower levels of alpha-1-antitrypsin, resulting from the presence of the Z and S alleles of *SERPINA1*, lead to increased levels of circulating PR3 and possibly trigger the synthesis of anti-PR3-ANCA.⁴³ This hypothesis implies that the association of AAV with alpha-1-antitrypsin deficiency is restricted to PR3-ANCA positive patients; however, in this meta-analysis, the association between the Z allele of *SERPINA1* was present in both PR3-ANCA-positive and MPO-ANCA-positive patients and in both c-ANCA-positive and p-ANCA-positive patients. Another hypothesis is that patients with AAV and alpha-1-antitrypsin

deficiency have a reduced ability to bind PR3 released by previously activated neutrophils, thus promoting PR3-mediated proteolytic vessel damage.

As noted, 20 genetic variants in the MHC region were associated with AAV in this meta-analysis. We, therefore, confirm an important role for the MHC region, but because of linkage disequilibrium, were unable to determine the nature of this association, that is, whether it represents single or multiple independent associations. Both GWAS showed that the SNP association signal in the MHC region was fully accounted for by *HLA-DPBI*, dramatically diminishing the associations of other SNPs in this region.^{15, 16} The results of our meta-analysis also support a role for other inflammatory processes in the pathogenesis of AAV, with the associations with *CTLA-4* and *PTPN22* suggesting a role for a threshold of activation or suppression of T cells.

The different subtypes generally grouped under the umbrella term AAV have profound differences in ANCA specificities³ and clinical outcomes.⁴ The results of this meta-analysis indicate that these different AAV subtypes also have distinct genetic backgrounds, as previously shown in a GWAS.¹⁵ Moreover, we found significant associations in opposite directions for the different AAV subgroups. Significant associations of the same SNP in opposite directions for different types of autoimmune diseases have been described before and could be indicative of different mechanisms of disease.⁴⁴ Larger studies are required to investigate this issue further in AAV.

The subdivision of AAV based on ANCA serotype had the stronger genetic basis in our meta-analysis; in 76% of the genetic variants, subdivision based on ANCA serotype resulted in higher ORs than subdivision based on clinical diagnosis. The results of these analyses should, however, be interpreted with caution because of the limited number of studies included in some of the analyses and need to be validated in other studies. Although until now the concept of a single disease spectrum has resulted in similar treatment strategies in patients with AAV, our limited results suggest that syndrome-specific therapeutics based on ANCA serotype strategies may be considered.

Our study has some limitations. First, in some of our analyses, the number of subjects or studies was limited; this limitation was especially the case in the subgroup analyses. Second, publication bias is an issue of concern in all meta-analyses. Authors might omit non-significant genetic associations and report only those associations that reach statistical significance. However, none of the tests performed to assess funnel plot asymmetry in this meta-analysis were significant. Furthermore, the studies included in this meta-analysis show heterogeneity with respect to clinical diagnosis, ANCA serotype, disease characteristics, ethnicity and study design. The clinical heterogeneity was accompanied by statistical heterogeneity for 16 of the 140 included genetic variants. However, there is no fully accepted statistical measure that precisely determines clinical heterogeneity.²⁷ To account for heterogeneity, random-effects models were

performed where possible.²⁵ Nevertheless, estimates reported in this study should be interpreted with caution, especially when statistical heterogeneity was present or when a small number of studies and/or relatively small groups of participants were included. Finally, it should be kept in mind that the genetic associations identified do not imply causality. While they provide insight into pathogenicity and suggest the involvement of certain pathways, these may not represent therapeutic targets.

In summary, this meta-analysis identified 33 genetic variants, in or near 15 genes, associated with AAV. Moreover, we showed genetic distinctions among the different AAV subtypes, supporting the concept that these subtypes may represent distinct autoimmune syndromes. These subtypes are most likely driven by ANCA serotype and not by clinical diagnosis.

References

1. Berden A, Goceroğlu A, Jayne D, *et al.* Diagnosis and management of ANCA associated vasculitis. *BMJ* 2012;344:e26.
2. Sable-Fourtassou R, Cohen P, Mahr A, *et al.* Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. *Ann Intern Med* 2005;143:632–8.
3. Hagen EC, Daha MR, Hermans J, *et al.* Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. *Kidney Int* 1998;53:743–53.
4. Mukhtyar C, Flossmann O, Hellmich B, *et al.* Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. *Ann Rheum Dis* 2008;67:1004–10.
5. Hogan SL, Falk RJ, Nachman PH, *et al.* Various forms of life in antineutrophil cytoplasmic antibody-associated vasculitis. *Ann Intern Med* 2006;144:377–8; author reply 8–9.
6. Hoffman GS, Langford CA. Are there different forms of life in the antineutrophil cytoplasmic antibody universe? *Ann Intern Med* 2005;143:683–5.
7. Linder R, Orth I, Hagen EC, *et al.* Differentiation between Wegener's granulomatosis and microscopic polyangiitis by an artificial neural network and by traditional methods. *J Rheumatol* 2011;38:1039–47.
8. Jayne D, Rasmussen N, Andrassy K, *et al.* A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. *N Engl J Med* 2003;349:36–44.
9. Jones RB, Tervaert JW, Hauser T, *et al.* Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. *N Engl J Med* 2010;363:211–20.
10. Stone JH, Merkel PA, Spiera R, *et al.* Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med* 2010;363:221–32.
11. Monach PA, Merkel PA. Genetics of vasculitis. *Curr Opin Rheumatol* 2010;22:157–63.
12. de Lind van Wijngaarden RA, van Rijn L, Hagen EC, *et al.* Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known. *Clin J Am Soc Nephrol* 2008;3:237–52.
13. Piram M, Maldini C, Mahr A. Effect of race/ethnicity on risk, presentation and course of connective tissue diseases and primary systemic vasculitides. *Curr Opin Rheumatol* 2012;24:193–200.
14. Knight A, Sandin S, Askling J. Risks and relative risks of Wegener's granulomatosis among close relatives of patients with the disease. *Arthritis Rheum* 2008;58:302–7.
15. Lyons PA, Rayner TF, Trivedi S, *et al.* Genetically distinct subsets within ANCA-associated vasculitis. *N Engl J Med* 2012;367:214–23.
16. Xie G, Roshandel D, Sherva R, *et al.* Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. *Arthritis Rheum* 2013;65:2457–68.
17. Ioannidis JP, Ntzani EE, Trikalinos TA, *et al.* Replication validity of genetic association studies. *Nat Genet* 2001;29:306–9.
18. Wacholder S, Chanock S, Garcia-Closas M, *et al.* Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. *J Natl Cancer Inst* 2004;96:434–42.
19. Jennette JC, Falk RJ, Andrassy K, *et al.* Nomenclature of systemic vasculitides. Proposal

- of an international consensus conference. *Arthritis Rheum* 1994;37:187–92.
20. Leavitt RY, Fauci AS, Bloch DA, *et al.* The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. *Arthritis Rheum* 1990;33:1101–7.
21. Watts R, Lane S, Hanslik T, *et al.* Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. *Ann Rheum Dis* 2007;66:222–7.
22. Tsuchiya N, Kobayashi S, Kawasaki A, *et al.* Genetic background of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: association of HLA-DRB1*0901 with microscopic polyangiitis. *J Rheumatol* 2003;30:1534–40.
23. Wiczorek S, Holle JU, Bremer JP, *et al.* Contrasting association of a non-synonymous leptin receptor gene polymorphism with Wegener's granulomatosis and Churg-Strauss syndrome. *Rheumatology (Oxford)* 2010;49:907–14.
24. Husmann CA, Holle JU, Moosig F, *et al.* Genetics of toll like receptor 9 in ANCA associated vasculitides. *Ann Rheum Dis* 2014;73:890–6.
25. Borenstein M, Hedges LV, Higgins JTH, *et al.* A basic introduction to fixed-effect and random-effects models for meta-analysis. *Res Synth Methods* 2010;1:97–111.
26. Higgins JP, Thompson SG, Deeks JJ, *et al.* Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.
27. Egger M, Davey Smith G, Schneider M, *et al.* Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.
28. Kurreeman F, Liao K, Chibnik L, *et al.* Genetic basis of autoantibody positive and negative rheumatoid arthritis risk in a multi-ethnic cohort derived from electronic health records. *Am J Hum Genet* 2011;88:57–69.
29. Stahl EA, Raychaudhuri S, Remmers EF, *et al.* Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. *Nat Genet* 2010;42:508–14.
30. Barrett JC, Clayton DG, Concannon P, *et al.* Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. *Nat Genet* 2009;41:703–7.
31. Todd JA, Walker NM, Cooper JD, *et al.* Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. *Nat Genet* 2007;39:857–64.
32. Barrett JC, Hansoul S, Nicolae DL, *et al.* Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. *Nat Genet* 2008;40:955–62.
33. Franke A, McGovern DP, Barrett JC, *et al.* Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. *Nat Genet* 2010;42:1118–25.
34. Anderson CA, Massey DC, Barrett JC, *et al.* Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship. *Gastroenterology* 2009;136:523–9.e3.
35. Baranathan V, Stanford MR, Vaughan RW, *et al.* The association of the PTPN22 620W polymorphism with Behcet's disease. *Ann Rheum Dis* 2007;66: 1531–3.
36. Gateva V, Sandling JK, Hom G, *et al.* A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. *Nat Genet* 2009;41:1228–33.
37. Graham RR, Hom G, Ortmann W, *et al.* Review of recent genome-wide association scans in lupus. *J Intern Med* 2009;265:680–8.

38. Harley JB, Alarcon-Riquelme ME, Criswell LA, *et al.*, International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN). Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXX1, KIAA1542 and other loci. *Nat Genet* 2008;40:204–10.
39. Serrano A, Marquez A, Mackie SL, *et al.* Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis. *Ann Rheum Dis* 2013;72:1882–6.
40. Carmona FD, Mackie SL, Martin JE, *et al.* A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. *Am J Hum Genet* 2015;96:565–80.
41. Hemminki K, Li X, Sundquist J, *et al.* Familial associations of rheumatoid arthritis with autoimmune diseases and related conditions. *Arthritis Rheum* 2009;60: 661–8.
42. Knight A, Sandin S, Askling J. Increased risk of autoimmune disease in families with Wegener's granulomatosis. *J Rheumatol* 2010;37:2553–8.
43. Segelmark M, Elzouki AN, Wieslander J, *et al.* The PiZ gene of alpha 1-antitrypsin as a determinant of outcome in PR3-ANCA-positive vasculitis. *Kidney Int* 1995;48:844–50.
44. Sirota M, Schaub MA, Batzoglu S, *et al.* Autoimmune disease classification by inverse association with SNP alleles. *PLoS Genet* 2009;5:e1000792. 1692

Chapter III

Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials.

C. Rahmattulla, R.A. de Lind van Wijngaarden, A.E Berden, H.A. Hauer, O. Floßmann, D.R. Jayne, G. Gaskin, N. Rasmussen, L.H. Noël LH, F. Ferrario F, R. Waldherr, R. Wolterbeek, A. Göçeroğlu, C.D. Pusey, E.C. Hagen, J.A. Bruijn, I.M. Bajema IM & European Vasculitis Study Group (EUVAS)

Rheumatology (Oxford). 2015:899-907

Abstract

Objective

We investigated whether ENT involvement is associated with renal biopsy findings and renal function in patients with ANCA-associated vasculitis (AAV).

Methods

Newly diagnosed AAV patients derived from three international, multicentre trials were included. To investigate an association between ENT involvement and estimated glomerular filtration rate (eGFR) at diagnosis and 5-year follow-up, we performed multivariable regression analyses including clinical and histopathological parameters. To investigate whether our findings are specific to ENT involvement, we performed comparable analyses between eGFR and other early disease manifestations (arthralgia/arthritis, cutaneous and lung involvement).

Results

One hundred and eighty-five of the 414 patients had ENT involvement. The mean presenting eGFR of patients with and without ENT involvement was 39.16 and 23.88 ml/min/1.73m², respectively ($P < 0.001$). Mean eGFR increased by 6.76 ml/min/1.73m² with each added ENT symptom ($P = 0.007$). Patients with ENT involvement had less interstitial fibrosis and tubular atrophy and a prognostically more favourable histopathological class on renal biopsy examination. Multivariable regression analyses correcting for clinical and histopathological parameters showed that ENT involvement is associated with both baseline and 5-year follow-up eGFR. There were no associations between baseline and 5-year follow-up eGFR and arthralgia/arthritis, cutaneous or lung involvement, suggesting that our findings are specific to ENT involvement.

Conclusion

The presence of ENT involvement in AAV patients is associated with prognostically favourable renal biopsy findings and better renal function. These results indicate that there may be different phenotypes of AAV defined by ENT involvement.

Introduction

Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are the major clinical subtypes of ANCA-associated vasculitis (AAV)¹. Establishing an early diagnosis of AAV is complicated by the diversity and lack of specificity of symptoms AAV patients present with, introducing both patient and doctor delay². To what extent clinical outcome of AAV depends on early recognition of the disease is largely unknown; however, it seems likely that early diagnosis and treatment can prevent progressive organ damage, particularly the occurrence of end-stage renal disease (ESRD).

The presence of ENT involvement may be an early sign of AAV³. ENT involvement occurs in ~53% of AAV patients⁴ and is reflected in symptoms such as hearing loss, otalgia, (bloody) rhinorrhoea, otorrhoea, sinusitis, nasal crusting and recurrent otitis media². The presence of ENT involvement is closely associated with the presence of PR3-ANCA and is observed much less often in MPO-ANCA-positive patients.

Approximately 80% of AAV patients will develop renal involvement during their disease course⁵⁻⁷, which in a considerable proportion of patients will lead to ESRD and/or death⁸⁻¹⁰. Previously we found that patients with MPO-ANCA have more chronic lesions in their renal biopsy than patients with PR3-ANCA, which may reflect the association of a more smouldering disease with MPO-ANCA and a more active disease with PR3-ANCA³.

Recent data from a genome-wide association study (GWAS) indicate that within AAV, distinct subtypes may be recognized¹¹. Positivity for either MPO-ANCA or PR3-ANCA was found to be the most important indicator of these subtypes, supporting the hypothesis that PR3-ANCA vasculitis and MPO-ANCA vasculitis are distinct autoimmune syndromes.

The diagnosis of AAV is based on a combination of clinical symptoms, ANCA serology and histological findings. This combination of findings may also form the basis for a patient profile with respect to outcome and may be representative of certain distinct AAV phenotypes^{12,13}. One factor of interest is the presence or absence of ENT involvement, because the absence of ENT involvement has been shown to increase mortality risk in AAV patients¹⁴⁻¹⁹. In this study we focused on ENT involvement in AAV patients in relation to renal biopsy findings and renal outcome. In addition, we performed a subgroup analysis based on ANCA serotype, because of the well-known association of ENT disease and PR3-ANCA. We hypothesized that ENT involvement in AAV is associated with fewer chronic lesions in the renal biopsy and better renal outcome.

Methods

Study population and clinical parameters

Patients were recruited from 62 hospitals located in 15 countries. All patients were enrolled in three international, prospective multicentre trials conducted by the European Vasculitis Society (EUVAS): CYCAZAREM (Cyclophosphamide Versus Azathioprine During Remission For Generalised Vasculitis), CYCLOPS (Daily Oral Versus Pulse Cyclophosphamide During The Induction Phase For Generalised Vasculitis) and MEPEX (Plasma Exchange Versus Methylprednisolone For Severe Renal Vasculitis)²⁰⁻²². Inclusion and exclusion criteria for all trials are described elsewhere²⁰⁻²². Local research ethics committees approved the studies and all patients provided informed consent. All trials were performed in accordance with the Declaration of Helsinki. Disease definitions were adopted from the 1994 Chapel Hill Consensus Conference²³ and previous European Union studies^{24, 25}. All patients had been newly diagnosed as having GPA or MPA as determined by local physicians. Only patients with generalized AAV and available BVAS data were included in this study²⁶. The four-variable Modification of Diet in Renal Disease was used to determine the estimated glomerular filtration rate (eGFR) in all patients, including the patients with ESRD²⁷.

ENT involvement was assessed at trial entry and was defined as present if patients had at least one of the ENT items scored using the BVAS. These items included nasal obstruction, bloody nasal discharge, nasal crusts, sinus involvement, conductive hearing loss, sensorineural hearing loss, hoarseness/stridor, granulomatous sinusitis and subglottic inflammation²⁶. When ENT involvement was suspected, this was confirmed by local ENT specialists.

To assess whether associations with renal function are related to ENT involvement or are confounded by reduced diagnostic delay in patients with ENT symptoms, we did comparative analyses investigating associations between eGFR and other organ manifestations that are likely to reduce diagnostic delay in a similar fashion, specifically looking at cutaneous involvement, lung involvement and arthralgia/arthritis as scored by the BVAS. Cutaneous involvement included cutaneous infarcts, purpura, other skin vasculitis, ulcers, gangrene and multidigit gangrene²⁶. Lung involvement included persistent cough, dyspnoea or wheeze, haemoptysis/haemorrhage, massive haemoptysis, respiratory failure and nodules or cavities, pleural effusion/pleurosis or infiltrate on chest radiology²⁶.

Histopathological parameters

Paraffin sections of diagnostic renal biopsies stained with silver, periodic acid-Schiff, haematoxylin and eosin and trichrome were examined. Sections were reviewed by two of five participating pathologists (I.M.B., F.F., L.H.N., R.W. or J.A.B.). Both pathologists, blinded to patient data and the other observer's results, scored the biopsies separately and according to a previously standardized protocol

and the histopathological classification of ANCA-associated glomerulonephritis (AAGN)²⁸⁻³⁰. Discrepancies between observers were resolved during central reviews to achieve consensus for each biopsy.

A predefined set of histopathological parameters, including interstitial fibrosis and tubular atrophy (IFTA), interstitial infiltrate, tubulitis and histopathological class, were included in multivariable analyses. In analyses including the histopathological classification, only biopsies containing a minimum of seven whole glomeruli were included.

Statistical analysis

Student's *t*-test was used to investigate an association between baseline and 5-year follow-up eGFR and overall ENT involvement. Student's *t*-test was also used to investigate an association between baseline eGFR and individual BVAS ENT subitems. A chi-squared test was used to investigate the association between ANCA subtype and the distribution of ENT symptoms. A chi-squared test for trend (linear-by-linear association) was used to investigate the association between histological parameters and ENT involvement. Linear regression analysis was used to explore the relationship between the number of ENT symptoms and eGFR at presentation. A quadratic term analysis was not significant, therefore a linear model was considered appropriate for this analysis. Seven patients were positive for five ENT symptoms, but because including these patients violated the linearity of the model, these patients were excluded from the analysis.

Correlations of ENT involvement, age, PR3-ANCA, tubulitis, interstitial infiltrate, IFTA and histopathological class according to the AAGN classification with baseline and 5-year follow-up eGFR were assessed using Pearson's or Spearman's correlation test as appropriate. Along with ENT involvement, the following entry parameters were selected for inclusion in the multivariable model investigating baseline eGFR: age, PR3-ANCA, IFTA, tubulitis, interstitial infiltrate and histopathological class according to the AAGN classification. ENT involvement, age, PR3-ANCA, IFTA, tubulitis, interstitial infiltrate and protocolized treatment received during the trial period were included in a model investigating 5-year follow-up eGFR. Histopathological class was not included in this model, as including this parameter strongly reduced the number of patients that could be included in the analysis. Analysis of covariance (ANCOVA) investigating 5-year follow-up eGFR was performed by including baseline eGFR in the model. In prespecified sensitivity analyses, the same models were used to investigate the effect of ENT involvement on baseline and 5-year follow-up eGFR in patients only positive for PR3-ANCA. Multicollinearity statistics demonstrated no multicollinearity in the multivariable regression analyses performed, indicating that it was legitimate to perform these analyses. We did not include diagnosis (GPA or MPA) in the analyses, as diagnosis is often dependent on ENT involvement (patients with ENT involvement are often diagnosed as GPA

and patients without ENT involvement are often diagnosed as MPA). Correcting for diagnosis would mask the effect of ENT involvement.

Since renal biopsies were not available for all patients, including the predefined histopathological parameters limited the number of patients included in the analysis. This was particularly true for histopathological class since biopsies needed to contain at least seven whole glomeruli. To be able to include all patients we therefore created three models. The first model included only clinical data: ENT involvement, age and PR3-ANCA. In the second model we added the following histopathological parameters: tubulitis, interstitial infiltrate and IFTA. The third model included all of the above parameters as well as the histopathological class.

To investigate whether possible associations with renal function are specific to ENT involvement and not confounded by reduced diagnostic delay in patients with ENT involvement, we performed comparable analyses between baseline and 5-year follow-up eGFR and other early disease manifestations - specifically arthralgia/ arthritis, cutaneous involvement and lung involvement.

A *P*-value of <0.05 was considered significant. All analyses were performed using SPSS version 20.0 (IBM, Armonk, NY, USA).

Results

Patients

A total of 414 patients with generalized AAV recruited from the CYCAZAREM²⁰, CYCLOPS²² and MEPEX²¹ trials were included in this study. All 149 patients from the CYCLOPS trial were included. From the CYCAZAREM and MEPEX trials, 149 of the 155 and 116 of the 137 patients were included, respectively. Exclusion of 27 patients was based on incomplete data about the presence or absence of ENT involvement. Diagnostic renal biopsies were obtained from 199 patients, of which 152 contained a minimum of seven whole glomeruli. Two patients did not have renal involvement at trial entry. Both patients were included in the CYCAZAREM trial because of other disease manifestations that were considered to be life-threatening. Baseline eGFR of these patients was 102 and 118 ml/min/1.73m².

ENT involvement

Of the 414 patients included in the study, 185 (45%) presented with ENT involvement. Detailed clinical data at baseline of patients with and without ENT involvement are provided in Table 1. ENT involvement was associated with higher eGFR, younger age, diagnosis of GPA and PR3-ANCA positivity. ENT symptoms as scored using the BVAS are outlined in supplementary Table S1. Nasal obstruction, bloody nasal discharge and nasal crusting were the most common

symptoms. In patients with ENT involvement, the distribution of symptoms was similar in PR3-ANCA and MPO-ANCA-positive patients (supplementary Table S2).

Table 1. Baseline characteristics of patients with and without ENT involvement


	ENT positive (n=185)	ENT negative (n=229)	P Value
eGFR, mL/min/1.73 m ² (±SD)	39.16 (±33.11)	23.88 (±20.05)	<0.001
Gender, male / female	111 / 74	122 / 107	0.17
Age, years (SD)	56.49 (14.90)	60.89 (12.87)	0.001
Diagnosis, n (%)			<0.001
Granulomatosis with polyangiitis	142 (77)	41 (18)	
Microscopic polyangiitis	43 (23)	188 (82)	
ANCA-subtype, n (%)			<0.001
PR3-ANCA	124 (67)	77 (34)	
MPO-ANCA	46 (25)	138 (61)	
Double positive	9 (5)	3 (1)	
Negative	6 (3)	9 (4)	
Trial, n (%)			0.22
CYCAZAREM	75 (40)	74 (32)	
CYCLOPS	49 (27)	67 (29)	
MEPEX	61 (33)	88 (39)	

ANCA-serotype data was available for 412 of the 414 patients. Patients with and without ENT involvement are referred to as ENT positive and ENT negative, respectively. ENT, ear-, nose-, and throat; eGFR, estimated glomerular filtration rate; ANCA, anti-neutrophil cytoplasm antibody; PR3, proteinase 3; MPO, myeloperoxidase.

ENT involvement and baseline eGFR

The mean baseline eGFR of patients with and without ENT involvement was 39.16 (S.D. 33.11) and 23.88 (S.D. 20.05) mL/min/1.73m², respectively. The presence of overall ENT involvement was associated with higher eGFR [$P < 0.001$ (95% CI 10.09, 20.46)]. Regarding specific ENT symptoms, the presence of nasal obstruction, bloody nasal discharge, nasal crusting, granulomatous sinusitis and conductive hearing loss was significantly associated with higher eGFR (supplementary Table S3). Moreover, the more ENT symptoms a patient had, the higher the eGFR was at presentation; average eGFR increased by 6.76 (95% CI 1.86-11.67) mL/min/1.73m² with each additional ENT symptom ($P = 0.007$; Fig. 1).

Figure 1. Increasing numbers of ENT symptoms are associated with increasing eGFR at diagnosis.



On average, eGFR increased 6.76 (95% CI 1.86 – 11.67) mL/min/1.73 m² with each additional ENT symptom ($p=0.007$). Data are presented as mean $\pm$ SEM. ENT, ear-, nose-, and throat; eGFR, estimated glomerular filtration rate.

ENT involvement and renal histology

The absence of IFTA in the renal biopsy was associated with ENT involvement ($P<0.001$; Table 2). Seventeen patients (20%) with ENT involvement had no IFTA in their renal biopsy, compared with four patients (4%) without ENT involvement. Nineteen patients (23%) with ENT involvement had severe IFTA in their renal biopsy, compared with 45 patients (39%) without ENT involvement. Furthermore, there was an association between histopathological class in the AAGN classification³⁰ and ENT involvement ($P = 0.04$; Table 2). Nineteen patients (30%) with ENT involvement had a focal class renal biopsy, compared with 16 patients (18%) without ENT involvement. Six patients (9%) with ENT involvement had a sclerotic class renal biopsy, compared with 13 patients (15%) without ENT involvement. Residuals analysis showed that the focal and sclerotic classes contributed most to the chi-square statistic.

Table 2. Histological variables in relation to ENT involvement

	ENT positive	ENT negative	P Value
IFTA, n (%)			< 0.001
None	17 (20)	4 (4)	
Focal interstitial fibrosis / small foci of tubular atrophy	48 (57)	66 (57)	
Diffuse interstitial fibrosis / extensive foci of tubular atrophy	19 (23)	45 (39)	
Histopathological classification of AAGN*, n (%)			0.04
Focal	19 (30)	16 (18)	
Crescentic	32 (50)	42 (48)	
Mixed	7 (11)	17 (19)	
Sclerotic	6 (9)	13 (15)	
Interstitial infiltrates**, n (%)			0.18
None	9 (11)	4 (3)	
Mild	32 (39)	48 (42)	
Moderate	32 (39)	45 (39)	
Severe	9 (11)	18 (16)	
Tubulitis, n (%)			
Absent	29 (34)	36 (31)	0.63
Present	55 (66)	79 (69)	

*Only biopsies with a minimum of seven whole glomeruli were included in this analysis (n=152).

**Data available for 197 patients. Renal biopsy specimens were available for 199 patients. Patients with and without ENT involvement are referred to as ENT positive and ENT negative, respectively. ENT, ear-, nose-, and throat; IFTA, interstitial fibrosis and tubular atrophy; AAGN, anti-neutrophil cytoplasm antibody-associated glomerulonephritis.

ENT involvement is associated with higher eGFR independently of PR3-ANCA

Univariate analyses showed a correlation between baseline eGFR and ENT involvement, age, PR3-ANCA, tubulitis, interstitial infiltrate, IFTA and histopathological class (supplementary Table S4). ENT involvement was independently associated with higher baseline renal function in all three multivariable linear regression models (Table 3; supplementary Table S5). In addition to ENT involvement, age, tubulitis, interstitial infiltrate, IFTA and histopathological class were independently associated with eGFR. In this model including ENT involvement, PR3-ANCA is not associated with eGFR. To investigate whether a strong association between ENT involvement and PR3-ANCA is the reason why PR3-ANCA is not associated with eGFR in this model, we conducted the multivariable model excluding ENT involvement. In this analysis, PR3-ANCA was not associated with eGFR (data not shown). Moreover,

we also performed a stratified analysis in which we started with ENT disease and then investigated the effect of ANCA specificity on eGFR in patients both with and without ENT involvement. In these analyses, PR3-ANCA was again not associated with eGFR (data not shown). Both findings contradict that an association between ENT involvement and PR3-ANCA is the reason why PR3-ANCA is not significantly associated with eGFR.

A prespecified subgroup analysis that included only PR3-ANCA-positive patients revealed that ENT involvement was also independently associated with baseline eGFR in this subgroup of patients. In addition to ENT involvement, age, tubulitis, interstitial infiltrate and histopathological class were independently associated with baseline eGFR (Table 3).

ENT involvement is associated with higher eGFR independently of GPA diagnosis

Because of the strong association between ENT involvement and GPA diagnosis, it was not possible to include both parameters in the same multivariable linear regression model. To investigate the possibility of ENT involvement being a surrogate for the GPA phenotype instead of being independently associated with eGFR, we therefore conducted the multivariable regression analysis including only GPA patients. ENT involvement was independently associated with baseline eGFR in this analysis (supplementary Table S6), indicating that ENT involvement is not a surrogate for the GPA phenotype but is associated with eGFR independently of GPA diagnosis. In addition to ENT involvement, age, interstitial infiltrate, IFTA and histopathological class were independently associated with eGFR. PR3-ANCA was not associated with eGFR.

ENT involvement and renal function at 5-year follow-up

Data on renal function at 5-year follow-up were available for 81 and 72 patients with and without ENT involvement, respectively. Univariate analyses showed a correlation between 5-year follow-up eGFR and ENT involvement, age, interstitial infiltrate, IFTA and histopathological class (supplementary Table S4). As shown in Fig. 2, eGFR increased in patients both with and without ENT involvement during follow-up. Patients with ENT involvement had a better eGFR at 5-year follow-up compared with patients without ENT involvement. Mean eGFR at 5-year follow-up was 54.58 (S.D. 25.43) and 44.02 (S.D. 20.01) ml/min/1.73m² in patients with and without ENT involvement, respectively ($P = 0.005$). Multivariate analysis showed that ENT involvement, age and IFTA were independently associated with eGFR at 5-year follow-up (Table 3). PR3-ANCA was not associated with 5-year follow-up eGFR. When adding baseline eGFR to the multivariate model, ENT involvement was no longer associated with 5-year follow-up eGFR (supplementary Table S7). This finding implies that ENT involvement is not associated with an accelerated increase in eGFR, but that


Table 3. Multivariable regression analyses investigating the relationship between ENT involvement and baseline and 5-year follow-up eGFR

	Model investigating baseline eGFR			Model investigating 5-year follow-up eGFR ^a			Model investigating baseline eGFR in PR3-ANCA-positive patients			Model investigating 5-year follow-up eGFR in PR3-ANCA-positive patients ^a		
	β (95% CI)	P Value		β (95% CI)	P Value		β (95% CI)	P Value		β (95% CI)	P Value	
ENT involvement	9.14 (2.30 – 15.98)	0.009		9.86 (2.23 – 17.50)	0.01		12.92 (2.11 – 23.72)	0.02		16.40 (5.58 – 27.22)	0.004	
Age	-0.60 (-0.83 – -0.36)	<0.001		-0.33 (-0.61 – -0.05)	0.02		-0.72 (-1.10 – -0.35)	<0.001		-0.17 (-0.54 – 0.21)	0.37	
PR3-ANCA	-1.26 (-8.28 – 5.75)	0.72		-6.22 (-14.31 – 1.87)	0.13		N/A	N/A		N/A	N/A	
Tubulitis	-17.82 (-25.78 – -9.86)	<0.001		-5.36 (-14.21 – 3.50)	0.23		-14.37 (-27.67 – -1.07)	0.04		-7.59 (-20.31 – 5.13)	0.24	
Interstitial infiltrate	-6.86 (-11.20 – -2.52)	0.002		-3.54 (-10.15 – 3.07)	0.29		-8.91 (-16.52 – -1.31)	0.02		-5.14 (-14.44 – 4.17)	0.27	
IFTA	-8.72 (-14.67 – -2.77)	0.004		-9.06 (-15.59 – -2.54)	0.007		-9.55 (-19.90 – 0.80)	0.07		-9.15 (-17.91 – -0.39)	0.04	
AAGN classification	-6.20 (-9.84 – -2.57)	0.001		N/A	N/A		-8.41 (-14.97 – -1.85)	0.01		N/A	N/A	

ENT involvement is associated with better eGFR at diagnosis and 5-year follow-up. A prespecified sensitivity analysis including only PR3-ANCA positive patients showed that this finding also held in this subgroup of patients. In all models, age is included per year unit. ^aModel is adjusted for within-trial therapy. 95% CI, 95% confidence interval; ENT, ear-, nose-, and throat; eGFR, estimated glomerular filtration rate; PR3-ANCA, anti-proteinase 3 anti-neutrophil cytoplasm antibody; IFTA, interstitial fibrosis and tubular atrophy; AAGN, anti-neutrophil cytoplasm antibody associated glomerulonephritis; N/A, not applicable.

patients with ENT involvement start with a higher presenting eGFR and preserve this advantage during the 5-year follow-up. A prespecified subgroup analysis including only PR3-ANCA-positive patients revealed that ENT involvement is also associated with 5-year follow-up eGFR in this subgroup of patients (Table 3). Also in this subgroup of PR3-ANCA-positive patients, ENT involvement is no longer associated with 5-year follow-up eGFR when adding baseline eGFR to the model (supplementary Table S7).

Figure 2. Patients with ENT involvement have significantly better eGFR at diagnosis and 5-year follow-up.



Data are presented as mean $\pm$ SEM. ENT, ear-, nose-, and throat; eGFR, estimated glomerular filtration rate.

Cutaneous involvement, arthralgia/arthritis and lung involvement are not associated with baseline and 5-year follow-up eGFR

To investigate whether the higher eGFR in patients with ENT involvement is specific for ENT involvement or is attributable to less diagnostic delay in these patients, we analysed the relationship between eGFR and cutaneous involvement, arthralgia/arthritis and lung involvement, as these symptoms are likewise expected to reduce diagnostic delay. Of the 414 included patients, 98 (24%) had cutaneous involvement, 162 (39%) had arthralgia/arthritis and 207 (50%) had lung involvement. Multivariable linear regression analyses demonstrated no association between cutaneous involvement, arthralgia/arthritis or lung involvement and baseline eGFR (Table 4; supplementary Table S8). In all three

Table 4. Multivariable regression analyses investigating the relationships between baseline eGFR and other early disease manifestations

	Cutaneous model		Arthralgia/arthritis model		Lung model	
	β (95% CI)	P Value	β (95% CI)	P Value	β (95% CI)	P Value
Cutaneous involvement	-2.98 (-11.58 – 5.62)	0.49	N/A	N/A	N/A	N/A
Arthralgia/arthritis	N/A	N/A	-4.85 (-11.40 – 1.71)	0.15	N/A	N/A
Lung involvement	N/A	N/A	N/A	N/A	-4.74 (-11.19 – 1.70)	0.15
Age	-0.63 (-0.87 – -0.38)	<0.001	-0.54 (-0.78 – -0.29)	<0.001	-0.61 (-0.85 – -0.37)	<0.001
PR3-ANCA	1.29 (-5.62 – 8.21)	0.71	0.41 (-6.52 – 7.33)	0.91	1.86 (-5.06 – 8.78)	0.60
Tubulitis	-16.54 (-24.62 – -8.47)	<0.001	-14.71 (-22.91 – -6.50)	0.01	-16.83 (-24.87 – -8.79)	<0.001
Interstitial infiltrate	-7.48 (-11.96 – -3.00)	0.001	-7.38 (-11.83 – -2.93)	0.001	-7.12 (-11.53 – -2.71)	0.002
IFTA	-9.57 (-15.62 – -3.51)	0.002	-9.92 (-16.01 – -3.83)	0.002	-9.97 (-15.97 – -3.97)	0.001
AAGN classification	-6.82 (-10.61 – -3.03)	0.001	-6.98 (-10.79 – -3.17)	<0.001	-6.79 (-10.49 – -3.09)	<0.001

To investigate whether our associations are specific to ENT involvement, analyses between baseline eGFR and other early disease manifestations were performed. There were no associations between baseline eGFR and cutaneous involvement, arthralgia/arthritis, or lung involvement. In all models, age is included per year unit. 95% CI, 95% confidence interval; eGFR, estimated glomerular filtration rate; PR3-ANCA, anti-proteinase 3 anti-neutrophil cytoplasm antibody; IFTA, interstitial fibrosis and tubular atrophy; AAGN, anti-neutrophil cytoplasm antibody associated glomerulonephritis; N/A, not applicable.

models, age, tubulitis, interstitial infiltrate, IFTA and histopathological class were associated with eGFR. Multivariable linear regression analyses also demonstrated no association between cutaneous involvement, lung involvement or arthralgia/arthritis and eGFR at 5-year follow-up (supplementary Table S9).

Discussion

Our study demonstrates that AAV patients with ENT involvement have a higher eGFR at diagnosis and 5-year follow-up than AAV patients without ENT involvement. Specifically, nasal obstruction, bloody nasal discharge, nasal crusting, granulomatous sinusitis and conductive hearing loss were associated with higher eGFR. Moreover, the number of ENT symptoms was related to renal function, with eGFR increasing with each added ENT symptom. Patients with ENT involvement had less IFTA and less chronic damage in their renal biopsies. We also found that renal histology of AAV patients with ENT involvement had features associated with better renal prognosis compared with renal histology of AAV patients without ENT involvement. In the multivariable analysis, PR3-ANCA was no longer associated with eGFR when including histological parameters in the model. This finding indicates an association between ANCA serotype and renal histological findings, as previously described³. Interestingly, we found that ENT involvement is associated with renal function independently of GPA diagnosis and PR3-ANCA.

Our findings can be explained by two possible mechanisms. It is possible that through ENT involvement, patients are diagnosed earlier with AAV. Therefore, in patients with ENT involvement, renal function may still be relatively preserved at presentation. Alternatively, the presence or absence of ENT involvement may represent different phenotypes of AAV. We will discuss a number of features that are either in favour or against these two notions.

Clinically overt ENT symptoms may lead to an earlier diagnosis of AAV by reducing patient and possibly doctor delay, as previously proposed³. This may explain the relatively preserved renal function in patients with ENT involvement. However, in our study, manifestations of the skin, lung and arthralgia/arthritis that would supposedly reduce patient and/or doctor delay were not associated with baseline and 5-year follow-up eGFR. Generalized symptoms (such as fever) have been shown to occur earlier in the disease than manifestations of the skin, lung and arthralgia/arthritis³¹. However, these symptoms were not associated with a higher eGFR in this cohort (data not shown). This lack of distinctiveness is probably due to the large proportion of patients with general symptoms at diagnosis (91% in our cohort).

Even though a number of studies have investigated diagnostic delay in AAV³¹⁻³³, to our knowledge, very few studies have investigated diagnostic delay for specific

organ involvement. Recently Poulton *et al.*³⁴ showed that AAV patients with ENT involvement were more likely to experience a delay in diagnosis because both physicians and patients focused on the more common causes of the ENT symptoms instead of regarding them as signs of vasculitis. Even though there was a risk of recall bias in this study, the authors tried to minimize this by interviewing patients within 5 years after diagnosis. Bligny *et al.*¹⁸ showed that patients with ENT involvement have better survival than patients without ENT involvement. They argued that the better prognosis was likely related to different pathogenic routes and not to earlier diagnosis and treatment, as 13 of the 15 patients without ENT involvement had lung involvement, which can lead to earlier diagnosis. Interestingly, in AAV patients with ENT involvement, ENT symptoms mostly start within 12 months after diagnosis³⁵. Considering these findings, the argument that ENT involvement is an easily recognizable sign of vasculitis that can lead to early recognition and better eGFR does not appear to hold.

A recently published GWAS provided support for the concept that PR3-ANCA vasculitis and MPO-ANCA vasculitis are distinct autoimmune syndromes¹¹. Single nucleotide polymorphisms were shown to be associated more strongly with PR3-ANCA and MPO-ANCA than with the clinical syndromes MPA and GPA. In general, AAV patients with ENT involvement are likely to be PR3-ANCA positive and AAV patients without ENT involvement are likely to be MPO-ANCA positive². In our multivariable analyses, ENT involvement overruled ANCA subtype in relation to the preservation of baseline and 5-year follow-up renal function, and in a prespecified subgroup analysis consisting of only PR3-ANCA-positive patients, ENT involvement was still associated with higher baseline and 5-year follow-up eGFR. Both findings indicate that ENT involvement is associated with a favourable renal profile independent of ANCA serotype and may be an important factor in the determination of different phenotypes of AAV.

One limitation of our study is that no data about the time from onset of symptoms to diagnosis of AAV were available. However, low reliability of a patient's interpretation of symptoms that may or may not have been attributable to AAV makes it hard and perhaps not desirable to use these data in an analysis. One strength of our study is the large number of patients we were able to include due to a large European collaboration. Moreover, renal biopsies were available for a large proportion of patients. Because our patients were recruited from three randomized controlled trials, clinical data were accurately documented prospectively.

Our study demonstrates that ENT involvement itself is an important clinical parameter of AAV, first because it is closely related to renal histology and outcome, and second because it may be a determinant of different phenotypes in AAV. Taking the findings of the GWAS into consideration, it is possible that within the subdivision of PR3-ANCA vasculitis and MPO-ANCA vasculitis,

AAV patients can be further categorized as ENT positive or ENT negative. Just as in SLE, where presenting symptoms in relation to clinical outcome have been compared to a hand of cards, in AAV, PR3-ANCA positivity together with the presence of ENT involvement may be representative of a relatively good hand of cards. Regarding future diagnostic and classification criteria for AAV, we suggest that the presence or absence of ENT should be taken into account as an important clinical parameter.

Key messages

- ENT involvement in ANCA-associated vasculitis patients is associated with higher baseline and 5-year follow-up estimated glomerular filtration rate.
- ENT involvement in ANCA-associated vasculitis patients is associated with prognostically favourable findings on renal biopsy examination.
- The presence or absence of ENT involvement may define different phenotypes of ANCA-associated vasculitis.

Reference

- Jennette JC, Falk RJ. Small-vessel vasculitis. *N Engl J Med* 1997;337:1512-23.
- Berden A, Goceroglu A, Jayne D *et al.* Diagnosis and management of ANCA associated vasculitis. *BMJ* 2012; 344:e26.
- Hauer HA, Bajema IM, van Houwelingen HC *et al.* Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. *Kidney Int* 2002;61:80-9.
- Walsh M, Flossmann O, Berden A *et al.* Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum* 2012;64:542-8.
- Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. *Am J Med* 2004;117:39-50.
- Hoffman GS, Kerr GS, Leavitt RY *et al.* Wegener granulomatosis: an analysis of 158 patients. *Ann Intern Med* 1992;116:488-98.
- Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. *Ann Intern Med* 1983;98:76-85.
- Little MA, Nazar L, Farrington K. Outcome in glomerulonephritis due to systemic small vessel vasculitis: effect of functional status and non-vasculitic co-morbidity. *Nephrol Dial Transplant* 2004;19:356-64.
- Mukhtyar C, Flossmann O, Hellmich B *et al.* Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. *Ann Rheum Dis* 2008;67:1004-10.
- Flossmann O, Berden A, de Groot K *et al.* Long-term patient survival in ANCA-associated vasculitis. *Ann Rheum Dis* 2011;70:488-94.
- Lyons PA, Rayner TF, Trivedi S *et al.* Genetically distinct subsets within ANCA-associated vasculitis. *N Engl J Med* 2012;367:214-23.
- Mahr A, Katsahian S, Varet H *et al.* Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. *Ann Rheum Dis* 2013;72:1003-10.
- Millet A, Pederzoli-Ribeil M, Guillevin L, Witko-Sarsat V, Mouthon L. Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group? *Ann Rheum Dis* 2013;72:1273-9.
- Pavone L, Grasselli C, Chierici E *et al.* Outcome and prognostic factors during the course of primary small vessel vasculitides. *J Rheumatol* 2006;33:1299-306.
- Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis: clinical features and mortality. *QJM* 2005;98:97-111.
- Luqmani RA, Bacon PA, Beaman M *et al.* Classical versus non-renal Wegener's granulomatosis. *QJ Med* 1994;87: 161-7.
- Mahr A, Girard T, Agher R, Guillevin L. Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow-up. *Rheumatology* 2001;40:492-8.
- Bligny D, Mahr A, Toumelin PL, Mouthon L, Guillevin L. Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. *Arthritis Rheum* 2004;51:83-91.
- Mohammad AJ, Jacobsson LT, Westman KW, Sturfelt G, Segelmark M. Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. *Rheumatology* 2009; 48:1560-5.
- Jayne D, Rasmussen N, Andrassy K *et al.* A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. *N Engl J Med*

- 2003;349:36-44.
21. Jayne DR, Gaskin G, Rasmussen N *et al.* Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. *J Am Soc Nephrol* 2007;18:2180-8.
22. de Groot K, Harper L, Jayne DR *et al.* Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. *Ann Intern Med* 2009;150: 670-80.
23. Jennette JC, Falk RJ, Andrassy K *et al.* Nomenclature of systemic vasculitides. Proposal of an international consensus conference. *Arthritis Rheum* 1994;37:187-92.
24. Hagen EC, Daha MR, Hermans J *et al.* Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. *Kidney Int* 1998;53: 743-53.
25. Jayne DR, Rasmussen N. Treatment of anti-neutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. *Mayo Clin Proc* 1997;72: 737-47.
26. Luqmani RA, Exley AR, Kitas GD, Bacon PA. Disease assessment and management of the vasculitides. *Baillieres Clin Rheumatol* 1997;11:423-46.
27. Levey AS, Bosch JP, Lewis JB *et al.* A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999;130: 461-70.
28. Bajema IM, Hagen EC, Hermans J *et al.* Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. *Kidney Int* 1999;56:1751-8.
29. Bajema IM, Hagen EC, Hansen BE *et al.* The renal histopathology in systemic vasculitis: an international survey study of inter- and intra-observer agreement. *Nephrol Dial Transplant* 1996;11:1989-95.
30. Berden AE, Ferrario F, Hagen EC *et al.* Histopathologic classification of ANCA-associated glomerulonephritis. *J Am Soc Nephrol* 2010;21:1628-36.
31. Takala JH, Kautiainen H, Malmberg H, Leirisalo-Repo M. Wegener's granulomatosis in Finland in 1981-2000: clinical presentation and diagnostic delay. *Scand J Rheumatol* 2008;37:435-8.
32. Lal DP, O'Donoghue DJ, Haeney M. Effect of diagnostic delay on disease severity and outcome in glomerulonephritis caused by anti-neutrophil cytoplasmic antibodies. *J Clin Pathol* 1996;49:942-4.
33. Koldingsnes W, Nossent H. Epidemiology of Wegener's granulomatosis in northern Norway. *Arthritis Rheum* 2000; 43:2481-7.
34. Poulton C, Nachman P, Hu P *et al.* Pathways to renal biopsy and diagnosis among patients with ANCA smallvessel vasculitis. *Clin Exp Rheumatol* 2013;31:0032-7.
35. Martinez Del Pero M, Walsh M, Luqmani R *et al.* Long-term damage to the ENT system in Wegener's granulomatosis. *Eur Arch Otorhinolaryngol* 2011;268: 733-9.

Chapter IV

Histopathological classification of antineutrophil cytoplasmic antibody-associated glomerulonephritis: an update

C. Rahmattulla, J.A. Bruijn & I.M. Bajema

Curr Opin Nephrol Hypertens. 2014;224-31

Abstract

Purpose of review

This review discusses the findings of studies validating the histopathological classification of antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis, which was devised in 2010 by an international working group of pathologists and nephrologists in collaboration with the European Vasculitis Society.

Recent findings

So far, eight studies have validated the histopathological classification of ANCA-associated glomerulonephritis. The studies came from Japan, China, Australia, the United States, the Netherlands, and Turkey. These validation studies confirmed that the histopathological classification of ANCA-associated glomerulonephritis is of predictive value for renal outcome. This was especially the case for patients with either a focal or sclerotic-class renal biopsy, whereas the crescentic and mixed classes showed different results in the validation studies. These differences could be due to differences in patient populations or therapy, inter-rater reliability and lack of inclusion of tubulointerstitial lesions in the classification. Therapy is known to influence renal outcome, but due to the retrospective design of the to-date performed validation studies, this parameter could not be fully accounted for in these validation studies. Inter-rater reliability among three histopathologists was investigated in one study and was moderate.

Summary

The histopathological classification of ANCA-associated glomerulonephritis predicts renal outcome during follow-up, especially in patients with a focal or sclerotic-class renal biopsy. A large international validation study is currently being performed.

Introduction

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a systemic autoimmune disease affecting small and middle-sized blood vessels¹. Microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) are the major clinical syndromes of ANCA-associated vasculitis, whereas renal limited vasculitis (RLV) and eosinophilic GPA (EGPA) occur less frequently². Approximately 90% of ANCA-associated vasculitis patients have circulating antibodies against proteinase 3 (PR3)-ANCA or myeloperoxidase (MPO)-ANCA. These antibodies probably play a pathogenic role in the disease process and have recently been shown to represent genetically distinct subsets of patients with ANCA-associated vasculitis^{3, 4, 5, 6, 7}. Renal involvement is a common and severe feature of ANCA-associated vasculitis, leading to end-stage renal failure (ESRF) and even death in a considerable number of patients⁸⁻¹⁰.

ANCA-associated glomerulonephritis may show a variety of lesions, of which crescentic and focal necrotizing glomerulonephritis are the most prominent¹¹. Clinicopathologic studies have demonstrated that the presence or absence of specific pathologic lesions in the renal biopsy is of important prognostic value for renal outcome, independently of baseline estimated glomerular filtration rate (eGFR). A high percentage of normal glomeruli is the strongest histological predictor of a favorable renal outcome; a high percentage of globally sclerotic glomeruli is associated with a worse renal outcome¹²⁻¹⁴. The percentage of cellular crescents is associated with recovery of renal function, irrespective of baseline eGFR¹³. Tubulointerstitial lesions, especially tubular atrophy, are associated with a worse renal outcome¹²⁻¹⁴.


In 2010, the histopathological classification of ANCA-associated glomerulonephritis was devised by an international working group of pathologists and nephrologists in collaboration with the European Vasculitis Society (EUVAS)¹⁵. This review discusses the findings of studies validating the histopathological classification of ANCA-associated glomerulonephritis.

The histopathological classification of antineutrophil cytoplasmic antibody associated glomerulonephritis

The histopathological classification of ANCA-associated glomerulonephritis is built around glomerular pathology and encompasses four classes: focal, crescentic, mixed, and sclerotic-class renal biopsies¹⁵. The focal class is defined by the predominance of normal glomeruli ($\geq 50\%$), the crescentic class by the predominance of cellular crescentic glomeruli ($\geq 50\%$), and the sclerotic class by the predominance of globally sclerotic glomeruli ($\geq 50\%$). The mixed class represents a heterogeneous glomerular phenotype in which no glomerular

feature predominates. A flowchart through which renal biopsies can be evaluated according to this classification system is depicted in Fig. 1. Tubulointerstitial lesions were not included in the classification system because these lesions did not improve the predictive value of the classification system in a first validation study incorporated in the publication by Berden *et al.*¹⁵, and only increased its complexity.

Figure 1. Classification system flowchart



Biopsies are scored for glomerular lesions in the following order: globally sclerotic glomeruli, normal glomeruli and cellular crescentic glomeruli. Biopsies that do not fit into one of these classes will automatically be included in the mixed class. Reprinted, with permission from the *Journal of the American Society of Nephrology*.¹⁵

Baseline characteristics of the 100 patients of European descent included in the validation study incorporated in the publication by Berden *et al.* are depicted in Table 1. The phenotypical order of focal, crescentic, mixed, and sclerotic-class renal biopsies corresponded to the eGFR at baseline and at 1 and 5-year follow-up (Table 2). In addition, the histopathological classification and the baseline eGFR were the only independent predictors for eGFR at both 1 and 5 year follow-up in a multivariable analysis taking patient age, treatment, baseline eGFR, and the histopathological classification of ANCA-associated glomerulonephritis into account. The percentage of patients who developed ESRF increased with ascending class.

Table 1. Baseline characteristics of the patients included in the validation studies.

	Berden <i>et al.</i> ¹⁵	Iwakiri <i>et al.</i> ¹⁶	Togashi <i>et al.</i> ¹⁷	Muso <i>et al.</i> ¹⁸	Chang <i>et al.</i> ¹⁹	Hilhorst <i>et al.</i> ²⁰	Ford <i>et al.</i> ²¹	Ellis <i>et al.</i> ²²	Unlu <i>et al.</i> ²³
Number of patients	100	102	54	87	121	164	120	76	141
Age (median^a or mean^b; (SD^c or range^d))	62.6 ^a (20.4 - 80.7 ^b)	66.3 ^b (±11.3 ^c)	66.9 ^b (36-85 ^d)	63.0 ^a (17-85 ^b)	57.2 ^b (15-81 ^d)	61.0 ^b (±14.6 ^c)	66 ^b (8-87 ^b)	58 (NR)	49.09 ^b (7 - 80 ^d)
Male (n; (%))	54 (54)	54 (53)	28 (52)	37 (43)	64 (53)	113 (69)	72 (60)	43 (57)	80 (57 %)
Period	1995 - 2002	2000 - 2010	1990 - 2010	2001 - 2010	1997 - 2010	1979 - 2011	1993 - 2011	1995 - 2011	NR
Geographical area	Europe	Japan	Japan	Japan	China	Netherlands	Australia	US	Turkey
Number of glomeruli per biopsy (mediana or mean^b; (range or SD^d))	14.8 ^a (10.0-49.0) ^c	19.0 ^b (10-61) ^c	25.8 ^b (10-64) ^c	26.5 ^a (10-98) ^c	25.7 ^b (±10.4) ^d	NR	22 ^a (±14) ^d	NR	18.5 ^b (7-60) ^c
Diagnosis						NR	NR		
GPA (n; (%))	39 (39)	3 (3)	28 (52)	0 (0)	49 (40.5)			43 (57)	55 (39)
MPA (n; (%))	61 (61)	97 (95)	25 (46)	87 (100)	68 (56.2)			31 (41)	20 (14)
EGPA (n; (%))	0 (0)	2 (2)	1 (2)	0 (0)	0 (0)			0 (0)	0 (0)
RLV (n; (%))	0 (0)	0 (0)	0 (0)	0 (0)	4 (3.3)			3 (3)	39 (28)
Unknown (n; (%))	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)			0 (0)	27 (19)
ANCA-subtype									
PR3-ANCA (n; (%))	45 (45)	5 (5)	0 (0)	0 (0)	13 (11)	83 (51)	28 (23)**	30 (39)**	60 (43)**
MPO-ANCA (n; (%))	47 (47)	86 (84)	54 (100)	76 (87)	108 (89)	81 (49)	75 (63)**	32 (42)**	61 (43)**
Double positive (n; (%))	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	17 (14)	0 (0)	5 (4)
Negative (n; (%))	2 (2)	11 (11)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	14 (18)	25 (18)
Missing (n; (%))	2 (3)	0 (0)	0 (0)	11 (13)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Table 1. Baseline characteristics of the patients included in the validation studies. (Continued)

	Berden <i>et al.</i> ¹⁵	Iwakiri <i>et al.</i> ¹⁶	Togashi <i>et al.</i> ¹⁷	Muso <i>et al.</i> ¹⁸	Chang <i>et al.</i> ¹⁹	Hilhorst <i>et al.</i> ²⁰	Ford <i>et al.</i> ²¹	Ellis <i>et al.</i> ²²	Unlu <i>et al.</i> ²³
Histopathological class									
Focal class (n; (%))	16 (16)	46 (45)	17 (31)	40 (46.0)	33 (27.3)	81 (49)	34 (28)	20 (26)	31 (22)
Crescentic class (n; (%))	55 (55)	32 (31)	8 (15)	7 (8.0)	53 (43.8)	43 (26)	33 (28)	18 (24)	69 (49)
Mixed class (n; (%))	16 (16)	18 (18)	19 (35)	26 (29.9)	24 (19.8)	39 (24)	33 (28)	27 (36)	29 (21)
Sclerotic class (n; (%))	13 (13)	6 (6)	10 (19)	14 (16.1)	11 (9.1)	1 (1)	20 (17)	11 (14)	12 (9)

NR, not reported; GPA, granulomatosis with polyangitis; MPA, microscopic polyangitis; EGPA, eosinophilic granulomatosis with polyangitis; RLV, renal limited vasculitis; ANCA, Antineutrophil cytoplasmic antibodies; PR3, against proteinase 3; MPO, myeloperoxidase. amedian; bmean; crange; dSD; ** C-ANCA and p-ANCA were reported instead of PR3-ANCA and MPO-ANCA, respectively.

Table 2. Outcomes of the validation studies performed up to date.

Renal function at baseline	Berden <i>et al.</i> ¹⁵	Iwakiri <i>et al.</i> ¹⁶	Togashi <i>et al.</i> ¹⁷	Muso <i>et al.</i> ¹⁸	Chang <i>et al.</i> ¹⁹	Hilhorst <i>et al.</i> ²⁰	Ford <i>et al.</i> ²¹	Ellis <i>et al.</i> ²²	Unlu <i>et al.</i> ²³
	Mean eGFR (±SD)	Median eGFR (IQR)	Mean eGFR (±SD)	Mean serum creatinine (±SD)	Mean eGFR (±SD)	Mean eGFR (±SD)	Median eGFR (range)	Mean eGFR ± SD	NR
Focal class	56.4 (36.8)	38.1 (22.5–57.4)	49.1 (26.2)	1.51 ± 1.49	55.3 (39.9)	39.3 (29.4)	31 (3.4–128)	50.2 (63.4)	
Crescentic class	11.2 (10.9)	12.0 (7.1–19.7)	12.4 (5.1)	2.42 ± 1.67	37.8 (63.7)	16.8 (14.7)	8 (2.5–108)	16.4 (10.3)	
Mixed class	15.4 (16.2)	16.5 (8.7–31.6)	17.4 (9.6)	3.37 ± 3.17	17.9 (17.7)	24.3 (19.5)	21 (5–60)	26.5 (23.3)	
Sclerotic class	10.8 (9.5)	12.4 (9.8–27.4)	13.3 (4.9)	7.52 ± 4.92	8.3 (8.1)	14.6	10 (1.9–45)	26.5 (15.0)	
eGFR 1-year	Mean (±SD)	Median (NR)	Mean (±SD)	NR	NR	Mean (±SD)	Median (range)	Mean (±SD)	NR
Focal class	63.3 (23.7)	45.7	52.9 (11.4)			54.5 (20.9)	42 (67.2–104)	70.8 (29.6)	
Crescentic class	32.8 (20.8)	24.5	25.5 (6.3)			41.0 (21.1)	26 (4.6–95)	42.1 (22.4)	
Mixed class	24.5 (21.4)	26.0	31.3 (20.4)			36.7 (18.6)	34 (6.1–102)	37.8 (19.8)	
Sclerotic class	16.6 (15.9)	16.9	15.5 (4.1)			-	8 (3.3–41)	32.7 (15.3)	

Table 2. Outcomes of the validation studies performed up to date. (Continued)

	Berden <i>et al.</i>¹⁵	Iwakiri <i>et al.</i>¹⁶	Togashi <i>et al.</i>¹⁷	Muso <i>et al.</i>¹⁸	Chang <i>et al.</i>¹⁹	Hilhorst <i>et al.</i>²⁰	Ford <i>et al.</i>²¹	Ellis <i>et al.</i>²²	Unlu <i>et al.</i>²³
eGFR at 2- or 5-year follow-up	5-year	NR	2-year	NR	NR	2-year	NR	2-year	NR
Focal class	65.6 (20.3)		60.9 (17.6)			53.5 (20.8)		76.7 (29.5)	
Crescentic class	39.5 (22.5)		33.9 (9.4)			38.8 (22.3)		41.7 (18.1)	
Mixed class	29.9 (16.7)		29.1 (9.2)			38.3 (16.0)		42.9 (21.6)	
Sclerotic class	20.4 (15.1)		7.4 (3.4)			-		37.8 (16.8)	
Renal survival at 1-year follow-up		NR				NR	NR	NR	NR
Focal class (%)	93		2	100	100				
Crescentic class (%)	84		22	86	73				
Mixed class (%)	69		11	96	83				
Sclerotic class (%)	50		33	35	29				
Renal survival at 2- or 5-year follow-up	5-year	NR	NR	5-year	5-year	5-year	NR	NR	NR
Focal class (%)	93			100	93	91			
Crescentic class (%)	76			86	60	64			
Mixed class (%)	61			96	72	69			
Sclerotic class (%)	50			29	29	-			
Development of ESRF or death	ESRF	ESRF	ESRF	NR	ESRF	NR	ESRF or death	NR	ESRF
Focal class (n; (%))	1 / 14 (7%)	2 / 46 (4.3)	2 / 46 (4)		3 / 33 (9)		11 / 34 (32)		4 / 31 (13)
Crescentic class (n; (%))	11 / 45 (45%)	9 / 32 (28)	9 / 32 (28)		15 / 53 (28)		14 / 33 (42)		20 / 69 (29)
Mixed class (n; (%))	6 / 13 (46%)	8 / 18 (44)	8 / 18 (44)		4 / 24 (17)		13 / 33 (39)		10 / 29 (34)
Sclerotic class (n; (%))	7 / 10 (70%)	4 / 6 (67)	4 / 6 (67)		8 / 11 (73)		16 / 20 (80)		8 / 12 (67)

eGFR, estimated glomerular filtration rate; ESRF, end-stage renal failure; IQR, interquartile range; NR, not reported.

Validation of the histopathological classification of antineutrophil cytoplasmic antibody-associated glomerulonephritis

So far, eight studies from Japan, China, Australia, the United States, the Netherlands, and Turkey have validated the histopathological classification of ANCA-associated glomerulonephritis^{16–23}. Five of these studies included more than 100 patients^{16,19–21,23}. The distributions of diagnoses and ANCA serotype varied and are depicted in Table 1. We will review these validation studies below.

Validation of the classification system in the Asian population

Four validation studies came from Asia, three of which were from Japan and one from China^{16–19}. All these studies had a predominance of MPO-ANCA-positive patients. The diagnosis of GPA or MPA was equally distributed in two studies^{17,19}. Two other studies consisted of 95 and 100% of MPA patients, respectively^{16,18}. At baseline, eGFR levels in all four studies showed a similar distribution over the four classes, with the best eGFR levels for patients with a renal biopsy classified as focal class and worst levels for patients with a renal biopsy classified as sclerotic class. In all these studies, patients with renal biopsies classified as crescentic and mixed class showed intermediate eGFR levels. The outcome with respect to renal function during follow-up in relation to the histopathological class varied somewhat amongst the studies as discussed below in detail. This may have been influenced by the different end-points of the studies.

Iwakiri *et al.*¹⁶ reported a significant relationship between the four histopathological classes and eGFR at baseline and 1-year follow-up, which was greatly determined by a relatively good eGFR in patients with a focal-class renal biopsy (Tables 1 and 2). A renal survival curve over 120 months showed a distribution pattern similar to that of the validation study in the publication by Berden *et al.*, with patients with focal and sclerotic-class renal biopsies having the best and worst renal survival, respectively. There was no significant difference in the eGFR of patients with renal biopsies classified as crescentic or mixed class. The authors comment that discrimination between these two classes was hindered because, in their cohort, both the proportion of normal and sclerotic glomeruli was higher in the mixed class than in the crescentic-class renal biopsies.

Togashi *et al.*¹⁷ reported that the phenotypical order of focal, crescentic, mixed and sclerotic class corresponded to the severity of renal function impairment at baseline and 1 and 5-year follow-up in a cohort of Japanese MPO-ANCA-positive patients (Tables 1 and 2). However, at all time points, the eGFR of patients with crescentic and mixed-class renal biopsies was similar. Overall, renal survival was relatively good with only five of the 54 patients developing ESRF during the 5-year follow-up. Of the patients developing ESRF, two patients had a crescentic and three patients had a sclerotic-class renal biopsy.

Muso *et al.*¹⁸ focused on baseline eGFR and the development of ESRF in a Japanese cohort (Tables 1 and 2). The phenotypical order of focal, crescentic, mixed, and sclerotic-class renal biopsies corresponded to the order of severity of renal function impairment at baseline. At 5-year follow-up, the risk of ESRF development was not increased in patients with focal and mixed-class renal biopsies. Patients with a renal biopsy classified as sclerotic had a highly increased risk to develop ESRF. Patients with focal, mixed and crescentic-class renal biopsies had similar renal survival curves, particularly after 10 months of follow-up.

Chang *et al.*¹⁹ validated the histopathological classification of ANCA-associated glomerulonephritis in a Chinese cohort (Table 1). The phenotypical order of focal, crescentic, mixed, and sclerotic-class renal biopsies corresponded to the order of severity of renal function impairment at baseline (Table 2). Renal survival was best for patients with a focal-class renal biopsy and worst for patients with a sclerotic-class renal biopsy. Comparing patients with a mixed and crescentic-class renal biopsy, 5-year renal survival was 72 and 60%, respectively. The authors stated that the patients with a mixed-class ANCA-associated glomerulonephritis in this cohort had relatively milder lesions than patients with a mixed-class ANCA-associated glomerulonephritis in the Berden *et al.* cohort, with more normal glomeruli, fewer sclerosed glomeruli and fewer glomeruli with fibrous crescents. In addition, tubulointerstitial lesions were not independent predictors of ESRF in a multivariable analysis taking the histopathological classification of ANCA-associated glomerulonephritis into account.

Summarizing the data from the Asian studies, we conclude that all studies show a clear tendency for eGFR at baseline being related to the phenotypical order of focal, crescentic, mixed, and sclerotic-class renal biopsies. Patients with a focal-class renal biopsy had the best eGFRs and patients with a sclerotic-class renal biopsy had the worst eGFRs. Follow-up data varied in time periods and whether ESRF or eGFR was chosen as the end-point. It may be tentatively concluded that there was no clear-cut difference in the outcome of patients with crescentic and mixed-class renal biopsies. In some studies, there was a tendency for patients in the mixed-class to have a slightly better renal outcome than patients in the crescentic class. The Asian studies differed from the studies in the Caucasian population which we discuss below, in terms of ANCA-serotype distribution, diagnosis distribution, and a patient population from the Asian race.

Validation of the classification system in the Caucasian population

The largest validation study reported so far came from a Dutch cohort consisting of 164 patients with an equal distribution of PR3-ANCA and MPO-ANCA patients (Table 1)²⁰. There was only one patient with a renal biopsy classified as being in the sclerotic class, therefore this class could not be part of the analysis. The histopathological classification of ANCA-associated glomerulonephritis

predicted eGFR at both 1 and 2-year follow-up (Table 2). At both time points, eGFR differed significantly between patients with a focal and crescentic-class renal biopsy, and between patients with a focal and mixed-class renal biopsy, but not between patients with a crescentic and mixed-class renal biopsy. In addition, 5-year renal survival was significantly higher in patients with a focal-class renal biopsy than in patients with a crescentic or mixed-class renal biopsy, whereas renal survival in these two latter groups was similar. Subdividing the crescentic and mixed-class renal biopsies on the basis of more or less than 25% normal glomeruli in the renal biopsy showed that patients with more than 25% normal glomeruli had a significantly better renal survival.

A recently published study by Ford *et al.*²¹ is the only study so far which investigated the inter-rater reliability of the classification system, showing variability among three histopathologists scoring 145 renal biopsies ($k=0.46$). Good agreement was found for classifying the sclerotic class ($k=0.70$), but only moderate agreement for classifying the focal, crescentic, and mixed classes ($k=0.47$, $k=0.23$, and $k=0.51$, respectively). There was no significant difference in ANCA subtype between patients in the different classification groups (Table 2). Most tubulointerstitial lesions were found in the sclerotic class. Renal function at presentation was best in patients with a focal or mixed-class renal biopsy, and worst in patients with a sclerotic or crescentic-class renal biopsy. At 1-year follow-up, eGFR declined in the phenotypical order of focal, crescentic, mixed, and sclerotic-class renal biopsies. Patients with a sclerotic-class renal biopsy had a significantly increased risk of ESRF development or death compared with patients with a focal, crescentic, or mixed-class renal biopsy. When taking ESRF development or death as outcome, there was no difference in outcome between patients with focal, crescentic or mixed-class renal biopsies. A drawback of this study is that no minimum amount of glomeruli was required in the renal biopsies.

Ellis *et al.*²² performed a validation study in 76 patients from the United States. Diagnosis and ANCA serotype were equally distributed in this cohort (Table 1). Renal function at baseline was best in patients with a renal biopsy classified as focal and did not differ between patients with renal biopsies classified as crescentic, mixed, or sclerotic (Table 2). At both 1 and 2-year follow-up, renal function was best in patients with a focal-class renal biopsy, worst in patients with a sclerotic-class renal biopsy, and intermediate in patients with a crescentic or mixedclass renal biopsy. In contrast to the study by Ford *et al.*, this study showed that patients in the crescentic class were significantly more often c-ANCA-positive with a GPA phenotype. Renal survival at 1-year follow-up did not differ significantly between the classes, but the histopathological class was an independent predictor of eGFR at 1-year follow-up in linear regression analyses.


Unlu *et al.*²³ reported a study in Turkish patients that was not primarily focused on the validation of the histopathological classification for ANCA-associated glomerulonephritis, but evaluated the classification system with dialysis

as outcome in a subanalysis (Table 1). The classification system did predict for dialyses requirement in the log-rank test, but not in the Cox regression model (Table 2). Similar to the study performed by Ford *et al.*, in this study, no minimum amount of glomeruli was required in the renal biopsies.

Points of consideration and future perspectives

The studies validating the histopathological classification of ANCA-associated glomerulonephritis show that the classification system predicts clinical outcome, in particular, in patients with either a focal or sclerotic-class renal biopsy. There are conflicting outcomes with respect to the crescentic and the mixed-class renal biopsies. In a number of studies, the outcome of patients with a crescentic-class renal biopsy is similar to that of patients with a mixed-class renal biopsy. In other studies, patients with focal and crescentic-class renal biopsies seem to have similar outcomes. There is some evidence that the proportion of normal glomeruli is an important determinant of outcome and is taken as a parameter to subcategorize the classes. Whether additionally, the variation of study results is due to differences in patient populations, moderate inter-rater reliability, or other factors is currently unknown. Only one study investigated inter-rater reliability, showing moderate variability among histopathologists. In particular, the mixed-class renal biopsies may be ‘suffering’ from an ‘identity crisis’, as exemplified in Fig. 2. This figure shows that biopsies in this class may indeed show mixed findings as their denominator suggests, in which either an acute or chronic phenotype predominated. This may have important consequences for renal outcome if different phenotypes prevail in different studies. Renal outcome is also greatly influenced by the therapy a patient receives. However, due to the retrospective design of all to-date performed validation studies, it was not possible to fully account for this parameter in these studies. Another important issue is the influence of interstitial lesions on outcome, in addition to the classes which are primarily based on glomerular lesions. In a recent review by Haas *et al.*²⁴, it was questioned whether the lack of inclusion of tubulointerstitial changes would affect the value of the classification system. It was also questioned whether the classification system identified specific lesions most likely to respond to one or more immunosuppressive agents. These issues are being addressed in a large international validation study, which is currently being performed and incorporates histopathological, clinical, and therapeutical data.

Figure 2. Different phenotypes of mixed class ANCA-associated glomerulonephritis



Hypothetical example of how mixed class biopsies may represent quite different phenotypes of ANCA-associated glomerulonephritis in terms of activity and chronicity.

Conclusion

In general, validation studies supported the predictive value of the histopathological classification of ANCA-associated glomerulonephritis for renal outcome. This was especially the case in patients with a focal or sclerotic-class renal biopsy, whereas the crescentic and mixed classes showed different results in the validation studies. These differences could be due to differences in patient populations or therapy, moderate inter-rater reliability, and lack of inclusion of tubulointerstitial lesions in the classification system. To address these issues, a large international validation study is currently being performed.

Key points

- The histopathological classification of ANCA-associated glomerulonephritis predicts renal outcome during follow-up, especially in patients with either a focal or sclerotic-class renal biopsy.
- There are conflicting outcomes with respect to the crescentic and the mixed-class renal biopsies.
- This could be due to differences in patient populations or therapy, moderate inter-rater reliability, and lack of inclusion of tubulointerstitial lesions in the classification system.
- A large international validation study is currently being performed to address these issues.

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest.

1. • Berden A, Goceroğlu A, Jayne D, *et al.* Diagnosis and management of ANCA associated vasculitis. *Br Med J* 2012; 344:e26. This review discusses the diagnosis and management of ANCA-associated vasculitis.
2. Jennette JC, Falk RJ, Bacon PA, *et al.* 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum* 2013; 65:1–11.
3. •• Free ME, Bunch DO, McGregor JA, *et al.* Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population. *Arthritis Rheum* 2013; 65:1922–1933. This study shows that ANCA-associated vasculitis is associated with disruption of the suppressive Treg cell network and with increased frequency of a distinct proinflammatory effector T-cell subset that comprises the majority of peripheral CD4⁺ T cells.
4. • Jennette JC, Falk RJ, Hu P, Xiao H. Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. *Annu Rev Pathol* 2013; 8:139–160. This review describes the current knowledge regarding the pathogenesis of ANCA-associated vasculitis.
5. •• Roth AJ, Ooi JD, Hess JJ, *et al.* Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. *J Clin Invest* 2013; 123: 1773–1783. The findings in this study imply that in the pathology of ANCA-associated vasculitis immunodominant epitopes play an important role.
6. Xiao H, Ciavatta D, Aylor DL, *et al.* Genetically determined severity of antimyeloperoxidase glomerulonephritis. *Am J Pathol* 2013; 182:1219–1226.
7. •• Lyons PA, Rayner TF, Trivedi S, *et al.* Genetically distinct subsets within ANCA-associated vasculitis. *N Engl J Med* 2012; 367:214–223. This genome-wide association study confirms that ANCA-associated vasculitis has a genetic basis and provides support for the concept that PR3 ANCA-associated vasculitis and MPO-ANCA-associated vasculitis are distinct autoimmune syndromes.
8. Little MA, Nazar L, Farrington K. Outcome in glomerulonephritis due to systemic small vessel vasculitis: effect of functional status and nonvasculitic co-morbidity. *Nephrol Dial Transplant* 2004; 19:356–364.
9. Mukhtyar C, Flossmann O, Hellmich B, *et al.* Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. *Ann Rheum Dis* 2008; 67:1004–1010.
10. Flossmann O, Berden A, de Groot K, *et al.* Long-term patient survival in ANCA-associated vasculitis. *Ann Rheum Dis* 2011; 70:488–494.
11. Bajema IM, Hagen EC, Ferrario F, *et al.* Immunopathological aspects of systemic vasculitis. *Springer Semin Immunopathol* 2001; 23:253–265.
12. Bajema IM, Hagen EC, Hermans J, *et al.* Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. *Kidney Int* 1999; 56:1751–1758.
13. Hauer HA, Bajema IM, Van Houwelingen HC,

- et al.* Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. *Kidney Int* 2002; 62:1732–1742.
14. de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, *et al.* Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. *J Am Soc Nephrol* 2006; 17:2264–2274.
15. Berden AE, Ferrario F, Hagen EC, *et al.* Histopathologic classification of ANCA-associated glomerulonephritis. *J Am Soc Nephrol* 2010; 21:1628–1636.
16. Iwakiri T, Fujimoto S, Kitagawa K, *et al.* Validation of a newly proposed histopathological classification in Japanese patients with anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. *BMC Nephrol* 2013; 14: 125.
17. Togashi M, Komatsuda A, Nara M, *et al.* Validation of the 2010 histopathological classification of ANCA-associated glomerulonephritis in a Japanese single-center cohort. *Mod Rheumatol* 2014; 24:300–303.
18. Muso E, Endo T, Itabashi M, *et al.* Evaluation of the newly proposed simplified histological classification in Japanese cohorts of myeloperoxidase-antineutrophil cytoplasmic antibody-associated glomerulonephritis in comparison with other Asian and European cohorts. *Clin Exp Nephrol* 2013; 17:659–662.
19. Chang DY, Wu LH, Liu G, *et al.* Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. *Nephrol Dial Transplant* 2012; 27:2343–2349.
20. Hilhorst M, Wilde B, van Breda Vriesman P, *et al.* Estimating renal survival using the ANCA-associated GN classification. *J Am Soc Nephrol* 2013; 24:1371–1375.
21. Ford SL, Polkinghorne KR, Longano A, *et al.* Histopathologic and clinical predictors of kidney outcomes in ANCA-associated vasculitis. *Am J Kidney Dis* 2014; 63:227–235.
22. Ellis CL, Manno R, Racusen LC, Geetha D. New histopathologic classification of anti-neutrophil cytoplasmic antibody associated pauci-immune glomerulonephritis: correlation with renal outcome [Abstract]. *J Am Soc Nephrol* 2012; 23:711A.
23. Unlu M, Kiremitci S, Ensari A, *et al.* Pauci-immune necrotizing crescentic glomerulonephritis with crescentic and full moon extracapillary proliferation: clinico-pathologic correlation and follow-up study. *Pathol Res Pract* 2013; 209:75–82.
24. Haas M, Rastaldi MP, Fervenza FC. Histologic classification of glomerular diseases: clinicopathologic correlations, limitations exposed by validation studies, and suggestions for modification. *Kidney Int* 2013; doi: 10.1038/ki.2013.375. [Epub ahead of print]

Chapter V

Incidence of malignancies in patients diagnosed with ANCA-associated vasculitis between 1991 and 2013

*C. Rahmattulla, A.E. Berden, S.C. Wakker, M.E. Reinders, E.C. Hagen, R. Wolterbeek,
J.A. Bruijn & I.M. Bajema*

Arthritis & Rheumatology 2015 Dec;67(12):3270-8

Abstract

Objective

To investigate the incidence of malignancies during longitudinal follow-up of patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV), and to examine the effect of immunosuppressive therapy on malignancy risk in these patients.

Methods

The study population consisted of patients with histopathologically confirmed AAV, diagnosed between 1991 and 2013 at a large university hospital. The mean duration of followup was 10 years. Malignancy incidence was assessed using the Dutch National Pathology Database. Incidence rates from the Netherlands Cancer Registry were used to compare malignancy incidence in the AAV cohort to that in the general Dutch population.

Results

Thirty-six of 138 patients with AAV developed a total of 85 malignancies during a mean followup of 9.7 years. The sex-, age-, and calendar year-adjusted malignancy risk was 2.21-fold higher (95% confidence interval [95% CI] 1.64-2.92) than that in the general population. Non-melanoma skin cancers occurred most frequently (standardized incidence ratio 4.23 [95% CI 2.76-6.19]). The incidence rates of other malignancies were not significantly increased. Malignancy risk was associated with the duration of cyclophosphamide (CYC) therapy and, interestingly, was not increased in patients who had received CYC for <1 year.

Conclusion

Patients with AAV have a higher risk of malignancy than the general population, but this risk is accounted for solely by non-melanoma skin cancers. Over the years, the risk of other malignancies – specifically bladder and hematologic malignancies – has decreased in patients with AAV. This finding reflects ongoing efforts to reduce CYC exposure by developing new treatment regimens.

Introduction

The antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs), including granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA), are small-to-medium vessel vasculitides that affect multiple organs and are life-threatening when untreated¹. The availability of immunosuppressive therapy has dramatically improved prognosis in patients with AAV. Before the introduction of immunosuppressive therapy for this disorder, the mortality rate within 1 year after diagnosis was 80%. Currently, the remission rate is 90%²⁻⁴. Moreover, the life expectancy of patients with AAV who survive 5 years after diagnosis approaches that of the general population^{4, 5}. As a result, attention has shifted to the long-term complications experienced by patients with AAV. Malignancies have been shown to be the second most common cause of death >1 year after diagnosis⁴. In previous studies, the incidence of malignancies among patients with AAV has been shown to be increased compared to the general population⁶⁻¹². This was particularly the case for bladder cancer, malignant lymphomas, leukemia, and non-melanoma skin cancers (NMSCs).

The results of earlier studies of malignancy risk in AAV must be interpreted in light of a number of factors. First, in previous studies, except for one published in 1992⁶, followup was limited to ~5 years^{7, 9, 10, 13}. Second, in some studies information on malignancy incidence was based on patient or physician questionnaires, which may have introduced reporting bias. Most importantly, the observation period in most studies dated from the 1960s to the 1990s^{6-8, 13}. In recent years, immunosuppressive therapy regimens have changed, based on efforts to reduce exposure to steroids and cyclophosphamide (CYC)¹⁴⁻¹⁶. Therefore, previous data on malignancy incidence mostly reflect risks associated with therapy regimens that are no longer used.

In the current study, we investigated the incidence of malignancies in 138 patients with AAV treated with current immunosuppressive therapy regimens, who were followed up for a mean of 10 years. Specifically, we examined the effect of duration of CYC exposure on the risk of malignancy in these patients. A nationwide histology database was used to assess the incidence of malignancy in this cohort.

Patients and methods

Study population and data collection

This study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki.

We enrolled patients with histopathologically confirmed AAV diagnosed at Leiden University Medical Center between 1991 and 2013. Patients with coexisting autoimmune diseases were excluded. Definitions provided in the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides¹⁷ were used. Of the 138 patients enrolled, 134 (97%) had undergone renal biopsy in which AAV was confirmed histopathologically (i.e., crescentic and/or necrotizing glomerulonephritis with few or no immune deposits detected by immunofluorescence and/or electron microscopy). In the 4 patients who did not undergo renal biopsy, the biopsies showing AAV originated from the lung (3 patients), the ear/nose/throat (ENT) (3 patients), and the skin (2 patients). All 4 of these patients had a clinical diagnosis of GPA, and all exhibited ANCA positivity. Twenty of the 138 patients in the study were negative for ANCA or had an unknown ANCA serotype; AAV in these patients was confirmed histologically by renal biopsy findings as defined above. Seven of these patients also had a second biopsy from another organ showing AAV (skin [4 patients], lung [2 patients], and ENT region [1 patient]).

Primary malignancies were identified via the Dutch National Pathology Database, a nationwide histopathology and cytopathology network and registry in The Netherlands. The database includes data from all pathology laboratories¹⁸. The cohort was linked to the Central Population Registry to obtain information on death and emigration. The observation time started on the date of AAV diagnosis and ended on the date of death, the date of last followup, or on May 1, 2013, whichever occurred first. We retrieved medical records to collect information on sex, date of birth, clinical diagnosis (GPA/MPA), ANCA serotype, renal function at diagnosis, renal transplantation, renal transplantation date (when applicable), and use of immunosuppressive medication (type and duration).

Standardized incidence ratio calculation

Malignancy occurrence in our cohort was compared to that in the general population by determining standardized incidence ratios (SIRs), calculated as the observed number of malignancies divided by the expected number of malignancies. To obtain the most accurate value, SIRs were calculated with matching for sex, age (5-year age groups), and calendar-year period (1-year time periods). The observed number of malignancies was the total number of malignancies that occurred in the cohort. If a patient developed multiple NMSCs, only the first NMSC was taken into account in the analyses. The expected number of malignancies was defined as the person-years at risk multiplied by the national cancer incidence rate data provided by the Netherlands Cancer Registry. Subgroup analyses were performed for the following variables: sex, age at study entry (dichotomous according to the median value), renal transplantation, clinical diagnosis, ANCA serotype, followup duration, and history of malignancy before AAV diagnosis. Moreover, we considered that the landmark European Vasculitis

Society (EUVAS) trial Cyclophosphamide versus Azathioprine as Remission Maintenance Therapy for ANCA-Associated Vasculitis (CYCAZAREM), published in 2003¹⁹, led to a drastic reduction in CYC exposure in patients with AAV. Consequently, we performed separate subgroup analyses of patients diagnosed before 2003 and patients diagnosed in or after 2003, to investigate whether this change in immunosuppressive therapy regimen had an effect on malignancy risk.

Statistical analysis

Student's *t*-test and the chi-square test were used to assess the significance of differences in baseline characteristics of patients who did and those who did not develop malignancies. Survival rates were analyzed by log rank test. Malignancy-free survival time was calculated with the Kaplan-Meier method; the observation time started at AAV diagnosis and ended at the date of the first malignancy diagnosis, death, or May 1, 2013, whichever occurred first. SIRs and 95% confidence intervals (95% CIs) were calculated with an exact Poisson regression analysis, which allowed incorporation of patients with multiple malignancies, assuming a Poisson distribution of the observed number of cases²⁰⁻²². For all subgroup analyses, exact Poisson regression models were performed to calculate the relative risk. *P* values less than 0.05 were considered significant.

Results

Patient characteristics

A total of 138 patients with histopathologically confirmed AAV were included in the study. Of the 117 patients (85%) with available clinical diagnoses, 79 (68%) had a diagnosis of GPA and 38 (32%) had a diagnosis of MPA; none had a diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Of the 128 patients (93%) with available data on ANCA serotype, 55 (43%) were positive for proteinase 3 (PR3)-ANCA; 47 (37%) for myeloperoxidase (MPO)-ANCA, and 5 (4%) for both PR3-ANCA and MPO-ANCA; 11 patients (9%) were positive for ANCA but with no available data on whether they were PR3-ANCA or MPO-ANCA positive, and 10 patients (8%) were negative for ANCA. The mean $\pm$ SD age at AAV diagnosis was 59.3 ± 14.8 years, and did not differ significantly between patients who did and those who did not develop malignancy during followup. Fourteen patients had a history of malignancy occurrence prior to the AAV diagnosis. No malignancy diagnosed prior to the AAV diagnosis metastasized during the followup period. Additional demographic and clinical data are summarized in Table 1.

Table 1. Characteristics of the AAV patients included in the study

	Total sample	No malignancy occurrence	Malignancy occurrence	p-value
Mean age at diagnosis, years (SD)	59.3 (14.8)	58.9 (15.6)	60.7 (12.0)	0.533
Male, n (%)	87 (63)	62 (61)	25 (69)	0.355
Clinical diagnosis, n (%)				0.753
GPA	79 (57)	56 (55)	23 (64)	
MPA	38 (28)	28 (27)	10 (28)	
Unknown	21 (15)	18 (18)	3 (8)	
ANCA-serotype, n (%)				0.079
PR3-ANCA	55 (40)	35 (34)	20 (56)	
MPO-ANCA	47 (34)	39 (38)	8 (22)	
ANCA-negative	10 (7)	7 (7)	3 (8)	
PR3- and MPO-ANCA positive	5 (4)	5 (5)	0 (0)	
ANCA positive ¹	11 (8)	9 (9)	2 (6)	
Unknown	10 (7)	7 (7)	3 (8)	
Mean baseline serum creatinine, µl/l (SD)	337.0 (303.6)	332.5 (279.1)	348.0 (361.0)	0.813
Renal transplantation, n (%)	10 (7)	8 (8)	2 (6)	0.649
Previous history of malignancy, n (%)	14 (10)	11 (11)	3 (8)	0.675
Organ involvement, n (%) ²				
Cutaneous	36 (31)	21 (25)	15 (46)	0.044
Eyes	35 (30)	21 (25)	14 (42)	0.075
Ear, nose, and throat	78 (67)	53 (63)	25 (76)	0.276
Chest	61 (52)	45 (54)	16 (49)	0.683
Cardiovascular	7 (6)	6 (7)	1 (3)	0.671
Gastrointestinal	16 (14)	13 (16)	3 (9)	0.551
Kidney	138 (100)	0 (0)	138 (100)	N/A
Nervous system	32 (27)	25 (30)	7 (21)	0.490
Deaths, n (%)	56 (41)	39 (38)	17 (47)	0.255 ³

The study population consisted of 138 patients with histologically confirmed antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). Data on clinical diagnosis and ANCA serotype were available for 117 patients and 128 patients, respectively. Except where indicated otherwise, values are the number (%). GPA = granulomatosis with polyangiitis (Wegener’s); MPA = microscopic polyangiitis.

¹ Patients who were ANCA positive, but with no information in the medical records regarding whether they were positive for proteinase 3 (PR3)–ANCA or myeloperoxidase (MPO)–ANCA.

² All 138 patients had renal involvement; data on involvement of other organs were available for 117 patients.

³ P = 0.044 versus patients with no malignancy occurrence.

Observed malignancies

Thirty-six patients developed malignancies (total of 85 malignancies) during the followup period (mean 9.7 years, median 8.0 years; 1,339 person-years). Of these malignancies, 61 were NMSCs, and they occurred in a total of 22 patients. The NMSCs included 42 basal cell carcinomas and 19 squamous cell carcinomas. In addition, 3 colon carcinomas, 3 breast carcinomas, 3 prostate carcinomas, 2 lung carcinomas, 2 soft tissue sarcomas, 2 unknown primary malignancies, and a variety of malignancies that occurred only once were observed (Table 2). Malignancy-free survival at 2, 5, and 10 years of followup was 99%, 84%, and 80%, respectively (Figure 1).




Figure 1. Years of malignancy-free survival in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV) (solid line) compared to the age- and sex-matched general population (dashed line).

Comparison with the general population

The sex-, age-, and calendar year-adjusted malignancy risk among the AAV patients in this cohort was 2.21-fold higher than the risk in the general population (95% CI 1.64-2.92) (Table 2). This increased risk was attributable solely to an increased risk of developing NMSC (SIR 4.23 95% CI 2.76-6.19). We observed only 1 bladder carcinoma and 1 non-Hodgkin's lymphoma in the cohort. These incidences were not significantly increased compared to the general population, with SIRs of 1.43 (95% CI 0.04-7.96) and 1.37 (95% CI 0.03-7.63), respectively. The risk of developing any of the other reported malignancies was also not increased compared to that in the general population (Table 2).

Table 2. SIRs calculated for malignancies overall and per observed malignancy

Malignancy type	PY	N malignancies	SIR	95% CI	p-value
All malignancies	1339	85	2.21	1.64 – 2.92	<0.001
NMSC	1339	61	4.23	2.76 – 6.19	<0.001
Non-NMSC	1339	24	1.46	0.93 – 2.17	0.095
By malignancy					
Breast carcinoma	1339	3	2.04	0.42 – 5.96	0.367
Colon carcinoma	1339	3	1.85	0.38 – 5.41	0.444
Prostate carcinoma	795	3	0.99	0.20 – 2.89	1.000
Lung carcinoma	1339	2	0.75	0.23 – 3.30	0.993
Soft tissue sarcomas	1339	2	7.69	0.93 – 27.79	0.057
Unknown primary malignancy	1339	2	3.92	0.47 – 14.17	0.187
Brain carcinoma	1339	1	5.56	0.14 – 30.95	0.329
Parotis carcinoma	1339	1	33.33	0.84 – 185.72	0.059
Bladder carcinoma	1339	1	1.43	0.04 – 7.96	1.000
Uterus carcinomas	544	1	4.00	0.10 – 22.29	0.442
Non-Hodgkin lymphoma	1339	1	1.37	0.03 – 7.63	1.000
Renal cell carcinoma	1339	1	2.44	0.06 – 13.59	0.672
Chondrosarcoma	1339	1	28.57	0.72 – 159.19	0.068
Esophageal carcinoma	1339	1	2.70	0.07 – 15.06	0.602
Melanoma	1339	1	1.92	0.05 – 10.71	0.811

The analysis encompassed 1,339 person-years (except for the sex-specific malignancies prostate carcinoma [795 person-years] and uterus carcinoma [544 person-years]). Standardized incidence ratio (SIR) (ratio of observed to expected malignancies) was adjusted for sex, age (5-year age groups), and calendar time period (1-year time periods). 95% CI = 95% confidence interval; NMSC = non-melanoma skin cancer.

Malignancy risk by clinical diagnosis and ANCA subtype

We performed prespecified subgroup analyses with stratification by sex, age, followup duration, clinical diagnosis, ANCA subtype, history of malignancy before AAV diagnosis, diagnosis and treatment initiation before or after publication of the CYCAZAREM trial (2003), and renal transplantation (Table 3). The risk of malignancy became increased compared to the general population after the duration of AAV exceeded 5 years (Table 3).

Table 3. SIRs for malignancy in the AAV patients stratified into various subgroups

	N patients	N malignancies	SIR (95% CI)	SIR p-value	RR (95% CI)	RR p-value
Gender						
Male	87	61	2.33 (1.64 – 3.21)	<0.001		
Female	51	24	1.93 (1.03 – 3.31)	0.041	0.83 (0.40 – 1.60)	0.680
Age						
≥ 61 years	68	44	2.20 (1.47 – 3.18)	0.001		
< 61 years	70	41	2.22 (1.39 – 3.36)	<0.001	0.99 (0.55 – 1.82)	1.000
Clinical diagnosis						
MPA	38	23	1.89 (0.98 – 3.30)	0.058		
GPA	79	54	2.53 (1.76 – 3.52)	<0.001	1.34 (0.68 – 2.83)	0.478
ANCA-serotype						
MPO-ANCA	47	16	1.87 (0.93 – 3.34)	0.076		
PR3-ANCA	55	53	2.72 (1.80 – 3.93)	<0.001	1.46 (0.70 – 3.24)	0.371
Renal transplantation						
No	128	78	2.17 (1.59 – 2.91)	<0.001		
Yes	10	7	3.33 (1.08 – 7.78)	0.037	1.53 (0.48 – 3.85)	0.495
Follow-up						
0 – 5	55	6	1.60 (0.52 – 3.73)	0.414		
5 - 10 years	29	19	2.91 (1.45 – 5.21)	0.004	1.82 (0.58 – 6.67)	0.385
>10 years	54	60	2.17 (1.50 – 3.03)	<0.001	1.36 (0.53 – 4.44)	0.702
Year of diagnosis						
<2003	83	73	2.43 (1.76 – 3.26)	<0.001		
≥2003	55	12	1.34 (0.49 – 2.92)	0.586	1.81 (0.77 – 5.20)	0.220
Previous history of malignancy						
No	124	80	2.24 (1.64 – 2.98)	<0.001		
Yes	14	5	1.97 (0.54 – 5.05)	0.297	1.13 (0.41 – 4.34)	1.000

Standardized incidence ratio (SIR) (ratio of observed to expected malignancies) depicts malignancy risk compared to the general population. Relative risk (RR) depicts malignancy risk compared to the referent group. None of the RR values were statistically significant. 95% CI = 95% confidence interval (see Table 1 for other definitions).

Analysis of the clinical diagnosis and ANCA serotype subgroups showed a significantly increased malignancy risk in patients with GPA and/or with PR3-ANCA compared to the general population, but not in patients with MPA and/or MPO-ANCA. However, within the AAV cohort, the malignancy risk was not significantly different between those who had GPA and/or were positive for PR3-ANCA and those who had MPA and/or were positive for MPO-ANCA (Table 3).

Malignancy risk in patients with a history of malignancy before AAV diagnosis

Fourteen of the 138 patients had a history of malignancy before AAV diagnosis and 124 did not. The total number of malignancies that developed in these 2 groups during followup were 5 and 80, respectively. SIRs were similar between patients with and patients without a history of malignancy before the AAV diagnosis (Table 3).

Malignancy risk before and after publication of the CYCAZAREM trial in 2003

Eighty-three of the 138 AAV patients were diagnosed before 2003, and 55 in or after 2003 (Table 3). The mean $\pm$ SD duration of CYC therapy was 14.5 ± 17.4 months and 5.1 ± 4.1 months in patients diagnosed before 2003 and patients diagnosed in or after 2003, respectively ($P < 0.001$). The 83 patients diagnosed before 2003 developed a total of 73 malignancies, which resulted in a 2.43-fold increase in malignancy risk compared to the general population (95% CI 1.76-3.26). The 55 patients diagnosed in or after 2003 developed a total of 12 malignancies; the malignancy risk in these patients was not significantly increased compared to the general population (SIR 1.34 [95% CI 0.49-2.92]).

Malignancy risk in patients with renal transplants

Ten patients (7%) underwent renal transplantation during followup. The mean $\pm$ SD time from AAV diagnosis to renal transplantation was 6.7 ± 4.8 years. Two of the 10 patients with renal transplants developed a total of 7 malignancies, during a mean $\pm$ SD followup of 12.8 ± 4.8 years. These malignancies included 3 squamous cell carcinomas, 2 basal cell carcinomas, 1 prostate carcinoma, and 1 parotid carcinoma. Malignancy risk compared to the general population was significantly increased among patients with AAV who had undergone renal transplantation (SIR 3.33 [95% CI 1.08-7.78]) as well as those who had not undergone transplantation (SIR 2.17 [95% CI 1.59-2.91]). We did not observe a significant effect of transplantation on malignancy risk in these subgroups ($P = 0.495$); however, since only 10 patients in the cohort had undergone transplantation, this subanalysis was presumably not sufficiently powered to detect a significant difference.

Effects of immunosuppressive therapy on malignancy risk

Data on immunosuppressive therapy were available for 117 patients (85%) (Table 4). All 117 patients received prednisolone, 110 (94%) received CYC, 62 (53%) received azathioprine (AZA), and 24 (21%) received mycophenolate mofetil (MMF) at some time during their disease. Moreover, 4 patients (3%) received methotrexate, and 5 patients (4%) received rituximab. The mean $\pm$ SD duration of CYC therapy was 17.6 ± 17.9 months and 8.0 ± 11.8 months, respectively, in patients who did and those who did not develop a malignancy during followup ($P = 0.001$) (Table 4).

Table 4. Immunosuppressive therapy in the AAV patients

	Total sample (n=117)	No malignancy occurrence (n=84)	Malignancy occurrence (n=33)	p-value
Ever treatment, n (%)				
Prednisolone	117 (100)	84 (100)	33 (100)	N/A
Cyclophosphamide	110 (94)	80 (95)	30 (91)	0.374
Azathioprine	62 (53)	43 (51)	19 (58)	0.533
Mycophenolate mofetil	24 (21)	20 (24)	4 (12)	0.159
Mean duration, months (SD)				
Prednisolone	37.7 (42.3)	29.7 (39.2)	58.1 (43.7)	0.001
Cyclophosphamide	10.7 (14.4)	8.0 (11.8)	17.6 (17.9)	0.001
Azathioprine	18.5 (31.4)	14.2 (28.3)	29.5 (36.5)	0.017
Mycophenolate mofetil	7.6 (21.1)	7.5 (16.7)	7.8 (29.9)	0.943

Some of the patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV) received consecutive treatments with cyclophosphamide and/or azathioprine and/or mycophenolate mofetil (47 patients received cyclophosphamide and azathioprine, 8 patients received cyclophosphamide and mycophenolate mofetil, 1 patient received azathioprine and mycophenolate mofetil, and 13 patients received cyclophosphamide, azathioprine, and mycophenolate mofetil).

NA = not applicable (analyses on prednisolone were not possible as all patients were treated with this immunosuppressant).

The duration of CYC exposure was directly associated with malignancy risk (Table 5). The malignancy risk in patients with AAV who had received CYC for <1 year was not significantly different from that in the general population. Patients treated with CYC for 12–24 months and those treated for >24 months showed increased malignancy risks, with SIRs of 3.83 (95% CI 1.98–6.70) and 4.67 (95% CI 2.55–7.83), respectively.

The duration of CYC exposure was directly associated with malignancy risk (Table 5). The malignancy risk in patients with AAV who had received CYC for 1 year was not significantly different from that in the general population. Patients treated with CYC for 12–24 months and those treated for >24 months

showed increased malignancy risks, with SIRs of 3.83 (95% CI 1.98–6.70) and 4.67 (95% CI 2.55–7.83), respectively.

The risk of malignancy in patients treated with CYC and corticosteroids was not different from that in patients treated with AZA or MMF maintenance therapy following CYC treatment (SIR 2.62 [95% CI 1.53–4.19] and SIR 2.02 [95% CI 1.29–3.01], respectively). The average duration of CYC treatment was 14 months in patients treated with CYC and corticosteroids and 10 months in patients who received other immunosuppressive agents for maintenance therapy after CYC treatment ($P = 0.234$).

Table 5. SIRs calculated according to duration of cyclophosphamide therapy

Cyclophos- phamide therapy duration	N patients	N malig- nancies	SIR (95% CI)	SIR p-value	RR (95% CI)	RR p-value
0 – 6 months	65	15	1.52 (0.78 – 2.64)	0.212		
6 – 12 months	21	14	1.82 (0.79 – 3.59)	0.156	1.20 (0.43 – 3.19)	0.847
12 – 24 months	16	30	3.83 (1.98 – 6.70)	<0.001	2.53 (1.04 – 6.17)	0.040
> 24 months	15	18	4.67 (2.55 – 7.83)	<0.001	3.08 (1.31 – 7.32)	0.008

Standardized incidence ratio (SIR) (ratio of observed to expected malignancies) depicts malignancy risk compared to the general population. Relative risk (RR) depicts malignancy risk compared to the referent group. 95% CI = 95% confidence interval.

Discussion

This is the first published study to investigate malignancy incidence in relation to current therapy regimens in a cohort of patients with AAV followed up for a long period (mean 10 years). During this period, the risk of malignancy was 2.21-fold higher in patients with AAV compared to the general population. This increased risk was attributable solely to the occurrence of NMSC. There was no increased risk for all other reported malignancies compared to the general population. In particular, there was no increased risk of bladder cancer, leukemia, or malignant lymphomas, in contrast to data presented in previous reports^{6–11,13}. In our cohort, risk of malignancy was directly associated with the duration of CYC therapy. Interestingly, malignancy risk was not increased among patients who had been exposed to CYC for <1 year.

Previous studies on malignancy risk in AAV showed 2.4–33-fold increases in the risk of developing bladder cancer, 3.2–5.9-fold increases in the risk of developing leukemia, and 1.1–11-fold increases in the risk of developing malignant lymphomas¹². Followup periods in those studies were ~5 years^{7,9–11} or were

not reported^{8, 13}, except in the case of one study conducted from 1967 to 1990 with a median followup of 8 years⁶. As noted, patients in our AAV cohort had no increased risk of developing any of these malignancies after a mean followup period of 10 years. Only 1 patient in our cohort, who received CYC for 4 years, developed bladder carcinoma (9 years after AAV was diagnosed). In addition, there was 1 non-Hodgkin's lymphoma (which occurred 13 years after the AAV diagnosis). This patient was treated with CYC for 4.5 years and AZA for 3.8 years.

The discrepancies between our findings and those of previous studies likely reflect the changes in AAV treatment regimens over the years. Most previous studies were conducted from the 1960s to the 1990s^{6-8, 13}. Since that time, large, international therapeutic trials have been conducted^{14-16, 19}, which resulted in dramatic reductions in exposure to CYC. A previous 5-year followup study of patients initially recruited in those trials demonstrated no increased risk of bladder or hematologic malignancies compared to the general population¹⁰. Our study validates those results and, moreover, shows that even after 10 years of followup, the risk of developing these malignancies is not increased.

The followup period of our study (1991–2013) overlaps publication of the reports of the therapeutic trials conducted by the EUVAS^{14-16, 19}. In the landmark EUVAS CYCAZAREM study published in 2003, it was concluded that early withdrawal of CYC and substitution of AZA at the time of remission did not increase relapse rates in patients with AAV, and that the duration of exposure to CYC therefore could be safely reduced by switching to maintenance therapy at the time of remission achievement¹⁹. In our cohort, the mean duration of CYC therapy was ~3 times longer in patients diagnosed before 2003 compared to patients diagnosed in or after 2003. Interestingly, we found that the malignancy risk compared to the general population is significantly increased among AAV patients diagnosed before 2003, but not among those diagnosed later. This indicates that the reduction in CYC exposure over time has resulted in a decrease in malignancy risk among patients with AAV.

Apart from increased malignancy risk induced through immunosuppressive therapy regimens, it has been suggested that an increased risk of malignancy may arise from chronic stimulation of the immune system due to vasculitis²³. Moreover, more severe disease with greater disease activity is generally associated with longer duration of immunosuppressive therapy; thus, it is difficult to separate disease-related and therapy-related effects on malignancy risk. Our finding of a high incidence of malignancies only after 5 years of followup (i.e., after longer exposure to immunosuppressive therapy) suggests that this therapy may have an important effect on the development of malignancies, because intrinsic disease-associated malignancies would be more likely to occur within the first 5 years. Moreover, we found that the malignancy risk in patients with AAV decreased after reduction of CYC exposure, which clearly indicates a dose-dependent effect.

Subgroup analyses demonstrated a significantly increased malignancy risk among patients with GPA and/or PR3-ANCA positivity, but not among patients with MPA and/or MPO-ANCA positivity. Possible explanations for this could be that patients with GPA and/or PR3-ANCA positivity had superior survival or a higher risk of relapses and need for more immunosuppressive treatment compared to patients with MPA and/or MPO-ANCA positivity. Further analyses demonstrated that survival was not different between patients with GPA and/or PR3-ANCA positivity and patients with MPA and/or MPO-ANCA positivity (data not shown). However, the duration of CYC treatment was significantly longer among patients with PR3-ANCA positivity than among those with MPO-ANCA positivity (mean 14 months and 8 months, respectively). This finding further supports the notion that immunosuppressive treatment exposure increases malignancy risk in patients with AAV.

Currently, immunosuppressive therapy for AAV seems to be complicated by the occurrence of NMSC. It has been suggested that AZA might accelerate NMSC development by sensitizing the skin cell genome to ultraviolet A radiation²⁴. Previous studies have shown an association between AZA exposure and the occurrence of NMSC in patients with transplants, myasthenia, autoimmune inflammatory rheumatic diseases, and inflammatory bowel disease²⁵⁻²⁹. Our data imply that there is also an association between AZA and NMSC in patients with AAV (Table 4). In contrast, we found no difference in the occurrence of NMSC between patients treated with CYC alone and those treated with AZA following CYC therapy, despite similar durations of CYC exposure. However, our analysis may not have been sufficiently powered to detect a significant difference. Although mortality associated with NMSCs is low, their impact should not be underestimated because they can cause significant morbidity. Our results support the notion that patients with AAV who receive immunosuppressive therapy should undergo regular skin cancer screening and be advised to protect themselves against ultraviolet radiation exposure³⁰.

One limitation of this study is the fact that the clinical data were collected retrospectively. However, for most patients these data were accessible and recorded punctually. Moreover, the analysis was confined to a Dutch patient population, which should be taken into account in comparing our results with those from the previous multicenter European study¹⁰. Finally, the limited number of patients included in this study could have resulted in insufficient power to detect significant differences, particularly in the subgroup analyses. One of the strengths of the study is the long followup period. This is the first study on malignancy risk in patients with AAV with a mean followup duration as long as 10 years. Moreover, the diagnosis of AAV was confirmed histologically in all of our patients. Finally, no malignancy in our patient cohort could have been missed, due to the accurate data reporting through the Dutch National Pathology Database.

In conclusion, the results of this 10-year followup study indicate that patients with AAV have a higher risk of NMSC than the general population. There was no increased risk of bladder cancer, leukemia, or malignant lymphomas, as was previously reported in patients with AAV. With current treatment regimens, CYC treatment appears to be safe for up to 1 year without causing an increase in malignancy risk. Longer exposure to CYC increased the risk of malignancy occurrence. Our results demonstrate that with treatment regimens currently in use for AAV, the risk of developing bladder and hematologic malignancies is lower than with previous standard regimens, underscoring the success of international efforts to find less cytotoxic treatment regimens for the disease. However, other toxicities associated with current therapies, e.g., in terms of infertility and infection, remain a concern. Quite recently, rituximab was introduced as part of AAV treatment regimens, showing success and with the promise of further reducing malignancy risk in AAV patients^{16, 31, 32}. Continued efforts aimed at developing additional safe and effective therapies for AAV are, nevertheless, still warranted.

References

1. Berden A, Goceroglu A, Jayne D, Luqmani R, Rasmussen N, Bruijn JA, *et al.* Diagnosis and management of ANCA associated vasculitis. *BMJ* 2012;344:e26.
2. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. *Ann Intern Med* 1983;98:76-85.
3. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). *Br Med J* 1958;2:265-70.
4. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, *et al.* Long-term patient survival in ANCA-associated vasculitis. *Ann Rheum Dis* 2011;70:488-94.
5. Eriksson P, Jacobsson L, Lindell A, Nilsson JA, Skogh T. Improved outcome in Wegener's granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts. *J Intern Med* 2009;265:496-506.
6. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, *et al.* Wegener granulomatosis: an analysis of 158 patients. *Ann Intern Med* 1992;116:488-98.
7. Westman KW, Bygren PG, Olsson H, Ransam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. *J Am Soc Nephrol* 1998;9:842-52.
8. Knight A, Askling J, Ekblom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. *Int J Cancer* 2002;100:82-5.
9. Faurschou M, Sorensen IJ, Mellekjaer L, Loft AG, Thomsen BS, Tvede N, *et al.* Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. *J Rheumatol* 2008;35:100-5.
10. Heijl C, Harper L, Flossmann O, Stucker I, Scott DG, Watts RA, *et al.* Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. *Ann Rheum Dis* 2011;70:1415-21.
11. Silva F, Seo P, Schroeder DR, Stone JH, Merkel PA, Hoffman GS, *et al.* Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. *Arthritis Rheum* 2011;63:2495-503.
12. Mahr A, Heijl C, Le Guenno G, Faurschou M. ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships. *Best Pract Res Clin Rheumatol* 2013;27:45-56.
13. Holle JU, Gross WL, Latza U, Nolle B, Ambrosch P, Heller M, *et al.* Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. *Arthritis Rheum* 2011;63:257-66.
14. de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, *et al.* Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. *Ann Intern Med* 2009;150:670-80.
15. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, *et al.* Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum* 2005;52:2461-9.
16. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, *et al.* Rituximab

- versus cyclophosphamide in ANCA-associated renal vasculitis. *N Engl J Med* 2010;363:211-20.
17. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, *et al.* 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum* 2013;65:1-11.
18. Casparie M, Tiebosch AT, Burger G, Blauweegers H, van de Pol A, van Krieken JH, *et al.* Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. *Cell Oncol* 2007;29:19-24.
19. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadonienė J, *et al.* A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. *N Engl J Med* 2003;349:36-44.
20. Ulm K. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR). *Am J Epidemiol* 1990;131:373-5.
21. Sun J, Ono Y, Takeuchi Y. A simple method for calculating the exact confidence interval of the SMR with a SAS function. *J Occup Health* 1996;38:196-7.
22. Thomsen JL, Parner ET. Methods for analysing recurrent events in health care data. Examples from admissions in Ebeltoft Health Promotion Project. *Fam Pract* 2006;23:407-13.
23. Mody GM, Cassim B. Rheumatologic manifestations of malignancy. *Curr Opin Rheumatol* 1997;9:75-9.
24. O'Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, *et al.* Azathioprine and UVA light generate mutagenic oxidative DNA damage. *Science* 2005;309:1871-4.
25. van den Reek JM, van Lumig PP, Janssen M, Schers HJ, Hendriks JC, van de Kerkhof PC, *et al.* Increased incidence of squamous cell carcinoma of the skin after long-term treatment with azathioprine in patients with autoimmune inflammatory rheumatic diseases. *J Eur Acad Dermatol Venereol* 2014;28:27-33.
26. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. *N Engl J Med* 2003;348:1681-91.
27. Pedersen EG, Pottgard A, Hallas J, Friis S, Hansen K, Jensen PE, *et al.* Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine. *Eur J Neurol* 2014;21:454-8.
28. Smith MA, Irving PM, Marinaki AM, Sanderson JD. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. *Aliment Pharmacol Ther* 2010;32:119-30.
29. Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. *J Gastroenterol Hepatol* 2012;27:385-9.
30. Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. *J Am Acad Dermatol* 2011;65:263-79; quiz 80.
31. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, *et al.* Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med* 2010;363:221-32.
32. Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, *et al.* Efficacy of remission-induction regimens for ANCA-associated vasculitis. *N Engl J Med* 2013;369:417-27.

Chapter VI

Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis

*E. van Daalen, R. Rizzo, A. Kronbichler, R. Wolterbeer, J.A. Bruijn JA, D.R. Jayne,
I.M. Bajema & C. Rahmattulla*

Ann Rheum Dis. 2017;76:1064-1069

Abstract

Objectives

Patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) treated with cyclophosphamide have an increased malignancy risk compared with the general population. We investigated whether treatment with rituximab instead of cyclophosphamide has decreased the malignancy risk in patients with AAV.

Methods

The study included patients with AAV treated at a tertiary vasculitis referral centre between 2000 and 2014. The malignancy incidence in these patients was compared with the incidence in the general population by calculating standardised incidence ratios (SIRs), adjusted for sex, age and calendar year. Malignancy incidence was compared between rituximab-treated and cyclophosphamide-treated patients.

Results

Of the 323 included patients, 33 developed a total of 45 malignancies during a mean follow-up of 5.6 years. This represented a 1.89-fold increased (95% CI 1.38 to 2.53) malignancy risk, and a non-significantly increased risk if non-melanoma skin cancer was excluded (SIR, 1.09; 95% CI 0.67 to 1.69). The risk of non-melanoma skin cancer was 4.58-fold increased (95% CI 2.96 to 6.76). Cyclophosphamide-treated patients had an increased malignancy risk compared with the general population (SIR, 3.10; 95% CI 2.06 to 4.48). In contrast, rituximab-treated patients had a malignancy risk similar to the general population (SIR, 0.67; 95% CI 0.08 to 2.43). The malignancy risk in cyclophosphamide-treated patients was 4.61-fold higher (95% CI 1.16 to 39.98) than in rituximab-treated patients.

Conclusions

The malignancy risk in patients with AAV was lower in rituximab-treated patients than in cyclophosphamide-treated patients. Notably, rituximab treatment was not associated with an increased malignancy risk compared with the general population. Rituximab could therefore be a safe alternative to cyclophosphamide in the treatment of AAV.

Introduction

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic autoimmune disease that affects small-sized to medium-sized blood vessels in multiple organs. AAV comprises granulomatosis with polyangiitis (formerly Wegener's granulomatosis), microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome).¹ Autoantibodies against proteinase 3 (PR3-ANCA) and myeloperoxidase (MPO-ANCA) assist in the diagnosis of AAV, but patients can also be negative for ANCA.² Although the introduction of cyclophosphamide therapy for AAV has improved patient survival considerably,^{3, 4} the carcinogenic effects of cyclophosphamide put patients at increased risk of developing malignancies. Several studies have reported increased malignancy risks in patients with AAV who were treated with cyclophosphamide compared with the general population, especially for non-melanoma skin cancer, bladder cancer, malignant lymphoma and leukaemia.^{5–12} Moreover, two studies found a dose–response association between cyclophosphamide and malignancy risk.^{8, 13} These results are restricted to patients with granulomatosis with polyangiitis and microscopic polyangiitis, and the malignancy risk in patients with eosinophilic granulomatosis with polyangiitis has not been investigated in detail before.

International efforts have been devoted to find less cytotoxic regimens for the treatment of AAV. In particular, the cumulative cyclophosphamide doses have been lowered,^{14, 15} and rituximab has emerged as a promising substitute for cyclophosphamide.^{16, 17} The initial findings from randomised controlled trials showed similar treatment efficacy in patients treated with either cyclophosphamide or rituximab.^{18–20} However, concerns were raised about a possible higher malignancy rate in patients treated with rituximab.^{21, 22} Notably, the trials focused on treatment efficacy; thus, their results regarding malignancy incidence should be interpreted in light of their small sample sizes and the short follow-up of a maximum of 24 months.

This study investigated the long-term malignancy risk in 323 patients with AAV. This is, to our knowledge, the first study to compare the long-term malignancy risks between patients treated with rituximab and patients treated with cyclophosphamide.

Methods

Study population

The study included patients with AAV (granulomatosis with polyangiitis, microscopic polyangiitis or eosinophilic granulomatosis with polyangiitis) who were treated at the Vasculitis and Lupus Clinic at Addenbrooke's Hospital,

Cambridge, UK, between 2000 and 2014. The diagnosis was established according to the European Medicines Agency algorithm.²³ Follow-up began on the date of diagnosis and ended on the date of death, the date the patient was lost to follow-up or on 1 July 2015, whichever occurred first. Follow-up surveillance was performed at Addenbrooke's Hospital. This study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki.

Clinical data

The following data were obtained from the medical records of the patients: demographic characteristics, diagnosis, date of diagnosis, ANCA serotype, organ involvement, therapy regimen, renal transplantation and the occurrence of malignancies. Patients with incomplete or missing medical records were excluded from further analyses. The cumulative doses of cyclophosphamide and rituximab during follow-up were determined. For subgroup analysis, patients were categorised according to their cyclophosphamide and/or rituximab exposure into the following categories: patients treated only with cyclophosphamide, patients treated only with rituximab, patients treated with both cyclophosphamide and rituximab, or patients who were not treated with either cyclophosphamide or rituximab. In all categories, the treatment may also have included other immunosuppressive agents, such as glucocorticoids, azathioprine, mycophenolate mofetil, methotrexate and/or tumour necrosis factor (TNF)- α inhibitors.

Standardised incidence ratio calculations

Standardised incidence ratios (SIRs) were calculated to compare the malignancy incidence between the study cohort and the general UK population, expressing the malignancy risk relative to the general population and matching for sex, age and calendar year. The SIR is the observed number of malignancies divided by the expected number of malignancies. The observed number of malignancies was the total number of primary invasive malignancies. The expected number of malignancies was the number of person-years at risk in our cohort multiplied by the malignancy incidence rates in the general UK population as obtained from the Office for National Statistics and matched for sex, 5-year age group and 1-year calendar time period.²⁴ Since the malignancy incidence rates were available until 2013, the malignancy incidence rate in 2013 was extrapolated to 2014 and 2015. The SIR was calculated for malignancies at all sites, for all malignancies except non-melanoma skin cancers and for each malignancy site as reported in the study population. SIRs were stratified by sex, age category at diagnosis (younger than the median age of 59 years vs 59 years or older), clinical diagnosis, ANCA serotype, renal transplantation and follow-up duration. Moreover, SIRs were compared in different treatment categories and according to the cumulative doses of cyclophosphamide and rituximab.

Statistical analyses

Student's t-test, the χ^2 test, Fisher's exact test and the one-way analysis of variance (ANOVA) test were used to compare the characteristics of different subgroups (SPSS statistical software, V.23). SIR values were compared between subgroups by calculating relative risks (RRs). Exact Poisson regression analysis was used to calculate 95% CIs for the SIR and RR values assuming a Poisson distribution of the observed number of cases (SAS software, V.9.3; SAS Institute).²⁵⁻²⁷ p Values less than 0.05 were considered significant in all analyses.

Results

Patient characteristics

The characteristics of the 323 patients with AAV included in this study are shown in table 1. The mean (SD) age at diagnosis was 56.4 (16.1) years, and the mean follow-up was 5.6 (3.2) years (1802 person-years). A total of 160 (49%) patients were diagnosed with microscopic polyangiitis; 109 patients (34%) were diagnosed with granulomatosis with polyangiitis; and 54 patients (17%) were diagnosed with eosinophilic granulomatosis with polyangiitis. Finally, 12 patients (4%) underwent renal transplantation, and 39 patients (12%) died during follow-up.

Malignancy occurrence

Of the 323 patients, 33 developed a total of 45 malignancies during follow-up. The sex, age and calendar year-adjusted malignancy risk was 1.89-fold higher in the patients with AAV than in the general population (95% CI 1.38 to 2.53) (table 2). There were 13 different malignancy types, with non-melanoma skin cancer occurring most frequently (10 basal cell carcinomas and 15 squamous cell carcinomas). The SIR for non-melanoma skin cancer was significantly increased (SIR, 4.58; 95% CI 2.96 to 6.76), while the risk for all malignancies excluding non-melanoma skin cancer was comparable to that of the general population (SIR, 1.09; 95% CI 0.67 to 1.69) (table 2).

Malignancy occurrence in the subgroups

The SIR for overall malignancy risk was stratified by gender, age, clinical diagnosis, ANCA serotype, renal transplantation and follow-up duration (supplementary table S1). Patients with eosinophilic granulomatosis with polyangiitis had the highest malignancy risk (SIR, 2.75; 95% CI 1.19 to 5.40), followed by those with granulomatosis with polyangiitis (SIR, 2.20; 95% CI 1.20 to 3.68) and those with microscopic polyangiitis (SIR, 1.59; 95% CI 1.01 to 2.38). Transplanted patients had a higher malignancy risk (SIR, 4.31; 95% CI 1.17 to 11.04) than patients who did not undergo renal transplantation (SIR, 1.79; 95% CI 1.29 to

Table 1. Characteristics of the patients with ANCA-associated vasculitis who were included in this study*

	All patients (N=323)	No malignancy occurrence (N=290)	Malignancy occurrence (N=33)	p Value†
Age (years) at diagnosis, mean (SD)	56.4 (16.1)	55.9 (16.3)	61.3 (12.7)	0.03
Follow-up (years), mean (SD)	5.6 (3.2)	5.5 (3.2)	6.3 (3.2)	0.20
Male, n (%)	149 (46)	135 (47)	14 (42)	0.65
Clinical diagnosis, n (%)				0.64
Microscopic polyangiitis	160 (49)	146 (50)	14 (42)	
Granulomatosis with polyangiitis	109 (34)	97 (33)	12 (36)	
Eosinophilic granulomatosis with polyangiitis	54 (17)	47 (16)	7 (21)	
ANCA serotype, n (%)‡				0.89
MPO-ANCA	110 (34)	99 (34)	11 (33)	
PR3-ANCA	152 (47)	136 (47)	16 (49)	
Organ involvement, mean (SD)	2.3 (1.5)	2.3 (1.5)	2.2 (1.2)	0.85
Deaths, n (%)	39 (12)	30 (10)	9 (27)	0.01
Relapsing disease, n (%)	86 (28)	79 (28)	7 (22)	0.54
Renal transplantation, n (%)	12 (4)	11 (4)	1 (3)	1.00
Treatment, n (%)				
Glucocorticoids	318 (99)	286 (99)	32 (97)	0.33
Cyclophosphamide	233 (72)	207 (72)	26 (79)	0.38
Rituximab	155 (48)	144 (50)	11 (33)	0.07
Cyclophosphamide and rituximab	114 (35)	105 (36)	9 (27)	0.31
Azathioprine	218 (68)	196 (68)	22 (67)	0.89
Mycophenolate mofetil	154 (48)	141 (50)	13 (39)	0.31
Methotrexate	39 (12)	35 (12)	4 (12)	1.00
TNF- α inhibitors	19 (6)	15 (5)	4 (12)§	0.12

*Values are reported as means (SD) or as numbers (%).

†p Values were calculated using Student's t-test, χ^2 test or Fisher's exact test.

‡ANCA serotype data were not available for 61 patients.

§Four of the 19 patients (21%) who received TNF- α inhibitors developed, in total, two basal cell carcinomas, one breast carcinoma and one prostate carcinoma. All four patients were also treated with cyclophosphamide, and one was treated with rituximab. Malignancy risk was similar in patients treated with and without a TNF- α inhibitor. ANCA, antineutrophil cytoplasmic antibody; MPO-ANCA, myeloperoxidase-ANCA; PR3-ANCA, proteinase 3 ANCA; TNF, tumour necrosis factor.

2.43). The treatment duration and cumulative doses of cyclophosphamide and rituximab in subgroups are shown in supplementary table S2.

Table 2. SIR for malignancies overall and per observed malignancy site*

Malignancy or malignancy site	N observed malignancies	N expected malignancies	SIR (95% CI)†	p Value†
All sites	45	23.80	1.89 (1.38 to 2.53)	<0.001
Non-melanoma skin cancer	25	5.46	4.58 (2.96 to 6.76)	<0.001
All malignancies excluding non-melanoma skin cancer	20	18.33	1.09 (0.67 to 1.69)	0.76
Lung	4	2.61	1.53 (0.42 to 3.92)	0.53
Breast	3	2.82	1.06 (0.22 to 3.11)	1.00
Colon or rectum	3	1.98	1.52 (0.31 to 4.44)	0.63
Prostate	2	2.74	0.73 (0.09 to 2.64)	0.97
Bladder	1	0.65	1.53 (0.04 to 8.57)	0.96
Pancreas	1	0.52	1.94 (0.05 to 10.81)	0.81
Testis	1	0.04	24.66 (0.62 to 137.41)	0.08
Ovary	1	0.39	2.54 (0.06 to 14.14)	0.65
Melanoma	1	0.66	1.52 (0.04 to 8.49)	0.96
Tongue	1	0.07	13.70 (0.35 to 76.34)	0.14
Central nervous system	1	0.25	3.94 (0.10 to 21.95)	0.45
Kidney	1	0.49	2.03 (0.05 to 11.32)	0.78

*SIR is the ratio of the observed to expected malignancies adjusted for sex, age (per 5-year age group) and calendar time period (per 1-year calendar time period).

†Calculated by exact Poisson regression analysis.

SIR, standardised incidence ratio.

Effects of cyclophosphamide and rituximab on malignancy risk

Patients treated only with cyclophosphamide had a 3.10-fold higher (95% CI 2.06 to 4.48) malignancy risk than the general population (table 3), and a 1.14-fold higher (95% CI 0.49 to 2.25) malignancy risk if non-melanoma skin cancer was excluded. Patients treated only with rituximab had no increased malignancy risk compared with the general population (SIR, 0.67; 95% CI 0.08 to 2.43), which was similar if non-melanoma skin cancer was excluded (SIR, 0.88; 95% CI 0.11 to 3.19). The malignancy risk in patients treated only with cyclophosphamide was 4.61-fold higher (95% CI 1.16 to 39.98) than in patients treated only with rituximab and was 3.05-fold higher (95% CI 1.40 to 7.35) than in patients treated with both cyclophosphamide and rituximab (table 4). The mean cumulative cyclophosphamide dose was lower in patients treated only with cyclophosphamide

Table 3. SIR stratified according to treatment category*

Treatment†	N patients	SIR (95% CI)‡	SIR p value‡	Cyclophosphamide cumulative dose (g), mean (SD)§	Follow-up (years), mean (SD)¶	Organ involvement, mean¶
Only cyclophosphamide	119	3.10 (2.06 to 4.48)	<0.001	7.26 (4.94)	4.92 (3.10)	2.11 (1.49)
Only rituximab	41	0.67 (0.08 to 2.43)	0.86	0.00	6.34 (3.56)	2.35 (1.09)
Both	114	1.01 (0.46 to 1.93)	1.00	11.05 (11.63)	6.60 (2.84)	2.56 (1.63)
None	48	2.10 (0.77 to 4.56)	0.14	0.00	4.20 (2.94)	1.96 (1.44)

*Values are reported as means (SD) unless otherwise indicated. The SIR is the ratio of the observed to expected malignancies adjusted for sex, age (per 5-year age group) and calendar time period (per 1-year calendar time period).

†The 'only cyclophosphamide' group was treated with cyclophosphamide but not with rituximab. The 'only rituximab' group was treated with rituximab but not with cyclophosphamide. 'Both' indicates a group that received cyclophosphamide and rituximab. 'None' indicates a patient group that neither received cyclophosphamide nor rituximab, but instead had various heterogeneous treatments including glucocorticoids, azathioprine, mycophenolate mofetil and methotrexate. Other immunosuppressive drugs were also administered in all of the groups.

‡Calculated by exact Poisson regression analysis.

§The mean cumulative cyclophosphamide dose differed between the 'only cyclophosphamide' and 'both' groups (Student's t-test, $p=0.002$).

¶The mean follow-up duration differed between groups (ANOVA, $p<0.001$). The mean follow-up duration also differed when the 'only rituximab' and 'both group' were compared with the 'only cyclophosphamide' and 'none' group (Student's t-test, $p<0.001$).

**The mean organ involvement did not differ between groups (ANOVA, $p=0.07$). ANOVA, analysis of variance; SIR, standardised incidence ratio.

than in patients treated with both cyclophosphamide and rituximab (7.3 g vs 11.1 g; $p=0.002$). The duration of follow-up was longer for patients who received rituximab than for patients who did not receive rituximab ($p<0.001$). In terms of mean organ involvement, the disease extent did not differ between the treatment groups ($p=0.07$) (table 3). Patients treated with cyclophosphamide received azathioprine maintenance therapy more frequently than those treated with rituximab (81% vs 42%; $p<0.001$). The SIR of malignancy for patients receiving a combination of cyclophosphamide and azathioprine was 3.20 (95% CI 2.05 to 4.76; $p<0.001$), whereas patients receiving a combination of rituximab and azathioprine expressed a comparable malignancy risk to that of the general population (SIR, 1.52; 95% CI 0.18 to 5.50; $p=0.38$).

Table 4. Relative risks (RR) according to treatment category

Treatment*	RR (95% CI)†	p Value‡
Only cyclophosphamide versus only rituximab	4.61 (1.16 to 39.98)	0.03
Only cyclophosphamide versus both	3.05 (1.40 to 7.35)	0.003
Only cyclophosphamide versus none	1.48 (0.60 to 4.36)	0.52

*The 'only cyclophosphamide' group was treated with cyclophosphamide but not with rituximab. The 'only rituximab' group was treated with rituximab but not with cyclophosphamide. 'Both' indicates a group that received cyclophosphamide and rituximab. 'None' indicates a group that did not receive cyclophosphamide or rituximab. Other immunosuppressive drugs were also administered in all of the groups.

†RR represents the risk of malignancy compared with the reference group. Calculated by exact Poisson regression analysis.

Effects of cumulative cyclophosphamide and rituximab doses on malignancy risk

The mean (SD) cumulative cyclophosphamide and rituximab doses were 9.1 (9.0) g and 5.9 (3.4) g, respectively. The highest cyclophosphamide dose was 108 g, given intermittently for 7.6 years, during a follow-up period of 8.1 years, in which the patient experienced no relapses. The highest rituximab dose was 18 g, given intermittently over 6.1 years, during a follow-up period of 9.1 years, in which one relapse occurred. A positive dose–response relationship was found between cyclophosphamide therapy and the overall malignancy risk (table 5), and between cyclophosphamide therapy and the risk of non-melanoma skin cancer (supplementary table S3). The opposite relationship was found for patients treated with rituximab: the higher the cumulative rituximab dose, the lower the overall malignancy risk (table 5), and the lower the risk of non-melanoma skin cancer (supplementary table S3). Patients who did not receive rituximab had a 2.86-fold higher (95% CI 1.98 to 3.99) malignancy risk than the general population. No increased risk was observed when patients had a cumulative rituximab dose below

6.0 g (SIR, 1.41; 95% CI 0.57 to 2.90). A total of 83 patients received more than 6.0 g rituximab, and these patients had a non-significantly lower malignancy risk than the general population (SIR, 0.45; 95% CI 0.09 to 1.32) and a 6.32-fold lower (95% CI 1.99 to 32.15) malignancy risk than patients who did not receive rituximab (table 5). The cumulative cyclophosphamide and rituximab doses individually received by the patients who developed a malignancy during follow-up are shown in supplementary table S4.

Table 5. SIR stratified according to cumulative cyclophosphamide and rituximab doses*

Cumulative dose (g)	N patients	N observed malignancies	SIR (95% CI)†	SIR p value†	RR (95% CI)†	RR p value†
Cyclophosphamide						
0	89	8	1.37 (0.59–2.70)	0.47	1 (reference)	
0.1–20	207	31	1.91 (1.30–2.71)	0.001	1.39 (0.63–3.50)	0.52
20–108	16	5	5.06 (1.64–11.82)	0.007	3.69 (0.95–12.78)	0.06
Rituximab						
0	167	34	2.86 (1.98–3.99)	<0.001	1 (reference)	
0.1–6	70	7	1.41 (0.57–2.90)	0.47	0.49 (0.18–1.13)	0.11
6–18	83	3	0.45 (0.09–1.32)	0.10	0.16 (0.03–0.50)	<0.001

*SIR is the ratio of the observed to expected malignancies adjusted for sex, age (per 5-year age group) and calendar time period (per 1-year calendar time period). SIR represents the malignancy risk compared with the general population, and the RR represents the malignancy risk compared with the reference group.

†Calculated by exact Poisson regression analysis.

RR, relative risk; SIR, standardised incidence ratio.

Discussion

This study compared the malignancy risks in patients with AAV treated with rituximab versus cyclophosphamide. Strikingly, patients treated with cyclophosphamide had a 4.61-fold higher risk than those treated with rituximab. In patients treated with cyclophosphamide, the malignancy risk was 3.10-fold higher than in the general population; in contrast, patients treated with rituximab did not show an increased risk compared with the general population. Patients treated with both rituximab and cyclophosphamide (N=114) had a lower malignancy risk than those treated with only cyclophosphamide, even though the mean cyclophosphamide dose was lower in the latter group. In addition,

there was a non-significant trend towards an inverse dose–response relationship between the cumulative rituximab dose and malignancy risk: the more rituximab a patient received, the lower the malignancy risk, with the risk actually falling below the risk in the general population if more than a cumulative dose of 6.0 g was given. The relative risk for developing a malignancy was more than six times lower in patients who had received a cumulative dose of rituximab of more than 6.0 g than in patients who had not received rituximab at all.

Interestingly, our findings – although the number of patients was relatively low – may point towards the possibility that rituximab has a protective role in the development of malignancies. This hypothesis is underlined by data showing a trend of an inverse dose–response relationship, and by the difference in malignancy development of the combined treatment group (i.e., patients receiving both cyclophosphamide and rituximab). Depletion of B cells due to rituximab may increase antitumour immunity, as was demonstrated in mouse models in which B-cell-deficient mice are resistant to the development of certain malignancies.^{28, 29} The enhanced antitumour immune response in these mice is probably caused by decreased IL-10 production by B cells, leading to enhancement of the antitumour effects of cytotoxic T cells.²⁸ There is emerging evidence that regulatory B cells are the main mediators of this mechanism.³⁰ In humans, the hypothesis that rituximab enhances the antitumour immune response is supported by the trend towards a lower risk of developing a second primary malignancy in patients with non-Hodgkin's lymphoma treated with rituximab-containing chemotherapy compared with patients treated with chemotherapy that does not include rituximab.^{31, 32} However, clarification of the effects of B-cell depletion on antitumour immunity in humans requires further investigation.

The increased risks of bladder and haematological malignancies that have been previously reported for patients treated with cyclophosphamide did not materialise in this study, possibly reflecting the ongoing efforts to reduce cumulative cyclophosphamide doses.¹¹ In accordance with two recent studies, only the risk of non-melanoma skin cancer was increased in the current study.^{9, 11} To prevent the development of these lesions, all patients were given written information concerning the risks of non-melanoma skin cancer. Moreover, they were advised to avoid ultraviolet radiation, to use sunscreens and to promptly report skin lesions. Of the patients who developed non-melanoma skin cancer despite these preventative measures, the majority had received azathioprine as maintenance therapy before the occurrence of this malignancy. Therefore, the previously reported association between non-melanoma skin cancer and azathioprine exposure is confirmed in our study.^{33–37} However, in our study, only the combination of cyclophosphamide and azathioprine treatment was associated with an increased malignancy risk. In contrast, patients treated with rituximab and azathioprine had a malignancy risk similar to the general population. Lowering cyclophosphamide and azathioprine exposure will most likely decrease

the malignancy risk. For patients with AAV who receive azathioprine, especially those who received cyclophosphamide as induction therapy, regular skin cancer screening should be started to control and prevent the development of non-melanoma skin cancers. Moreover, patients should be advised as to how to protect themselves against ultraviolet radiation.³⁸

Previous studies that investigated the malignancy risk in patients with AAV were restricted to patients with granulomatosis with polyangiitis and microscopic polyangiitis, and did not include patients with eosinophilic granulomatosis with polyangiitis. Eosinophilic granulomatosis with polyangiitis has a lower incidence than granulomatosis with polyangiitis and microscopic polyangiitis, and it is treated similarly.³⁹ The 54 patients with eosinophilic granulomatosis with polyangiitis who were included in this study had a 2.75-fold increased malignancy risk compared with the general population. We therefore recommend that clinicians monitor patients with eosinophilic granulomatosis with polyangiitis for malignancies as carefully as patients with granulomatosis with polyangiitis and microscopic polyangiitis.

One limitation of this study is its retrospective design. However, it excluded patients with unclear or missing data. A second limitation is the relative short follow-up, with a mean of 5.6 years. Longer follow-up studies are now required to validate our findings. A third limitation of this study is the relatively small number of patients, particularly in the subgroup analyses. This could explain the non-significance of the inverse dose–response relationship between rituximab and malignancy risk. This relationship merits further investigation in larger studies. Finally, the study involved just one medical centre, so the findings may not be generalisable to other settings. One strength of this study is the large study population, in which, for the first time, the malignancy risk was evaluated in patients treated with rituximab during long-term follow-up. This is also the first study to analyse the malignancy risk in patients with eosinophilic granulomatosis with polyangiitis. Another strength of our study is the calculation of cumulative cyclophosphamide and rituximab doses. Finally, the calculation of sex, age and calendar-year period-matched SIRs ensured reliable comparisons between our cohort and the general population.

In conclusion, we demonstrated that patients with AAV who are treated with rituximab have a decreased burden of malignancy, which surpasses expectations from clinical trials data.^{18, 19} Moreover, our results suggest that rituximab may protect against the occurrence of malignancies, a possibility that should be explored in further detail using larger cohort populations. Patients with AAV treated with rituximab had a strikingly lower malignancy risk than those treated with cyclophosphamide and no increased malignancy risk compared with the general population. Therefore, the rituximab dose currently used in clinical practice could be a safe alternative to cyclophosphamide in the treatment of AAV.

References

- Jennette JC, Falk RJ, Bacon PA, *et al.* 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum* 2013;65:1–11.
- Hagen EC, Daha MR, Hermans J, *et al.* Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. *Kidney Int* 1998;53:743–53.
- Flossmann O, Berden A, de Groot K, *et al.* Long-term patient survival in ANCA-associated vasculitis. *Ann Rheum Dis* 2011;70:488–94.
- Eriksson P, Jacobsson L, Lindell A, *et al.* Improved outcome in Wegener's granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts. *J Intern Med* 2009;265:496–506.
- Hoffman GS, Kerr GS, Leavitt RY, *et al.* Wegener granulomatosis: an analysis of 158 patients. *Ann Intern Med* 1992;116:488–98.
- Westman KW, Bygren PG, Olsson H, *et al.* Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. *J Am Soc Nephrol* 1998;9:842–52.
- Knight A, Askling J, Ekblom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. *Int J Cancer* 2002;100:82–5.
- Faurschou M, Sorensen IJ, Mellemkjaer L, *et al.* Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. *J Rheumatol* 2008;35:100–5.
- Heijl C, Harper L, Flossmann O, *et al.* Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. *Ann Rheum Dis* 2011;70:1415–21.
- Silva F, Seo P, Schroeder DR, *et al.* Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. *Arthritis Rheum* 2011;63:2495–503.
- Rahmattulla C, Berden AE, Wakker SC, *et al.* Incidence of malignancies in patients with antineutrophil cytoplasmic antibody-associated vasculitis diagnosed between 1991 and 2013. *Arthritis Rheum* 2015;67:3270–8.
- Faurschou M, Mellemkjaer L, Voss A, *et al.* Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis. *Rheumatology (Oxford)* 2015;54:1345–50.
- Knight A, Askling J, Granath F, *et al.* Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. *Ann Rheum Dis* 2004;63:1307–11.
- Jayne D, Rasmussen N, Andrassy K, *et al.* A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. *N Engl J Med* 2003;349:36–44.
- de Groot K, Harper L, Jayne DR, *et al.* Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. *Ann Intern Med* 2009;150:670–80.
- Specks U, Fervenza FC, McDonald TJ, *et al.* Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. *Arthritis Rheum* 2001;44:2836–40.
- Keogh KA, Ytterberg SR, Fervenza FC, *et al.* Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. *Am J Respir Crit Care Med* 2006;173:180–7.

18. Jones RB, Furuta S, Tervaert JW, *et al.* Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. *Ann Rheum Dis* 2015;74:1178–82.
19. Specks U, Merkel PA, Seo P, *et al.* Efficacy of remission-induction regimens for ANCA-associated vasculitis. *N Engl J Med* 2013;369:417–27.
20. Stone JH, Merkel PA, Spiera R, *et al.* Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med* 2010;363:221–32.
21. Karassa FB. Rituximab or cyclophosphamide in ANCA-associated renal vasculitis. *N Engl J Med* 2010;363:2073; author reply 73–4.
22. Falk RJ, Jennette JC. Rituximab in ANCA-associated disease. *N Engl J Med* 2010;363:285–6.
23. Watts R, Lane S, Hanslik T, *et al.* Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. *Ann Rheum Dis* 2007;66:222–7.
24. Cancer Statistics: Registration Series MB1 (Accessed October 2015) <http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Cancer+Registrations>
25. Ullm K. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR). *Am J Epidemiol* 1990;131:373–5.
26. Thomsen JL, Parner ET. Methods for analysing recurrent events in health care data. Examples from admissions in Ebeltoft Health Promotion Project. *Fam Pract* 2006;23:407–13.
27. Sun J, Ono Y, Takeuchi Y. A simple method for calculating the exact confidence interval of the SMR with a SAS function. *J Occup Health* 1996;38:196–7.
28. Inoue S, Leitner WW, Golding B, *et al.* Inhibitory effects of B cells on antitumor immunity. *Cancer Res* 2006;66:7741–7.
29. Schioppa T, Moore R, Thompson RG, *et al.* B regulatory cells and the tumor-promoting actions of TNF- α during squamous carcinogenesis. *Proc Natl Acad Sci USA* 2011;108:10662–7.
30. Balkwill F, Montfort A, Capasso M. B regulatory cells in cancer. *Trends Immunol* 2013;34:169–73.
31. Cho SF, Wu WH, Yang YH, *et al.* Risk of second primary cancer in patients with B-cell non-Hodgkin lymphoma receiving rituximab-containing chemotherapy: a nationwide population-based study. *Anticancer Res* 2015;35:1809–14.
32. Xu Y, Wang H, Zhou S, *et al.* Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma. *Leuk Lymphoma* 2013;54:1396–404.
33. van den Reek JM, van Lümmig PP, Janssen M, *et al.* Increased incidence of squamous cell carcinoma of the skin after long-term treatment with azathioprine in patients with autoimmune inflammatory rheumatic diseases. *J Eur Acad Dermatol Venereol* 2014;28:27–33.
34. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. *N Engl J Med* 2003;348:1681–91.
35. Pedersen EG, Pottegård A, Hallas J, *et al.* Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine. *Eur J Neurol* 2014;21:454–8.
36. Smith MA, Irving PM, Marinaki AM, *et al.* Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. *Aliment Pharmacol Ther* 2010;32:119–30.
37. Setshedi M, Epstein D, Winter TA, *et al.* Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. *J Gastroenterol Hepatol* 2012;27:385–9.

38. Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients. *J Am Acad Dermatol* 2011;65:263–79; quiz 80.
39. Mukhtyar C, Guillevin L, Cid MC, *et al.* EULAR recommendations for the management of primary small and medium vessel vasculitis. *Ann Rheum Dis* 2009;68:310–17.

Chapter VII

Summary and general discussion

More than 150 years after the publication of the first case-report of a patient with, what is now considered to be, antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis, considerable progress has been made in the understanding of the pathogenesis, the diagnostic approach, and the treatment of this disease.¹ Research in ANCA-associated vasculitis has come a long way. However, the heart of the matter is still unsolved, as the exact nature of this complex disease and, consequently, the most appropriate disease classification system and optimal treatment strategies are still not unravelled. In this thesis, several aspects of ANCA-associated vasculitis concerning genetics, clinical and histopathological classification, and long-term outcome were investigated.

Genetics and disease classification

Despite the considerable progress made in recent decades, the pathophysiology of ANCA-associated vasculitis is still not fully unravelled. Amongst others, genetic factors are believed to contribute to the pathogenesis of this complex disease.² In **Chapter 2** of this thesis we conducted a meta-analysis to investigate the genetic variants that are most likely associated with ANCA-associated vasculitis. To increase the validity of our meta-analysis, we included raw data from a large genome-wide association study (GWAS).³ This study provides the first complete and comprehensive overview of all genetic variants investigated in ANCA-associated vasculitis in at least two independent studies.

Thirty-three genetic variants, located in or near 15 genes, were found to be associated with ANCA-associated vasculitis. The genetic variants were located in or near the following genes: *CD226*, *CTLA-4*, *FCGR2A*, *HLA-B*, *HLA-DP*, *HLA-DQ*, *HLA-DR*, *HSD17B8*, *IRF5*, *PTPN22*, *RING1/RXR*, *RXR*, *STAT4*, *SERPINA1*, and *TLR9*. The results of this meta-analysis confirm that genetic factors contribute to the pathogenesis of ANCA-associated vasculitis. In particular, they support a role for the major histocompatibility complex (MHC), the innate and adaptive immune system, and several inflammatory processes in the pathogenesis of this complex disease; the identified genetic factors could potentially result in altered HLA mediated antigen presentation, inadequate T- and B-lymphocyte activation, and abnormal target antigen structure and/or function. The mechanisms whereby and the extent to which these genetic variants directly cause disease requires further investigation.

Most importantly, the results of our meta-analysis provide clear evidence of a genetic susceptibility that differed between granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) patients and between proteinase 3 (PR3)-ANCA positive and myeloperoxidase (MPO)-ANCA positive patients. Moreover, the associations were primarily aligned with ANCA-serotype rather than with the clinically defined syndromes: in 76% of the genetic variants,

subdivision based on ANCA-serotype resulted in higher odds ratios than subdivision based on clinical diagnosis.

Considerable debate surrounds the classification of ANCA-associated vasculitis. GPA and MPA have overlapping clinical features, and while patients with typical characteristics are easy to classify, many patients are allocated inconsistently even by experienced clinicians. Moreover, even though the Chapel Hill Consensus Conference (CHCC) and European Medicines Agency (EMA) classification systems use identical names for the ANCA-associated vasculitis disease categories, a study performed by Lionaki *et al.* demonstrated substantial discrepancies between the two classification systems in the allocation of patients to these categories: 78% of patients classified as having MPA using the CHCC system were considered to have GPA by the EMA system.⁴ The authors argued that this resulted in part from differences in disease definitions. For instance, the EMA system over-represents the diagnostic category of GPA because, according to the American College of Rheumatology criteria, essentially any upper respiratory involvement is considered to be GPA.⁵ Overall, the inconsistencies between clinicians and between the classification systems and the lack of diagnostic criteria make the use of the terms GPA and MPA less accurate and less predictive of outcome.

Interestingly, a number of clinical studies demonstrated that disease course, treatment response, and patient outcome align more closely with ANCA-serotype than with clinical diagnosis. Lionaki *et al.* demonstrated that ANCA-serotype is closely associated with clinical features and the relative frequency of organ system involvement.⁴ ANCA-serotype was shown to be more strongly associated with relapse than clinical diagnosis, and patients with PR3-ANCA positive GPA were shown to have a significantly different disease course than patients with MPO-ANCA positive GPA.^{4,6} Unizony *et al.* investigated treatment response in patients enrolled in the Rituximab in ANCA-associated Vasculitis (RAVE) trial according to both clinical diagnosis (GPA versus MPA) and ANCA-serotype (PR3-ANCA versus MPO-ANCA).⁷ Treatment response did not differ between GPA and MPA patients. In contrast, treatment response did differ between PR3-ANCA positive and MPO-ANCA positive patients: PR3-ANCA positive patients were shown to respond better to rituximab than to the combination of cyclophosphamide and azathioprine. These findings have led to the following question: is it the name of the disease or is it the serotype that is more important with respect to disease classification and individual patient prognosis?

Our genetic findings taken together with the clinical findings discussed previously underscore the need to account for ANCA-serotype in the classification of ANCA-associated vasculitis. Arguments to incorporate ANCA-serotype in the classification of ANCA-associated vasculitis include:

- Distinct genetic subsets correlate more strongly with ANCA-serotype than with clinical classification
- ANCA-serotype correlates better with clinical features than clinical classification
- ANCA-serotype is more reproducible and reliable than clinical classification
- ANCA-serotype better reflects the disease mechanism

However, there are problems with using only ANCA-serotype to classify patients. For example, using current assays, 5-10% of ANCA-associated vasculitis patients are ANCA-negative.⁸⁻¹³ Moreover, better understanding of the granuloma formation in ANCA-associated vasculitis may reveal therapies that specifically target this component of the disease, which requires acknowledging this phenotype. Therefore, for now, a classification system based primarily on ANCA-serotype with subsequent subdivision based on clinical diagnosis – e.g. PR3-ANCA positive GPA – may be the best way to characterize patients until we truly understand the similarities and differences in the pathogenesis of the ANCA-associated vasculitides. This will provide practical classification criteria better aligned to patient phenotype, treatment responses, and outcomes, and will allow logical design and testing of future therapies.

In **Chapter 3**, we focused on ear, nose, and throat (ENT) involvement and ANCA-serotype with respect to renal histology at diagnosis and renal outcome. Previously, Hauer *et al.* demonstrated that MPO-ANCA positive vasculitis patients have more chronic lesions in their renal biopsies than PR3-ANCA positive vasculitis patients. The authors hypothesized that this finding may reflect an association of MPO-ANCA with a clinical phenotype of smouldering disease.¹⁴ This could be indicative of different disease mechanisms in PR3-ANCA vasculitis and MPO-ANCA vasculitis, in line with the results presented in **Chapter 2**. However, PR3-ANCA positivity is also closely correlated with ENT disease.¹⁵¹⁶ Thus, another hypothesis for the fewer chronic lesions in the renal biopsies of PR3-ANCA positive patients is that the clinically overt ENT manifestations in these patients lead to earlier diagnosis of ANCA-associated vasculitis by reducing patient's and/or doctor's delay.

In our study, patients with ENT involvement had fewer chronic lesions in their renal biopsies and better renal function at diagnosis and 5-year follow-up than patients without ENT involvement. Our results suggest that this is not caused by earlier diagnosis due to the clinically overt ENT symptoms: in the same patients, other manifestations that would also have reduced patient and/or doctor's delay, such as lung involvement, cutaneous manifestations, and

arthralgia/arthritis, were not associated with renal histology or renal outcome. To exemplify this point further; a study by Bligny *et al.* reported higher survival in ANCA-associated vasculitis patients with ENT involvement than patients without ENT involvement.¹⁷ The authors argued that this is not likely caused by earlier diagnosis and treatment, as 87% of patients without ENT involvement had lung involvement, which, theoretically, also would have led to earlier diagnosis. Interestingly, a study by Poulton *et al.* even demonstrated an increased diagnostic delay in ANCA-associated vasculitis patients with ENT involvement.¹⁸ The authors argued that both physicians and patients focused on the more common causes of the ENT symptoms instead of regarding them as signs of vasculitis. As could be expected, patients with skin manifestations often had a prompt diagnosis of ANCA-associated vasculitis.¹⁸

In our study, ENT involvement overruled ANCA-serotype in the multivariable analysis and was still associated with better renal outcome in a sub-analysis including only PR3-ANCA positive patients. Thus, independent of ANCA-serotype, ENT involvement itself seems to be associated with better renal histology and outcome. The findings of this study can be viewed in the context of the two distinct pathological features in GPA, namely: vasculitis, which is predominantly localized in the kidneys, and granulomatosis, which predominantly involves the airways.¹⁹ The clinical heterogeneity of GPA reflects a spectrum of manifestations ranging from predominantly vasculitic disease at one end to predominantly granulomatous disease at the other. Thus, in our study, the patients with ENT involvement could have had a predominantly granulomatous disease, while the patients without ENT involvement had a predominantly vasculitic disease. In this light, the better renal prognosis in the patients with ENT involvement could be representative of the more benign renal course of 'granulomatous GPA' compared to 'vasculitic GPA'.

The pathological pathways leading to vasculitis or granuloma formation are hypothesized to be different. Immunological studies indicate that these two distinct pathological features correspond to different T cell immune responses; i.e. a T helper cell 1 (Th1)-type response in granulomatous disease and a Th2-type response in vasculitic disease.²⁰⁻²² Further studies are needed to adequately assess the potential prognostic value of ENT involvement, which, in turn, might provide further insight into the pathogenesis of GPA.

Histopathological classification of ANCA-associated glomerulonephritis

The histopathological classification of ANCA-associated glomerulonephritis was devised by an international working group of renal pathologists and nephrologists with the aim of further adding to the prognostication of patients with ANCA-

associated glomerulonephritis.²³ Thus far, 21 validation studies, consisting of cohorts from Asia, North-America, Australia, and Europe, have investigated the prognostic value of the classification system.²⁴⁻⁴⁴ **Chapter 4** reviews the findings of these validation studies and puts them into a broader perspective. In general, the studies confirmed the predictive value of the classification system for renal outcome in the focal and sclerotic classes. However, several studies showed conflicting results with respect to the crescentic and mixed classes.²⁴⁻³⁷

A number of factors may have contributed to the inconsistent results between the validation studies. As indicated by their denominator, biopsies in the mixed class may indeed show mixed lesions in which either an acute or chronic phenotype can predominate. Therefore, differences in the compositions of the mixed classes in the various validation studies may have contributed to the different outcomes reported for this class. It could be argued that, in its current form, this class is too heterogeneous to have a straightforward predictive value in the classification system. A second explanation for the inconsistent results between the validation studies might be a problem of definitions; the crescentic class was originally defined as the predominance of cellular crescents, however, this definition may have lacked important details leading to inter-observer discrepancies among pathologists.^{23, 29} Differences in patient population and treatment most probably also contributed to the variable results between the validation studies. Unfortunately, due to their retrospective design, it was not possible to fully account for treatment in most of the validation studies. A number of validation studies suggested that inclusion of tubulointerstitial parameters could increase the predictive value of the classification system. In contrast, Berden *et al.* argued that inclusion of tubulointerstitial parameters does not add meaningfully to the predictive value of the classification system and only increases its complexity.²³

Currently ongoing studies that aim at the optimization of the histopathological classification of ANCA-associated glomerulonephritis are discussed in the 'Future perspectives' section of this chapter.

Treatment and outcome

Over the last decades, the introduction of immunosuppressive treatment has improved the prognosis of patients with ANCA-associated vasculitis dramatically. Maintenance of remission, on the other hand, still represents a challenge, necessitating prolonged immunosuppressive treatment.⁴⁵ Despite the clear success of conventional immunosuppressive therapies, their long-term side effects jeopardize outcomes. One of the long-term side effects of immunosuppressive treatment is the occurrence of malignancies.⁴⁶

Chapter 5 reports the results of the first 10-year follow-up study investigating malignancy risk in patients with ANCA-associated vasculitis treated with current

treatment regimens. In these patients, overall malignancy risk was 2.21 times increased compared to the general population. This increased malignancy risk was attributable solely to the increased risk of non-melanoma skin cancer (NMSC). Importantly, in contrast to previous studies,⁴⁷ in our study the risks of bladder cancer, lymphomas, and leukaemia were not increased. These findings most likely reflect the decrease in cyclophosphamide exposure in the treatment of ANCA-associated vasculitis in the last decade.^{8-10, 13}

The close relationship between disease activity and immunosuppressive treatment exposure makes it difficult to distinguish disease-related from treatment-related effects on malignancy risk. Nonetheless, a subgroup analysis – based on year of diagnosis and subsequent treatment – demonstrated that malignancy risk was no longer significantly increased after the major reduction in cyclophosphamide exposure that resulted from the publication of the CYCAZAREM trial.¹⁰ Moreover, malignancy risk was directly correlated to the duration of cyclophosphamide treatment.

In summary, the data reported in **Chapter 5** demonstrate the effectiveness of international efforts to reduce toxicity in the treatment of ANCA-associated vasculitis. Despite the advances achieved, the road towards treatment modalities with less adverse effects in terms of, amongst others, infection risk, infertility, and malignancy occurrence in patients with prolonged cyclophosphamide exposure, is still long. Recently, rituximab was successfully introduced in the treatment of ANCA-associated vasculitis with the aim of, amongst others, further reducing these adverse treatment effects.^{13, 48, 49}

Chapter 6 reports the first study that compares the long-term malignancy risks between rituximab-based and cyclophosphamide-based treatment in ANCA-associated vasculitis. Strikingly, malignancy risk was 4.61 fold increased in patients treated with cyclophosphamide compared to patients treated with rituximab. Malignancy risk was 3.10 fold increased in patients treated with cyclophosphamide compared to the general population. This increased malignancy risk was again solely attributable to the occurrence of NMSC. In contrast, malignancy risk was not increased in patients treated with rituximab. Interestingly, patients treated with both rituximab and cyclophosphamide had a lower malignancy risk than patients treated with cyclophosphamide alone, despite the mean cumulative cyclophosphamide dose being lower in the latter group. In addition, there was a trend towards an inverse dose-response relationship between the cumulative rituximab dose and malignancy risk, i.e., the more rituximab a patient received, the lower the malignancy risk. Notably, patients who cumulatively received more than 6.0g rituximab had a lower malignancy risk than the general population. This effect was observed for both haematological and non-haematological malignancies.

These findings hint towards the possibility that rituximab has an inhibitory effect on (haematological and non-haematological) malignancy occurrence. B cell

depletion – the mechanism of action of rituximab – was shown to increase anti-tumour immunity in murine models.^{50, 51} This enhanced anti-tumour immune response is hypothesized to be caused by decreased IL-10 production by B regulatory cells, leading to enhancement of the anti-tumour effects of cytotoxic T cells.⁵⁰ In humans, the hypothesis that rituximab enhances the anti-tumour immune response is supported by the trend towards a lower risk of developing a second primary (non-haematological) malignancy in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy, compared to patients treated with conventional chemotherapy not including rituximab.^{52, 53} Clearly, elucidation of the effects of B-cell depletion on anti-tumour immunity requires further investigation.

In conclusion, the results of the study reported in **Chapter 6** demonstrate that patients with ANCA-associated vasculitis treated with rituximab have a decreased burden of malignancy, surpassing expectations from clinical trial data.^{54, 55} Moreover, our results suggest that rituximab may have an inhibitory effect on malignancy occurrence. Therefore, regarding the occurrence of malignancies, rituximab seems a superior alternative to cyclophosphamide in the treatment of ANCA-associated vasculitis.

Future perspectives

Despite the major advances made in the understanding of the pathogenesis, the diagnostic approach, and the treatment of ANCA-associated vasculitis, many questions are still unanswered and new questions arise every day. The results of the meta-analysis presented in this thesis confirm that genetic factors contribute to the pathogenesis of ANCA-associated vasculitis. However, functional studies remain to be performed to establish the precise role of these genetic variants and their effects on the disease process. Future studies in genetics and epigenetics will likely not only lead to a deeper understanding of the pathogenesis of ANCA-associated vasculitis, but perhaps also to a personalised medicine approach to clinical management and therapeutic target selection. In systemic lupus erythematosus, researchers have developed a personalized transcriptional immunomonitoring approach that enables patient stratification based on molecular networks best correlating with disease progression.⁵⁶ The development of such a personalized transcriptional immunomonitoring approach in ANCA-associated vasculitis would create some order in this complex heterogeneous disease, bringing patient-tailored treatment one step closer.

The genetic differences between PR3-ANCA vasculitis and MPO-ANCA vasculitis indicate that future genetic and clinical studies should be sufficiently powered to allow for independent analysis of PR3-ANCA positive and MPO-ANCA positive patients. Currently, a GWAS including GPA and MPA patients

is being conducted that is sufficiently powered to investigate genetic associations in the PR3-ANCA and MPO-ANCA subgroups independently.⁵⁷ Moreover, an ongoing GWAS is investigating whether there are genetic differences between MPO-ANCA positive and MPO-ANCA negative patients with eosinophilic granulomatosis with polyangiitis (EGPA).⁵⁷ Preliminary results of this GWAS point towards profound differences in the pathogenesis of these two EGPA subtypes and suggest a number of therapeutic approaches that might be effective in EGPA.

Current treatment strategies in ANCA-associated vasculitis do not take into account specific patient and disease characteristics. However, genetic and clinical data suggest that treatment should be tailored to specific parameters. Possible parameters that, now or in the future, could be taken into consideration for refining treatment, in the form of patient-tailored therapy, are: genetic markers, ANCA-serotype, severity scores, and scores and/or markers predicting relapse. A step in this direction is set by the identification of altered gene expressions that can predict treatment response in MPA patients.⁵⁸ The MAINRITSAN 2 trial (ClinicalTrials.gov NCT01731561) is currently investigating treatment response in rituximab treatment according to a fixed administration protocol versus individually tailored rituximab treatment based on ANCA-status and peripheral blood CD19 lymphocyte reappearance. In refractory rheumatoid arthritis, similar parameters (rheumatoid factor, anti-CCP antibodies, and serum IgG concentration) were shown to predict treatment response to rituximab.⁵⁹

Presently, we are stepping into a new therapeutic era with targeted therapies – e.g. monoclonal antibodies such as rituximab – that could further improve the treatment of ANCA-associated vasculitis. This is a field for ongoing and future trials that investigate the optimal dosing and duration of rituximab both as induction and maintenance treatment. The currently ongoing RITAZAREM trial (ClinicalTrials.gov NCT01697267) will provide the largest trial dataset for the use of rituximab as remission-induction treatment for ANCA-associated vasculitis. This trial compares rituximab and azathioprine maintenance treatment following rituximab induction-treatment, and explores whether prolonged B-cell depletion leads to sustained treatment-free remission after treatment discontinuation. Although the first studies, as demonstrated in this thesis, indicate that rituximab treatment has resulted in less morbidity in the long run, more long-term follow-up studies with longer follow-up are warranted.

Moreover, it becomes more and more apparent that the burden of corticosteroids is responsible for a substantial part of the treatment-related adverse events in ANCA-associated vasculitis. Several ongoing studies are investigating different dosing regimens of steroids regarding efficacy and safety. The currently ongoing PEXIVAS trial (ClinicalTrials.gov NCT00987389) is the largest trial conducted in ANCA-associated vasculitis thus far and has recruited more than 700 patients from over 100 centres over the world. This 2-by-2 trial addresses the

effect of a reduced cumulative dosing regimen of glucocorticoids and the effect of adjuvant plasma exchange in patients with severe ANCA-associated vasculitis.

Regarding histology, future studies might answer the question whether renal biopsy findings will be directly useful to guide therapeutic decision-making. A large international validation study of the histopathological classification of ANCA-associated glomerulonephritis in which histopathological, clinical, and therapeutic data are being incorporated is currently being conducted. Moreover, the biopsies included in the 21 previously performed validation studies are now being collected with the aim of re-evaluating them by a group of experienced pathologists. The aim of these studies is to evaluate the predictive value of the classification system, formulate clearer and more concise definitions, and possibly also revise the histopathological classification of ANCA-associated glomerulonephritis.

Overall, the vasculitis patient and research communities can be optimistic about the future of research in ANCA-associated vasculitis and the potential for this work to unravel the puzzle of this complex disease and, most importantly, to improve the lives of patients with ANCA-associated vasculitis.

References

1. Kussmaul A, Maier R. Über eine bisher nicht beschriebene eigenthümliche arterienkrankung (periarteritis nodosa), die mit morbus brightii und rapid fortschreitender allgemeiner muskellähmung einhergeht. *Dtsch Arch Klin Med* 1866;1:484-518.
2. Xiao H, Hu P, Falk RJ, *et al.* Overview of the Pathogenesis of ANCA-Associated Vasculitis. *Kidney Dis (Basel)* 2016;1:205-15.
3. Lyons PA, Rayner TF, Trivedi S, *et al.* Genetically distinct subsets within ANCA-associated vasculitis. *N Engl J Med* 2012;367:214-23.
4. Lionaki S, Blyth ER, Hogan SL, *et al.* Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. *Arthritis Rheum* 2012;64:3452-62.
5. Fries JF, Hunder GG, Bloch DA, *et al.* The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. *Arthritis Rheum* 1990;33:1135-6.
6. Schirmer JH, Wright MN, Herrmann K, *et al.* Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive Granulomatosis With Polyangiitis (Wegener's) Is a Clinically Distinct Subset of ANCA-Associated Vasculitis: A Retrospective Analysis of 315 Patients From a German Vasculitis Referral Center. *Arthritis Rheumatol* 2016;68:2953-63.
7. Unizony S, Villarreal M, Miloslavsky EM, *et al.* Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. *Ann Rheum Dis* 2016;75:1166-9.
8. de Groot K, Harper L, Jayne DR, *et al.* Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. *Ann Intern Med* 2009;150:670-80.
9. De Groot K, Rasmussen N, Bacon PA, *et al.* Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum* 2005;52:2461-9.
10. Jayne D, Rasmussen N, Andrassy K, *et al.* A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. *N Engl J Med* 2003;349:36-44.
11. Jayne DR, Gaskin G, Rasmussen N, *et al.* Randomized trial of plasma exchange or high-dose methylprednisolone as adjunctive therapy for severe renal vasculitis. *J Am Soc Nephrol* 2007;18:2180-8.
12. Schmitt WH, Hagen EC, Neumann I, *et al.* Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. *Kidney Int* 2004;65:1440-8.
13. Jones RB, Tervaert JW, Hauser T, *et al.* Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. *N Engl J Med* 2010;363:211-20.
14. Hauer HA, Bajema IM, van Houwelingen HC, *et al.* Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. *Kidney Int* 2002;61:80-9.
15. Hoffman GS, Kerr GS, Leavitt RY, *et al.* Wegener granulomatosis: an analysis of 158 patients. *Ann Intern Med* 1992;116:488-98.
16. Jennette JC, Falk RJ. Small-vessel vasculitis. *N Engl J Med* 1997;337:1512-23.
17. Bligny D, Mahr A, Toumelin PL, *et al.* Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. *Arthritis Rheum* 2004;51:83-91.
18. Poulton CJ, Nachman PH, Hu Y, *et al.* Path-

- ways to renal biopsy and diagnosis among patients with ANCA small-vessel vasculitis. *Clin Exp Rheumatol* 2013;31:S32-7.
19. Bacon PA. Vasculitis from the rheumatologist's viewpoint. *Adv Exp Med Biol* 1993;336:185-95.
20. Balding CE, Howie AJ, Drake-Lee AB, *et al.* Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis. *Clin Exp Immunol* 2001;125:332-9.
21. Csernok E, Trabandt A, Muller A, *et al.* Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. *Arthritis Rheum* 1999;42:742-50.
22. Muller A, Trabandt A, Gloeckner-Hofmann K, *et al.* Localized Wegener's granulomatosis: predominance of CD26 and IFN-gamma expression. *J Pathol* 2000;192:113-20.
23. Berden AE, Ferrario F, Hagen EC, *et al.* Histopathologic classification of ANCA-associated glomerulonephritis. *J Am Soc Nephrol* 2010;21:1628-36.
24. Chang DY, Wu LH, Liu G, *et al.* Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. *Nephrol Dial Transplant* 2012;27:2343-9.
25. Muso E, Endo T, Itabashi M, *et al.* Evaluation of the newly proposed simplified histological classification in Japanese cohorts of myeloperoxidase-anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in comparison with other Asian and European cohorts. *Clin Exp Nephrol* 2013;17:659-62.
26. Hilhorst M, Wilde B, van Breda Vriesman P, *et al.* Estimating renal survival using the ANCA-associated GN classification. *J Am Soc Nephrol* 2013;24:1371-5.
27. Ellis CL, Manno RL, Havill JP, *et al.* Validation of the new classification of pauci-immune glomerulonephritis in a United States cohort and its correlation with renal outcome. *BMC Nephrol* 2013;14:210.
28. Togashi M, Komatsuda A, Nara M, *et al.* Validation of the 2010 histopathological classification of ANCA-associated glomerulonephritis in a Japanese single-center cohort. *Mod Rheumatol* 2014;24:300-3.
29. Ford SL, Polkinghorne KR, Longano A, *et al.* Histopathologic and clinical predictors of kidney outcomes in ANCA-associated vasculitis. *Am J Kidney Dis* 2014;63:227-35.
30. Unlu M, Kiremitci S, Ensari A, *et al.* Pauci-immune necrotizing crescentic glomerulonephritis with crescentic and full moon extracapillary proliferation: clinico-pathologic correlation and follow-up study. *Pathol Res Pract* 2013;209:75-82.
31. Naidu GS, Sharma A, Nada R, *et al.* Histopathological classification of pauci-immune glomerulonephritis and its impact on outcome. *Rheumatol Int* 2014;34:1721-7.
32. Chen YX, Xu J, Pan XX, *et al.* Histopathological Classification and Renal Outcome in Patients with Antineutrophil Cytoplasmic Antibodies-associated Renal Vasculitis: A Study of 186 Patients and Metaanalysis. *J Rheumatol* 2017;44:304-13.
33. Quintana LF, Perez NS, De Sousa E, *et al.* ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis. *Nephrol Dial Transplant* 2014;29:1764-9.
34. Moroni G, Binda V, Leoni A, *et al.* Predictors of renal survival in ANCA-associated vasculitis. Validation of a histopathological classification schema and review of the literature. *Clin Exp Rheumatol* 2015;33:S-56-63.
35. Diaz-Crespo F, Villacorta J, Acevedo M, *et al.* The predictive value of kidney biopsy in renal vasculitis: a multicenter cohort study. *Hum Pathol* 2016;52:119-27.
36. Kristensen T, Gregersen JW, Krag SR, *et al.* The relation between histopathological classification and renal outcome, ANCA subtype

- and treatment regimens in ANCA-associated vasculitis. *Clin Exp Rheumatol* 2016;34:S105-10.
37. Bjornekleit R, Sriskandarajah S, Bostad L. Prognostic Value of Histologic Classification of ANCA-Associated Glomerulonephritis. *Clin J Am Soc Nephrol* 2016;11:2159-67.
38. Li X, Liang S, Zheng C, et al. Clinicopathological characteristics and outcomes of pediatric patients with systemic small blood vessel vasculitis. *Pediatr Nephrol* 2014;29:2365-71.
39. Khalighi MA, Wang S, Henriksen KJ, et al. Pauci-immune glomerulonephritis in children: a clinicopathologic study of 21 patients. *Pediatr Nephrol* 2015;30:953-9.
40. Noone DG, Twilt M, Hayes WN, et al. The new histopathologic classification of ANCA-associated GN and its association with renal outcomes in childhood. *Clin J Am Soc Nephrol* 2014;9:1684-91.
41. Iwakiri T, Fujimoto S, Kitagawa K, et al. Validation of a newly proposed histopathological classification in Japanese patients with anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. *BMC Nephrol* 2013;14:125.
42. Nohr E, Girard L, James M, et al. Validation of a histopathologic classification scheme for antineutrophil cytoplasmic antibody-associated glomerulonephritis. *Hum Pathol* 2014;45:1423-9.
43. Cordova-Sanchez BM, Mejia-Vilet JM, Morales-Buenrostro LE, et al. Clinical presentation and outcome prediction of clinical, serological, and histopathological classification schemes in ANCA-associated vasculitis with renal involvement. *Clin Rheumatol* 2016;35:1805-16.
44. Tanna A, Guarino L, Tam FW, et al. Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic factors. *Nephrol Dial Transplant* 2015;30:1185-92.
45. Karras A, Pagnoux C, Haubitz M, et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. *Ann Rheum Dis* 2017.
46. Flossmann O, Berden A, de Groot K, et al. Long-term patient survival in ANCA-associated vasculitis. *Ann Rheum Dis* 2011;70:488-94.
47. Mahr A, Heijl C, Le Guenno G, et al. ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships. *Best Pract Res Clin Rheumatol* 2013;27:45-56.
48. Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. *N Engl J Med* 2013;369:417-27.
49. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med* 2010;363:221-32.
50. Inoue S, Leitner WW, Golding B, et al. Inhibitory effects of B cells on antitumor immunity. *Cancer Res* 2006;66:7741-7.
51. Schioppa T, Moore R, Thompson RG, et al. B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. *Proc Natl Acad Sci U S A* 2011;108:10662-7.
52. Cho SF, Wu WH, Yang YH, et al. Risk of second primary cancer in patients with B-cell non-Hodgkin lymphoma receiving rituximab-containing chemotherapy: a nationwide population-based study. *Anticancer Res* 2015;35:1809-14.
53. Xu Y, Wang H, Zhou S, et al. Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma. *Leuk Lymphoma* 2013;54:1396-404.
54. Karassa FB. Rituximab or cyclophosphamide in ANCA-associated renal vasculitis. *N Engl J Med* 2010;363:2073; author reply -4.

55. Falk RJ, Jennette JC. Rituximab in ANCA-associated disease. *N Engl J Med* 2010;363:285-6.
56. Banchereau R, Hong S, Cantarel B, *et al.* Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. *Cell* 2016;165:551-65.
57. Smith KGC. SY1_2 Genetic studies in ANCA-associated vasculitis point to a new, practical disease classification based on autoantibody specificity *Rheumatology* 2017;56:iii3-iii4.
58. Ishizu A, Tomaru U, Masuda S, *et al.* Prediction of response to remission induction therapy by gene expression profiling of peripheral blood in Japanese patients with microscopic polyangiitis. *Arthritis Res Ther* 2017;19:117.
59. Sellam J, Hendel-Chavez H, Rouanet S, *et al.* B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. *Arthritis Rheum* 2011;63:933-8.

Chapter VIII

Samenvatting in het Nederlands

Vasculitis betekent letterlijk: ontsteking van bloedvaten. Ontstekingen van bloedvaten kunnen overal in het lichaam voorkomen. In de meeste gevallen leiden zij, afhankelijk van de ernst van de ontstekingen, in meer of mindere mate tot functieverlies van de betrokken organen. Dit proefschrift gaat specifiek over vasculitis die gekenmerkt wordt door de aanwezigheid van anti-neutrofiele cytoplasmatische antilichamen (ANCA) in het bloed van patiënten. ANCA zijn afweerstoffen die gericht zijn tegen componenten in het celvocht (cytoplasma) van bepaalde typen witte bloedcellen (neutrofiele granulocyten en monocytten). De klassieke eiwitten waar ANCA zich tegen richten zijn proteïnase 3 (PR3) en myeloperoxidase (MPO).

ANCA-geassocieerde vasculitis omvat de volgende ziektebeelden:

- granulomatose met polyangiitis (GPA, voorheen de ziekte van Wegener genoemd);
- microscopische polyangiitis (MPA);
- eosinofiele granulomatose met polyangiitis (EGPA, voorheen Churg-Strauss-syndroom genoemd).

De meeste patiënten met GPA hebben PR3-ANCA in het bloed en de meeste patiënten met MPA hebben MPO-ANCA in het bloed. Ongeveer de helft van de EGPA patiënten heeft MPO-ANCA in het bloed, de andere helft heeft geen ANCA in het bloed. ANCA lijken een rol te spelen bij het ontstaan van ANCA-geassocieerde vasculitis; onder bepaalde omstandigheden activeren ANCA witte bloedcellen. Deze geactiveerde witte bloedcellen veroorzaken de bloedvatontstekingen.

Patiënten met ANCA-geassocieerde vasculitis hebben vaak 'algemene' klachten zoals malaisegevoel en gewichtsverlies. Daarnaast zijn vaak het keel-, neus- en oorgebied (KNO-gebied), de longen en de nieren van deze patiënten aangedaan. De ziekte kan zich ook manifesteren in de gewrichten, het zenuwstelsel en het maagdarmsstelsel. Bij het uitblijven van een behandeling overlijden de meeste patiënten met ANCA-geassocieerde vasculitis kort na het stellen van de diagnose. Zonder behandeling is één jaar na de diagnose nog slechts één op de vijf patiënten in leven. De behandeling van ANCA-geassocieerde vasculitis bestaat uit ontstekingsremmende en afweersonderdrukkende medicijnen. Hoewel deze behandeling op korte termijn erg effectief is, keert de ziekte bij ongeveer de helft van de patiënten na verloop van tijd terug. Bovendien hebben deze medicijnen ernstige bijwerkingen waar patiënten zelfs aan kunnen overlijden.

Ongeveer 150 jaar geleden werd in de wetenschappelijke literatuur de eerste patiënt met ANCA-geassocieerde vasculitis beschreven. Sindsdien is de kennis omtrent het ziekteproces en de behandeling van dit complexe ziektebeeld aanzienlijk toegenomen. Vraagstukken omtrent de oorzaak van ANCA-geassocieerde vasculitis, de meest geschikte ziekteclassificatiesystemen en de meest optimale behandelstrategieën vormen de focus van de huidige studies naar

ANCA-geassocieerde vasculitis. De studies die in dit proefschrift zijn beschreven onderzoeken:

- de genetische achtergrond van ANCA-geassocieerde vasculitis;
- de klinische en histopathologische classificaties van ANCA-geassocieerde vasculitis;
- het ontstaan van maligniteiten (kankergezwellen) als gevolg van de behandeling van ANCA-geassocieerde vasculitis.

Genetica en ziekteclassificatie

Het ziekteproces waardoor ANCA-geassocieerde vasculitis ontstaat, is complex en nog niet volledig ontrafeld. Wetenschappers veronderstellen dat onder meer genetische factoren een rol spelen bij het ontstaan van ANCA-geassocieerde vasculitis. In **hoofdstuk 2** van dit proefschrift wordt de genetische achtergrond van ANCA-geassocieerde vasculitis onderzocht. In de afgelopen jaren hebben verschillende onderzoeksgroepen over de wereld een groot aantal studies uitgevoerd naar de genetische achtergrond van ANCA-geassocieerde vasculitis. Veel van deze studies zijn echter uitgevoerd met relatief kleine aantallen patiënten en controles. Hierdoor zijn de resultaten van deze studies soms lastig te interpreteren en/of onbetrouwbaar. **Hoofdstuk 2** beschrijft een meta-analyse van de genetische associatiestudies die zijn uitgevoerd bij patiënten met ANCA-geassocieerde vasculitis. Een meta-analyse is een statistische methode om resultaten van verschillende studies samen te voegen om zo tot een meer robuust resultaat te komen. Om de validiteit van de meta-analyse te vergroten zijn tevens ruwe data uit een grote Europese genomwijde associatiestudie (GWAS) geïncludeerd. GWAS is een relatief nieuwe methode voor wetenschappers om genen te identificeren die betrokken zijn bij een bepaalde ziekte. Door middel van deze methode onderzoeken wetenschappers het genoom op kleine variaties, genaamd single nucleotide polymorphisms (SNPs), die vaker voorkomen bij mensen met een bepaalde ziekte dan bij mensen zonder deze ziekte.

De genetische varianten die in de meta-analyse significant geassocieerd waren met ANCA-geassocieerde vasculitis liggen in of dicht bij de volgende genen: *CD226*, *CTLA-4*, *FCGR2A*, *HLA-B*, *HLA-DP*, *HLA-DQ*, *HLA-DR*, *HSD17B8*, *IRF5*, *PTPN22*, *RING1/RXR*, *RXR*, *STAT4*, *SERPINA1* en *TLR9*. De resultaten van deze meta-analyse bevestigen dat genetische factoren bijdragen aan het ontstaan van ANCA-geassocieerde vasculitis. In het bijzonder ondersteunen zij een rol voor het major histocompatibility complex (MHC), het aangeboren en adaptieve immuunsysteem en verschillende ontstekingsprocessen in het ontstaan van deze complexe ziekte. Verder onderzoek naar het werkingsmechanisme van bovenstaande genen zal hopelijk niet alleen leiden tot nieuwe inzichten in de

ontstaanswijze, maar ook tot nieuwe aangrijpingspunten voor de therapie van ANCA-geassocieerde vasculitis.

De meta-analyse gepresenteerd in **hoofdstuk 2** toont genetische verschillen tussen patiënten met GPA en patiënten met MPA. Eveneens toont de meta-analyse genetische verschillen tussen patiënten met PR3-ANCA in het bloed en patiënten met MPO-ANCA in het bloed. De genetische verschillen tussen de ANCA-serotypes (PR3-ANCA en MPO-ANCA) waren groter dan de genetische verschillen tussen de klinische diagnoses (GPA en MPA). Deze bevinding impliceert dat PR3-ANCA-vasculitis en MPO-ANCA-vasculitis genetisch verschillende ziektebeelden zijn. Op grond van de sterke overeenkomsten in hun klinische en histologische manifestaties worden GPA en MPA tot op heden beschouwd als verschillende entiteiten binnen hetzelfde ziektebeeld. Niettemin wordt steeds meer duidelijk dat er opvallende verschillen tussen deze ziektebeelden zijn. Zo hebben GPA / PR3-ANCA-positieve patiënten een groter risico op een terugkeer van de ziekte dan MPA / MPO-ANCA-positieve patiënten. Daarnaast is behandeling met het relatief nieuwe geneesmiddel rituximab effectiever bij patiënten met PR3-ANCA dan bij patiënten met MPO-ANCA. Deze verschillen hebben geleid tot de vraag of de verschillende entiteiten binnen ANCA-geassocieerde vasculitis verschillende uitingen van eenzelfde ziektebeeld zijn of dat zij juist verschillende ziektebeelden representeren.

De sterke genetische verschillen tussen PR3-ANCA- en MPO-ANCA-positieve patiënten tezamen met de klinische verschillen tussen deze patiënten wijzen erop dat PR3-ANCA-vasculitis en MPO-ANCA-vasculitis verschillende ziektebeelden zijn. Dit onderstreept de noodzaak voor de incorporatie van het ANCA-serotype in de classificatie van ANCA-geassocieerde vasculitis. Deze nieuwe classificatie zal in de toekomst hopelijk leiden tot de ontwikkeling van meer specifieke therapeutische strategieën.

Hoofdstuk 3 van dit proefschrift richt zich op het voorkomen van KNO-betrokkenheid en het ANCA-serotype in relatie tot renale betrokkenheid bij ANCA-geassocieerde vasculitis. Eerder onderzoek heeft aangetoond dat patiënten met MPO-ANCA-vasculitis meer chronische laesies in het nierbiopt hebben dan patiënten met PR3-ANCA-vasculitis. Dit kan enerzijds – in lijn met de bevindingen uit **hoofdstuk 2** van dit proefschrift – duiden op verschillende ziektemechanismen in PR3-ANCA-vasculitis en MPO-ANCA-vasculitis. Anderzijds komen KNO-manifestaties – onder andere recidiverende bloedneuzen en gehoorverlies – vaker voor bij ANCA-geassocieerde vasculitispatiënten die PR3-ANCA-positief zijn. Het is mogelijk dat de PR3-ANCA-positieve patiënten door de klinisch aanwezige KNO-manifestaties vroeger gediagnosticeerd en behandeld worden dan MPO-ANCA-positieve patiënten. Dit zou een verklaring kunnen zijn voor de prognostisch gunstigere nierbiopten van de PR3-ANCA-positieve patiënten.

Vierhonderdenveertien patiënten met ANCA-geassocieerde vasculitis afkomstig uit 62 ziekenhuizen in 15 landen namen deel aan de studie gepresenteerd in **hoofdstuk 3** van dit proefschrift. In vergelijking met patiënten zonder KNO-manifestaties hadden patiënten met KNO-manifestaties minder chronische laesies in de nierbipten en een betere nierfunctie tijdens de diagnose en 5 jaar na de diagnose. Andere manifestaties die ook tot een snellere diagnose kunnen leiden, zoals gewrichtsklachten, vasculitis van de huid en vasculitis van de longen (zich onder andere uitend door het opgeven van bloed), waren niet geassocieerd met de nierfunctie tijdens de diagnose en 5 jaar na de diagnose. Hieruit volgt dat de betere renale uitkomsten bij patiënten met KNO-betrokkenheid waarschijnlijk niet worden veroorzaakt doordat deze patiënten vroeger gediagnosticeerd en behandeld worden. KNO-betrokkenheid was nog steeds geassocieerd met de nierfunctie in een subgroep-analyse waarin alleen PR3-ANCA positieve patiënten waren geïncludeerd. KNO-betrokkenheid lijkt dus een belangrijke klinische parameter te zijn die, onafhankelijk van ANCA-serotype, geassocieerd is met een betere nierfunctie.

De histopathologische classificatie van ANCA-geassocieerde glomerulonefritis

Bij circa 80 tot 90 procent van de patiënten met ANCA-geassocieerde vasculitis zijn de nieren betrokken bij het ziekteproces. Dat juist de nieren zo vaak aangetast worden door de vasculitis is niet verwonderlijk. Het filtersysteem van de nieren bestaat namelijk uit kluwens van kleine bloedvaatjes, de glomeruli. Bij de patiënten waarbij de nieren betrokken zijn bij het ziekteproces ontsteken deze bloedvaatjes. Hierdoor kunnen de nieren op den duur schadelijke afvalstoffen niet meer uitscheiden en hopen deze stoffen zich in het lichaam op. Bij ernstige nierfunctiestoornissen is nierfunctievervangende therapie in de vorm van dialyse of niertransplantatie op den duur noodzakelijk.

In 2010 werd de histopathologische classificatie van ANCA-geassocieerde glomerulonefritis (ziektemanifestaties van vasculitis in de nier) ontwikkeld door een internationale werkgroep van nefropathologen en nefrologen. De histopathologische classificatie heeft als voornaamste doel het bijdragen aan een betere inschatting van de prognose van patiënten met ANCA-geassocieerde glomerulonefritis. Het classificatiesysteem is opgebouwd rondom glomerulaire pathologie en onderscheidt vier categorieën:

- De focale categorie; in deze categorie zijn minimaal 50 procent van de glomeruli niet aangetast door vasculitis.
- De crescentische categorie; in deze categorie tonen minimaal 50 procent van de glomeruli cellulaire crescents.

- De gemengde categorie; in deze categorie is geen van de karakteristieke afwijkingen dominant.
- De sclerotische categorie; in deze categorie zijn minimaal 50 procent van de glomeruli globaal gescleroseerd (verlittekend).

Een validatiestudie toonde aan dat deze categorieën in de genoemde volgorde geassocieerd zijn met oplopende ernst van nierfunctieverlies op de lange termijn.

Tot op heden is de histopathologische classificatie van ANCA-geassocieerde glomerulonefritis gevalideerd in 21 studies afkomstig uit Azië, Noord-Amerika, Australië en Europa. In **hoofdstuk 4** worden de bevindingen uit deze validatiestudies bediscussieerd en in breder perspectief geplaatst. De resultaten van deze studies bevestigen de voorspellende waarde van de focale en sclerotische categorieën voor de nierfunctie op de lange termijn. De verschillende validatiestudies toonden echter bij de crescentische en gemengde categorieën tegenstrijdige resultaten. In sommige studies hadden de patiënten met een nierbiopsie in de crescentische categorie betere renale uitkomsten dan patiënten met een nierbiopsie in de gemengde categorie. In andere studies was dit andersom en hadden patiënten met een nierbiopsie in de gemengde categorie een betere nierfunctie. De gemengde categorie in haar huidige vorm lijkt dan ook te divers van aard te zijn om een voorspellende waarde voor de nierfunctie op de lange termijn te hebben.

Behandeling en langetermijnuitskomst

Zoals hiervoor besproken is behandeling van ANCA-geassocieerde vasculitis van levensbelang. Zonder behandeling is één jaar na de diagnose slechts één op de vijf patiënten in leven. Bij de behandeling van ANCA-geassocieerde vasculitis wordt onderscheid gemaakt tussen de initiële therapie om de vasculitis te onderdrukken (inductietherapie) en de therapie om de vasculitis onderdrukt te houden (onderhoudstherapie). De inductietherapie bestaat klassiek uit het afweeronderdrukkend medicijn cyclofosfamide in combinatie met prednison (een corticosteroïde). De onderhoudstherapie bestaat uit azathioprine of methotrexaat waarbij de prednison wordt afgebouwd en waar mogelijk wordt gestopt. Azathioprine en methotrexaat zijn afweeronderdrukkende medicijnen die milder zijn dan cyclofosfamide. Met deze behandeling is 90 procent van de patiënten met ANCA-geassocieerde vasculitis één jaar na het stellen van de diagnose nog in leven.

De behandeling van ANCA-geassocieerde vasculitis is erg effectief maar gaat helaas ook gepaard met ernstige complicaties. Een mogelijke complicatie van het langdurig gebruik van afweeronderdrukkende medicijnen is het optreden van maligniteiten. In **hoofdstuk 5** van dit proefschrift werd het risico op

maligniteiten onderzocht bij patiënten met ANCA-geassocieerde vasculitis die zijn behandeld met cyclofosfamide. De patiënten met ANCA-geassocieerde vasculitis hadden een tweemaal hoger risico op het ontwikkelen van maligniteiten ten opzichte van leeftijdsgenoten uit de algemene bevolking. Het risico op maligniteiten hield direct verband met de cumulatieve dosis cyclofosfamide die een patiënt kreeg; hoe meer cyclofosfamide, des te hoger het risico op het ontwikkelen van een maligniteit. Alleen het risico op het ontwikkelen van basaalcelcarcinomen en plaveiselcelcarcinomen van de huid was verhoogd. In tegenstelling tot oudere studies was in de studie gepresenteerd in **hoofdstuk 5** het risico op blaaskanker, leukemie en lymfomen niet verhoogd. Deze vooruitgang is waarschijnlijk het resultaat van internationale inspanningen (onder andere door middel van het uitvoeren van grote internationale klinische trials) om de behandeling van ANCA-geassocieerde vasculitis effectiever en veiliger te maken. Dit werd onder andere verwezenlijkt door een sterke verlaging van de totale dosis cyclofosfamide bij de behandeling van ANCA-geassocieerde vasculitis.

Cyclofosfamide blijft echter nog altijd ongunstige bijwerkingen hebben, met risico's op onder andere infecties, onvruchtbaarheid en, bij patiënten met veel cyclofosfamidegebruik, maligniteiten. In de wetenschappelijke wereld wordt dan ook voortdurend gezocht naar nieuwere en veiligere therapieën. Onlangs is rituximab met succes geïntroduceerd in de behandeling van ANCA-geassocieerde vasculitis. Twee klinische trials (RITUXVAS en RAVE) demonstreerden dat rituximab effectief is in de behandeling van ANCA-geassocieerde vasculitis en relatief weinig bijwerkingen heeft. Deze studies leidden echter wel tot zorgen over een mogelijk verhoogd risico op maligniteiten bij de ANCA-geassocieerde vasculitispatiënten die met rituximab werden behandeld.

Hoofdstuk 6 beschrijft de eerste langetermijnstudie waarin het risico op maligniteiten wordt onderzocht bij patiënten met ANCA-geassocieerde vasculitis die worden behandeld met rituximab. Patiënten die werden behandeld met cyclofosfamide hadden een ruim vier en een half maal hoger risico op het ontwikkelen van maligniteiten ten opzichte van de patiënten die werden behandeld met rituximab. Het risico op maligniteiten was bij de patiënten die werden behandeld met cyclofosfamide ruim 3 maal hoger ten opzichte van leeftijdsgenoten uit de algemene bevolking. Daarentegen hadden de patiënten die werden behandeld met rituximab geen verhoogd risico op het ontwikkelen van maligniteiten ten opzichte van leeftijdsgenoten uit de algemene bevolking. De cumulatieve dosis cyclofosfamide hield – net zoals in de studie beschreven in **hoofdstuk 5** – ook in deze studie direct verband met het risico op het ontwikkelen van maligniteiten. Concluderend laten de resultaten van de studie gepresenteerd in **hoofdstuk 6** zien dat, wat betreft het risico op maligniteiten, rituximab een veiliger alternatief is dan cyclofosfamide in de behandeling van ANCA-geassocieerde vasculitis.

Toekomstperspectieven

De resultaten uit dit proefschrift tonen aan dat genetische factoren betrokken zijn bij het ontstaan van ANCA-geassocieerde vasculitis. Vervolgstudies zullen de precieze rol van deze genetische varianten in het ziekteproces moeten vaststellen. Deze (epi)genetische studies zullen hopelijk niet alleen leiden tot diepere inzichten in het ontstaan van ANCA-geassocieerde vasculitis, maar ook tot therapie gericht op specifieke karakteristieken van de individuele patiënt (*personalized medicine*).

Daarnaast tonen de resultaten uit dit proefschrift ook aan dat PR3-ANCA vasculitis en MPO-ANCA vasculitis verschillende genetische achtergronden hebben. Deze bevinding ondersteunt de noodzaak voor een nieuw classificatiesysteem van ANCA-geassocieerde vasculitis. Dit nieuwe classificatiesysteem behoort primair gebaseerd te zijn op ANCA-serotype in plaats van klinische diagnose. In dit classificatiesysteem zal dus gesproken worden van PR3-ANCA vasculitis en MPO-ANCA vasculitis in plaats van GPA en MPA. De genetische verschillen tussen patiënten met PR3-ANCA en MPO-ANCA impliceren ook dat toekomstige genetische en klinische studies zodanig opgezet moeten worden dat afzonderlijke analyse van deze patiëntengroepen zinvol is.

Bij de behandeling van ANCA-geassocieerde vasculitis wordt momenteel een deel van de specifieke patiënt- en ziektekenmerken buiten beschouwing gelaten. De resultaten van genetische en klinische studies impliceren echter dat het afstemmen van de behandeling op specifieke patiënt- en ziekteparameters tot betere behandelresultaten zal leiden. Mogelijke parameters die, nu of in de toekomst, in aanmerking komen voor het realiseren van ‘therapie op maat’ zijn: genetische markers, ANCA-serotype (PR3-ANCA of MPO-ANCA), scores die de ziekte-ernst weergeven en markers die een terugval voorspellen.

De resultaten uit dit proefschrift suggereren dat rituximab veelbelovend is in de behandeling van ANCA-geassocieerde vasculitis. De langetermijneffecten van rituximab bij patiënten met ANCA-geassocieerde vasculitis zijn echter onbekend en zullen door middel van vervolgstudies onderzocht moeten worden. Daarnaast wordt steeds duidelijker dat corticosteroiden verantwoordelijk zijn voor een substantieel deel van de, aan therapie gerelateerde, complicaties die patiënten met ANCA-geassocieerde vasculitis ervaren. Toekomstige studies zullen dan ook verschillende doseringsschema's met betrekking tot de werkzaamheid en veiligheid van corticosteroiden moeten onderzoeken. Tot slot zullen toekomstige studies ook moeten uitwijzen of bevindingen in het nierbiopt van patiënten met ANCA-geassocieerde vasculitis direct bruikbaar zijn om de therapeutische besluitvorming te sturen.

Appendices

Supplementary data
Authors and affiliations
Curriculum vitae
List of publications
Acknowledgements

Supplementary data

<i>I. Supplementary data Chapter II</i>	<i>155</i>
<i>Genetic variants in ANCA-associated vasculitis: a meta-analysis</i>	
<i>II. Supplementary data Chapter III</i>	<i>301</i>
<i>Renal function and ear, nose, throat involvement in ANCA-associated vasculitis: prospective data from the European Vasculitis Society clinical trials</i>	
<i>III. Supplementary data Chapter VI</i>	<i>311</i>
<i>Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis</i>	

I. Supplementary data Chapter II

Genetic variants in ANCA-associated vasculitis: a meta-analysis

<i>European Vasculitis Genetics Consortium authors and affiliations</i>	<i>156</i>
<i>Table S1. Literature search strategies</i>	<i>158</i>
<i>Table S2. Study characteristics of the included studies</i>	<i>163</i>
<i>Table S3. Genetic variants not associated with AAV after meta-analysis</i>	<i>215</i>
<i>Table S4. Results of the meta-analyses stratified by diagnostic and serologic subgroups</i>	<i>220</i>
<i>Table S5. Results of the meta-analyses stratified by ethnic subgroups</i>	<i>235</i>
<i>Figure S1. Forest plots</i>	<i>239</i>
<i>Figure S2. Forest plots by diagnostic and serologic subgroups</i>	<i>255</i>
<i>Figure S3. Forest plots by ethnic subgroups</i>	<i>292</i>
<i>References</i>	<i>295</i>

European Vasculitis Genetics Consortium authors and affiliations

Paul A. Lyons, Tim F. Rayner, Sapna Trivedi, Julia U. Holle, Richard A. Watts, David R.W. Jayne, Bo Baslund, Paul Brenchley, Annette Bruchfeld, Afzal N. Chaudhry, Jan Willem Cohen Tervaert, Conleth Feighery, Wolfgang L. Gross, Loïc Guillevin, Iva Gunnarsson, Lorraine Harper, Zdenka Hrušková, Mark A. Little, Davide Martorana, Thomas Neumann, Sophie Ohlsson, Sandosh Padmanabhan, Charles D. Pusey, Alan D. Salama, Jan-Stephan F. Sanders, Caroline O. Savage, Mårten Segelmark, Coen A Stegeman, Vladimír Tesař, Augusto Vaglio, Stefan Wiczorek, Benjamin Wilde, Jochen Zwerina, Andrew J. Rees and Kenneth G.C. Smith.

From the Cambridge Institute for Medical Research (P.A.L., T.F.R., S.T., K.G.C.S.), and Department of Medicine (P.A.L., T.F.R., S.T., D.R.W.J., A.N.C., K.G.C.S.), University of Cambridge School of Clinical Medicine, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0XY, UK; Vasculitis and SLE service, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 2QQ (S.T., A.N.C., D.R.W.J., K.G.C.S.); Department of Rheumatology, University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany (W.L.G.); Department of Rheumatology and Immunology, Klinikum Bad Bramstedt, Bad Bramstedt, Germany (J.U.H., W.L.G.); Department of Rheumatology, Ipswich Hospital NHS Trust, Heath Road, Ipswich, Suffolk, IP4 5PD, and Norwich Medical School, University of East Anglia, Norwich NR7 4TJ, UK (R.A.W.); Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark (B.B.); Cardiovascular Research, School of Biomedicine, University of Manchester, UK (P.B.); Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden (A.B.); Department of Internal Medicine, Division of Clinical & Experimental Immunology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands (J.W.C.T., B.W.); Department of Immunology, Trinity College Dublin, Dublin 2, and St James's Hospital Dublin, Dublin 8, Ireland (C.F.); Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, France (L.G.); Department of Medicine, Unit of Rheumatology, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden (I.G.); School of Immunity and Infection, University of Birmingham, Edgbaston, Birmingham, UK (L.H., C.O.S.); Department of Nephrology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic (Z.H., V.T.); UCL Centre for Nephrology, Royal Free Hospital, London, UK (M.L., A.D.S.); Unit of Molecular Genetics (D.M.) and Unit of Nephrology (A.V.), University Hospital of Parma, Via Gramsci 14, 43126 Parma, Italy; Department of Internal Medicine III, University Hospital Jena, Germany (T.N.); Section of Nephrology, Department of Clinical Sciences, Lund University, Sweden (S.O., M.S.) and the Department of Medical and

Health Sciences, Linköping University, Linköping, Sweden (M.S.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G12 8TA, UK (S.P.); Renal Section, Department of Medicine, Imperial College London, London, UK (C.D.P., A.D.S.); Department of Internal Medicine/Division of Nephrology, University of Groningen, University Medical Center Groningen, The Netherlands (J.F.S., C.A.S.); Human Genetics, Ruhr-University, Bochum, Germany (S.W.); Department of Internal Medicine 3, University of Erlangen-Nuremberg, Germany, and currently Ludwig Boltzmann Institute of Osteology at Hanusch Hospital of WGKK and AUVA Trauma Centre Meidling, 1st Medical Department Hanusch Hospital, Vienna, Austria (J.Z.); and Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria (A.J.R.).

Supplementary table 1. Literature search strategies

Database	Search Strategy
PubMed	<i>Two strategies:</i> 1. AAV and genes ("Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis"[Mesh] OR "ANCA-associated vasculitis"[all fields] OR "ANCA associated vasculitis"[all fields] OR "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis"[all fields] OR "Pauci-Immune Vasculitis"[all fields] OR "Pauci-Immune Vasculitides"[all fields] OR "ANCA-Associated Vasculitides"[all fields] OR "ANCA Associated Immune Vasculitis"[all fields] OR "Pauci-Immune Vasculitides"[all fields] OR "ANCA"[all fields] AND vasculit*[all fields] OR ("Anti-Neutrophil"[all fields] AND "Cytoplasmic"[all fields] AND "Antibody-Associated"[all fields] AND vasculit*[all fields]) OR "Churg-Strauss Syndrome"[all fields] OR "Churg Strauss Syndrome"[all fields] OR "Allergic Granulomatous Angitis"[all fields] OR "Allergic Granulomatous Angitides"[all fields] OR "Allergic Angitis"[all fields] OR "Churg-Strauss Vasculitis"[all fields] OR "eosinophilic granulomatosis with polyangiitis"[all fields] OR "Microscopic polyphic"[all fields] AND "granulomatosis"[all fields] OR "polyangiitis"[all fields] OR "Wegener's Granulomatosis"[all fields] OR "Wegeners Granulomatosis"[all fields] OR "Wegener Granulomatosis"[all fields] OR "granulomatosis with polyangiitis"[all fields] AND "polyangiitis"[all fields] OR "anca"[tw] OR ("pr3"[all fields] OR "pr-3"[all fields] OR "mpo"[all fields]) AND ("Vasculitis"[mesh] OR vasculit*[all fields] OR "anca"[tw])) OR "Antibodies, Antineutrophil Cytoplasmic"[Mesh] OR "Antineutrophil Cytoplasmic Antibody"[all fields] OR "Anti-Neutrophil Cytoplasmic Antibody"[all fields] OR "Anti Neutrophil Cytoplasmic Antibodies"[all fields] OR "Antineutrophil Cytoplasmic Antibodies"[all fields] AND ("genes"[mesh] OR "genes"[all fields] OR "gene"[all fields] OR "genetic"[all fields] OR "genetics"[Subheading] OR "genetics"[all fields] OR "genetics"[mesh] OR "polymorphism, genetic"[mesh] OR "polymorphism"[all fields] OR "polymorphisms"[all fields] OR "dna"[mesh] OR "genome"[mesh] OR "genome"[all fields] OR "genomes"[all fields] OR "genomics"[mesh] OR "genomics"[all fields] OR "genomic"[all fields] OR "Genetic Phenomena"[mesh] OR "Genetic Structures"[Mesh])

Supplementary table 1. Literature search strategies (Continued)

Database	Search Strategy
PubMed	2. Vasculitis and genes (excluding AAV) ((“Vasculitis”[majr] OR vasculit*[ti]) AND (“genes”[majr] OR “gene”[ti] OR “genetic”[ti] OR “genetics”[ti] OR “genomics”[majr] OR “polymorphism, genetic”[ti] OR “polymorphisms”[ti] OR “dna”[majr] OR “genome”[majr] OR “genome”[ti] OR “genomes”[ti] OR “genomics”[majr] OR “genomics”[ti] OR “genetic phenomena”[majr] OR “Genetic Structures”[majr])) NOT ((“Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis”[Mesh] OR “ANCA-associated vasculitis”[all fields] OR “ANCA associated vasculitis”[all fields] OR “Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis”[all fields] OR “Pauci-Immune Vasculitis”[all fields] OR “Pauci Immune Vasculitis”[all fields] OR “Pauci-Immune Vasculitides”[all fields] OR “ANCA-Associated Vasculitides”[all fields] OR “ANCA Associated Vasculitides”[all fields] OR “ANCA-Associated Vasculitide”[all fields] OR (“ANCA”[all fields] AND vasculit*[all fields]) OR (“Churg-Strauss Syndrome”[all fields] OR “Churg Strauss Syndrome”[all fields] AND “Antibody-Associated”[all fields] AND vasculit*[all fields]) OR “Allergic Granulomatous Angiitides”[all fields] OR “Allergic Angiitis”[all fields] OR “Churg-Strauss Vasculitis”[all fields] OR “eosinophilic granulomatosis with polyangiitis”[all fields] OR (“eosinophilic”[all fields] AND “granulomatosis”[all fields] OR “Wegener’s Granulomatosis”[all fields] OR “Microscopic Polyangiitis”[all fields] OR “granulomatosis with polyangiitis”[all fields] AND “polyangiitis”[all fields]) OR “Wegeners Granulomatosis”[all fields] OR “pr-3”[all fields] OR “mpo”[all fields] AND (“granulomatosis”[all fields] AND “polyangiitis”[all fields]) OR “anca”[tw]) OR “Antibodies, Antineutrophil Cytoplasmic”[Mesh] OR “Antineutrophil Cytoplasmic Antibody”[all fields] OR “Anti-Neutrophil Cytoplasmic Antibody”[all fields] OR “Anti Neutrophil Cytoplasmic Antibodies”[all fields] OR “Antineutrophil Cytoplasmic Antibodies”[all fields] AND (“genes”[mesh] OR “genes”[all fields] OR “gene”[all fields] OR “genetic”[all fields] OR “genetics”[Subheading] OR “genetics”[all fields] OR “genetics”[mesh] OR “polymorphism, genetic”[mesh] OR “polymorphism”[all fields] OR “polymorphisms”[all fields] OR “dna”[mesh] OR “dna”[all fields] OR “genome”[mesh] OR “genome”[all fields] OR “genomes”[all fields] OR “genomics”[mesh] OR “genomics”[all fields] OR “genomic”[all fields] OR “Genetic Phenomena”[mesh] OR “Genetic Structures”[Mesh]))

Supplementary table 1. Literature search strategies (Continued)

Database	Search Strategy
Embase	<i>Two strategies:</i> <u>1. AAV and genes</u> (ANCA associated vasculitis/ OR "ANCA-associated vasculitis".mp OR "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis".mp OR "Pauci-Immune Vasculitis".mp OR "Pauci-Immune Vasculitides".mp OR "ANCA-Associated Vasculitides".mp OR "ANCA-Associated Vasculitide".mp OR "ANCA".mp AND vasculit*.mp) OR ("Anti-Neutrophil".mp AND "Cytoplasmic".mp AND "Antibody-Associated".mp AND vasculit*.mp) OR "Churg-Strauss Syndrome".mp OR "Churg Strauss Syndrome".mp OR "Allergic Granulomatous Angiitis".mp OR "Allergic Granulomatous Angiitides".mp OR "Allergic Angiitis".mp OR "Churg-Strauss Vasculitis".mp OR "eosinophilic granulomatosis with polyangiitis".mp OR ("eosinophilic".mp OR "Wegener Granulomatosis".mp OR "Wegener's Granulomatosis".mp OR "Microscopic Polyangiitis".mp OR "Microscopic Polyangitis".mp OR "Wegener's Granulomatosis".mp OR "granulomatosis with polyangiitis".mp OR "granulomatosis with polyangitis".mp OR "pr-3".mp OR "pr3".mp) AND (exp Vasculitis/ OR vasculit*.mp OR "anca".mp) OR neutrophil cytoplasmic antibody/ OR "Antineutrophil Cytoplasmic Antibody".mp OR "Anti-Neutrophil Cytoplasmic Antibody".mp OR "Antineutrophil Cytoplasmic Antibodies".mp AND (exp Gene/ OR gene.mp OR genom*.mp OR genes.mp OR exp genetic polymorphism/ OR polymorphism*.mp OR dna.mp OR exp dna/ OR exp *Heredity/)

Supplementary table 1. Literature search strategies (Continued)

Database	Search Strategy
Embase	2. Vasculitis and genes (excluding AAV) ((exp *Vasculitis/ OR vasculit*.ti) AND (exp *Gene/ OR gene.ti OR genom*.ti OR genes.ti OR exp *genetic polymorphism/ OR polymorphism*.ti OR dna.ti OR exp *dna/ OR exp *Heredity/)) NOT ((ANCA associated vasculitis/ OR "ANCA-associated vasculitis".mp OR "ANCA associated vasculitis".mp OR "Pauci-Immune Vasculitis".mp OR "Pauci-Immune Vasculitides".mp OR "ANCA-Associated Vasculitis".mp OR "ANCA-Associated Vasculitides".mp OR "ANCA-Associated Vasculitis".mp OR "ANCA-Associated Vasculitides".mp OR "Churg-Strauss Syndrome".mp OR "Churg-Strauss Vasculitis".mp OR "Eosinophilic Granulomatous Angiitis".mp OR "Allergic Granulomatous Angiitis".mp OR "Allergic Angitis".mp OR "Churg-Strauss Syndrome".mp OR "Churg-Strauss Vasculitis".mp OR "Microscopic Polyangitis".mp OR "Eosinophilic".mp AND "granulomatosis".mp AND "polyangitis".mp OR "Wegener's Granulomatosis".mp OR "Wegeners Granulomatosis".mp OR "granulomatosis with polyangitis".mp OR "Wegener Granulomatosis".mp AND "polyangitis".mp OR "anca".mp OR ((pr3".mp OR pr-3".mp OR "mpo".mp) AND (exp Vasculitis/ OR vasculit*.mp OR "granulomatosis".mp AND "polyangitis".mp OR "anca".mp)) OR neutrophil cytoplasmic antibody/ OR "Antineutrophil Cytoplasmic Antibody".mp OR "Anti-Neutrophil Cytoplasmic Antibody".mp OR "Anti Neutrophil Cytoplasmic Antibody".mp OR "Anti Neutrophil Cytoplasmic Antibodies".mp AND (exp Gene/ OR gene.mp OR genom*.mp OR genes.mp OR exp genetic polymorphism/ OR polymorphism*.mp OR dna.mp OR exp dna/ OR exp *Heredity/))

Supplementary table 1. Literature search strategies (Continued)

Database	Search Strategy
Web of Science	<i>Two strategies:</i> <u>1. AAV and genes</u> TS=((“ANCA-associated vasculitis” OR “ANCA associated vasculitis” OR “Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis” OR “Pauci-Immune Vasculitis” OR “Pauci-Immune Vasculitides” OR “ANCA-Associated Vasculitides” OR “ANCA Associated Vasculitides” OR “ANCA-Associated Vasculitide” OR “ANCA” AND vasculit*) OR (“Anti-Neutrophil” AND “Cytoplasmic” AND “Antibody-Associated” AND vasculit*) OR “Churg-Strauss Syndrome” OR “Churg-Strauss Syndrome” OR “Allergic Granulomatous Angiitis” OR “Allergic Granulomatous Angiitides” OR “Churg-Strauss Vasculitis” OR “eosinophilic granulomatosis with polyangiitis” OR “Microscopic Polyangiitis” OR “Microscopic Polyangitis” OR “Wegener’s Granulomatosis” OR “Wegener’s Granulomatosis” OR “granulomatosis with polyangiitis” OR “neutrophil cytoplasmic antibody” OR “Antineutrophil Cytoplasmic Antibody” OR “Anti-Neutrophil Cytoplasmic Antibody” OR “Anti Neutrophil Cytoplasmic Antibodies” OR “Antineutrophil Cytoplasmic Antibodies”) AND (gene OR genes OR genom* OR genetic* OR Polymorphism* OR dna)) <u>2. Vasculitis and genes (excluding AAV)</u> (TI=((vasculit*) AND (gene OR genes OR genom* OR genetic* OR Polymorphism* OR dna))) NOT (TS=((“ANCA-associated vasculitis” OR “ANCA associated vasculitis” OR “Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis” OR “Pauci-Immune Vasculitis” OR “Pauci-Immune Vasculitides” OR “ANCA-Associated Vasculitides” OR “ANCA Associated Vasculitides” OR “ANCA-Associated Vasculitide” OR “ANCA” AND vasculit*) OR (“Anti-Neutrophil” AND “Cytoplasmic” AND “Antibody-Associated” AND vasculit*) OR “Churg-Strauss Syndrome” OR “Churg-Strauss Syndrome” OR “Allergic Granulomatous Angiitis” OR “Allergic Granulomatous Angiitides” OR “Wegener’s Granulomatosis” OR “Wegener’s Granulomatosis” OR “granulomatosis with polyangiitis” OR “Microscopic Polyangiitis” OR “Microscopic Polyangitis” OR “Wegener’s Granulomatosis” OR “granulomatosis with polyangiitis” OR “neutrophil cytoplasmic antibody” OR “Antineutrophil Cytoplasmic Antibody” OR “Anti-Neutrophil Cytoplasmic Antibody” OR “Anti Neutrophil Cytoplasmic Antibodies” OR “Antineutrophil Cytoplasmic Antibodies”) AND (gene OR genes OR genom* OR genetic* OR Polymorphism* OR dna)))

Supplementary table 2. Study characteristics of the included studies

Variants	Article	Study details		Definitions		Participants (n)			OR (95% CI)
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	
CD226 rs763361 (T)	Wieczorek et al. 2009 ^{1*}	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy subjects	761/1226	GPA (642), EGPA (119)	PR3-ANCA (438), MPO-ANCA (32), ANCA negative (43)	1.24 (1.11 – 1.39)
		Case-Control	UK	ACR and CHCC criteria	Geographically matched subjects from the general population	105/9337	GPA (all patients)	NR	1.17 (0.89 – 1.54)
		Case-Control	USA	ACR criteria	Geographically matched subjects with no (family) history of autoimmune disease	424/469	GPA (all patients)	PR3-ANCA (339), MPO-ANCA (44), ANCA negative (39)	1.08 (0.90 – 1.30)
CTLA-4 (AT) ₈₆	Chung et al. 2012 ^{2**}	Case-Control	Canada	ACR criteria	Geographically matched subjects with no history of autoimmune disease	456/1500	GPA (all patients)	NR	1.09 (0.94 – 1.26)
		Case-control (GWAS)	UK	EMA algorithm, supported by either serology or histology	Wellcome Trust Case Control Consortium (UK)	676/5366	GPA (394), MPA (156)	PR3-ANCA (326), MPO-ANCA (167)	1.08 (0.96 – 1.21)
		Case-Control	Sweden	ACR criteria	Geographically and ethnically matched healthy subjects	32/109	GPA (all patients)	PR3-ANCA (29)	0.18 (0.10 – 0.35)
CTLA-4 (AT) ₈₆	Huang et al. 2000 ⁴	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	49/111	MPA (all patients)	MPO-ANCA (all patients)	1.31 (0.76 – 2.25)
		Case-Control	USA	ACR criteria	Geographically and ethnically matched healthy, unrelated subjects	117/123	GPA (all patients)	PR3-ANCA (82), MPO-ANCA (5), PR3- and MPO-AN-CA positive (2), ANCA negative (25)	0.38 (0.26 – 0.55)
		Case-Control	USA	ACR criteria	Geographically and ethnically matched healthy, unrelated subjects	117/123	GPA (all patients)	PR3-ANCA (82), MPO-ANCA (5), PR3- and MPO-AN-CA positive (2), ANCA negative (25)	0.38 (0.26 – 0.55)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)			OR (95% CI)
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	
<i>CTLA-4</i> (AT) ₁₀₂	Persson et al. 2013 ⁷	Case-Control	Sweden	ACR and CHCC criteria, EMA algorithm	Blood donors	105/200	GPA (61), MPA (44)	PR3-ANCA (62), MPO-ANCA (43)	0.72 (0.51 – 1.02)
	Huang et al. 2000 ⁴	Case-Control	Sweden	ACR criteria	Geographically and ethnically matched healthy subjects	32/109	GPA (all patients)	PR3-ANCA (29)	1.71 (0.15 – 19.22)
	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria		49/111	MPA (all patients)	MPO-ANCA (all patients)	0.89 (0.47 – 1.68)
	Persson et al. 2013 ⁷	Case-Control	Sweden	ACR and CHCC criteria, EMA algorithm	Blood donors	105/200	GPA (61), MPA (44)	PR3-ANCA (62), MPO-ANCA (43)	1.73 (0.85 – 3.54)
<i>CTLA-4</i> (AT) ₁₀₄	Huang et al. 2000 ⁴	Case-Control	Sweden	ACR criteria	Geographically and ethnically matched healthy subjects	32/109	GPA (all patients)	PR3-ANCA (29)	1.74 (0.96 – 3.13)
	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria		49/111	MPA (all patients)	MPO-ANCA (all patients)	1.15 (0.70 – 1.91)
	Persson et al. 2013 ⁷	Case-Control	Sweden	ACR and CHCC criteria, EMA algorithm	Blood donors	105/200	GPA (61), MPA (44)	PR3-ANCA (62), MPO-ANCA (43)	1.09 (0.70 – 1.59)
	Huang et al. 2000 ⁴	Case-Control	Sweden	ACR criteria	Geographically and ethnically matched healthy subjects	32/109	GPA (all patients)	PR3-ANCA (29)	2.84 (0.74 – 10.91)
<i>CTLA-4</i> (AT) ₁₀₆	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria		49/111	MPA (all patients)	MPO-ANCA (all patients)	0.41 (0.14 – 1.22)
	Persson et al. 2013 ⁷	Case-Control	Sweden	ACR and CHCC criteria, EMA algorithm	Blood donors	105/200	GPA (61), MPA (44)	PR3-ANCA (62), MPO-ANCA (43)	2.63 (1.09 – 6.35)
	Huang et al. 2000 ⁴	Case-Control	Sweden	ACR criteria	Geographically and ethnically matched healthy subjects	32/109	GPA (all patients)	PR3-ANCA (29)	0.90 (0.42 – 1.95)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)		OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level
<i>CTLA-4</i> (AT) ₁₁₀	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	49/111	MPA (all patients)	MPO-ANCA (all patients)	0.89 (0.47 – 1.68)
	Persson et al. 2013 ⁷	Case-Control	Sweden	ACR and CHCC criteria, EMA algorithm	Blood donors	105/200	GPA (61), MPA (44)	PR3-ANCA (62), MPO-ANCA (43)	1.78 (1.05 – 3.03)
	Huang et al. 2000 ⁴	Case-Control	Sweden	ACR criteria	Geographically and ethnically matched healthy subjects	32/109	GPA (all patients)	PR3-ANCA (29)	0.48 (0.02–9.36)
	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	49/111	MPA (all patients)	MPO-ANCA (all patients)	0.25 (0.01 – 4.62)
	Persson et al. 2013 ⁷	Case-Control	Sweden	ACR and CHCC criteria, EMA algorithm	Blood donors	105/200	GPA (61), MPA (44)	PR3-ANCA (62), MPO-ANCA (43)	0.74 (0.34 – 1.61)
<i>CTLA-4</i> (AT) ₁₁₆	Huang et al. 2000 ⁴	Case-Control	Sweden	ACR criteria	Geographically and ethnically matched healthy subjects	32/109	GPA (all patients)	PR3-ANCA (29)	1.37 (0.26 – 7.26)
	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	49/111	MPA (all patients)	MPO-ANCA (all patients)	0.75 (0.03 – 18.56)
	Persson et al. 2013 ⁷	Case-Control	Sweden	ACR and CHCC criteria, EMA algorithm	Blood donors	105/200	GPA (61), MPA (44)	PR3-ANCA (62), MPO-ANCA (43)	0.540 (0.11 – 2.62)
	Huang et al. 2000 ⁴	Case-Control	Sweden	ACR criteria	Geographically and ethnically matched healthy subjects	32/109	GPA (all patients)	PR3-ANCA (29)	3.44 (0.21 – 55.85)
<i>CTLA-4</i> (AT) ₁₁₈	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	49/111	MPA (all patients)	MPO-ANCA (all patients)	0.75 (0.08 – 7.33)
	Persson et al. 2013 ⁷	Case-Control	Sweden	ACR and CHCC criteria, EMA algorithm	Blood donors	105/200	GPA (61), MPA (44)	PR3-ANCA (62), MPO-ANCA (43)	0.27 (0.06 – 1.18)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Controls			Participants (n)		OR (95% CI)	
		Design	Setting	Cases	Controls	Cases /	Diagnoses	ANCA serotype				
<i>CTLA-4</i> (AT) ₁₂₂	Huang et al. 2000 ⁴	Case-Control	Sweden	ACR criteria	Geographically and ethnically matched healthy subjects	32/109	GPA (all patients)	PR3-ANCA (29)	10.32 (0.42 – 256.50) 2.32 (0.57 – 9.47) 0.47 (0.05 – 4.27) 14.47 (1.59 – 131.86) 2.28 (0.14 – 36.59) 0.63 (0.13 – 3.16) 4.78 (1.04 – 21.93) 0.45 (0.05 – 3.88) 0.81 (0.21 – 3.18) 1.12 (0.05 – 27.93) 6.98 (0.72 – 67.95)			
	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	49/111	MPA (all patients)	MPO-ANCA (all patients)				
	Persson et al. 2013 ⁷	Case-Control	Sweden	ACR and CHCC criteria, EMA algorithm	Blood donors	105/200	GPA (61), MPA (44)	PR3-ANCA (62), MPO-ANCA (43)				
	Huang et al. 2000 ⁴	Case-Control	Sweden	ACR criteria	Geographically and ethnically matched healthy subjects	32/109	GPA (all patients)	PR3-ANCA (29)				
<i>CTLA-4</i> (AT) ₁₂₄	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	49/111	MPA (all patients)	MPO-ANCA (all patients)	2.28 (0.14 – 36.59) 0.63 (0.13 – 3.16) 4.78 (1.04 – 21.93) 0.45 (0.05 – 3.88) 0.81 (0.21 – 3.18) 1.12 (0.05 – 27.93) 6.98 (0.72 – 67.95)			
	Persson et al. 2013 ⁷	Case-Control	Sweden	ACR and CHCC criteria, EMA algorithm	Blood donors	105/200	GPA (61), MPA (44)	PR3-ANCA (62), MPO-ANCA (43)				
	Huang et al. 2000 ⁴	Case-Control	Sweden	ACR criteria	Geographically and ethnically matched healthy subjects	32/109	GPA (all patients)	PR3-ANCA (29)				
	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	49/111	MPA (all patients)	MPO-ANCA (all patients)				
<i>CTLA-4</i> (AT) ₁₂₆	Huang et al. 2000 ⁴	Case-Control	Sweden	ACR criteria	Geographically and ethnically matched healthy subjects	32/109	GPA (all patients)	PR3-ANCA (29)	4.78 (1.04 – 21.93) 0.45 (0.05 – 3.88) 0.81 (0.21 – 3.18) 1.12 (0.05 – 27.93) 6.98 (0.72 – 67.95)			
	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	49/111	MPA (all patients)	MPO-ANCA (all patients)				
	Persson et al. 2013 ⁷	Case-Control	Sweden	ACR and CHCC criteria, EMA algorithm	Blood donors	105/200	GPA (61), MPA (44)	PR3-ANCA (62), MPO-ANCA (43)				
	Huang et al. 2000 ⁴	Case-Control	Sweden	ACR criteria	Geographically and ethnically matched healthy subjects	32/109	GPA (all patients)	PR3-ANCA (29)				
<i>CTLA-4</i> (AT) ₁₂₈	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	49/111	MPA (all patients)	MPO-ANCA (all patients)	6.98 (0.72 – 67.95)			

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Cases / Controls	Participants (n)		OR (95% CI)
		Design	Setting	Cases	Controls		Diagnoses	ANCA serotype	
CTLA-4 rs231775 (G)	Persson et al. 2013 ⁷	Case-Control	Sweden	ACR and CHCC criteria, EMA algorithm	Blood donors	105/200	GPA (61), MPA (44)	PR3-ANCA (62), MPO-ANCA (43)	0.69 (0.22 – 2.18)
	Slot et al. 2008 ⁸	Case-Control	The Netherlands	CHCC criteria	Geographically and ethnically matched healthy subjects	104/185	GPA (50), MPA (24), EGPA (7), RLV (21)	PR3-ANCA (49), MPO-ANCA (34), PR3- and MPO-ANCA positive (2), ANCA negative (17)	1.53 (1.09 – 2.17)
	Kamesh et al. 2009 ⁹	Case-Control	UK	CHCC criteria	Ethnically matched healthy subjects with no (family) history of autoimmune disease	222/629	GPA (116), MPA (96)	NR	1.32 (1.06 – 1.65)
	Previously unpublished Lyons et al. 2012 GWAS data ³	Case-control (GWAS)	UK	EMA algorithm, supported by either serology or histology	Wellcome Trust Case Control Consortium (UK)	676/5365	GPA (394), MPA (156)	PR3-ANCA (326), MPO-ANCA (167)	1.09 (0.97 – 1.22)
CTLA-4 rs3087243 (A)	Kamesh et al. 2009 ⁹	Case-Control	UK	CHCC criteria	Ethnically matched healthy subjects with no (family) history of autoimmune disease	222/629	GPA (116), MPA (96)	NR	0.67 (0.54 – 0.83)
	Chung et al. 2012 ^{2*}	Case-Control	USA	ACR criteria	Geographically matched subjects with no (family) history of autoimmune disease	424/469	GPA (all patients)	PR3-ANCA (339), MPO-ANCA (44), ANCA negative (39)	0.80 (0.66 – 0.97)
		Case-Control	Canada	ACR criteria	Geographically matched subjects with no history of autoimmune disease	456/1500	GPA (all patients)	NR	0.78 (0.67 – 0.91)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)			OR (95% CI)
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	
<i>FCAR</i> rs16986050 (G)	Previously unpublished Lyons et al. 2012 GWAS data ³	Case-control (GWAS)	UK	EMA algorithm, supported by either serology or histology	Wellcome Trust Case Control Consortium (UK)	913/5257	GPA (565), MPA (262)	PR3-ANCA (478), MPO-ANCA (264)	0.85 (0.77 - 0.94)
	Kelley et al. 2011 ^{10**}	Case-Control	USA	ACR and CHCC criteria	Geographically matched subjects with no (family) history of autoimmune disease	445/413	GPA (all patients)	NR	0.65 (0.50 – 0.83)
		Case-Control	USA, Canada	ACR and CHCC criteria	HapMap Caucasians	190/113	GPA (all patients)	NR	0.79 (0.52 – 1.21)
	Previously unpublished Lyons et al. 2012 GWAS data ³	Case-control (GWAS)	UK	EMA algorithm, supported by either serology or histology	Wellcome Trust Case Control Consortium (UK)	676/5365	GPA (394), MPA (156)	PR3-ANCA (326), MPO-ANCA (167)	1.07 (0.93 – 1.24)
	Edberg et al. 1997 ¹¹	Case-Control	USA, Chile, Germany, Canada	ACR and CHCC criteria	Ethnically matched healthy volunteers	147/149	GPA (all patients)	NR	0.85 (0.61 – 1.17)
<i>FCGR2A</i> rs1801274 (C)	Dijstelbloem et al. 1999 ¹²	Case-Control	The Netherlands	ACR criteria	Ethnically matched healthy blood donors	91/154	GPA (all patients)	PR3-ANCA (all patients)	0.98 (0.68 – 1.41)
	Tse et al. 1999 ¹³	Case-Control	UK	CHCC criteria	Ethnically matched healthy subjects	107/100	GPA (48), MPA (54), EGPA (1), PAN (4)	PR3-ANCA (75), MPO-ANCA (32)	1.00 (0.68 – 1.48)
	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	50/303	MPA (all patients)	MPO-ANCA (all patients)	0.68 (0.37 – 1.24)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)		OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level
FCGR3A rs396991 (G)	Previously unpublished	Case-control (GWAS)	UK	EMA algorithm, supported by either serology or histology	Wellcome Trust Case Control Consortium (UK)	676/5365	GPA (394), MPA (156)	PR3-ANCA (326), MPO-ANCA (167)	0.89 (0.79 – 0.99)
	Lyons et al. 2012								
	GWAS data ³								
	Persson et al. 2013 ⁷	Case-Control	Sweden	ACR and CHCC criteria, EMA algorithm	Blood donors	105/200	GPA (61), MPA (44)	PR3-ANCA (62), MPO-ANCA (43)	1.03 (0.73 – 1.43)
	Dijstelbloem et al. 1999 ¹²	Case-Control	The Netherlands	ACR criteria	Ethnically matched healthy blood donors	91/154	GPA (all patients)	PR3-ANCA (all patients)	1.30 (0.89 – 1.91)
FCGR3B (NA1)	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	50/303	MPA (all patients)	MPO-ANCA (all patients)	0.65 (0.39 – 1.07)
	Dijstelbloem et al. 1999 ¹²	Case-Control	The Netherlands	ACR criteria	Ethnically matched healthy blood donors	91/154	GPA (all patients)	PR3-ANCA (all patients)	1.05 (0.72 – 1.53)
	Tse et al. 2000 ⁴	Case-Control	UK	CHCC criteria	Ethnically matched healthy subjects	101/100	GPA (45), MPA (52), EGPA (1), PAN (3)	PR3-ANCA (61), MPO-ANCA (30)	1.24 (0.8 – 1.87)
	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	50/303	MPA (all patients)	MPO-ANCA (all patients)	1.29 (0.82 – 2.03)
	Kelley et al. 2011 ¹⁰	Case-Control	USA	ACR and CHCC criteria	Geographically matched subjects with no (family) history of autoimmune disease	673/413	GPA (all patients)	NR	0.86 (0.72 – 1.03)
GHSR rs509035 (A)	Wieczorek et al. 2010 ^{15**}	Case-Control	Germany	CHCC criteria	Geographically matched healthy subjects	454/820	GPA (all patients)	NR	1.22 (1.02 – 1.45)
		Case-Control	Germany	CHCC criteria	Geographically matched healthy subjects	179/516	GPA (all patients)	NR	0.94 (0.72 – 1.23)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)			OR (95% CI)
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	
<i>GHSR</i> rs519384 (A)	Previously unpublished Lyons et al. 2012 GWAS data ³	Case-control (GWAS)	UK	EMA algorithm, supported by either serology or histology	Wellcome Trust Case Control Consortium (UK)	914/5259	GPA (565), MPA (262)	PR3-ANCA (478), MPO-ANCA (264)	1.00 (0.90 – 1.11)
	Wieczorek et al. 2010 ^{15**}	Case-Control	Germany	CHCC criteria	Geographically matched healthy subjects	449/813	GPA (all patients)	NR	1.17 (0.98 – 1.40)
<i>GHSR</i> rs572169 (A)	Wieczorek et al. 2010 ^{15**}	Case-Control	Germany	CHCC criteria	Geographically matched healthy subjects	179/515	GPA (all patients)	NR	1.01 (0.77 – 1.33)
		Case-Control	Germany	CHCC criteria	Geographically matched healthy subjects	442/812	GPA (all patients)	NR	1.21 (1.01 – 1.44)
<i>HLA-A1</i>	Strimlan et al. 1978 ¹⁶	Case-Control	USA	Histologically proven AAV	Geographically matched healthy blood donors	178/492	GPA (all patients)	NR	0.96 (0.73 – 1.25)
	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Ethnically matched healthy blood donors	31/701	GPA (all patients)	NR	1.53 (0.81 – 2.87)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	41/700	GPA (all patients)	NR	0.84 (0.47 – 1.52)
	Stassen et al. 2009 ¹⁹	Case-Control	The Netherlands	CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	0.92 (0.42 – 2.03)
<i>HLA-A2</i>	Strimlan et al. 1978 ¹⁶	Case-Control	USA	Histologically proven AAV	Geographically matched healthy blood donors	304/5872	GPA (241), MPA (30), EGPA (12), RVL (21)	PR3-ANCA (218), MPO-ANCA (64), other (4), ANCA negative (18)	1.08 (0.87 – 1.35)
	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Ethnically matched healthy blood donors	31/701	GPA (all patients)	NR	0.78 (0.42 – 1.45)
		Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR	1.04 (0.62 – 1.73)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)		OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level
<i>HLA-A3</i>	Nakamaru et al. 1996 ²⁰	Case-Control	Japan	Clinical, histological, serological criteria	Geographically matched healthy subjects	16/472	GPA (all patients)	c-ANCA (all patients)	0.90 (0.37 – 2.23)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	0.87 (0.48 – 1.58)
	Stassen et al. 2009 ¹⁹	Case-Control	The Netherlands	CHCC criteria	Geographically matched healthy blood donors	304/5872	GPA (241), MPA (30), EGPA (12), RVL (21)	PR3-ANCA (218), MPO-ANCA (64), other (4), ANCA negative (18)	0.98 (0.81 – 1.17)
	Strimlan et al. 1978 ¹⁶	Case-Control	USA	Histologically proven AAV	Ethnically matched healthy blood donors	31/701	GPA (all patients)	NR	1.73 (0.90 – 3.31)
	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR	1.51 (0.86 – 2.66)
<i>HLA-A9</i>	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	1.88 (0.89 – 3.98)
	Stassen et al. 2009 ¹⁹	Case-Control	The Netherlands	CHCC criteria	Geographically matched healthy blood donors	304/5872	GPA (241), MPA (30), EGPA (12), RVL (21)	PR3-ANCA (218), MPO-ANCA (64), other (4), ANCA negative (18)	1.04 (0.84 – 1.31)
	Strimlan et al. 1978 ¹⁶	Case-Control	USA	Histologically proven AAV	Ethnically matched healthy blood donors	31/701	GPA (all patients)	NR	1.09 (0.46 – 2.59)
	Katz et al. 1979 ²¹	Case-Control	USA	Clinical and histological criteria	Ethnically matched subjects	31/418	GPA (all patients)	NR	69.13 (3.28 – 456.19)

Supplementary table 2. Study characteristics of the included studies (Continued)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)			OR (95% CI)
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	
HLA-A24	Stassen et al. 2009 ¹⁹	Case-Control	The Netherlands	CHCC criteria	Geographically matched healthy blood donors	304/5872	GPA (241), MPA (30), EGPA (12), RVL (21)	PR3-ANCA (218), MPO-ANCA (64), other (+), ANCA negative (18)	0.62 (0.39 – 0.99)
	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR	0.91 (0.36 – 2.31)
	Nakamaru et al. 1996 ²⁰	Case-Control	Japan	Clinical, histological, serological criteria	Geographically matched healthy subjects	16/472	GPA (all patients)	c-ANCA (all patients)	0.75 (0.34 – 1.65)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	1.81 (0.51 – 6.37)
	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR	1.43 (0.33 – 6.17)
HLA-A25	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	2.09 (0.61 – 7.16)
	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR	0.68 (0.09 – 5.07)
HLA-A26	Nakamaru et al. 1996 ²⁰	Case-Control	Japan	Clinical, histological, serological criteria	Geographically matched healthy subjects	16/472	GPA (all patients)	c-ANCA (all patients)	2.36 (1.00. – 5.60)
	Papasteriades et al. 1997 ²²	Case-Control	Greece	Histologically proven AAV	Geographically and ethnically matched healthy subjects	23/405	MPA (all patients)	NR	2.49 (1.01 – 6.18)
HLA-A28	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	0.39 (0.07 – 2.05)
	Sririmlan et al. 1978 ¹⁶	Case-Control	USA	Histologically proven AAV	Ethnically matched healthy blood donors	31/701	GPA (all patients)	NR	0.40 (0.02 – 6.68)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)			OR (95% CI)
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	
HLA-A29	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR	0.32 (0.04 – 2.34)
	Stassen et al. 2009 ¹⁹	Case-Control	The Netherlands	CHCC criteria	Geographically matched healthy blood donors	304/5872	GPA (241), MPA (30), EGPA (12), RVL (21)	PR3-ANCA (218), MPO-ANCA (64), other (+), ANCA negative (18)	0.88 (0.57 – 1.38)
	Strimlan et al. 1978 ¹⁶	Case-Control	USA	Histologically proven AAV	Ethnically matched healthy blood donors	31/701	GPA (all patients)	NR	2.11 (0.68 – 6.57)
	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR	0.31 (0.04 – 2.25)
HLA-A30	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	0.66 (0.11 – 4.04)
	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR	0.68 (0.09 – 5.07)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	2.02 (0.18 – 22.63)
	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR	1.07 (0.25 – 4.54)
HLA-A31	Nakamaru et al. 1996 ²⁰	Case-Control	Japan	Clinical, histological, serological criteria	Geographically matched healthy subjects	16/472	GPA (all patients)	c-ANCA (all patients)	1.55 (0.46 – 5.24)
HLA-A32	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	0.33 (0.03 – 3.20)
	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR	3.73 (1.24 – 11.22)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)		OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level
<i>HLA-B5</i>	Nakamaru et al. 1996 ²⁰	Case-Control	Japan	Clinical, histological, serological criteria	Geographically matched healthy subjects	16/472	GPA (all patients)	c-ANCA (all patients)	2.07 (0.60 – 7.04)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	0.24 (0.03 – 2.21)
	Strimlan et al. 1978 ¹⁶	Case-Control	USA	Histologically proven AAV	Ethnically matched healthy blood donors	31/701	GPA (all patients)	NR	0.93 (0.28 – 3.02)
	Stassen et al. 2009 ¹⁹	Case-Control	The Netherlands	CHCC criteria	Geographically matched healthy blood donors	304/5872	GPA (241), MPA (30), EGPA (12), RVL (21)	PR3-ANCA (218), MPO-ANCA (64), other (4), ANCA negative (18)	0.56 (0.35 – 0.89)
	Strimlan et al. 1978 ¹⁶	Case-Control	USA	Histologically proven AAV	Ethnically matched healthy blood donors	31/701	GPA (all patients)	NR	1.54 (0.77 – 3.08)
<i>HLA-B7</i>	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR	1.74 (1.02 – 2.96)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	1.07 (0.52 – 2.22)
	Stassen et al. 2009 ¹⁹	Case-Control	The Netherlands	CHCC criteria	Geographically matched healthy blood donors	304/5872	GPA (241), MPA (30), EGPA (12), RVL (21)	PR3-ANCA (218), MPO-ANCA (64), other (4), ANCA negative (18)	1.00 (0.80 – 1.26)
	Strimlan et al. 1978 ¹⁶	Case-Control	USA	Histologically proven AAV	Ethnically matched healthy blood donors	31/701	GPA (all patients)	NR	1.24 (0.60 – 2.56)
	Katz et al. 1979 ²¹	Case-Control	USA	Clinical and histological criteria	Ethnically matched subjects	31/418	GPA (all patients)	NR	2.30 (1.18 – 4.50)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)			OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level	
<i>HLA-B12</i>	Elkon et al. 1983 ²³	Case-Control	UK	Clinical and histological criteria	Geographically matched subjects	17/113	GPA (all patients)	NR	2.47 (1.01 – 6.05)	
	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR	1.03 (0.55 – 1.93)	
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	3.27 (1.02 – 10.50)	
	Stassen et al. 2009 ¹⁹	Case-Control	The Netherlands	CHCC criteria	Geographically matched healthy blood donors	304/5872	GPA (241), MPA (30), EGPA (12), RVL (21)	PR3-ANCA (218), MPO-ANCA (64), other (4), ANCA negative (18)	1.11 (0.88 – 1.40)	
	Strimlan et al. 1978 ¹⁶	Case-Control	USA	Histologically proven AAV	Ethnically matched healthy blood donors	31/701	GPA (all patients)	NR	1.01 (0.47 – 2.15)	
<i>HLA-B13</i>	Stassen et al. 2009 ¹⁹	Case-Control	The Netherlands	CHCC criteria	Geographically matched healthy blood donors	304/5872	GPA (241), MPA (30), EGPA (12), RVL (21)	PR3-ANCA (218), MPO-ANCA (64), other (4), ANCA negative (18)	0.96 (0.74 – 1.24)	
	Strimlan et al. 1978 ¹⁶	Case-Control	USA	Histologically proven AAV	Ethnically matched healthy blood donors	31/701	GPA (all patients)	NR	0.87 (0.12 – 6.50)	
	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR	2.09 (0.62 – 7.07)	
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	0.79 (0.21 – 3.03)	
	Stassen et al. 2009 ¹⁹	Case-Control	The Netherlands	CHCC criteria	Geographically matched healthy blood donors	304/5872	GPA (241), MPA (30), EGPA (12), RVL (21)	PR3-ANCA (218), MPO-ANCA (64), other (4), ANCA negative (18)	0.63 (0.31 – 1.28)	

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)		OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level
<i>HLA-B14</i>	Strimlan et al. 1978 ¹⁶	Case-Control	USA	Histologically proven AAV	Ethnically matched healthy blood donors	31/701	GPA (all patients)	NR	0.32 (0.02 – 5.24)
	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR	0.51 (0.16 – 1.63)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	1.52 (0.25 – 9.26)
	Stassen et al. 2009 ¹⁹	Case-Control	The Netherlands	CHCC criteria	Geographically matched healthy blood donors	304/5872	GPA (241), MPA (30), EGPA (12), RVL (21)	PR3-ANCA (218), MPO-ANCA (64), other (4), ANCA negative (18)	1.16 (0.63 – 2.14)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	1.38 (0.55 – 3.43)
<i>HLA-B15</i>	Stassen et al. 2009 ¹⁹	Case-Control	The Netherlands	CHCC criteria	Geographically matched healthy blood donors	304/5872	GPA (241), MPA (30), EGPA (12), RVL (21)	PR3-ANCA (218), MPO-ANCA (64), other (4), ANCA negative (18)	0.98 (0.74 – 1.29)
	Strimlan et al. 1978 ¹⁶	Case-Control	USA	Histologically proven AAV	Ethnically matched healthy blood donors	31/549	GPA (all patients)	NR	1.16 (0.35 – 3.85)
<i>HLA-B18</i>	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR	0.53 (0.13 – 2.21)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	0.78 (0.296 – 2.072)
	Stassen et al. 2009 ¹⁹	Case-Control	The Netherlands	CHCC criteria	Geographically matched healthy blood donors	304/5872	GPA (241), MPA (30), EGPA (12), RVL (21)	PR3-ANCA (218), MPO-ANCA (64), other (4), ANCA negative (18)	0.75 (0.435 – 1.283)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Controls			Participants (n)		OR (95% CI)
		Design	Setting	Cases	Controls	Cases /	Diagnoses	ANCA serotype			Allele level
<i>HLA-B27</i>	Sririmlan et al. 1978 ¹⁶	Case-Control	USA	Histologically proven AAV	Ethnically matched healthy blood donors	31/600	GPA (all patients)	NR			0.74 (0.18 – 3.093)
	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR			0.60 (0.14 – 2.503)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR			0.06 (0.00 – 1.102)
	Stassen et al. 2009 ¹⁹	Case-Control	The Netherlands	CHCC criteria	Geographically matched healthy blood donors	304/5872	GPA (241), MPA (30), EGPA (12), RVL (21)	PR3-ANCA (218), MPO-ANCA (64), other (4), ANCA negative (18)			0.77 (0.48 – 1.247)
<i>HLA-B35</i>	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR			0.45 (0.11 – 1.86)
	Nakamaru et al. 1996 ²⁰	Case-Control	Japan	Clinical, histological, serological criteria	Geographically matched healthy subjects	16/472	GPA (all patients)	c-ANCA (all patients)			0.80 (0.187 – 3.40)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR			0.85 (0.28 – 2.62)
	Stassen et al. 2009 ¹⁹	Case-Control	The Netherlands	CHCC criteria	Geographically matched healthy blood donors	304/5872	GPA (241), MPA (30), EGPA (12), RVL (21)	PR3-ANCA (218), MPO-ANCA (64), other (4), ANCA negative (18)			0.81 (0.59 – 1.12)
<i>HLA-B37</i>	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR			0.14 (0.01 – 2.72)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)		OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level
<i>HLA-B39</i>	Stassen et al. 2009 ¹⁹	Case-Control	The Netherlands	CHCC criteria	Geographically matched healthy blood donors	304/5872	GPA (241), MPA (30), EGPA (12), RVL (21)	PR3-ANCA (218), MPO-ANCA (64), other (+), ANCA negative (18)	1.07 (0.58 – 1.98)
	Nakamaru et al. 1996 ²⁰	Case-Control	Japan	Clinical, histological, serological criteria	Geographically matched healthy subjects	16/472	GPA (all patients)	c-ANCA (all patients)	0.86 (0.11 – 6.51)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	0.33 (0.01 – 8.20)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	1.65 (0.52 – 5.23)
<i>HLA-B40</i>	Stassen et al. 2009 ¹⁹	Case-Control	The Netherlands	CHCC criteria	Geographically matched healthy blood donors	304/5872	GPA (241), MPA (30), EGPA (12), RVL (21)	PR3-ANCA (218), MPO-ANCA (64), other (+), ANCA negative (18)	0.90 (0.67 – 1.22)
	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR	1.07 (0.58 – 2.00)
	Nakamaru et al. 1996 ²⁰	Case-Control	Japan	Clinical, histological, serological criteria	Geographically matched healthy subjects	16/472	GPA (all patients)	c-ANCA (all patients)	2.50 (0.845 – 7.403)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	3.27 (1.02 – 10.50)
<i>HLA-B49</i>	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR	1.27 (0.30 – 5.44)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	2.02 (0.18 – 22.63)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)			OR (95% CI)
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	
<i>HLA-B51</i>	Nakamaru et al. 1996 ²⁰	Case-Control	Japan	Clinical, histological, serological criteria	Geographically matched healthy subjects	16/472	GPA (all patients)	c-ANCA (all patients)	1.87 (0.64 – 5.49)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	0.61 (0.19 – 1.92)
<i>HLA-B55</i>	Nakamaru et al. 1996 ²⁰	Case-Control	Japan	Clinical, histological, serological criteria	Geographically matched healthy subjects	16/472	GPA (all patients)	c-ANCA (all patients)	7.35 (2.33 – 23.14)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	0.07 (0.00 – 1.30)
<i>HLA-B57</i>	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR	2.78 (1.05 – 7.32)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	1.00 (0.06 – 16.21)
<i>HLA-B60</i>	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR	3.51 (0.99 – 12.36)
	Nakamaru et al. 1996 ²⁰	Case-Control	Japan	Clinical, histological, serological criteria	Geographically matched healthy subjects	16/472	GPA (all patients)	c-ANCA (all patients)	1.19 (0.28 – 5.13)
<i>HLA-B62</i>	Murty et al. 1991 ¹⁷	Case-Control	Ireland, UK	Histologically proven AAV	Geographically matched healthy subjects	41/700	GPA (all patients)	NR	2.38 (0.70 – 8.12)
	Nakamaru et al. 1996 ²⁰	Case-Control	Japan	Clinical, histological, serological criteria	Geographically matched healthy subjects	16/472	GPA (all patients)	c-ANCA (all patients)	1.71 (0.58 – 4.99)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)		OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level
<i>HLA-Cw1</i>	Nakamaru et al. 1996 ²⁰	Case-Control	Japan	Clinical, histological, serological criteria	Geographically matched healthy subjects	16/472	GPA (all patients)	c-ANCA (all patients)	1.45 (0.58 – 3.58)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	52/51	GPA (all patients)	NR	0.98 (0.24 – 4.03)
	Nakamaru et al. 1996 ²⁰	Case-Control	Japan	Clinical, histological, serological criteria	Geographically matched healthy subjects	16/472	GPA (all patients)	c-ANCA (all patients)	1.40 (0.65 – 3.01)
<i>HLA-Cw3</i>	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	52/51	GPA (all patients)	NR	1.32 (0.62 – 2.81)
	Nakamaru et al. 1996 ²⁰	Case-Control	Japan	Clinical, histological, serological criteria	Geographically matched healthy subjects	16/472	GPA (all patients)	c-ANCA (all patients)	0.50 (0.12 – 2.10)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	52/51	GPA (all patients)	NR	1.10 (0.62 – 1.96)
<i>HLA-DPA1 rs9277341 (C)</i>	Heckmann et al. 2008 ²⁴	Case-Control	Germany	ACR criteria	Geographically matched healthy blood donors	282/380	GPA (all patients)	ANCA+ (250), ANCA- (27)	0.38 (0.29 – 0.51)
	Xie et al. 2013 ^{3**}	Case-control (GWAS)	Canada, USA	ACR criteria	Geographically matched healthy subjects	459/1503	GPA (all patients)	c-ANCA (351)	0.30 (0.24 – 0.37)
	Zhang et al. 1995 ²⁶	Case-control (GWAS)	USA	ACR criteria	Geographically matched healthy subjects	291/317	GPA (all patients)	c-ANCA (227)	0.43 (0.32 – 0.57)
<i>HLA-DPBI*0101</i>		Case-Control	UK	CHCC criteria	Geographically matched healthy subjects	94/50	GPA (56), MPA (31), RVL (7)	PR3-ANCA (36), MPO-ANCA (19), PR3- and MPO-AN-CA positive (3)	1.20 (0.53 – 2.75)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)			OR (95% CI)
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	
<i>HLA-DPB1*0201</i>	Jagiello et al. 2004 ²⁷	Case-Control	Germany	ACR and CHCC criteria, biopsy	Geographically matched subjects	148/89	GPA (all patients)	PR3-ANCA (all patients)	0.17 (0.05 – 0.63)
	Jagiello et al. 2004 ²⁷	Case-Control	Germany	ACR and CHCC criteria, biopsy	Geographically matched subjects	148/89	GPA (all patients)	PR3-ANCA (all patients)	0.78 (0.49 – 1.23)
	Tsuchiya et al. 2006 ²⁸	Case-Control	Japan	Japanese 1998 criteria	Geographically matched healthy subjects	50/77	MPA (all patients)	MPO-ANCA (all patients)	0.44 (0.21 – 0.91)
	Heckmann et al. 2008 ²⁴	Case-Control	Germany	ACR criteria	Geographically matched healthy blood donors	135/369	GPA (all patients)	ANCA+ (108), ANCA- (27)	1.38 (0.75 – 2.52)
	Wieczorek et al. 2008 ²⁹	Case-Control	Germany	ACR criteria	Geographically matched healthy subjects	102/369	EGPA (all patients)	NR	0.93 (0.57 – 1.51)
<i>HLA-DPB1*0301</i>	Zhang et al. 1995 ²⁶	Case-Control	UK	CHCC criteria	Geographically matched healthy subjects	94/50	GPA (56), MPA (31), RVL (7)	PR3-ANCA (36), MPO-ANCA (19), PR3- and MPO-AN-CA positive (3)	1.27 (0.56 – 2.89)
	Jagiello et al. 2004 ²⁷	Case-Control	Germany	ACR and CHCC criteria, biopsy	Geographically matched subjects	148/89	GPA (all patients)	PR3-ANCA (all patients)	0.02 (0.00 – 0.15)
	Heckmann et al. 2008 ²⁴	Case-Control	Germany	ACR criteria	Geographically matched healthy blood donors	135/369	GPA (all patients)	ANCA+ (108), ANCA- (27)	0.28 (0.14 – 0.55)
	Wieczorek et al. 2008 ²⁹	Case-Control	Germany	ACR criteria	Geographically matched healthy subjects	102/369	EGPA (all patients)	NR	0.65 (0.38 – 1.11)
	Arning et al. 2011 ^{10**}	Case-Control	Germany	CHCC criteria	Geographically and ethnically matched healthy blood donors	482/356	GPA (389), EGPA (56), MPA (37)	NR	0.30 (0.21 – 0.44)
		Case-Control	UK	CHCC criteria	Geographically and ethnically matched healthy blood donors	193/104	GPA (102), MPA (82), EGPA (9)	NR	0.35 (0.16 – 0.77)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)			OR (95% CI)
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	
<i>HLA-DPB1</i> *0401	Zhang et al. 1995 ²⁶	Case-Control	UK	CHCC criteria	Geographically matched healthy subjects	94/50	GPA (56), MPA (31), RVL (7)	PR3-ANCA (36), MPO-ANCA (19), PR3- and MPO-AN-CA positive (3)	1.42 (0.84 – 2.38)
	Jagiello et al. 2004 ²⁷	Case-Control	Germany	ACR and CHCC criteria, biopsy	Geographically matched subjects	148/89	GPA (all patients)	PR3-ANCA (all patients)	3.91 (2.62 – 5.84)
	Heckmann et al. 2008 ²⁴	Case-Control	Germany	ACR criteria	Geographically matched healthy blood donors	135/369	GPA (all patients)	ANCA+ (108), ANCA- (27)	2.15 (1.61 – 2.86)
	Wieczorek et al. 2008 ²⁹	Case-Control	Germany	ACR criteria	Geographically matched healthy subjects	102/369	EGPA (all patients)	NR	1.06 (0.78 – 1.45)
	Arning et al. 2011 ^{30**}	Case-Control	Germany	CHCC criteria	Geographically and ethnically matched healthy blood donors	482/356	GPA (389), EGPA (56), MPA (37)	NR	2.34 (1.92 – 2.85)
<i>HLA-DPB1</i> *0402		Case-Control	UK	CHCC criteria	Geographically and ethnically matched healthy blood donors	193/104	GPA (102), MPA (82), EGPA (9)	NR	2.02 (1.44 – 2.85)
	Zhang et al. 1995 ²⁶	Case-Control	UK	CHCC criteria	Geographically matched healthy subjects	94/50	GPA (56), MPA (31), RVL (7)	PR3-ANCA (36), MPO-ANCA (19), PR3- and MPO-AN-CA positive (3)	0.82 (0.38 – 1.78)
	Jagiello et al. 2004 ²⁷	Case-Control	Germany	ACR and CHCC criteria, biopsy	Geographically matched subjects	148/89	GPA (all patients)	PR3-ANCA (all patients)	1.11 (0.65 – 1.92)
	Heckmann et al. 2008 ²⁴	Case-Control	Germany	ACR criteria	Geographically matched healthy blood donors	135/369	GPA (all patients)	ANCA+ (108), ANCA- (27)	1.14 (0.78 – 1.68)
	Wieczorek et al. 2008 ²⁹	Case-Control	Germany	ACR criteria	Geographically matched healthy subjects	102/369	EGPA (all patients)	NR	1.15 (0.75 – 1.77)

Supplementary table 2. Study characteristics of the included studies (Continued)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)		OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level
<i>HLA-DQB1*02</i>	Xie et al. 2013 ²⁵	Case-control (GWAS)	Canada, USA	ACR criteria	Geographically matched healthy subjects	459/1503	GPA (all patients)	c-ANCA (351)	2.44 (2.10 – 2.84)
	Spriewald et al. 2005 ³¹	Case-Control	Germany	ACR and CHCC criteria	Ethnically matched healthy subjects	32/91	GPA (all patients)	PR3-ANCA (all patients)	0.98 (0.45 – 2.13)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/50	GPA (all patients)	NR	0.85 (0.41 – 1.77)
	Zhang et al. 1995 ²⁶	Case-Control	UK	CHCC criteria	Geographically matched healthy subjects	94/50	GPA (56), MPA (31), RVL (7)	PR3-ANCA (36), MPO-ANCA (19), PR3- and MPO-AN-CA positive (3)	1.07 (0.53 – 2.20)
<i>HLA-DQB1*0302</i>	Spriewald et al. 2005 ³¹	Case-Control	Germany	ACR and CHCC criteria	Ethnically matched healthy subjects	32/91	GPA (all patients)	PR3-ANCA (all patients)	0.94 (0.36 – 2.49)
	Zhang et al. 1995 ²⁶	Case-Control	UK	CHCC criteria	Geographically matched healthy subjects	94/50	GPA (56), MPA (31), RVL (7)	PR3-ANCA (36), MPO-ANCA (19), PR3- and MPO-AN-CA positive (3)	0.84 (0.27 – 2.65)
<i>HLA-DQB1*0303</i>	Spriewald et al. 2005 ³¹	Case-Control	Germany	ACR and CHCC criteria	Ethnically matched healthy subjects	32/91	GPA (all patients)	PR3-ANCA (all patients)	2.97 (0.72 – 12.23)
	Tsuchiya et al. 2006 ²⁸	Case-Control	Japan	Japanese 1998 criteria	Geographically matched healthy subjects	50/77	MPA (all patients)	MPO-ANCA (all patients)	2.11 (1.14 – 3.90)
	Spriewald et al. 2005 ³¹	Case-Control	Germany	ACR and CHCC criteria	Ethnically matched healthy subjects	32/91	GPA (all patients)	PR3-ANCA (all patients)	1.74 (0.40 – 7.50)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/50	GPA (all patients)	NR	1.49 (0.24 – 9.08)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)			OR (95% CI)
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	
<i>HLA-DQB1*0501</i>	Zhang et al. 1995 ²⁶	Case-Control	UK	CHCC criteria	Geographically matched healthy subjects	94/50	GPA (56), MPA (31), RVL (7)	PR3-ANCA (36), MPO-ANCA (19), PR3- and MPO-AN-CA positive (3)	1.77 (0.91 – 3.42)
	Spriewald et al. 2005 ³¹	Case-Control	Germany	ACR and CHCC criteria	Ethnically matched healthy subjects	32/91	GPA (all patients)	PR3-ANCA (all patients)	0.77 (0.32 – 1.88)
<i>HLA-DQB1*0602</i>	Zhang et al. 1995 ²⁶	Case-Control	UK	CHCC criteria	Geographically matched healthy subjects	94/50	GPA (56), MPA (31), RVL (7)	PR3-ANCA (36), MPO-ANCA (19), PR3- and MPO-AN-CA positive (3)	0.64 (0.29 – 1.42)
	Spriewald et al. 2005 ³¹	Case-Control	Germany	ACR and CHCC criteria	Ethnically matched healthy subjects	32/91	GPA (all patients)	PR3-ANCA (all patients)	12.86 (2.65 – 62.31)
<i>HLA-DQ7</i>	Zhang et al. 1995 ²⁶	Case-Control	UK	CHCC criteria	Geographically matched healthy subjects	94/50	GPA (56), MPA (31), RVL (7)	PR3-ANCA (36), MPO-ANCA (19), PR3- and MPO-AN-CA positive (3)	1.21 (0.70 – 2.10)
	Papasteriades et al. 1997 ²²	Case-Control	Greece	Histologically proven AAV	Geographically and ethnically matched healthy subjects	23/405	MPA (all patients)	NR	0.66 (0.34 – 1.30)
<i>HLA-DR1</i>	Spriewald et al. 2005 ³¹	Case-Control	Germany	ACR and CHCC criteria	Ethnically matched healthy subjects	32/91	GPA (all patients)	PR3-ANCA (all patients)	0.43 (0.16 – 1.16)
	Elkon et al. 1983 ²³	Case-Control	UK	Clinical and histological criteria	Geographically matched subjects	46/113	GPA (17), EGPA (14), PAN (15)	NR	2.17 (0.90 – 5.23)
	Papiha et al. 1992 ³²	Case-Control	UK	Clinical and histological criteria	Geographically matched subjects	27/105	GPA (all patients)	NR	4.37 (2.01 – 9.48)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)		OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level
	Zhang et al. ¹⁹⁹⁵ ²⁶	Case-Control	UK	CHCC criteria	Geographically matched healthy subjects	94/90	GPA (56), MPA (31), RVL (7)	PR3-ANCA (36), MPO-ANCA (19), PR3- and MPO-AN-CA positive (3)	0.89 (0.44 – 1.82)
	Tsuchiya et al. ²⁰⁰³ ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	64/265	GPA (3), MPA (50), EGPA (8), PAN (3)	MPO-ANCA (all patients)	1.12 (0.48 – 2.64)
	Spriewald et al. ²⁰⁰⁵ ³¹	Case-Control	Germany	ACR and CHCC criteria	Ethnically matched healthy subjects	32/91	GPA (all patients)	PR3-ANCA (all patients)	0.68 (0.67 – 1.75)
	Von Vietinghoff et al. ²⁰⁰⁶ ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	0.56 (0.23 – 1.35)
	Wieczorek et al. ²⁰⁰⁸ ²⁹	Case-Control	Germany	ACR criteria	Geographically matched healthy subjects	102/369	EGPA (all patients)	NR	0.71 (0.43 – 1.15)
	Stassen et al. ²⁰⁰⁹ ¹⁹	Case-Control	The Netherlands	CHCC criteria	Geographically matched healthy blood donors	304/5442	GPA (241), MPA (30), EGPA (12), RVL (21)	PR3-ANCA (218), MPO-ANCA (64), other (4), ANCA negative (18)	0.67 (0.49 – 0.92)
	Cao et al. ²⁰¹¹ ³³	Case-Control	USA (96 Caucasians and 41 African Americans)	Histologically proven AAV	Ethnically matched community-based control frequencies (Healthy Organ Donors North Carolina Services)	137/379	NR	PR3-ANCA (90), MPO-ANCA (47)	0.53 (0.34 – 0.81)
	Luo et al. ²⁰¹¹ ³⁴	Case-Control	China	EMA algorithm	Ethnically matched healthy blood donors	152/200	GPA (45), MPA (107)	PR3-ANCA (19), MPO-ANCA (130), PR3- and MPO-AN-CA positive (3)	0.79 (0.28 – 2.19)

Supplementary table 2. Study characteristics of the included studies (Continued)

Supplementary table 2. Study characteristics of the included studies (Continued)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)			OR (95% CI)
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	
	Zhang et al. ¹⁹⁹⁵ ²⁶	Case-Control	UK	CHCC criteria	Geographically matched healthy subjects	94/90	GPA (56), MPA (31), RVL (7)	PR3-ANCA (36), MPO-ANCA (19), PR3- and MPO-AN-CA positive (3)	1.24 (0.74 – 2.07)
	Nakamaru et al. ¹⁹⁹⁶ ²⁰	Case-Control	Japan	Clinical, histological, serological criteria	Geographically matched healthy subjects	16/472	GPA (all patients)	c-ANCA (all patients)	0.72 (0.27 – 1.88)
	Spriewald et al. ²⁰⁰⁵ ³¹	Case-Control	Germany	ACR and CHCC criteria	Ethnically matched healthy subjects	32/91	GPA (all patients)	PR3 (all patients)	1.25 (0.54 – 2.90)
	Von Vietinghoff et al. ²⁰⁰⁶ ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	1.57 (0.61 – 4.01)
	Vaglio et al. ²⁰⁰⁷ ³⁵	Case-Control	Italy	ACR and CHCC criteria	Geographically matched healthy subjects with no (family) history of autoimmune disease	48/350	EGPA (all patients)	MPO-ANCA (18), ANCA negative (26), undetermined (4)	1.73 (0.84 – 3.57)
	Wieczorek et al. ²⁰⁰⁸ ²⁹	Case-Control	Germany	ACR criteria	Geographically matched healthy subjects	102/341	EGPA (all patients)	NR	1.87 (1.23 – 2.82)
	Stassen et al. ²⁰⁰⁹ ¹⁹	Case-Control	The Netherlands	CHCC criteria	Geographically matched healthy blood donors	304/544	GPA (241), MPA (30), EGPA (12), RVL (21)	PR3-ANCA (218), MPO-ANCA (64), other (4), ANCA negative (18)	1.53 (1.25 – 1.87)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)		OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level
HLA-DR5	Cao et al. 2011 ^{33**}	Case-Control	USA (96 Caucasians and 41 African Americans)	Histologically proven AAV	Ethnically matched community-based control frequencies (Healthy Organ Donor-ncies (North Carolina Services)	137/379	NR	PR3-ANCA (90), MPO-ANCA (47)	0.73 (0.51 – 1.05)
		Case-Control	USA (all African Americans)	Histologically proven AAV	USA African Americans-Bethesda database	16/112	NR	PR3-ANCA (9), MPO-ANCA (4), p-ANCA (2), ANCA negative (1)	0.62 (0.08 – 5.01)
	Elkon et al. 1983 ²³	Case-Control	UK	Clinical and histological criteria	Geographically matched subjects	46/113	GPA (17), EGPA (14), PAN (15)	NR	0.72 (0.28 – 1.85)
	Papiha et al. 1992 ³²	Case-Control	UK	Clinical and histological criteria	Geographically matched subjects	27/105	GPA (all patients)	NR	0.18 (0.02 – 1.37)
	Zhang et al. 1995 ²⁶	Case-Control	UK	CHCC criteria	Geographically matched healthy subjects	94/90	GPA (56), MPA (31), RVL (7)	PR3-ANCA (36), MPO-ANCA (19), PR3- and MPO-AN-CA positive (3)	0.95 (0.45 – 2.01)
	Papasteriades et al. 1997 ²²	Case-Control	Greece	Histologically proven AAV	Geographically and ethnically matched healthy subjects	23/405	MPA (all patients)	NR	1.59 (0.80 – 3.15)
	Stassen et al. 2009 ¹⁹	Case-Control	The Netherlands	CHCC criteria	Geographically matched healthy blood donors	304/5442	GPA (241), MPA (30), EGPA (12), RVL (21)	PR3-ANCA (218), MPO-ANCA (64), other (4), ANCA negative (18)	0.80 (0.58 – 1.09)
HLA-DR6	Elkon et al. 1983 ²³	Case-Control	UK	Clinical and histological criteria	Geographically matched subjects	46/113	GPA (17), EGPA (14), PAN (15)	NR	0.16 (0.04 – 0.70)

Supplementary table 2. Study characteristics of the included studies (Continued)

Supplementary table 2. Study characteristics of the included studies (Continued)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)			OR (95% CI)
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	
HLA-DR9	Stassen et al. 2009 ¹⁹	Case-Control	UK	CHCC criteria	Geographically matched healthy subjects	94/90	GPA (56), MPA (31), RVL (7)	PR3-ANCA (36), MPO-ANCA (19), PR3- and MPO-AN-CA positive (3)	0.95 (0.59 – 1.54)
	Cao et al. 2011 ³³	Case-Control	USA (96 Caucasians and 41 African Americans)	Histologically proven AAV	Ethnically matched community-based control frequencies (Healthy Organ Donor-nities (North Carolina Services)	137/379	NR	PR3-ANCA (90), MPO-ANCA (47)	0.76 (0.37 – 1.55)
	Elkon et al. 1983 ²³	Case-Control	UK	Clinical and histo-logical criteria	Geographically matched subjects	46/113	GPA (17), EGPA (14), PAN (15)	NR	0.49 (0.02 – 10.21)
	Nakamaru et al. 1996 ²⁰	Case-Control	Japan	Clinical, histologi-cal, serological criteria	Geographically matched healthy subjects	16/472	GPA (all patients)	c-ANCA (all patients)	3.03 (1.40 – 6.56)
	Fujii et al. 2000 ³⁶	Case-Control	Japan	CHCC criteria	Geographically matched healthy subjects	12/472	NR	MPO-ANCA (all patients)	2.75 (1.12 – 6.76)
	Spriewald et al. 2005 ³¹	Case-Control	Germany	ACR and CHCC criteria	Ethnically matched healthy subjects	32/91	GPA (all patients)	PR3 (all patients)	0.94 (0.04 – 23.32)
	Von Vietinghoff et al. 2006 ⁴⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	0.66 (0.11 – 4.04)
	Vaglio et al. 2007 ³⁵	Case-Control	Italy	ACR and CHCC criteria	Geographically matched healthy subjects with no (family) history of autoimmune disease	48/350	EGPA (all patients)	MPO-ANCA (18), ANCA negative (26), undetermined (4)	1.83 (0.20 – 16.56)
	Wieczorek et al. 2008 ²⁹	Case-Control	Germany	ACR criteria	Geographically matched healthy subjects	102/369	EGPA (all patients)	NR	0.80 (0.17 – 3.74)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)		OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level
<i>HLA-DRB1*0401</i>	Stassen et al. 2009 ¹⁹	Case-Control	UK	CHCC criteria	Geographically matched healthy subjects	94/90	GPA (56), MPA (31), RVL (7)	PR3-ANCA (36), MPO-ANCA (19), PR3- and MPO-AN-CA positive (3)	0.35 (0.11 – 1.09)
	Cao et al. 2011 ³³	Case-Control	USA (96 Caucasians and 41 African Americans)	Histologically proven AAV	Ethnically matched community-based control frequencies (Healthy Organ Donor- North Carolina Services)	137/379	NR	PR3-ANCA (90), MPO-ANCA (47)	0.75 (0.208 – 2.72)
	Luo et al. 2011 ³⁴	Case-Control	China	EMA algorithm	Ethnically matched healthy blood donors	152/200	GPA (45), MPA (107)	PR3-ANCA (19), MPO-ANCA (130), PR3- and MPO-AN-CA positive (3)	0.68 (0.43 – 1.06)
	Tsuchiya et al. 2013 ³⁷	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	116/265	MPA (96)	MPO-ANCA (all patients)	1.74 (1.18 – 2.57)
<i>HLA-DRB1*0401</i>	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	64/265	GPA (3), MPA (50), EGPA (8), PAN (3)	MPO-ANCA (all patients)	2.10 (0.52 – 8.50)
	Luo et al. 2011 ³⁴	Case-Control	China	EMA algorithm	Ethnically matched healthy blood donors	152/200	GPA (45), MPA (107)	PR3-ANCA (19), MPO-ANCA (130), PR3- and MPO-AN-CA positive (3)	0.58 (0.18 – 1.90)
<i>HLA-DRB1*0403</i>	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	64/265	GPA (3), MPA (50), EGPA (8), PAN (3)	MPO-ANCA (all patients)	0.95 (0.27 – 3.40)

Supplementary table 2. Study characteristics of the included studies (Continued)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)		OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level
<i>HLA-DRB1*0410</i>	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	64/265	GPA (3), MPA (50), EGPA (8), PAN (3)	MPO-ANCA (all patients)	1.67 (0.32 – 8.69)
	Luo et al. 2011 ³⁴	Case-Control	China	EMA algorithm	Ethnically matched healthy blood donors	152/200	GPA (45), MPA (107)	PR3-ANCA (19), MPO-ANCA (130), PR3- and MPO-AN-CA positive (3)	0.44 (0.02 – 10.77)
<i>HLA-DRB1*0802</i>	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	64/265	GPA (3), MPA (50), EGPA (8), PAN (3)	MPO-ANCA (all patients)	1.16 (0.42 – 3.18)
	Luo et al. 2011 ³⁴	Case-Control	China	EMA algorithm	Ethnically matched healthy blood donors	152/200	GPA (45), MPA (107)	PR3-ANCA (19), MPO-ANCA (130), PR3- and MPO-AN-CA positive (3)	0.26 (0.01 – 5.47)
<i>HLA-DRB1*0803</i>	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	64/265	GPA (3), MPA (50), EGPA (8), PAN (3)	MPO-ANCA (all patients)	1.51 (0.78 – 2.93)
	Luo et al. 2011 ³⁴	Case-Control	China	EMA algorithm	Ethnically matched healthy blood donors	152/200	GPA (45), MPA (107)	PR3-ANCA (19), MPO-ANCA (130), PR3- and MPO-AN-CA positive (3)	1.19 (0.61 – 2.33)
<i>HLA-DRB1*10</i>	Spriewald et al. 2005 ³¹	Case-Control	Germany	ACR and CHCC criteria	Ethnically matched healthy subjects	32/91	GPA (all patients)	PR3 (all patients)	1.43 (0.13 – 16.03)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	5.10 (0.24 – 107.55)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)			OR (95% CI)
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	
HLA-DRB1*11	Wieczorek et al. 2008 ²⁹	Case-Control	Germany	ACR criteria	Geographically matched healthy subjects	102/369	EGPA (all patients)	NR	0.40 (0.02 – 7.44)
	Cao et al. 2011 ³³	Case-Control	USA (96 Caucasians and 41 African Americans)	Histologically proven AAV	Ethnically matched community-based control frequencies (Healthy Organ Donor- North Carolina Services)	137/379	NR	PR3-ANCA (90), MPO-ANCA (47)	0.75 (0.21 – 2.72)
	Spriewald et al. 2005 ³¹	Case-Control	Germany	ACR and CHCC criteria	Ethnically matched healthy subjects	32/91	GPA (all patients)	PR3 (all patients)	0.723 (0.26 – 2.04)
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	1.28 (0.48 – 3.38)
	Wieczorek et al. 2008 ²⁹	Case-Control	Germany	ACR criteria	Geographically matched healthy subjects	102/369	EGPA (all patients)	NR	0.88 (0.53 – 1.48)
	Cao et al. 2011 ³³	Case-Control	USA (96 Caucasians and 41 African Americans)	Histologically proven AAV	Ethnically matched community-based control frequencies (Healthy Organ Donor- North Carolina Services)	137/379	NR	PR3-ANCA (90), MPO-ANCA (47)	1.09 (0.66 – 1.80)
HLA-DRB1*1101	Luo et al. 2011 ³⁴	Case-Control	China	EMA algorithm	Ethnically matched healthy blood donors	152/200	GPA (45), MPA (107)	PR3-ANCA (19), MPO-ANCA (130), PR3- and MPO-AN-CA positive (3)	1.75 (1.02 – 3.00)
	Tsuchiya et al. 2013 ³⁷	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	116/265	MPA (96)	MPO-ANCA (all patients)	2.79 (0.84 – 9.23)
HLA-DRB1*12	Spriewald et al. 2005 ³¹	Case-Control	Germany	ACR and CHCC criteria	Ethnically matched healthy subjects	32/91	GPA (all patients)	PR3 (all patients)	2.97 (0.721 – 2.23)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)		OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level
<i>HLA-DRB1*1201</i>	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	6.31 (0.75 – 53.40)
	Wieczorek et al. 2008 ²⁹	Case-Control	Germany	ACR criteria	Geographically matched healthy subjects	102/369	EGPA (all patients)	NR	0.57 (0.17 – 1.93)
	Cao et al. 2011 ³³	Case-Control	USA (96 Caucasians and 41 African Americans)	Histologically proven AAV	Ethnically matched community-based control frequencies (Healthy Organ Donor-nics (Healthy Organ Donor-nics (North Carolina Services)	137/379	NR	PR3-ANCA (90), MPO-ANCA (47)	0.59 (0.17 – 2.06)
	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	64/265	GPA (3), MPA (50), EGPA (8), PAN (3)	MPO-ANCA (all patients)	0.21 (0.03 – 1.60)
	Luo et al. 2011 ³⁴	Case-Control	China	EMA algorithm	Ethnically matched healthy blood donors	152/200	GPA (45), MPA (107)	PR3-ANCA (19), MPO-ANCA (130), PR3- and MPO-AN-CA positive (3)	0.46 (0.16 – 1.29)
<i>HLA-DRB1*1202</i>	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	64/265	GPA (3), MPA (50), EGPA (8), PAN (3)	MPO-ANCA (all patients)	0.37 (0.05 – 2.90)
	Luo et al. 2011 ³⁴	Case-Control	China	EMA algorithm	Ethnically matched healthy blood donors	152/200	GPA (45), MPA (107)	PR3-ANCA (19), MPO-ANCA (130), PR3- and MPO-AN-CA positive (3)	1.70 (0.93 – 3.13)
<i>HLA-DRB1*13</i>	Spriewald et al. 2005 ³¹	Case-Control	Germany	ACR and CHCC criteria	Ethnically matched healthy subjects	32/91	GPA (all patients)	PR3 (all patients)	0.56 (0.20 – 1.53)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)			OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level	
HLA-DRB1*1302	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	0.65 (0.31 – 1.38)	
	Vaglio et al. 2007 ³⁵	Case-Control	Italy	ACR and CHCC criteria	Geographically matched healthy subjects with no (family) history of autoimmune disease	48/350	EGPA (all patients)	MPO-ANCA (18), ANCA negative (26), undetermined (4)	0.23 (0.07 – 0.73)	
	Wieczorek et al. 2008 ²⁹	Case-Control	Germany	ACR criteria	Geographically matched healthy subjects	102/341	EGPA (all patients)	NR	0.50 (0.28 – 0.89)	
	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	64/265	GPA (3), MPA (50), EGPA (8), PAN (3)	MPO-ANCA (all patients)	0.54 (0.24 – 1.23)	
HLA-DRB1*14	Luo et al. 2011 ³⁴	Case-Control	China	EMA algorithm	Ethnically matched healthy blood donors	152/200	GPA (45), MPA (107)	PR3-ANCA (19), MPO-ANCA (130), PR3- and MPO-AN-CA positive (3)	0.52 (0.16 – 1.67)	
	Spriewald et al. 2005 ³¹	Case-Control	Germany	ACR and CHCC criteria	Ethnically matched healthy subjects	32/91	GPA (all patients)	PR3 (all patients)	1.07 (0.27 – 4.16)	
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	2.02 (0.18 – 22.63)	
	Wieczorek et al. 2008 ²⁹	Case-Control	Germany	ACR criteria	Geographically matched healthy subjects	102/341	EGPA (all patients)	NR	1.83 (0.72 – 4.65)	

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)			OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level	
<i>HLA-DRB1*1403</i>	Cao et al. 2011 ³³	Case-Control	USA (96 Caucasians and 41 African Americans)	Histologically proven AAV	Ethnically matched community-based control frequencies (Healthy Organ Donor-nics (North Carolina Services)	137/379	NR	PR3-ANCA (90), MPO-ANCA (47)	2.82 (1.05 – 7.59)	
	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	64/265	GPA (3), MPA (50), EGPA (8), PAN (3)	MPO-ANCA (all patients)	1.25 (0.34 – 4.60)	
	Luo et al. 2011 ³⁴	Case-Control	China	EMA algorithm	Ethnically matched healthy blood donors	152/200	GPA (45), MPA (107)	PR3-ANCA (19), MPO-ANCA (130), PR3- and MPO-AN-CA positive (3)	1.32 (0.19 – 9.41)	
<i>HLA-DRB1*1405</i>	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	64/265	GPA (3), MPA (50), EGPA (8), PAN (3)	MPO-ANCA (all patients)	0.11 (0.01 – 1.91)	
	Luo et al. 2011 ³⁴	Case-Control	China	EMA algorithm	Ethnically matched healthy blood donors	152/200	GPA (45), MPA (107)	PR3-ANCA (19), MPO-ANCA (130), PR3- and MPO-AN-CA positive (3)	0.96 (0.44 – 2.13)	
<i>HLA-DRB1*15</i>	Spriewald et al. 2005 ³¹	Case-Control	Germany	ACR and CHCC criteria	Ethnically matched healthy subjects	32/91	GPA (all patients)	PR3 (all patients)	0.79 (0.34 – 1.83)	
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	1.13 (0.57 – 2.26)	

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details			Definitions		Participants (n)			OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level		
<i>HLA-DRB1*1501</i>	Cao et al. 2011 ^{33**}	Case-Control	USA (96 Caucasians and 41 African Americans)	Histologically proven AAV	Ethnically matched community-based control frequencies (Healthy Organ Donor-nics (Healthy Organ Donor-nics North Carolina Services)	137/379	NR	PR3-ANCA (90), MPO-ANCA (47)	2.72 (1.84 – 4.03)		
		Case-Control	USA (all African Americans)	Histologically proven AAV	USA African Americans-Bethesda database	16/112	NR	PR3-ANCA (9), MPO-ANCA (4), p-ANCA (2), ANCA negative (1)	2.08 (0.86 – 5.03)		
	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	64/265	GPA (3), MPA (50), EGPA (8), PAN (3)	MPO-ANCA (all patients)	1.62 (0.79 – 3.35)		
	Luo et al. 2011 ³⁴	Case-Control	China	EMA algorithm	Ethnically matched healthy blood donors	152/200	GPA (45), MPA (107)	PR3-ANCA (19), MPO-ANCA (130), PR3- and MPO-AN-CA positive (3)	1.69 (1.16 – 2.46)		
<i>HLA-DRB1*1502</i>	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	64/265	GPA (3), MPA (50), EGPA (8), PAN (3)	MPO-ANCA (all patients)	0.67 (0.32 – 1.39)		
	Luo et al. 2011 ³⁴	Case-Control	China	EMA algorithm	Ethnically matched healthy blood donors	152/200	GPA (45), MPA (107)	PR3-ANCA (19), MPO-ANCA (130), PR3- and MPO-AN-CA positive (3)	0.35 (0.10 – 1.27)		
<i>HLA-DRB1*16</i>	Spriewald et al. 2005 ³¹	Case-Control	Germany	ACR and CHCC criteria	Ethnically matched healthy subjects	32/91	GPA (all patients)	PR3 (all patients)	0.40 (0.02 – 7.80)		

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)		OR (95% CI)
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR
	Cao et al. 2011 ^{33**}	Case-Control	USA (96 Caucasians and 41 African Americans)	Histologically proven AAV	Ethnically matched community-based control frequencies (Healthy Organ Donor- North Carolina Services)	137/379	NR	PR3-ANCA (90), MPO-ANCA (47)
		Case-Control	USA (all African Americans)	Histologically proven AAV	USA African Americans-Bethesda database	16/112	NR	PR3-ANCA (9), MPO-ANCA (4), p-ANCA (2), ANCA negative (1)
						64/265	GPA (3), MPA (50), EGPA (8), PAN (3)	MPO-ANCA (all patients)
HLA-DRB1*1602	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	152/200	GPA (45), MPA (107)	PR3-ANCA (19), MPO-ANCA (130), PR3- and MPO-AN-CA positive (3)
	Luo et al. 2011 ³⁴	Case-Control	China	EMA algorithm	Ethnically matched healthy blood donors	59/1103	GPA (34), MPA (25)	c-ANCA (47), p-ANCA (10), ANCA negative (2)
HLA-DRB3	Spencer et al. 1992 ³⁸	Case-Control	UK	Clinical criteria	Geographically and ethnically matched subjects	51/51	GPA (all patients)	NR
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	48/350	EGPA (all patients)	MPO-ANCA (18), ANCA negative (26), undetermined (4)
	Vaglio et al. 2007 ³⁵	Case-Control	Italy	ACR and CHCC criteria	Geographically matched healthy subjects with no (family) history of autoimmune disease			

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)			OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level	
<i>HLA-DRB4</i>	Wieczorek et al. 2008 ²⁹	Case-Control	Germany	ACR criteria	Geographically matched healthy subjects	102/341	EGPA (all patients)	NR	0.61 (0.44 – 0.86)	
	Spencer et al. 1992 ³⁸	Case-Control	UK	Clinical criteria	Geographically and ethnically matched subjects	59/1103	GPA (34), MPA (25)	c-ANCA (47), p-ANCA (10), ANCA negative (2)	1.38 (0.89 – 2.13)	
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	0.89 (0.46 – 1.72)	
	Vaglio et al. 2007 ³⁵	Case-Control	Italy	ACR and CHCC criteria	Geographically matched healthy subjects with no (family) history of autoimmune disease	48/350	EGPA (all patients)	MPO-ANCA (18), ANCA negative (26), undetermined (4)	2.49 (1.58 – 3.90)	
<i>HLA-DRB5</i>	Wieczorek et al. 2008 ²⁹	Case-Control	Germany	ACR criteria	Geographically matched healthy subjects	102/341	EGPA (all patients)	NR	1.87 (1.34 – 2.61)	
	Spencer et al. 1992 ³⁸	Case-Control	UK	Clinical criteria	Geographically and ethnically matched subjects	59/1103	GPA (34), MPA (25)	c-ANCA (47), p-ANCA (10), ANCA negative (2)	1.35 (0.69 – 2.63)	
	Von Vietinghoff et al. 2006 ¹⁸	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	51/51	GPA (all patients)	NR	1.07 (0.82 – 2.18)	
<i>HSD17B8</i> <i>rs421446 (C)</i>	Heckmann et al. 2008 ²⁴	Case-Control	Germany	ACR criteria	Geographically matched healthy blood donors	282/369	GPA (all patients)	ANCA+ (250), ANCA- (27)	0.43 (0.32 – 0.57)	
	Xie et al. 2013 ²⁵	Case-control (GWAS)	Canada, USA	ACR criteria	Geographically matched healthy subjects	459/1503	GPA (all patients)	c-ANCA (351)	0.39 (0.32 – 0.48)	
<i>IL-1β (A2)</i>	Huang et al. 2000 ⁴	Case-Control	Sweden	ACR criteria	Geographically and ethnically matched healthy subjects	32/109	GPA (all patients)	PR3-ANCA (29)	1.21 (0.55 – 2.63)	
	Borgmann et al. 2003 ³⁹	Case-Control	Germany	CHCC criteria	Geographically matched healthy, unrelated subjects	109/196	NR	PR3-ANCA (79), MPO-ANCA (30)	0.89 (0.61 – 1.29)	

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)		OR (95% CI)
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype
	Zhou et al. 2004 ⁶	Case-Control	USA	ACR criteria	Geographically and ethnically matched healthy, unrelated subjects	117/123	GPA (all patients)	PR3-ANCA (82), MPO-ANCA (5), PR3- and MPO-AN-CA positive (2), ANCA negative (25)
	Previously unpublished Lyons et al. 2012	Case-control (GWAS)	UK	EMA algorithm, supported by either serology or histology	Wellcome Trust Case Control Consortium (UK)	914/5259	GPA (565), MPA (262)	PR3-ANCA (478), MPO-ANCA (264)
	GWAS data ³							
	Borgmann et al. 2003 ³⁹	Case-Control	Germany	CHCC criteria	Geographically matched healthy, unrelated subjects	109/234	NR	PR3-ANCA (79), MPO-ANCA (30)
<i>IL1RN*1</i>	Persson et al. 2013 ⁷	Case-Control	Sweden	ACR and CHCC criteria, EMA algorithm	Blood donors	105/200	GPA (61), MPA (44)	PR3-ANCA (62), MPO-ANCA (43)
<i>IL1RN*2</i>	Borgmann et al. 2003 ³⁹	Case-Control	Germany	CHCC criteria	Geographically matched healthy, unrelated subjects	109/234	NR	PR3-ANCA (79), MPO-ANCA (30)
	Persson et al. 2013 ⁷	Case-Control	Sweden	ACR and CHCC criteria, EMA algorithm	Blood donors	105/200	GPA (61), MPA (44)	PR3-ANCA (62), MPO-ANCA (43)
<i>IL1RN*3</i>	Borgmann et al. 2003 ³⁹	Case-Control	Germany	CHCC criteria	Geographically matched healthy, unrelated subjects	109/234	NR	PR3-ANCA (79), MPO-ANCA (30)
<i>IL1RN*4</i>	Persson et al. 2013 ⁷	Case-Control	Sweden	ACR and CHCC criteria, EMA algorithm	Blood donors	105/200	GPA (61), MPA (44)	PR3-ANCA (62), MPO-ANCA (43)
	Borgmann et al. 2003 ³⁹	Case-Control	Germany	CHCC criteria	Geographically matched healthy, unrelated subjects	109/234	NR	PR3-ANCA (79), MPO-ANCA (30)

Supplementary table 2. Study characteristics of the included studies (Continued)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)		OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level
IL-10 rs1800896 (G)	Murakozy et al. 2001 ⁴²	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	39/72	GPA (all patients)	NR	0.59 (0.34 – 1.03)
	Bartfai et al. 2003 ⁴³	Case-Control	Caucasian patients	ACR and CHCC criteria	Ethnically matched blood donors	161/153	GPA (125), MPA (36)	NR	0.74 (0.54 – 1.02)
	Spriewald et al. 2005 ³¹	Case-Control	Germany	ACR and CHCC criteria	Ethnically matched healthy subjects	32/91	GPA (all patients)	PR3-ANCA (all patients)	1.18 (0.67 – 2.10)
	Wieczorek et al. 2008 ⁴¹	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	506/507	GPA (403), EGPA (103)	ANCA+ (389), ANCA- (110)	0.88 (0.74 – 1.05)
	Previously unpublished Lyons et al. 2012 GWAS data ³	Case-control (GWAS)	UK	EMA algorithm, supported by either serology or histology	Wellcome Trust Case Control Consortium (UK)	676/5360	GPA (394), MPA (156)	PR3-ANCA (326), MPO-ANCA (167)	1.04 (0.93 – 1.17)
IRF5 rs10954213 (G)	Wieczorek et al. 2010 ⁴⁴	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	627/902	GPA (all patients)	NR	0.31 (0.26 – 0.37)
	Previously unpublished Lyons et al. 2012 GWAS data ³	Case-control (GWAS)	UK	EMA algorithm, supported by either serology or histology	Wellcome Trust Case Control Consortium (UK)	676/5365	GPA (394), MPA (156)	PR3-ANCA (326), MPO-ANCA (167)	1.04 (0.93 – 1.17)
	Kawasaki et al. 2013 ⁴⁵	Case-Control	Japan	EMA algorithm	Geographically matched healthy, unrelated subjects	232/710	GPA (28), MPA (177), EGPA (15), unclassified (12)	MPO (all patients)	1.28 (1.04 – 1.58)
	Wieczorek et al. 2010 ^{15***}	Case-Control	Germany	CHCC criteria	Geographically matched healthy subjects	456/818	GPA (all patients)	NR	0.72 (0.58 – 0.90)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)			OR (95% CI)
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	
<i>MPO</i> rs2333227 (A)	Reynolds et al. 2002 ⁴⁶	Case-Control	Germany	CHCC criteria	Geographically matched healthy subjects	226/508	GPA (all patients)	NR	0.71 (0.52 – 0.97)
		Case-Control	Germany	ACR criteria	Geographically matched healthy subjects	196/1327	EGPA (all patients)	NR	1.41 (1.10 – 1.81)
	Fiebelor et al. 2004 ⁴⁷	Case-Control	The Netherlands	CHCC criteria	Ethnically matched healthy subjects	142/192	GPA (96), MPA (26), EGPA (8), iRPGN (12)	PR3-ANCA (92), MPO-ANCA (50)	1.07 (0.70 – 1.63)
		Case-Control	Germany	Clinical criteria	Geographically matched healthy subjects	119/270	GPA (63), MPA (56)	PR3-ANCA (71), MPO-ANCA (48)	0.90 (0.62 – 1.32)
<i>PCD1</i> rs1156882 (A)	Rajp et al. 2007 ⁴⁸	Case-Control	UK	CHCC criteria and histological criteria	Ethnically matched healthy subjects	134/150	GPA (69), MPA (65)	PR3-ANCA (91), MPO-ANCA (43)	0.92 (0.61 – 1.39)
		Case-Control	The Netherlands	CHCC criteria	Geographically and ethnically matched healthy subjects	102/204	GPA (50), MPA (24), EGPA (7), RLV (21)	PR3-ANCA (49), MPO-ANCA (34), PR3- and MPO-AN-CA positive (2), ANCA negative (17)	0.94 (0.52 – 1.70)
	Sakthivel et al. 2009 ⁴⁹	Case-Control	Sweden	Clinical criteria	Geographically and ethnically matched blood donors	66/275	GPA (all patients)	NR	0.78 (0.37 – 1.64)
		Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy subjects	199/399	GPA (all patients)	c-ANCA+ (168), p-ANCA+ (1), ANCA negative (30)	1.75 (1.23 – 2.49)
<i>PTPN22</i> rs2476601 (A)	Chung et al. 2012 ^{28*}	Case-Control	USA	ACR criteria	Geographically matched subjects with no (family) history of autoimmune disease	424/469	GPA (all patients)	PR3-ANCA (339), MPO-ANCA (44), ANCA negative (39)	1.25 (0.91 – 1.71)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)		OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level
<i>RING1/</i> <i>RXRB</i> rs213213 (A)		Case-Control	Canada	ACR criteria	Geographically matched subjects with no history of autoimmune disease	456/1500	GPA (all patients)	NR	1.40 (1.11 – 1.78)
	Previously unpublished Lyons et al. 2012 GWAS data ³	Case-control (GWAS)	UK	EMA algorithm, supported by either serology or histology	Wellcome Trust Case Control Consortium (UK)	676/5365	GPA (394), MPA (156)	PR3-ANCA (326), MPO-ANCA (167)	1.35 (1.14 – 1.60)
	Martorana et al. 2012 ⁵¹	Case-Control	Italy	ACR and CHCC criteria	Geographically matched healthy subjects with no history of autoimmune disease	344/945	GPA (143), EGPA (99), MPA (102)	c-ANCA (126), p-ANCA (163), ANCA negative (39)	1.40 (0.97 – 2.04)
	Heckmann et al. 2008 ²⁴	Case-Control	Germany	ACR criteria	Geographically matched healthy blood donors	279/369	GPA (all patients)	ANCA+ (250), ANCA- (27)	2.13 (1.70 – 2.67)
	Previously unpublished Lyons et al. 2012 GWAS data ³	Case-control (GWAS)	UK	EMA algorithm, supported by either serology or histology	Wellcome Trust Case Control Consortium (UK)	676/5366	GPA (394), MPA (156)	PR3-ANCA (326), MPO-ANCA (167)	1.55 (1.38 – 1.74)
<i>RXRB</i> rs6531 (C)	Xie et al. 2013 ²⁵	Case-control (GWAS)	Canada, USA	ACR criteria	Geographically matched healthy subjects	459/1503	GPA (all patients)	c-ANCA (351)	1.83 (1.57 – 2.13)
	Szyld et al. 2006 ⁵²	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy subjects	187/201	GPA (all patients)	ANCA+ (151), ANCA- (36)	0.60 (0.45 – 0.80)
	Previously unpublished Lyons et al. 2012 GWAS data ³	Case-control (GWAS)	UK	EMA algorithm, supported by either serology or histology	Wellcome Trust Case Control Consortium (UK)	911/5251	GPA (565), MPA (262)	PR3-ANCA (478), MPO-ANCA (264)	1.79 (1.61 – 1.98)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)			OR (95% CI)
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	
RXRB rs9277935 (T)	Xie et al. 2013 ²⁵	Case-control (GWAS)	Canada, USA	ACR criteria	Geographically matched healthy subjects	459/1503	GPA (all patients)	c-ANCA (351)	1.81 (1.55 – 2.11)
	Wieczorek et al. 2009 ⁵³	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	282/380	GPA (all patients)	NR	0.39 (0.29 – 0.54)
	Previously unpublished Lyons et al. 2012 GWAS data ³	Case-control (GWAS)	UK	EMA algorithm, supported by either serology or histology	Wellcome Trust Case Control Consortium (UK)	676/5350	GPA (394), MPA (156)	PR3-ANCA (326), MPO-ANCA (167)	0.51 (0.43 – 0.61)
	Xie et al. 2013 ²⁵	Case-control (GWAS)	Canada, USA	ACR criteria	Geographically matched healthy subjects	459/1503	GPA (all patients)	c-ANCA (351)	0.34 (0.27 – 0.44)
	Lhotta et al. 1994 ⁵⁴	Case-Control	Austria	ACR	Geographically matched healthy subjects	32/868	GPA (29), MPA (2), iRPGN (1)	c-ANCA (all patients)	0.69 (0.09 – 5.11)
SERPINA1 Sallele	Griffith et al. 1996 ⁵⁵	Case-Control	UK	CHCC criteria	Geographically and ethnically matched unrelated subjects	102/2310	GPA (51), MPA (29), EGPA (9), PAN (2), iRPGN (11)	c-ANCA (70), p-ANCA (32)	1.42 (0.79 – 2.52)
	Mahr et al. 2010 ⁵⁶	Case-Control	USA	ACR criteria	Geographically matched healthy subjects with no (family) history of autoimmune disease	433/421	GPA (all patients)	PR3-ANCA (339), MPO-ANCA (44), ANCA negative (39)	1.68 (1.08 – 2.63)
	Morris et al. 2011 ⁵⁷	Case-Control	Germany (531), France (81), UK (244)	CHCC criteria	Geographically and ethnically matched healthy subjects with no (family) history of autoimmune disease	856/1505	GPA (723), MPA (133)	c-ANCA (605), p-ANCA (150), ANCA negative (54)	1.11 (0.81 – 1.51)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)		OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level
<i>SERPINA1</i> Z allele	Chorostowska-Wynimko et al. 2013 ³⁸	Case-Control	Poland	Clinical, histological, and serological criteria	Geographically matched neonates born alive	51/658	GPA (all patients)	c-ANCA (43), p-ANCA (2), ANCA negative (4)	2.61 (0.56 – 12.08)
	Lhotta et al. 1994 ⁵⁴	Case-Control	Austria	ACR criteria	Geographically matched healthy subjects	32/868	GPA (29), MPA (2), iRPGN (1)	c-ANCA (all patients)	8.76 (3.63 – 21.17)
	Griffith et al. 1996 ⁵⁵	Case-Control	UK	CHCC criteria	Geographically and ethnically matched unrelated subjects	102/2310	GPA (51), MPA (29), EGPA (9), PAN (2), iRPGN (11)	c-ANCA (70), p-ANCA (32)	2.20 (1.05 – 4.62)
	Callea et al. 1997 ⁵⁹	Case - Control	Italy	CHCC criteria	Healthy blood donors	84/200	GPA (33), MPA (28), iRPGN (23)	c-ANCA (38), p-ANCA (46)	4.90 (1.21 – 19.83)
	Borgmann et al. 2001 ⁶⁰	Case-Control	Germany	ACR and CHCC criteria	Geographically and ethnically matched healthy, unrelated subjects	97/752	GPA (all patients)	c-ANCA (all patients)	3.36 (1.45 – 7.79)
	Mahr et al. 2010 ⁵⁶	Case-Control	USA	ACR criteria	Geographically matched healthy subjects with no (family) history of autoimmune disease	433/421	GPA (all patients)	PR3-ANCA (339), MPO-ANCA (44), ANCA negative (39)	1.99 (1.12 – 3.52)
	Morris et al. 2011 ⁵⁷	Case-Control	Germany (531), France (81), UK (244)	CHCC criteria	Geographically and ethnically matched healthy subjects with no (family) history of autoimmune disease	856/1505	GPA (723), MPA (133)	c-ANCA (605), p-ANCA (150), ANCA negative (54)	2.25 (1.60 – 3.18)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)			OR (95% CI)
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level
STAT4 rs7574865 (T)	Previously unpublished Lyons et al. 2012 GWAS data ^{3**}	Case-control (GWAS)	UK	EMA algorithm, supported by either serology or histology	Wellcome Trust Case Control Consortium (UK)	562/805	GPA (391), MPA (143)	PR3-ANCA (322), MPO-ANCA (166)	2.59 (1.66 – 4.02)
		Case-control (GWAS)	Europe	EMA algorithm, supported by either serology or histology	Geographically matched subjects	1445/1062	NR	NR	4.19 (2.62 – 6.69)
	Chorostowska-Wynimko et al. 2013 ³⁸	Case-Control	Poland	Clinical, histological, serological criteria	Geographically matched neonates born alive	51/658	GPA (all patients)	c-ANCA (43), p-ANCA (2), ANCA negative (4)	2.19 (0.63 – 7.55)
	Wieczorek et al. 2010 ⁴⁴	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	612/880	GPA (all patients)	NR	1.01 (0.85 – 1.20)
TGF-β ₁ rs1800471 (C)	Previously unpublished Lyons et al. 2012 GWAS data ³	Case-control (GWAS)	UK	EMA algorithm, supported by either serology or histology	Wellcome Trust Case Control Consortium (UK)	676/5366	GPA (394), MPA (156)	PR3-ANCA (326), MPO-ANCA (167)	1.18 (1.04 – 1.35)
	Kawasaki et al. 2013 ⁴⁵	Case-Control	Japan	EMA algorithm	Geographically matched healthy, unrelated subjects	232/710	GPA (28), MPA (177), EGPA (15), unclassified (12)	MPO (all patients)	1.10 (0.89 – 1.37)
	Murakozy et al. 2001 ⁴²	Case-Control	Germany	ACR and CHCC criteria	Geographically matched healthy blood donors	39/72	GPA (all patients)	NR	2.20 (0.89 – 5.44)
	Bartfai et al. 2003 ⁴³	Case-Control	Caucasian patients	ACR and CHCC criteria	Ethnically matched blood donors	161/96	GPA (125), MPA (36)	NR	1.06 (0.52 – 2.14)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)		OR (95% CI)	
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype	Allele level
<i>TNFA</i> rs1800629 (A)	Spriewald et al. 2005 ³¹	Case-Control	Germany	ACR and CHCC criteria	Ethnically matched healthy subjects	32/91	GPA (all patients)	PR3-ANCA (all patients)	1.86 (0.73 – 4.71)
	Mascher et al. 1997 ⁶¹	Case-Control	Germany	ACR and CHCC criteria	Healthy blood donors	35/111	GPA (all patients)	c-ANCA (32), p-ANCA (1), ANCA negative (1)	1.54 (0.77 – 3.10)
	Zhou et al. 2004 ⁶	Case-Control	USA	ACR criteria	Geographically and ethnically matched healthy, unrelated subjects	117/123	GPA (all patients)	PR3-ANCA (82), MPO-ANCA (5), PR3- and MPO-AN-CA positive (2), ANCA negative (25)	0.88 (0.52 – 1.50)
	Spriewald et al. 2005 ³¹	Case-Control	Germany	ACR and CHCC criteria	Ethnically matched healthy subjects	32/91	GPA (all patients)	PR3-ANCA (all patients)	2.22 (0.93 – 5.29)
	Previously unpublished Lyons et al. 2012 GWAS data ³	Case-control (GWAS)	UK	EMA algorithm, supported by either serology or histology	Wellcome Trust Case Control Consortium (UK)	676/5366	GPA (394), MPA (156)	PR3-ANCA (326), MPO-ANCA (167)	1.06 (0.92 – 1.23)
<i>TNFAII</i> 196R	Tsuchiya et al. 2003 ⁵	Case-Control	Japan	CHCC and Japanese 1998 criteria	Geographically matched healthy subjects	50/262	MPA (all patients)	MPO-ANCA (all patients)	0.67 (0.31 – 1.45)

Supplementary table 2. Study characteristics of the included studies (Continued)

Variants	Article	Study details		Definitions		Participants (n)		OR (95% CI)
		Design	Setting	Cases	Controls	Cases / Controls	Diagnoses	ANCA serotype
	Zhou et al. 2004 ⁶	Case-Control	USA	ACR criteria	Geographically and ethnically matched healthy, unrelated subjects	117/123	GPA (all patients)	PR3-ANCA (82), MPO-ANCA (5), PR3- and MPO-AN-CA positive (2), ANCA negative (25)
<i>TLR9</i> rs352162 (T)	Husmann et al. 2014 ^{40**}	Case-Control	Germany	EMA algorithm	Geographically matched healthy blood donors	863/1344	GPA (646), MPA (53), EGPA (164)	NR
<i>TLR9</i> rs352140 (T)	Husmann et al. 2014 ^{40**}	Case-Control	The Netherlands, UK Germany	EMA algorithm EMA algorithm	Geographically and ethnically matched healthy subjects Geographically matched healthy blood donors	426/554 863/1344	GPA (273), MPA (100), EGPA (53) GPA (646), MPA (53), EGPA (164)	NR
<i>TLR9</i> rs352139 (T)	Husmann et al. 2014 ^{40**}	Case-Control	The Netherlands, UK Germany	EMA algorithm EMA algorithm	Geographically and ethnically matched healthy subjects Geographically matched healthy blood donors	426/554 863/1344	GPA (273), MPA (100), EGPA (53) GPA (646), MPA (53), EGPA (164)	NR
<i>TLR9</i> rs5743836 (G)	Husmann et al. 2014 ^{40**}	Case-Control	The Netherlands, UK Germany	EMA algorithm EMA algorithm	Geographically and ethnically matched healthy subjects Geographically matched healthy blood donors	426/554 863/1344	GPA (273), MPA (100), EGPA (53) GPA (646), MPA (53), EGPA (164)	NR
			The Netherlands, UK	EMA algorithm	Geographically and ethnically matched healthy subjects	426/554	GPA (273), MPA (100), EGPA (53)	NR
								1.05 (0.70 – 1.57)
								1.89 (1.67 – 2.14)
								1.07 (0.90 – 1.28)
								1.16 (1.03 – 1.31)
								1.06 (0.89 – 1.27)
								1.12 (0.99 – 1.27)
								1.08 (0.91 – 1.30)
								0.82 (0.69 – 0.98)
								1.22 (0.94 – 1.58)

ACR, American College of Rheumatology; ANCA, anti-neutrophil cytoplasm antibody; AAV, ANCA-associated vasculitis; c-ANCA, cytoplasmic ANCA; CHCC, Chapel Hill Consensus Conference; EGPA, eosinophilic granulomatosis with polyangiitis; EMA, European Medicines Agency; GPA, granulomatosis with polyangiitis; GWAS, genome-wide association study; IRPGN, idiopathic rapidly progressive glomerulonephritis; MPA, microscopic polyangiitis; MPO-ANCA, myeloperoxidase ANCA; NR, not reported; PAN, polyarteritis nodosa; p-ANCA, perinuclear ANCA; NR, not reported; RLV, renal limited vasculitis; PR3-ANCA, proteinase 3 ANCA; UK, United Kingdom; USA, United States of America. **Two cohorts described in the same publication; ***Three cohorts described in the same publication.

Supplementary table 3. Genetic variants not associated with AAV after meta-analysis

Variant by gene (minor allele)	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis	I ² (%)	P value for heterogeneity	P value for funnel plot asymmetry
<i>CTLA-4</i> (AT) ₁₀₂	3	186/420	1.20 (0.75 – 1.90)	0.449	0	0.375	0.986
<i>CTLA-4</i> (AT) ₁₀₄	3	186/420	1.21 (0.92 – 1.60)	0.180	0	0.390	0.227
<i>CTLA-4</i> (AT) ₁₀₆	3	186/420	1.30 (0.74 – 2.29)	0.359	75	0.018	0.674
<i>CTLA-4</i> (AT) ₁₀₈	3	186/420	0.88 (0.50 – 1.56)	0.963	0	0.963	0.473
<i>CTLA-4</i> (AT) ₁₁₀	3	186/420	0.74 (0.34 – 1.61)	0.441	0	0.667	0.171
<i>CTLA-4</i> (AT) ₁₁₆	3	186/420	0.80 (0.27 – 2.33)	0.677	0	0.724	0.786
<i>CTLA-4</i> (AT) ₁₁₈	3	186/420	0.46 (0.16 – 1.35)	0.158	26	0.258	0.155
<i>CTLA-4</i> (AT) ₁₂₂	3	186/420	1.70 (0.62 – 4.71)	0.304	26	0.260	0.557
<i>CTLA-4</i> (AT) ₁₂₄	3	186/420	1.97 (0.73 – 5.31)	0.178	61	0.080	0.637
<i>CTLA-4</i> (AT) ₁₂₆	3	186/420	1.25 (0.53 – 2.94)	0.609	53	0.121	0.701
<i>CTLA-4</i> (AT) ₁₂₈	3	186/420	1.15 (0.47 – 2.82)	0.760	37	0.204	0.826
<i>FCAR</i> rs16986050 (G)	2	1311/5891	0.93 (0.82 – 1.05)	0.211	84	0.002	0.523
<i>FCGR3A</i> rs396991 (G)	2	141/457	1.00 (0.74 – 1.34)	0.978	79	0.030	N/A
<i>FCGR3B</i> (NA1)	4	982/970	0.96 (0.84 – 1.11)	0.590	37	0.191	0.210
<i>GHSR</i> rs509035 (A)	2	1547/6595	1.04 (0.96 – 1.14)	0.342	52	0.123	0.874
<i>GHSR</i> rs519384 (A)	1	628/1328	1.12 (0.96 – 1.30)	0.140	0	0.389	N/A
<i>GHSR</i> rs572169 (A)	1	620/1304	1.12 (0.97 – 1.30)	0.118	50	0.158	N/A
<i>HLA-AI</i>	4	427/7324	1.07 (0.89 – 1.30)	0.455	0	0.567	0.996
<i>HLA-A2</i>	5	443/7796	0.96 (0.82 – 1.12)	0.582	0	0.956	0.335
<i>HLA-A3</i>	4	427/7324	1.18 (0.97 – 1.42)	0.092	35	0.201	0.273
<i>HLA-A9</i>	3	366/6991	0.85 (0.65 – 1.13)	0.266	77	0.014	0.311
<i>HLA-A10</i>	3	366/6991	0.79 (0.48 – 1.30)	0.356	78	0.010	0.273

Supplementary table 3. Genetic variants not associated with AAV after meta-analysis (Continued)

Variant by gene (minor allele)	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis	I ² (%)	P value for heterogeneity	P value for funnel plot asymmetry
HLA-A11	6	466/8107	0.97 (0.52 – 1.81)	0.924	65	0.013	0.273
HLA-A24	3	108/1223	0.94 (0.56 – 1.60)	0.830	0	0.510	0.090
HLA-A25	2	92/751	1.82 (0.72 – 4.58)	0.206	0	0.699	N/A
HLA-A26	4	131/1628	1.56 (0.89 – 2.74)	0.124	43	0.154	0.143
HLA-A28	3	376/6962	0.80 (0.52 – 1.23)	0.302	0	0.538	0.066
HLA-A29	3	123/988	0.88 (0.38 – 2.03)	0.760	42	0.178	0.801
HLA-A30	2	92/751	1.03 (0.25 – 4.28)	0.964	0	0.496	N/A
HLA-A31	3	108/1223	1.02 (0.43 – 2.44)	0.969	0	0.482	0.169
HLA-A32	3	108/1223	1.62 (0.74 – 3.54)	0.231	62	0.074	0.996
HLA-B7	4	427/7324	1.11 (0.91 – 1.35)	0.294	30	0.232	0.234
HLA-B12	2	335/6573	0.97 (0.76 – 1.23)	0.775	0	0.911	N/A
HLA-B13	4	427/7324	0.78 (0.46 – 1.34)	0.373	0	0.413	0.319
HLA-B14	4	427/7324	0.90 (0.54 – 1.49)	0.676	0	0.487	0.615
HLA-B15	2	355/5923	1.01 (0.77 – 1.31)	0.955	0	0.482	N/A
HLA-B18	4	427/7172	0.76 (0.50 – 1.16)	0.204	0	0.865	0.756
HLA-B27	4	412/7223	0.67 (0.44 – 1.02)	0.061	1	0.388	0.336
HLA-B35	4	412/7095	0.78 (0.58 – 1.06)	0.108	0	0.885	0.527
HLA-B37	2	355/5923	0.93 (0.51 – 1.70)	0.814	44	0.182	N/A
HLA-B39	2	67/523	0.65 (0.11 – 3.68)	0.622	0	0.619	N/A
HLA-B40	2	355/5923	0.94 (0.70 – 1.25)	0.652	0	0.319	N/A
HLA-B44	3	108/1223	1.53 (0.96 – 2.44)	0.072	46	0.157	0.225
HLA-B49	2	92/751	1.46 (0.43 – 4.92)	0.542	0	0.747	N/A

Supplementary table 3. Genetic variants not associated with AAV after meta-analysis (Continued)

Variant by gene (minor allele)	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis	I ² (%)	P value for heterogeneity	P value for funnel plot asymmetry
HLA-B51	2	67/523	1.03 (0.46 – 2.32)	0.943	50	0.158	N/A
HLA-B55	2	67/523	1.07 (0.40 – 2.88)	0.887	93	<0.001	N/A
HLA-B57	2	92/751	2.37 (0.92 – 6.11)	0.075	0	0.493	N/A
HLA-B60	2	57/1172	1.98 (0.77 – 5.09)	0.154	20	0.263	N/A
HLA-B62	2	57/1172	1.95 (0.87 – 4.37)	0.107	0	0.688	N/A
HLA-Cw1	2	68/523	1.28 (0.59 – 2.77)	0.534	0	0.650	N/A
HLA-Cw3	2	68/523	1.36 (0.79 – 2.33)	0.267	0	0.907	N/A
HLA-Cw7	2	68/523	0.96 (0.57 – 1.62)	0.877	3	0.309	N/A
HLA-DPB1*0101	2	242/139	0.65 (0.34 – 1.22)	0.178	84	0.013	N/A
HLA-DPB1*0201	4	435/904	0.85 (0.65 – 1.12)	0.241	49	0.118	0.708
HLA-DPB1*0402	4	479/877	1.10 (0.87 – 1.40)	0.433	0	0.893	0.074
HLA-DPB1*0501	2	242/139	0.86 (0.22 – 3.33)	0.823	7	0.300	N/A
HLA-DPB1*0601	2	242/139	1.25 (0.28 – 5.67)	0.769	7	0.300	N/A
HLA-DPB1*0901	2	242/139	0.63 (0.20 – 2.01)	0.438	0	0.476	N/A
HLA-DQB1*02	2	83/141	0.91 (0.53 – 1.55)	0.720	0	0.796	N/A
HLA-DQB1*0302	2	126/141	1.03 (0.58 – 1.82)	0.931	0	0.832	N/A
HLA-DQB1*04	2	83/141	1.63 (0.52 – 5.11)	0.404	0	0.893	N/A
HLA-DQB1*0501	2	209/282	1.32 (0.79 – 2.20)	0.287	53	0.143	N/A
HLA-DQB1*0602	2	126/141	1.36 (0.70 – 2.64)	0.360	91	0.001	N/A
HLA-DQ7	3	149/546	0.82 (0.56 – 1.20)	0.302	49	0.142	0.252
HLA-DR1	10	1009/7105	0.93 (0.64 – 1.34)	0.684	70	<0.001	0.105
HLA-DR2	5	487/6222	1.10 (0.80 – 1.54)	0.554	37	0.176	0.757

Supplementary table 3. Genetic variants not associated with AAV after meta-analysis (Continued)

Variant by gene (minor allele)	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis	I ² (%)	P value for heterogeneity	P value for funnel plot asymmetry
HLA-DR3	9	816/7045	1.05 (0.81 – 1.36)	0.740	41	0.096	0.946
HLA-DR4	11	914/7696	1.19 (0.95 – 1.50)	0.132	47	0.037	0.342
HLA-DR5	5	494/6155	0.90 (0.61 – 1.31)	0.570	32	0.206	0.965
HLA-DR7	7	610/6493	1.08 (0.73 – 1.60)	0.164	66	0.007	0.932
HLA-DR8	9	823/7157	1.10 (0.80 – 1.51)	0.552	15	0.307	0.375
HLA-DR9	11	1016/8204	1.16 (0.71 – 1.90)	0.560	60	0.005	0.925
HLA-DRB1*0401	2	216/465	0.93 (0.38 – 2.28)	0.869	48	0.167	N/A
HLA-DRB1*0403	2	216/465	0.49 (0.17 – 1.42)	0.190	53	0.144	N/A
HLA-DRB1*0405	2	216/465	0.78 (0.47 – 1.30)	0.344	27	0.242	N/A
HLA-DRB1*0406	2	216/465	1.22 (0.61 – 2.5)	0.580	44	0.182	N/A
HLA-DRB1*0407	2	216/465	1.95 (0.61 – 6.29)	0.263	13	0.283	N/A
HLA-DRB1*0410	2	216/465	1.17 (0.27 – 5.05)	0.832	0	0.463	N/A
HLA-DRB1*0802	2	216/465	0.94 (0.36 – 2.43)	0.897	0	0.359	N/A
HLA-DRB1*0803	2	216/465	1.33 (0.83 – 2.14)	0.236	0	0.622	N/A
HLA-DRB1*10	4	322/890	0.98 (0.39 – 2.46)	0.969	0	0.627	0.596
HLA-DRB1*11	4	322/890	0.98 (0.71 – 1.34)	0.818	0	0.818	1.000
HLA-DRB1*12	4	322/890	1.12 (0.60 – 2.09)	0.712	54	0.088	0.121
HLA-DRB1*1302	2	216/465	0.54 (0.27 – 1.05)	0.068	0	0.952	N/A
HLA-DRB1*1202	2	216/465	1.42 (0.81 – 2.49)	0.219	49	0.160	N/A
HLA-DRB1*1403	2	216/465	1.27 (0.43 – 3.76)	0.666	0	0.964	N/A
HLA-DRB1*1405	2	216/465	0.66 (0.32 – 1.37)	0.265	57	0.125	N/A
HLA-DRB1*1502	2	216/465	0.57 (0.30 – 1.07)	0.079	0	0.398	N/A

Supplementary table 3. Genetic variants not associated with AAV after meta-analysis (Continued)

Variant by gene (minor allele)	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis	I ² (%)	P value for heterogeneity	P value for funnel plot asymmetry
<i>HLA-DRB1*16</i>	3	236/633	0.91 (0.37 – 2.27)	0.842	15	0.315	0.436
<i>HLA-DRB1*1602</i>	2	216/465	0.17 (0.02 – 1.29)	0.086	0	0.734	N/A
<i>HLA-DRB5</i>	2	110/1154	1.20 (0.73 – 1.97)	0.470	0	0.643	N/A
<i>IL-1β (A2)</i>	4	1172/5687	1.00 (0.90 – 1.12)	0.995	0	0.805	0.645
<i>ILIRN*1</i>	2	214/434	1.06 (0.82 – 1.37)	0.662	0	0.659	N/A
<i>ILIRN*2</i>	2	214/434	1.00 (0.77 – 1.31)	0.980	0	0.956	N/A
<i>ILIRN*3</i>	2	214/434	0.61 (0.26 – 1.44)	0.257	45	0.176	N/A
<i>ILIRN*4</i>	2	214/434	0.85 (0.13 – 5.82)	0.872	0	0.888	N/A
<i>ILIRN*5</i>	2	214/434	0.88 (0.13 – 5.94)	0.892	0	0.796	N/A
<i>IL-6 rs1800795 (C)</i>	4	1926/6817	1.01 (0.94 – 1.09)	0.793	0	0.537	0.584
<i>IL-10 rs1800872 (A)</i>	2	538/598	1.01 (0.83 – 1.22)	0.963	0	0.795	N/A
<i>IL-10 rs1800896 (G)</i>	5	1414/6183	0.90 (0.76 – 1.07)	0.232	55	0.063	0.285
<i>LEPR rs8179183 (C)</i>	1	878/2653	0.89 (0.77 – 1.03)	0.118	89	<0.001	0.780
<i>MPO rs2333227 (A)</i>	3	395/299	0.96 (0.76 – 1.21)	0.696	0	0.822	0.478
<i>PCD1 rs1156882 (A)</i>	2	168/479	0.88 (0.55 – 1.38)	0.568	0	0.701	N/A
<i>TGF-β₁ rs1800471 (C)</i>	3	232/259	1.49 (0.92 – 2.41)	0.107	0	0.401	0.220
<i>TNFA rs1800629 (A)</i>	4	860/5691	1.14 (0.88 – 1.45)	0.327	29	0.236	0.389
<i>TNFR1 196R</i>	2	167/385	0.94 (0.66 – 1.34)	0.749	0	0.317	N/A
<i>TLR9 rs5743836 (G)</i>	1	1289/1898	0.93 (0.81 – 1.08)	0.343	83	0.014	N/A

Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic subgroups

Variant by gene	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis
<i>CD226</i> rs763361 (T)				
GPA	3	2021/17898	1.19 (1.11 – 1.28)	<0.001
MPA	1	156/5366	1.04 (0.83 – 1.31)	0.739
EGPA	1	119/1226	1.19 (0.91 – 1.56)	0.208
PR3-ANCA	2	764/6592	1.22 (1.09 – 1.36)	<0.001
MPO-ANCA	2	199/6592	1.20 (0.99 – 1.46)	0.066
<i>CTLA-4</i> (AT) ₈₆				
GPA	3	210/432	0.44 (0.34 – 0.57)	<0.001
MPA	2	93/311	0.87 (0.60 – 1.25)	0.450
PR3-ANCA	1	62/200	0.71 (0.47 – 1.09)	0.122
MPO-ANCA	2	92/311	0.94 (0.65 – 1.35)	0.733
<i>CTLA-4</i> (AT) ₁₀₂				
GPA	2	93/309	0.94 (0.45 – 1.94)	0.856
MPA	2	93/311	0.86 (0.51 – 1.45)	0.574
PR3-ANCA	1	62/200	0.87 (0.41 – 1.87)	0.722
MPO-ANCA	2	92/311	0.69 (0.26 – 1.81)	0.456
<i>CTLA-4</i> (AT) ₁₀₄				
GPA	2	93/309	0.84 (0.55 – 1.27)	0.398
MPA	2	93/311	0.87 (0.58 – 1.29)	0.474
PR3-ANCA	1	62/200	0.42 (0.22 – 0.79)	0.007
MPO-ANCA	2	92/311	0.85 (0.57 – 1.26)	0.412
<i>CTLA-4</i> (AT) ₁₀₆				
GPA	2	93/309	1.69 (0.67 – 4.25)	0.264
MPA	2	93/311	0.64 (0.28 – 1.46)	0.287
PR3-ANCA	1	62/200	1.83 (0.60 – 5.55)	0.289
MPO-ANCA	2	92/311	0.53 (0.22 – 1.30)	0.168
<i>CTLA-4</i> (AT) ₁₀₈				
GPA	2	93/309	0.40 (0.12 – 1.35)	0.141
MPA	2	93/311	0.75 (0.36 – 1.54)	0.431
PR3-ANCA	1	62/200	0.30 (0.07 – 1.28)	0.103
MPO-ANCA	2	92/311	0.66 (0.31 – 1.41)	0.291
<i>CTLA-4</i> (AT) ₁₁₀				
GPA	2	93/309	0.55 (0.18 – 1.74)	0.311
MPA	2	93/311	0.26 (0.05 – 1.36)	0.109
PR3-ANCA	1	62/200	0.56 (0.16 – 1.94)	0.359
MPO-ANCA	2	92/311	0.26 (0.05 – 1.38)	0.113

Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-groups (Continued)

Variant by gene	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis
<i>CTLA-4</i> (AT) ₁₁₆				
GPA	2	93/309	0.66 (0.17 – 2.60)	0.553
MPA	2	93/311	0.41 (0.05 – 3.38)	0.408
PR3-ANCA	1	62/200	0.21 (0.01 – 3.72)	0.288
MPO-ANCA	2	92/311	0.69 (0.12 – 3.98)	0.673
<i>CTLA-4</i> (AT) ₁₁₈				
GPA	2	93/309	0.32 (0.06 – 1.68)	0.176
MPA	2	93/311	0.31 (0.06 – 1.69)	0.175
PR3-ANCA	1	62/200	0.11 (0.01 – 1.81)	0.121
MPO-ANCA	2	92/311	0.44 (0.10 – 1.97)	0.283
<i>CTLA-4</i> (AT) ₁₂₂				
GPA	2	93/309	1.32 (0.26 – 6.80)	0.742
MPA	2	93/311	1.57 (0.48 – 5.19)	0.456
PR3-ANCA	1	62/200	0.35 (0.02 – 6.62)	0.487
MPO-ANCA	2	92/311	3.69 (1.40 – 9.71)	0.008
<i>CTLA-4</i> (AT) ₁₂₄				
GPA	2	93/309	1.69 (0.67 – 4.25)	0.264
MPA	2	93/311	0.64 (0.28 – 1.46)	0.287
PR3-ANCA	1	62/200	1.83 (0.60 – 5.55)	0.289
MPO-ANCA	2	92/311	0.53 (0.22 – 1.30)	0.168
<i>CTLA-4</i> (AT) ₁₂₆				
GPA	2	93/309	1.43 (0.47 – 4.35)	0.526
MPA	2	93/311	0.38 (0.08 – 2.11)	0.266
PR3-ANCA	1	62/200	0.21 (0.01 – 3.72)	0.288
MPO-ANCA	2	92/311	0.54 (0.12 – 2.46)	0.428
<i>CTLA-4</i> (AT) ₁₂₈				
GPA	2	93/309	0.39 (0.07 – 2.14)	0.278
MPA	2	93/311	1.27 (0.39 – 4.20)	0.694
PR3-ANCA	1	62/200	0.29 (0.04 – 2.25)	0.235
MPO-ANCA	2	92/311	1.29 (0.39 – 4.28)	0.674
<i>CTLA-4</i> rs231775 (G)				
GPA	2	510/5994	1.05 (0.92 – 1.20)	0.430
MPA	2	252/5994	1.17 (0.97 – 1.40)	0.100
PR3-ANCA	1	326/5365	1.00 (0.85 – 1.18)	0.983
MPO-ANCA	1	167/5365	0.96 (0.77 – 1.21)	0.747

Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic subgroups (Continued)

Variant by gene	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis
<i>CTLA-4</i> rs3087243 (A)				
GPA	3	1561/7855	0.80 (0.73 – 0.87)	<0.001
MPA	2	358/5886	0.79 (0.68 – 0.92)	0.003
PR3-ANCA	1	478/5257	0.81 (0.71 – 0.93)	0.003
MPO-ANCA	1	264/5257	0.96 (0.80 – 1.15)	0.658
<i>FCAR</i> rs16986050 (G)				
GPA	2	1029/5891	0.92 (0.80 – 1.05)	0.214
MPA	1	394/5365	0.93 (0.69 – 1.26)	0.647
PR3-ANCA	1	326/5365	1.13 (0.93 – 1.38)	0.211
MPO-ANCA	1	167/5365	1.00 (0.75 – 1.33)	0.988
<i>FCGR2A</i> rs1801274 (C)				
GPA	5	1082/5969	0.99 (0.94 – 1.05)	0.827
MPA	4	800/5766	0.97 (0.81 – 1.15)	0.698
PR3-ANCA	4	883/5820	0.91 (0.79 – 1.03)	0.138
MPO-ANCA	4	844/5969	0.80 (0.67 – 0.95)	0.011
<i>FCGR3A</i> rs396991 (G)				
GPA	1	91/154	1.30 (0.89 – 1.91)	0.172
MPA	1	50/303	0.65 (0.39 – 1.07)	0.090
PR3-ANCA	1	91/154	1.30 (0.89 – 1.91)	0.172
MPO-ANCA	1	50/303	0.65 (0.39 – 1.07)	0.090
<i>FCGR3B</i> (NA1)				
GPA	3	865/667	0.93 (0.80 – 1.08)	0.343
MPA	2	75/200	1.52 (1.03 – 2.25)	0.035
PR3-ANCA	2	143/254	1.07 (0.79 – 1.45)	0.664
MPO-ANCA	2	121/403	1.19 (0.86 – 1.64)	0.287
<i>GHSR</i> rs509035 (A)				
GPA	2	1198/6595	1.05 (0.96 – 1.16)	0.292
MPA	1	262/5259	1.00 (0.82 – 1.20)	0.966
PR3-ANCA	1	478/5259	1.05 (0.91 – 1.21)	0.521
MPO-ANCA	1	264/5259	0.83 (0.68 – 1.01)	0.057
<i>HLA-A2</i>				
GPA	5	380/7796	0.96 (0.81 – 1.14)	0.633
c-ANCA	1	16/96	0.90 (0.37 – 2.23)	0.826
<i>HLA-A11</i>				
GPA	5	380/7702	0.61 (0.41 – 0.90)	0.014

Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-groups (Continued)

Variant by gene	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis
MPA	1	23/405	2.97 (1.19 – 7.41)	0.020
c-ANCA	1	16/472	0.71 (0.17 – 3.03)	0.644
<i>HLA-A24</i>				
GPA	3	108/1223	0.94 (0.56 – 1.60)	0.830
c-ANCA	1	16/472	0.75 (0.34 – 1.65)	0.476
<i>HLA-A26</i>				
GPA	3	108/1223	1.24 (0.61 – 2.54)	0.550
MPA	1	23/405	2.49 (1.00 – 6.18)	0.049
c-ANCA	1	16/472	2.36 (1.00 – 5.60)	0.051
<i>HLA-A31</i>				
GPA	3	108/1223	1.02 (0.43 – 2.44)	0.969
c-ANCA	1	16/472	1.55 (0.46 – 5.24)	0.479
<i>HLA-A32</i>				
GPA	3	108/1223	1.62 (0.74 – 3.54)	0.231
c-ANCA	1	16/472	2.07 (0.61 – 7.04)	0.246
<i>HLA-B35</i>				
GPA	4	349/7095	0.62 (0.44 – 0.89)	0.010
c-ANCA	1	16/472	0.80 (0.19 – 3.40)	0.757
<i>HLA-B39</i>				
GPA	2	67/523	0.65 (0.11 – 3.68)	0.622
c-ANCA	1	16/472	0.86 (0.11 – 6.51)	0.887
<i>HLA-B44</i>				
GPA	3	108/1223	1.53 (0.96 – 2.44)	0.072
c-ANCA	1	16/472	2.50 (0.85 – 7.40)	0.098
<i>HLA-B51</i>				
GPA	2	67/523	1.03 (0.46 – 2.32)	0.943
c-ANCA	1	16/472	1.87 (0.64 – 5.49)	0.255
<i>HLA-B55</i>				
GPA	2	67/523	1.07 (0.40 – 2.88)	0.887
c-ANCA	1	16/472	7.35 (2.33 – 23.14)	0.001
<i>HLA-B60</i>				
GPA	2	57/1172	1.98 (0.77 – 5.09)	0.154
c-ANCA	1	16/472	1.19 (0.28 – 5.13)	0.814
<i>HLA-B62</i>				
GPA	2	57/1172	2.27 (1.05 – 4.90)	0.036

Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic subgroups (Continued)

Variant by gene	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis
c-ANCA	1	16/472	2.21 (0.83 – 5.91)	0.114
<i>HLA-Cw1</i>				
GPA	2	68/523	1.28 (0.59 – 2.77)	0.534
c-ANCA	1	16/472	1.45 (0.58 – 3.58)	0.426
<i>HLA-Cw3</i>				
GPA	2	68/523	1.36 (0.79 – 2.33)	0.267
c-ANCA	1	16/472	1.40 (0.65 – 3.01)	0.384
<i>HLA-Cw7</i>				
GPA	2	68/523	0.96 (0.57 – 1.62)	0.877
c-ANCA	1	16/472	0.50 (0.12 – 2.10)	0.340
<i>HLA-DPA1</i> rs9277341 (C)				
GPA	2	1032/2200	0.35 (0.30 – 0.41)	<0.001
c-ANCA	1	578/1820	0.27 (0.22 – 0.33)	<0.001
<i>HLA-DPB1*0101</i>				
GPA	1	148/89	0.17 (0.05 – 0.63)	0.008
PR3-ANCA	2	183/139	0.45 (0.20 – 0.99)	0.048
MPO-ANCA	1	22/50	1.01 (0.29 – 3.48)	0.986
<i>HLA-DPB1*0201</i>				
GPA	2	283/458	0.67 (0.45 – 0.99)	0.042
MPA	1	50/77	1.38 (0.75 – 2.52)	0.298
EGPA	1	102/369	0.93 (0.57 – 1.51)	0.759
PR3-ANCA	1	148/89	0.44 (0.21 – 0.91)	0.027
MPO-ANCA	1	50/77	1.38 (0.75 – 2.52)	0.298
<i>HLA-DPB1*0301</i>				
GPA	3	774/918	0.23 (0.16 – 0.32)	<0.001
MPA	1	119/460	0.67 (0.37 – 1.21)	0.186
EGPA	2	167/829	0.47 (0.29 – 0.75)	0.001
PR3-ANCA	2	183/139	0.19 (0.09 – 0.39)	<0.001
MPO-ANCA	1	22/50	1.71 (0.74 – 3.94)	0.210
ANCA negative	1	27/369	0.58 (0.21 – 1.65)	0.311
<i>HLA-DPB1*0401</i>				
GPA	3	774/918	2.89 (2.50 – 3.35)	<0.001
MPA	1	119/460	1.09 (0.80 – 1.49)	0.597
EGPA	2	167/829	1.08 (0.85 – 1.36)	0.548

Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-groups (Continued)

Variant by gene	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis
PR3-ANCA	2	183/139	3.93 (2.75 – 5.62)	<0.001
MPO-ANCA	1	22/50	1.43 (0.67 – 3.02)	0.351
ANCA negative	1	27/369	1.26 (0.73 – 2.20)	0.407
<i>HLA-DPB1*0402</i>				
GPA	2	283/458	1.13 (0.82 – 1.55)	0.439
EGPA	1	102/369	1.15 (0.75 – 1.75)	0.533
PR3-ANCA	2	183/139	1.11 (0.69 – 1.77)	0.674
MPO-ANCA	1	22/50	0.94 (0.31 – 2.85)	0.913
<i>HLA-DPB1*0501</i>				
GPA	1	148/89	0.20 (0.01 – 4.93)	0.324
PR3-ANCA	2	183/139	1.11 (0.26 – 4.76)	0.886
MPO-ANCA	1	22/50	1.14 (0.10 – 12.91)	0.916
<i>HLA-DPB1*0601</i>				
GPA	1	148/89	0.60 (0.08 – 4.29)	0.610
PR3-ANCA	2	183/139	1.12 (0.23 – 5.51)	0.887
MPO-ANCA	1	22/50	6.93 (0.28 – 173.53)	0.239
<i>HLA-DPB1*0901</i>				
GPA	1	148/89	1.81 (0.07 – 44.73)	0.716
PR3-ANCA	2	183/139	0.98 (0.27 – 3.62)	0.978
MPO-ANCA	1	22/50	0.91 (0.17 – 4.85)	0.907
<i>HLA-DPB2 rs3130215</i>				
(A)				
GPA	3	1135/7249	1.37 (0.88 – 2.13)	0.160
MPA	1	156/5366	1.33 (1.06 – 1.66)	0.013
PR3-ANCA	1	326/5366	0.65 (0.55 – 0.77)	<0.001
MPO-ANCA	1	167/5366	1.27 (1.02 – 1.58)	0.032
<i>HLA-DQB1*02</i>				
GPA	2	83/141	0.91 (0.53 – 1.55)	0.720
PR3-ANCA	1	32/91	0.98 (0.45 – 2.14)	0.954
<i>HLA-DQB1*0302</i>				
GPA	1	32/91	0.94 (0.36 – 2.49)	0.905
PR3-ANCA	2	67/141	1.03 (0.54 – 1.98)	0.924
MPO-ANCA	1	22/50	1.06 (0.37 – 2.99)	0.917
<i>HLA-DQB1*0303</i>				
GPA	1	32/91	2.97 (0.72 – 12.23)	0.132

Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic subgroups (Continued)

Variant by gene	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis
MPA	1	50/77	2.11 (1.14 – 3.90)	0.018
PR3-ANCA	2	67/141	0.79 (0.31 – 2.05)	0.634
MPO-ANCA	2	72/127	1.91 (1.12 – 3.26)	0.017
<i>HLA-DQB1*04</i>				
GPA	2	83/141	1.63 (0.52 – 5.11)	0.404
PR3-ANCA	1	32/91	1.74 (0.40 – 7.50)	0.457
<i>HLA-DQB1*0501</i>				
GPA	1	32/91	0.77 (0.32 – 1.88)	0.568
PR3-ANCA	2	67/141	1.05 (0.58 – 1.91)	0.865
MPO-ANCA	1	22/50	2.05 (0.84 – 4.97)	0.113
<i>HLA-DQB1*0602</i>				
GPA	1	32/91	0.89 (0.38 – 2.05)	0.779
PR3-ANCA	2	67/141	0.80 (0.42 – 1.54)	0.504
MPO-ANCA	1	22/50	0.35 (0.08 – 1.63)	0.181
<i>HLA-DQ7</i>				
GPA	1	32/91	0.43 (0.16 – 1.16)	0.095
MPA	1	23/405	0.66 (0.34 – 1.30)	0.234
PR3-ANCA	2	67/141	0.98 (0.58 – 1.66)	0.940
MPO-ANCA	1	22/50	1.26 (0.57 – 2.77)	0.569
<i>HLA-DR1</i>				
GPA	6	413/6002	0.76 (0.58 – 1.00)	0.054
MPA	4	223/6020	1.12 (0.72 – 1.74)	0.612
EGPA	3	128/5924	0.82 (0.53 – 1.26)	0.360
PR3-ANCA	3	157/560	0.57 (0.38 – 0.86)	0.008
MPO-ANCA	3	133/734	0.78 (0.49 – 1.25)	0.297
<i>HLA-DR2</i>				
GPA	4	301/6132	1.36 (1.08 – 1.72)	0.010
EGPA	1	14/113	1.40 (0.45 – 4.39)	0.561
PR3-ANCA	1	35/90	1.34 (0.63 – 2.86)	0.442
MPO-ANCA	1	22/90	1.03 (0.39 – 2.69)	0.958
c-ANCA	1	16/472	0.33 (0.08 – 1.38)	0.128
<i>HLA-DR3</i>				
GPA	5	368/5802	1.24 (1.00 – 1.56)	0.056
MPA	2	38/518	0.45 (0.17 – 1.14)	0.092
EGPA	2	116/482	0.70 (0.43 – 1.13)	0.139

Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-groups (Continued)

Variant by gene	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis
PR3-ANCA	3	157/560	1.29 (0.90 – 1.86)	0.170
MPO-ANCA	2	69/469	0.85 (0.49 – 1.48)	0.574
<i>HLA-DR4</i>				
GPA	7	425/6424	1.32 (1.09 – 1.60)	0.004
MPA	2	66/5555	1.50 (0.98 – 2.30)	0.060
EGPA	4	176/6246	1.70 (1.23 – 2.34)	0.001
PR3-ANCA	3	157/560	0.98 (0.71 – 1.36)	0.917
MPO-ANCA	2	69/202	2.51 (1.46 – 4.32)	0.001
c-ANCA	1	16/472	0.72 (0.27 – 1.88)	0.498
<i>HLA-DR5</i>				
GPA	3	285/5660	0.76 (0.54 – 1.06)	0.102
MPA	1	23/405	1.59 (0.80 – 3.15)	0.182
EGPA	1	14/113	1.24 (0.34 – 4.46)	0.746
PR3-ANCA	1	35/90	0.85 (0.30 – 2.42)	0.756
MPO-ANCA	1	22/90	0.52 (0.12 – 2.38)	0.402
<i>HLA-DR6</i>				
GPA	4	301/6132	0.45 (0.33 – 0.62)	<0.001
MPA	1	30/5442	0.29 (0.09 – 0.92)	0.035
EGPA	2	26/5555	0.19 (0.04 – 0.95)	0.043
PR3-ANCA	1	35/90	0.28 (0.06 – 1.25)	0.096
MPO-ANCA	1	22/90	0.70 (0.20 – 2.51)	0.586
c-ANCA	1	16/472	1.63 (0.56 – 4.77)	0.371
<i>HLA-DR7</i>				
GPA	5	368/5802	0.92 (0.71 – 1.19)	0.508
MPA	1	15/113	0.70 (0.20 – 2.44)	0.575
EGPA	3	164/804	1.71 (1.24 – 2.37)	0.001
PR3-ANCA	1	32/91	1.00 (0.40 – 2.48)	0.991
<i>HLA-DR8</i>				
GPA	5	381/6206	0.89 (0.57 – 1.39)	0.610
MPA	1	51/5442	0.31 (0.04 – 2.21)	0.242
EGPA	2	114/5811	3.08 (1.75 – 5.41)	<0.001
PR3-ANCA	3	157/560	0.68 (0.33 – 1.42)	0.308
MPO-ANCA	2	69/469	1.70 (0.80 – 3.60)	0.170
c-ANCA	1	16/472	1.63 (0.66 – 4.05)	0.291
<i>HLA-DR9</i>				

Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic subgroups (Continued)

Variant by gene	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis
GPA	6	402/6369	0.90 (0.58 – 1.39)	0.623
MPA	3	218/578	1.14 (0.83 – 1.56)	0.423
EGPA	3	164/832	1.07 (0.33 – 3.42)	0.915
PR3-ANCA	2	122/470	0.47 (0.09 – 2.58)	0.383
MPO-ANCA	3	175/1116	1.83 (1.29 – 2.60)	0.001
c-ANCA	1	16/472	3.03 (1.40 – 6.56)	0.005
<i>HLA-DRB1*0401</i>				
GPA	1	45/200	0.49 (0.06 – 3.90)	0.499
MPA	2	157/465	1.42 (0.60 – 3.41)	0.426
MPO-ANCA	1	64/265	2.10 (0.52 – 8.50)	0.300
<i>HLA-DRB1*0403</i>				
GPA	1	45/200	0.26 (0.02 – 4.46)	0.349
MPA	2	157/465	0.48 (0.14 – 1.59)	0.227
MPO-ANCA	1	64/265	0.95 (0.27 – 3.40)	0.943
<i>HLA-DRB1*0405</i>				
GPA	1	45/200	0.15 (0.01 – 2.49)	0.184
MPA	2	157/465	0.95 (0.56 – 1.62)	0.862
MPO-ANCA	1	64/265	0.61 (0.30 – 1.22)	0.159
<i>HLA-DRB1*0406</i>				
GPA	1	45/200	2.28 (0.67 – 7.74)	0.187
MPA	2	157/465	1.31 (0.62 – 2.78)	0.483
MPO-ANCA	1	64/265	0.65 (0.19 – 2.22)	0.487
<i>HLA-DRB1*0407</i>				
GPA	1	45/200	1.47 (0.06 – 36.42)	0.813
MPA	2	157/465	1.95 (0.54 – 6.99)	0.306
MPO-ANCA	1	64/265	2.82 (0.78 – 10.14)	0.113
<i>HLA-DRB1*0410</i>				
GPA	1	45/200	1.47 (0.06 – 36.42)	0.813
MPA	2	157/465	1.53 (0.35 – 6.64)	0.569
MPO-ANCA	1	64/265	1.67 (0.32 – 8.69)	0.544
<i>HLA-DRB1*0802</i>				
GPA	1	45/200	0.88 (0.04 – 18.50)	0.935
MPA	2	157/465	0.99 (0.35 – 2.79)	0.984
MPO-ANCA	1	64/265	1.16 (0.42 – 3.18)	0.778
<i>HLA-DRB1*0803</i>				

Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-groups (Continued)

Variant by gene	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis
GPA	1	45/200	1.18 (0.43 – 3.25)	0.749
MPA	2	157/465	1.25 (0.73 – 2.13)	0.413
MPO-ANCA	1	64/265	1.51 (0.78 – 2.93)	0.226
<i>HLA-DRB1*10</i>				
GPA	2	83/142	2.61 (0.45 – 15.24)	0.286
EGPA	1	102/369	0.40 (0.02 – 7.44)	0.538
PR3-ANCA	2	122/470	0.59 (0.13 – 2.65)	0.487
MPO-ANCA	1	47/379	1.48 (0.32 – 6.76)	0.616
<i>HLA-DRB1*11</i>				
GPA	2	83/142	0.97 (0.49 – 1.94)	0.932
EGPA	1	102/369	0.88 (0.53 – 1.48)	0.632
PR3-ANCA	2	122/470	0.97 (0.58 – 1.62)	0.908
MPO-ANCA	1	47/379	1.10 (0.51 – 2.38)	0.805
<i>HLA-DRB1*1101</i>				
GPA	1	45/200	0.16 (0.02 – 1.21)	0.076
MPA	2	223/465	2.57 (1.56 – 4.23)	<0.001
MPO-ANCA	1	116/265	2.79 (0.84 – 9.23)	0.093
<i>HLA-DRB1*12</i>				
GPA	2	83/142	4.06 (1.27 – 12.99)	0.018
EGPA	1	102/369	0.57 (0.17 – 1.93)	0.362
PR3-ANCA	2	122/470	1.01 (0.36 – 2.81)	0.983
MPO-ANCA	1	47/379	1.16 (0.26 – 5.16)	0.850
<i>HLA-DRB1*1201</i>				
GPA	1	45/200	0.15 (0.01 – 2.49)	0.184
MPA	2	157/465	0.51 (0.21 – 1.26)	0.146
MPO-ANCA	1	64/265	0.21 (0.03 – 1.60)	0.132
<i>HLA-DRB1*1202</i>				
GPA	1	45/200	2.92 (1.37 – 6.23)	0.005
MPA	2	157/465	1.07 (0.55 – 2.09)	0.838
PR3-ANCA	1	19/200	1.63 (0.46 – 5.75)	0.449
MPO-ANCA	2	89/465	1.00 (0.38 – 2.61)	1.000
<i>HLA-DRB1*13</i>				
GPA	2	83/142	0.61 (0.34 – 1.12)	0.111
EGPA	2	150/691	0.40 (0.24 – 0.68)	0.001
PR3-ANCA	1	32/91	0.56 (0.20 – 1.53)	0.257

Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic subgroups (Continued)

Variant by gene	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis
<i>HLA-DRB1*1302</i>				
GPA	1	45/200	0.89 (0.19 – 4.12)	0.878
MPA	2	157/465	0.46 (0.20 – 1.02)	0.055
MPO-ANCA	1	64/265	0.54 (0.24 – 1.23)	0.142
<i>HLA-DRB1*14</i>				
GPA	2	83/142	1.26 (0.40 – 4.01)	0.698
EGPA	1	102/341	1.83 (0.72 – 4.65)	0.205
PR3-ANCA	2	122/470	2.00 (0.87 – 4.56)	0.101
MPO-ANCA	1	47/379	2.04 (0.43 – 9.74)	0.372
<i>HLA-DRB1*1403</i>				
GPA	1	45/200	2.24 (0.20 – 24.93)	0.513
MPA	2	157/465	0.81 (0.21 – 3.19)	0.767
MPO-ANCA	1	64/265	1.25 (0.34 – 4.60)	0.739
<i>HLA-DRB1*1405</i>				
GPA	1	45/200	1.51 (0.53 – 4.27)	0.437
MPA	2	157/465	0.45 (0.18 – 1.15)	0.096
MPO-ANCA	1	64/265	0.11 (0.01 – 1.91)	0.131
<i>HLA-DRB1*15</i>				
GPA	2	83/142	0.97 (0.57 – 1.65)	0.921
PR3-ANCA	2	131/582	2.82 (2.00 – 3.96)	<0.001
MPO-ANCA	1	51/491	0.80 (0.37 – 1.73)	0.566
<i>HLA-DRB1*1501</i>				
GPA	1	45/200	1.70 (0.98 – 2.94)	0.059
MPA	2	157/465	1.65 (1.14 – 2.38)	0.007
PR3-ANCA	1	19/200	0.98 (0.40 – 2.45)	0.973
MPO-ANCA	2	89/465	2.03 (1.26 – 3.29)	0.004
<i>HLA-DRB1*1502</i>				
GPA	1	45/200	0.80 (0.18 – 3.69)	0.779
MPA	2	157/465	0.60 (0.30 – 1.21)	0.154
MPO-ANCA	1	64/265	0.67 (0.32 – 1.39)	0.279
<i>HLA-DRB1*16</i>				
GPA	2	83/142	0.23 (0.03 – 1.85)	0.166
PR3-ANCA	2	131/582	1.00 (0.29 – 3.41)	0.996
MPO-ANCA	1	51/491	3.55 (1.02 – 12.38)	0.047
<i>HLA-DRB1*1602</i>				

Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-groups (Continued)

Variant by gene	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis
GPA	1	45/200	0.40 (0.02 – 7.25)	0.533
MPA	2	157/465	0.23 (0.03 – 1.72)	0.151
MPO-ANCA	1	64/265	0.24 (0.01 – 4.17)	0.327
<i>HLA-DRB3</i>				
GPA	1	51/51	1.41 (0.76 – 2.60)	0.276
EGPA	2	150/691	0.58 (0.45 – 0.76)	<0.001
<i>HLA-DRB4</i>				
GPA	1	51/51	0.89 (0.46 – 1.72)	0.738
EGPA	2	150/691	2.06 (1.57 – 2.69)	<0.001
<i>IL-1β (A2)</i>				
GPA	3	714/5491	1.07 (0.93 – 1.22)	0.336
MPA	1	262/5259	0.89 (0.72 – 1.10)	0.286
PR3-ANCA	2	557/5455	1.01 (0.87 – 1.17)	0.930
MPO-ANCA	2	294/5455	1.00 (0.82 – 1.21)	0.971
<i>IL1RN*1</i>				
GPA	1	61/200	0.88 (0.57 – 1.37)	0.573
MPA	1	105/200	1.21 (0.83 – 1.77)	0.325
PR3-ANCA	2	122/434	1.12 (0.82 – 1.54)	0.476
MPO-ANCA	2	92/434	0.98 (0.69 – 1.40)	0.916
<i>IL1RN*2</i>				
GPA	1	61/200	1.22 (0.78 – 1.92)	0.380
MPA	1	105/200	0.77 (0.52 – 1.16)	0.212
PR3-ANCA	2	122/434	0.95 (0.68 – 1.31)	0.748
MPO-ANCA	2	92/434	1.02 (0.71 – 1.47)	0.921
<i>IL1RN*3</i>				
GPA	1	61/200	0.72 (0.15 – 3.40)	0.682
MPA	1	105/200	1.50 (0.55 – 4.08)	0.429
PR3-ANCA	2	122/434	0.61 (0.21 – 1.76)	0.358
MPO-ANCA	2	92/434	0.71 (0.22 – 2.29)	0.571
<i>IL1RN*4</i>				
GPA	1	61/200	0.65 (0.03 – 13.64)	0.782
MPA	1	105/200	1.91 (0.27 – 13.68)	0.518
PR3-ANCA	2	122/434	0.95 (0.11 – 8.63)	0.964
MPO-ANCA	2	92/434	3.08 (0.58 – 16.42)	0.188
<i>IL1RN*5</i>				

Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic subgroups (Continued)

Variant by gene	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis
GPA	1	61/200	1.09 (0.04 – 26.86)	0.959
MPA	1	105/200	0.63 (0.03 – 15.60)	0.779
PR3-ANCA	2	122/434	0.87 (0.10 – 7.74)	0.901
MPO-ANCA	2	92/434	2.18 (0.32 – 14.79)	0.424
<i>IL-6</i> rs1800795 (C)				
GPA	4	1360/1558	0.99 (0.94 – 1.04)	0.750
MPA	2	315/6593	0.98 (0.84 – 1.16)	0.829
EGPA	1	426/6593	0.96 (0.76 – 1.21)	0.730
PR3-ANCA	3	NR/6694	0.98 (0.89 – 1.09)	0.751
MPO-ANCA	2	NR/6603	1.04 (0.90 – 1.20)	0.616
<i>IL-10</i> rs1800872 (A)				
GPA	2	435/598	1.03 (0.84 – 1.27)	0.762
EGPA	1	103/507	0.89 (0.62 – 1.27)	0.512
PR3-ANCA	1	32/91	1.10 (0.55 – 2.20)	0.793
<i>IL-10</i> rs1800896 (G)				
GPA	5	993/6183	0.95 (0.85 – 1.05)	0.293
MPA	2	192/5513	0.95 (0.78 – 1.17)	0.655
EGPA	1	103/507	0.68 (0.50 – 0.92)	0.012
PR3-ANCA	2	358/5451	1.05 (0.90 – 1.22)	0.527
MPO-ANCA	1	167/5360	0.96 (0.77 – 1.19)	0.693
<i>IRF5</i> rs10954213 (G)				
GPA	2	1021/6267	0.66 (0.59 – 0.74)	<0.001
MPA	2	333/6075	1.22 (1.03 – 1.44)	0.018
PR3-ANCA	1	326/5365	1.09 (0.93 – 1.28)	0.293
MPO-ANCA	2	399/6075	1.12 (0.96 – 1.31)	0.142
<i>LEPR</i> rs8179183 (C)				
GPA	1	682/1326	0.72 (0.60 – 0.86)	<0.001
EGPA	1	196/1327	1.41 (1.10 – 1.81)	0.007
<i>MPO</i> rs2333227 (A)				
GPA	1	69/150	0.70 (0.41 – 1.21)	0.204
MPA	1	65/150	1.18 (0.72 – 1.93)	0.523
PR3-ANCA	3	258/549	1.00 (0.77 – 1.31)	0.977
MPO-ANCA	3	141/549	0.94 (0.68 – 1.31)	0.719
<i>PTPN22</i> rs2476601 (A)				
GPA	4	1616/8678	1.43 (1.26 – 1.62)	<0.001

Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic sub-groups (Continued)

Variant by gene	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis
MPA	2	258/6310	1.42 (1.06 – 1.89)	0.018
EGPA	1	99/945	0.52 (0.21 – 1.29)	0.158
PR3-ANCA	2	419/6310	1.42 (1.14 – 1.77)	0.002
MPO-ANCA	2	183/6310	1.47 (1.08 – 2.00)	0.014
<i>RING1/RXRΒ</i> rs213213 (A)				
GPA	3	1132/7238	1.91 (1.73 – 2.10)	<0.001
MPA	1	156/5366	1.15 (0.90 – 1.45)	0.264
PR3-ANCA	1	326/5366	2.06 (1.75 – 2.41)	<0.001
MPO-ANCA	1	167/5366	1.05 (0.83 – 1.32)	0.687
<i>RXRΒ</i> rs6531 (C)				
GPA	3	1211/6955	1.70 (1.55 – 1.86)	<0.001
MPA	1	262/5251	1.38 (1.15 – 1.66)	0.001
PR3-ANCA	1	478/5251	2.19 (1.92 – 2.51)	<0.001
MPO-ANCA	1	264/5251	1.21 (1.00 – 1.46)	0.046
ANCA negative	1	36/201	1.02 (0.59 – 1.74)	0.948
<i>RXRΒ</i> rs9277935 (T)				
GPA	3	1135/7233	0.37 (0.31 – 0.43)	<0.001
MPA	1	156/5350	0.93 (0.70 – 1.24)	0.629
PR3-ANCA	1	326/5350	0.24 (0.17 – 0.33)	<0.001
MPO-ANCA	1	167/5350	1.18 (0.92 – 1.53)	0.193
<i>SERPINA1</i> S allele				
GPA	2	484/1079	1.72 (1.12 – 2.66)	0.014
c-ANCA	3	145/3836	1.92 (1.12 – 3.29)	0.017
<i>SERPINA1</i> Z allele				
GPA	4	972/2636	2.40 (1.73 – 3.33)	<0.001
MPA	1	143/805	1.60 (0.76 – 3.39)	0.218
PR3-ANCA	1	322/805	2.58 (1.57 – 4.25)	<0.001
MPO-ANCA	1	166/805	2.01 (1.04 – 3.87)	0.037
c-ANCA	5	280/4788	3.53 (2.28 – 5.49)	<0.001
p-ANCA	2	78/2510	3.13 (1.21 – 8.13)	0.019
<i>STAT4</i> rs7574865 (T)				
GPA	2	1288/6246	1.06 (0.94 – 1.20)	0.331
MPA	1	676/5366	1.12 (0.86 – 1.46)	0.392
PR3-ANCA	1	676/5366	1.06 (0.88 – 1.28)	0.547

Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic subgroups (Continued)

Variant by gene	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis
MPO-ANCA	2	908/6076	1.24 (1.05 – 1.46)	0.009
<i>TGF-β₁</i> rs1800471 (C)				
GPA	3	196/259	1.52 (0.93 – 2.48)	0.096
MPA	1	36/96	1.03 (0.35 – 2.99)	0.960
PR3-ANCA	1	32/91	1.86 (0.73 – 4.71)	0.193
<i>TNFα</i> rs1800629 (A)				
GPA	4	578/5691	1.15 (0.98 – 1.35)	0.098
MPA	1	156/5366	1.13 (0.95 – 1.35)	0.182
PR3-ANCA	2	357/5457	1.21 (0.93 – 1.57)	0.149
MPO-ANCA	1	167/5366	0.88 (0.66 – 1.17)	0.375
<i>TNFRII</i> 196R				
GPA	1	177/123	1.05 (0.70 – 1.57)	0.819
MPA	1	50/262	0.67 (0.31 – 1.45)	0.313
MPO-ANCA	1	50/262	0.67 (0.31 – 1.45)	0.313
<i>TLR9</i> rs352162 (T)				
GPA	1	919/1898	1.20 (1.07 – 1.34)	0.001
MPA	1	153/1898	0.74 (0.58 – 0.95)	0.020
EGPA	1	217/1898	1.28 (1.05 – 1.57)	0.015
PR3-ANCA	1	NR/NR	1.30 (1.14 – 1.47)	<0.001
MPO-ANCA	1	NR/NR	0.79 (0.65 – 0.97)	0.028
ANCA negative	1	NR/NR	1.22 (0.99 – 1.50)	0.060
<i>TLR9</i> rs352140 (T)				
GPA	1	919/1898	1.20 (1.07 – 1.35)	0.001
MPA	1	153/1898	0.71 (0.55 – 0.91)	0.006
EGPA	1	217/1898	1.17 (0.96 – 1.43)	0.129
PR3-ANCA	1	NR/NR	1.28 (1.12 – 1.45)	<0.001
MPO-ANCA	1	NR/NR	0.75 (0.62 – 0.91)	0.004
ANCA negative	1	NR/NR	1.19 (0.97 – 1.47)	0.097
<i>TLR9</i> rs352139 (T)				
GPA	1	919/1898	1.18 (1.06 – 1.32)	0.003
MPA	1	153/1898	0.68 (0.52 – 0.87)	0.003
EGPA	1	217/1898	1.21 (0.99 – 1.47)	0.057
PR3-ANCA	1	NR/NR	1.23 (1.09 – 1.40)	0.001
MPO-ANCA	1	NR/NR	0.78 (0.63 – 0.96)	0.017
ANCA negative	1	NR/NR	1.20 (0.98 – 1.47)	0.086

Supplementary table 4. Results of the meta-analyses stratified by diagnostic and serologic subgroups (Continued)

Variant by gene	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis
<i>TLR9</i> rs5743836 (G)				
GPA	1	919/1898	0.83 (0.70 – 0.99)	0.037
MPA	1	153/1898	1.78 (1.32 – 2.39)	<0.001
EGPA	1	217/1898	0.90 (0.68 – 1.21)	0.499
PR3-ANCA	1	NR/NR	0.83 (0.70 – 1.00)	0.045
MPO-ANCA	1	NR/NR	1.20 (0.91 – 1.58)	0.207
ANCA negative	1	NR/NR	0.99 (0.74 – 1.34)	0.970

Supplementary table 5. Results of the meta-analyses stratified by ethnic subgroups

Variant by gene	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis
<i>CTLA-4</i> (AT) ₈₆				
Asian	1	49/111	1.31 (0.76 – 2.25)	0.333
Caucasian	3	254/432	0.46 (0.36 – 0.58)	<0.001
<i>CTLA-4</i> (AT) ₁₀₂				
Asian	1	49/111	0.89 (0.47 – 1.68)	0.714
Caucasian	2	137/309	1.73 (0.87 – 3.44)	0.117
<i>CTLA-4</i> (AT) ₁₀₄				
Asian	1	49/111	1.15 (0.70 – 1.91)	0.578
Caucasian	2	137/309	1.24 (0.88 – 1.73)	0.215
<i>CTLA-4</i> (AT) ₁₀₆				
Asian	1	49/111	0.41 (0.14 – 1.22)	0.109
Caucasian	2	137/309	2.69 (1.28 – 5.63)	0.009
<i>CTLA-4</i> (AT) ₁₀₈				
Asian	1	49/111	0.82 (0.33 – 2.02)	0.670
Caucasian	2	137/309	0.92 (0.44 – 1.92)	0.831
<i>CTLA-4</i> (AT) ₁₁₀				
Asian	1	49/111	0.25 (0.01 – 4.62)	0.349
Caucasian	2	137/309	0.84 (0.37 – 1.91)	0.679
<i>CTLA-4</i> (AT) ₁₁₆				
Asian	1	49/111	0.75 (0.03 – 18.56)	0.860
Caucasian	2	137/309	0.80 (0.26 – 2.50)	0.705
<i>CTLA-4</i> (AT) ₁₁₈				
Asian	1	49/111	0.75 (0.08 – 7.33)	0.807
Caucasian	2	137/309	0.41 (0.12 – 1.39)	0.152

Supplementary table 5. Results of the meta-analyses stratified by ethnic subgroups (Continued)

Variant by gene	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis
<i>CTLA-4</i> (AT) ₁₂₂				
Asian	1	49/111	2.32 (0.57 – 9.45)	0.241
Caucasian	2	137/309	1.22 (0.27 – 5.49)	0.799
<i>CTLA-4</i> (AT) ₁₂₄				
Asian	1	49/111	2.28 (0.14 – 36.80)	0.562
Caucasian	2	137/309	1.94 (0.67 – 5.58)	0.222
<i>CTLA-4</i> (AT) ₁₂₆				
Asian	1	49/111	0.45 (0.05 – 3.88)	0.466
Caucasian	2	137/309	1.65 (0.63 – 4.32)	0.305
<i>CTLA-4</i> (AT) ₁₂₈				
Asian	1	49/111	6.98 (0.72 – 67.95)	0.094
Caucasian	2	137/309	0.72 (0.24 – 2.15)	0.560
<i>FCGR2A</i> rs1801274 (C)				
Asian	1	50/303	0.68 (0.37 – 1.24)	0.208
Caucasian	5	1126/5969	0.91 (0.82 – 1.00)	0.043
<i>FCGR3A</i> rs396991 (G)				
Asian	1	50/303	0.65 (0.39 – 1.07)	0.090
Caucasian	1	91/154	1.30 (0.89 – 1.91)	0.172
<i>FCGR3B</i> (NA1)				
Asian	1	50/303	1.29 (0.82 – 2.03)	0.267
Caucasian	3	865/667	0.93 (0.80 – 1.08)	0.343
<i>HLA-A2</i>				
Asian	1	16/472	0.90 (0.37 – 2.23)	0.826
Caucasian	4	427/7324	0.96 (0.81 – 1.13)	0.595
<i>HLA-A11</i>				
Asian	1	16/472	0.71 (0.17 – 3.03)	0.644
Caucasian	5	450/7635	1.01 (0.50 – 2.05)	0.978
<i>HLA-A24</i>				
Asian	1	16/472	0.75 (0.34 – 1.65)	0.476
Caucasian	2	92/751	1.16 (0.57 – 2.38)	0.683
<i>HLA-A26</i>				
Asian	1	16/472	2.36 (1.00 – 5.60)	0.051
Caucasian	3	115/1156	1.21 (0.58 – 2.55)	0.612
<i>HLA-A31</i>				
Asian	1	16/472	1.55 (0.46 – 5.24)	0.479
Caucasian	2	92/751	0.73 (0.21 – 2.52)	0.613


Supplementary table 5. Results of the meta-analyses stratified by ethnic subgroups (Continued)

Variant by gene	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis
<i>HLA-A32</i>				
Asian	1	16/472	2.07 (0.61 – 7.04)	0.246
Caucasian	2	92/751	1.41 (0.52 – 3.84)	0.500
<i>HLA-B35</i>				
Asian	1	16/472	0.80 (0.17 – 3.40)	0.757
Caucasian	3	396/6623	0.78 (0.58 – 1.06)	0.115
<i>HLA-B39</i>				
Asian	1	16/472	0.86 (0.11 – 6.51)	0.887
Caucasian	1	51/51	0.33 (0.01 – 8.20)	0.499
<i>HLA-B44</i>				
Asian	1	16/472	2.50 (0.85 – 7.40)	0.098
Caucasian	2	92/751	1.41(0.85 – 2.35)	0.188
<i>HLA-B51</i>				
Asian	1	16/472	1.87 (0.64 – 5.49)	0.255
Caucasian	1	51/51	0.61 (0.19 – 1.92)	0.394
<i>HLA-B55</i>				
Asian	1	16/472	7.35 (2.34 – 23.14)	0.001
Caucasian	1	51/51	0.07 (0.00 – 1.30)	0.075
<i>HLA-B60</i>				
Asian	1	16/472	1.19 (0.28 – 5.13)	0.814
Caucasian	1	41/700	3.51 (0.99 – 12.36)	0.051
<i>HLA-B62</i>				
Asian	1	16/472	1.71 (0.58 – 4.99)	0.331
Caucasian	1	41/700	2.38 (0.70 – 8.12)	0.166
<i>HLA-Cw1</i>				
Asian	1	16/472	1.45 (0.58 – 3.58)	0.426
Caucasian	1	52/51	0.98 (0.24 – 4.03)	0.978
<i>HLA-Cw3</i>				
Asian	1	16/472	1.40 (0.66 – 3.01)	0.384
Caucasian	1	52/51	1.32 (0.62 – 2.81)	0.479
<i>HLA-Cw7</i>				
Asian	1	16/472	0.50 (0.12 – 2.10)	0.340
Caucasian	1	52/51	1.10 (0.62 – 1.96)	0.735
<i>HLA-DPB1*0201</i>				
Asian	1	50/77	1.38 (0.75 – 2.52)	0.298
Caucasian	3	385/827	0.76 (0.56 – 1.03)	0.073


Supplementary table 5. Results of the meta-analyses stratified by ethnic subgroups (Continued)

Variant by gene	Publications (n)	Cases (n) / Controls (n)	OR (95% CI)	P value for meta-analysis
<i>HLA-DQB1</i> *0303				
Asian	1	50/77	2.11 (1.14 – 3.90)	0.018
Caucasian	2	126/141	1.35 (0.55 – 3.33)	0.515
<i>HLA-DR1</i>				
Asian	1	64/265	1.12 (0.48 – 2.64)	0.793
Caucasian	9	945/6840	0.91 (0.61 – 1.36)	0.651
<i>HLA-DR2</i>				
Asian	1	16/472	0.33 (0.08 – 1.38)	0.128
Caucasian	4	471/5750	1.06 (0.87 – 1.29)	0.565
<i>HLA-DR4</i>				
Asian	1	16/472	0.72 (0.27 – 1.88)	0.498
Caucasian	10	882/7262	1.23 (0.97 – 1.57)	0.088
<i>HLA-DR6</i>				
Asian	1	16/472	1.63 (0.56 – 4.77)	0.371
Caucasian	4	471/5750	0.43 (0.30 – 0.61)	<0.001
<i>HLA-DR8</i>				
Asian	1	16/472	1.63 (0.66 – 4.05)	0.291
Caucasian	8	597/1483	1.05 (0.75 – 1.49)	0.768
<i>HLA-DR9</i>				
Asian	4	296/1409	1.67 (0.83 – 3.34)	0.148
Caucasian	7	510/1443	0.63 (0.34 – 1.19)	0.152
<i>IRF5</i> rs10954213 (G)				
Asian	1	232/710	1.28 (1.04 – 1.58)	0.022
Caucasian	2	1303/6267	0.69 (0.63 – 0.76)	<0.001
<i>STAT4</i> rs7574865 (T)				
Asian	1	232/710	1.10 (0.89 – 1.37)	0.388
Caucasian	2	1288/6246	1.11 (1.00 – 1.24)	0.044
<i>TNFR11</i> 196R				
Asian	1	50/262	0.67 (0.31 – 1.45)	0.313
Caucasian	1	117/123	1.05 (0.70 – 1.57)	0.819


Supplementary figure 1. Forest plots




CD226 rs763361 (T) forest plot. Harbold test: N/A, Egger test: $p=0.792$.
References: ¹*, ²*, ³




CTLA-4 (AT)₈₆ forest plot. Harbold test: $p=0.946$, Egger test: $p=0.788$.
References: ⁴, ⁵, ⁶, ⁷




CTLA-4 rs231775 (G) forest plot. Harbold test: $p=0.080$, Egger test: $p=0.081$.
References: ⁸, ⁹, ³



CTLA-4 rs3087243 (A) forest plot. Harbold test: N/A, Egger test: $p=0.122$.
References: ⁹, ^{2**}, ³




FCGR2A rs1801274 (C) forest plot. Harbold test: $p=0.788$, Egger test: $p=0.829$.
References: ¹¹, ¹², ¹³, ⁵, ⁷, ³



HLA-B5 forest plot. Harbold test: N/A, Egger test: N/A.
References: ¹⁶, ¹⁹


HLA-B8



HLA-B8 forest plot. Harbold test: $p=0.063$, Egger test: $p=0.077$.

References: ¹⁶, ²¹, ²³, ¹⁷, ¹⁸, ¹⁹


HLA-DPA1 rs9277341 (C)



HLA-DPA1 rs9277341 (C) forest plot. Harbold test: $p=0.215$, Egger test: $p=0.219$.

References: ²⁴, ²⁵**


HLA-DPB1*0301



HLA-DPB1*0301 forest plot. Harbold test: $p=0.938$, Egger test: $p=0.744$.


References: ²⁶, ²⁷, ²⁴, ²⁹, ³⁰**

HLA-DPB1*0401




HLA-DPB1*0401 forest plot. Harbold test: $p=0.738$, Egger test: $p=0.759$.


References: ²⁶, ²⁷, ²⁴, ²⁹, ³⁰**



HLA-DPB2 rs3130215 (A) forest plot. Harbold test: $p=0.446$, Egger test: $p=0.431$.
References: ²⁴, ³, ²⁵




*HLA-DQB1*0303* forest plot. Harbold test: $p=0.916$, Egger test: $p=0.834$.
References: ²⁶, ³¹, ²⁸




HLA-DR6 forest plot. Harbold test: $p=0.997$, Egger test: $p=0.989$.

References: ²³, ³², ²⁶, ²⁰, ¹⁹




*HLA-DRB1*1101* forest plot. Harbold test: N/A, Egger test: N/A.

References: ³⁴, ³⁷




*HLA-DRB1*1201* forest plot. Harbold test: N/A, Egger test: N/A.

References: ⁵, ³⁴




*HLA-DRB1*13* forest plot. Harbold test: $p=0.884$, Egger test: $p=0.467$.


References: ³¹, ¹⁸, ³⁵, ²⁹



*HLA-DRB1*14* forest plot. Harbold test: $p=0.700$, Egger test: $p=0.706$.
References: ³¹, ¹⁸, ²⁹, ³³




*HLA-DRB1*15* forest plot. Harbold test: $p=0.347$, Egger test: $p=0.214$.
References: ³¹, ¹⁸, ^{33**}




*HLA-DRB1*1501* forest plot. Harbold test: N/A, Egger test: N/A.

References: ⁵, ³⁴




HLA-DRB3 forest plot. Harbold test: $p=0.689$, Egger test: $p=0.958$.

References: ³⁸, ¹⁸, ³⁵, ²⁹




HLA-DRB4 forest plot. Harbold test: $p=0.533$, Egger test: $p=0.388$.

References: ^{38, 18, 35, 29}




HSD17B8 rs421446 (C) forest plot. Harbold test: N/A, Egger test: N/A.


References: ^{24, 25}




IRF5 rs10954213 (G) forest plot. Harbold test: $p=0.948$, Egger test: $p=0.833$.
References: ⁴⁴, ³, ⁴⁵




PTPN22 rs2476601 (A) forest plot. Harbold test: N/A, Egger test: $p=0.500$.
References: ⁵⁰, ^{2**}, ⁵¹, ³




RING1/RXR_B rs213213 (A) forest plot. Harbold test: $p=0.187$, Egger test: $p=0.169$.
References: ²⁴, ³, ²⁵




RXR_B rs6531 (C) forest plot. Harbold test: $p=0.292$, Egger test: $p=0.301$.
References: ⁵², ³, ²⁵




RXRB rs9277935 (T) forest plot. Harbold test: $p=0.393$, Egger test: $p=0.406$.
References: ⁵³, ³, ²⁵




STAT4 rs7574865 (T) forest plot. Harbold test: $p=0.590$, Egger test: $p=0.567$.
References: ⁴⁴, ⁴⁵, ³



TLR9 rs352162 (T) forest plot. Harbold test: N/A, Egger test: N/A.
References: ^{40**}




TLR9 rs352140 (T) forest plot. Harbold test: N/A, Egger test: N/A.
References: ^{40**}



TLR9 rs352139 (T) forest plot. Harbold test: N/A, Egger test: N/A.
References: ⁴⁰**


**Two cohorts described in the same publication.
***Three cohorts described in the same publication.
N/A, not applicable

Supplementary figure 2. Forest plots by diagnostic and serologic subgroups




References: ¹*, ²*, ³

Subgroup analysis CTLA-4 (AT)86




References: ⁴, ⁵, ⁶, ⁷

Subgroup analysis CTLA-4 (AT)104




References: ⁴, ⁷, ⁵

Subgroup analysis CTLA-4 (AT)122




References: ⁴, ⁷, ⁵

Subgroup analysis CTLA-4 rs3087243 (A)




References: ⁹, ^{2**}, ³

Subgroup analysis FCGR2A rs1801274 (C)




References: ¹¹, ¹², ¹³, ⁵, ⁷, ³

Subgroup analysis FCGR3B (NA1)




References: ¹², ¹⁴, ¹⁰, ⁵

Subgroup analysis HLA-A11




References: ¹⁶, ¹⁷, ²⁰, ²², ¹⁸, ¹⁹

Subgroup analysis HLA-B35




References: ¹⁷, ²⁰, ¹⁸, ¹⁹

Subgroup analysis HLA-B55




References: ²⁰, ¹⁸

Subgroup analysis HLA-B62




References: ¹⁷, ²⁰

Subgroup analysis HLA-DPA1 rs9277341 (C)




References: ²⁴, ^{25**}

Subgroup analysis HLA-DPB1*0101




References: ²⁷, ²⁶

Subgroup analysis HLA-DPB1*0201




References: ²⁷, ²⁴, ²⁸, ²⁹

Subgroup analysis HLA-DPB1*0301




References: ²⁶, ²⁷, ²⁴, ²⁹, ³⁰**

Subgroup analysis HLA-DPB1*0401




References: ²⁶, ²⁷, ²⁴, ²⁹, ^{30**}

Subgroup analysis HLA-DPB2 rs3130215 (A)




References: ²⁴, ³, ²⁵

Subgroup analysis HLA-DQB1*0303




References: ²⁶, ³¹, ²⁸

Subgroup analysis HLA-DR1




References: ²³, ³², ³¹, ¹⁸, ¹⁹, ³⁴, ⁵, ²⁹, ²⁶, ³³

Subgroup analysis HLA-DR2




References: ²³, ³², ²⁶, ²⁰, ¹⁹

Subgroup analysis HLA-DR4




References: ²³, ¹⁷, ³², ²⁰, ³¹, ¹⁸, ¹⁹, ³⁵, ²⁹, ²⁶, ³³

Subgroup analysis HLA-DR6




References: ²³, ³², ²⁶, ²⁰, ¹⁹

Subgroup analysis HLA-DR7




References: ²³, ³², ³¹, ¹⁸, ¹⁹, ³⁵, ²⁹

Subgroup analysis HLA-DR8




References: ¹⁷, ²⁰, ³¹, ¹⁸, ¹⁹, ²⁹, ²⁶, ³³

Subgroup analysis HLA-DR9




References: ²³, ²⁰, ³¹, ¹⁸, ¹⁹, ³⁴, ³⁷, ³⁵, ²⁹, ³³, ³⁶

Subgroup analysis HLA-DRB1*1101




References: ³⁴, ³⁷

Subgroup analysis HLA-DRB1*12




References: ³¹, ¹⁸, ²⁹, ³³


Subgroup analysis HLA-DRB1*1202

References: ⁵, ³⁴

Subgroup analysis HLA-DRB1*13


References: ³¹, ¹⁸, ³⁵, ²⁹

Subgroup analysis HLA-DRB1*15




References: ³¹, ¹⁸, ^{33**}

Subgroup analysis HLA-DRB1*1501





References: ⁵, ³⁴

Subgroup analysis HLA-DRB1*16

References: ³¹, ¹⁸, ³³**


Subgroup analysis HLA-DRB3

References: ¹⁸, ³⁵, ²⁹




References: ¹⁸, ³⁵, ²⁹

Subgroup analysis IL-10 rs1800896 (G)




References: ⁴², ⁴³, ³¹, ⁴¹, ³

Subgroup analysis IRF5 rs10954213 (G)




References: ⁴⁴, ³, ⁴⁵

Subgroup analysis LEPR rs8179183 (C)




References: ¹⁵*,*

Subgroup analysis PTPN22 rs2476601 (A)




References: ⁵⁰, ^{2**}, ⁵¹, ³

Subgroup analysis RING1/RXRB rs213213 (A)




References: ²⁴, ³, ²⁵

Subgroup analysis RXRB rs6531 (C)




References: ⁵², ³, ²⁵

Subgroup analysis RXRB rs9277935 (T)




References: ⁵³, ³, ²⁵

Subgroup analysis SERPINA1 S allele




References: ⁵⁴, ⁵⁵, ⁵⁶, ⁵⁸

Subgroup analysis SERPINA1 Z allele




References: ⁵⁴, ⁵⁵, ⁵⁹, ⁶⁰, ⁵⁶, ³, ⁵⁸

Subgroup analysis STAT4 rs7574865 (T)




References: ⁴⁴, ⁴⁵

Subgroup analysis TLR9 rs352162 (T)




References: ^{40**}

Subgroup analysis TLR9 rs352140 (T)




References: ^{40**}

Subgroup analysis TLR9 rs352139 (T)



References: ^{40**}

Subgroup analysis TLR9 rs5743836 (G)




References: ^{40**}


**Two cohorts described in the same publication.

***Three cohorts described in the same publication.

Supplementary figure 3. Forest plots by ethnic subgroups




References: ⁴, ⁵, ⁶, ⁷




References: ⁴, ⁵, ⁷

Subgroup analysis HLA-B55




References: ²⁰, ¹⁸

Subgroup analysis HLA-DR6



References: ²³, ³², ²⁶, ²⁰, ¹⁹



References: ⁴⁴, ³, ⁴⁵

References

1. Wiczorek S, Hoffjan S, Chan A, *et al.* Novel association of the CD226 (DNAM-1) Gly-307Ser polymorphism in Wegener's granulomatosis and confirmation for multiple sclerosis in German patients. *Genes Immun* 2009;10:591-5.
2. Chung SA, Xie G, Roshandel D, *et al.* Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis. *Arthritis Rheum* 2012;64:3463-71.
3. Lyons PA, Rayner TF, Trivedi S, *et al.* Genetically distinct subsets within ANCA-associated vasculitis. *N Engl J Med* 2012;367:214-23.
4. Huang D, Gisco R, Zhou Y, *et al.* Polymorphisms in CTLA-4 but not tumor necrosis factor- α or interleukin 1 β genes are associated with Wegener's granulomatosis. *J Rheumatol* 2000;27:397-401.
5. Tsuchiya N, Kobayashi S, Kawasaki A, *et al.* Genetic background of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: association of HLA-DRB1*0901 with microscopic polyangiitis. *J Rheumatol* 2003;30:1534-40.
6. Zhou Y, Huang D, Paris PL, *et al.* An analysis of CTLA-4 and proinflammatory cytokine genes in Wegener's granulomatosis. *Arthritis Rheum* 2004;50:2645-50.
7. Persson U, Gullstrand B, Pettersson A, *et al.* A candidate gene approach to ANCA-associated vasculitis reveals links to the C3 and CTLA-4 genes but not to the IL1-Ra and Fc γ RIIa genes. *Kidney Blood Press Res* 2013;37:641-8.
8. Slot MC, Sokolowska MG, Savellou KG, *et al.* Immunoregulatory gene polymorphisms are associated with ANCA-related vasculitis. *Clin Immunol* 2008;128:39-45.
9. Kamesh L, Heward JM, Williams JM, *et al.* CT60 and +49 polymorphisms of CTLA 4 are associated with ANCA-positive small vessel vasculitis. *Rheumatology (Oxford)* 2009;48:1502-5.
10. Kelley JM, Monach PA, Ji C, *et al.* IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. *Proc Natl Acad Sci U S A* 2011;108:20736-41.
11. Edberg JC, Wainstein E, Wu J, *et al.* Analysis of Fc γ RII gene polymorphisms in Wegener's granulomatosis. *Exp Clin Immunogenet* 1997;14:183-95.
12. Dijkstra HM, Scheepers RH, Oost WW, *et al.* Fc γ receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse. *Arthritis Rheum* 1999;42:1823-7.
13. Tse WY, Abadeh S, McTiernan A, *et al.* No association between neutrophil Fc γ RIIa allelic polymorphism and anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis. *Clin Exp Immunol* 1999;117:198-205.
14. Tse WY, Abadeh S, Jefferis R, *et al.* Neutrophil Fc γ RIIb allelic polymorphism in anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis. *Clin Exp Immunol* 2000;119:574-7.
15. Wiczorek S, Holle JU, Bremer JP, *et al.* Contrasting association of a non-synonymous leptin receptor gene polymorphism with Wegener's granulomatosis and Churg-Strauss syndrome. *Rheumatology (Oxford)* 2010;49:907-14.
16. Strimlan CV, Taswell HF, Kueppers F, *et al.* HLA-A antigens of patients with Wegener's granulomatosis. *Tissue Antigens* 1978;11:129-31.
17. Murty GE, Mains BT, Middleton D, *et al.* HLA antigen frequencies and Wegener's

- granulomatosis. *Clin Otolaryngol Allied Sci* 1991;16:448-51.
18. von Vietinghoff S, Busjahn A, Schonemann C, *et al.* Major histocompatibility complex HLA region largely explains the genetic variance exercised on neutrophil membrane proteinase 3 expression. *J Am Soc Nephrol* 2006;17:3185-91.
19. Stassen PM, Cohen-Tervaert JW, Lems SP, *et al.* HLA-DR4, DR13(6) and the ancestral haplotype A1B8DR3 are associated with ANCA-associated vasculitis and Wegener's granulomatosis. *Rheumatology (Oxford)* 2009;48:622-5.
20. Nakamaru Y, Maguchi S, Takizawa M, *et al.* The association between human leukocyte antigens (HLA) and cytoplasmic-antineutrophil cytoplasmic antibody (cANCA)-positive Wegener's granulomatosis in a Japanese population. *Rhinology* 1996;34:163-5.
21. Katz P, Alling DW, Haynes BF, *et al.* Association of Wegener's granulomatosis with HLA-B8. *Clin Immunol Immunopathol* 1979;14:268-70.
22. Papasteriades C, Hatzilyannakos D, Siakotos M, *et al.* HLA antigens in microscopic polyarteritis (MP) with renal involvement. *Dis Markers* 1997;13:117-22.
23. Elkon KB, Sutherland DC, Rees AJ, *et al.* HLA antigen frequencies in systemic vasculitis: increase in HLA-DR2 in Wegener's granulomatosis. *Arthritis Rheum* 1983;26:102-5.
24. Heckmann M, Holle JU, Arning L, *et al.* The Wegener's granulomatosis quantitative trait locus on chromosome 6p21.3 as characterised by tagSNP genotyping. *Ann Rheum Dis* 2008;67:972-9.
25. Xie G, Roshandel D, Sherva R, *et al.* Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. *Arthritis Rheum* 2013;65:2457-68.
26. Zhang L, Jayne DR, Zhao MH, *et al.* Distribution of MHC class II alleles in primary systemic vasculitis. *Kidney Int* 1995;47:294-8.
27. Jagiello P, Gencik M, Arning L, *et al.* New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes. *Hum Genet* 2004;114:468-77.
28. Tsuchiya N, Kobayashi S, Hashimoto H, *et al.* Association of HLA-DRB1*0901-DQB1*0303 haplotype with microscopic polyangiitis in Japanese. *Genes Immun* 2006;7:81-4.
29. Wiczorek S, Hellmich B, Gross WL, *et al.* Associations of Churg-Strauss syndrome with the HLA-DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody-associated vasculitides: comment on the article by Vaglio *et al.* *Arthritis Rheum* 2008;58:329-30.
30. Arning L, Holle JU, Harper L, *et al.* Are there specific genetic risk factors for the different forms of ANCA-associated vasculitis? *Ann Rheum Dis* 2011;70:707-8.
31. Spriewald BM, Witzke O, Wassmuth R, *et al.* Distinct tumour necrosis factor alpha, interferon gamma, interleukin 10, and cytotoxic T cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener's granulomatosis. *Ann Rheum Dis* 2005;64:457-61.
32. Papiha SS, Murty GE, Ad'Hia A, *et al.* Association of Wegener's granulomatosis with HLA antigens and other genetic markers. *Ann Rheum Dis* 1992;51:246-8.
33. Cao Y, Schmitz JL, Yang J, *et al.* DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans. *J Am Soc Nephrol* 2011;22:1161-7.
34. Luo H, Chen M, Yang R, *et al.* The association of HLA-DRB1 alleles with antineutrophil cytoplasmic antibody-associated systemic vasculitis in Chinese patients. *Hum Immunol* 2011;72:422-5.

35. Vaglio A, Martorana D, Maggiore U, *et al.* HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. *Arthritis Rheum* 2007;56:3159-66.
36. Fujii A, Tomizawa K, Arimura Y, *et al.* Epitope analysis of myeloperoxidase (MPO) specific anti-neutrophil cytoplasmic autoantibodies (ANCA) in MPO-ANCA-associated glomerulonephritis. *Clin Nephrol* 2000;53:242-52.
37. Tsuchiya N. Genetics of ANCA-associated vasculitis in Japan: a role for HLA-DRB1*09:01 haplotype. *Clin Exp Nephrol* 2013;17:628-30.
38. Spencer SJ, Burns A, Gaskin G, *et al.* HLA class II specificities in vasculitis with antibodies to neutrophil cytoplasmic antigens. *Kidney Int* 1992;41:1059-63.
39. Borgmann S, Endisch G, Hacker UT, *et al.* Proinflammatory genotype of interleukin-1 and interleukin-1 receptor antagonist is associated with ESRD in proteinase 3-ANCA vasculitis patients. *Am J Kidney Dis* 2003;41:933-42.
40. Husmann CA, Holle JU, Moosig F, *et al.* Genetics of toll like receptor 9 in ANCA associated vasculitides. *Ann Rheum Dis* 2014;73:890-6.
41. Wiczorek S, Hellmich B, Arning L, *et al.* Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis. *Arthritis Rheum* 2008;58:1839-48.
42. Murakozy G, Gaede KI, Ruprecht B, *et al.* Gene polymorphisms of immunoregulatory cytokines and angiotensin-converting enzyme in Wegener's granulomatosis. *J Mol Med (Berl)* 2001;79:665-70.
43. Bartfai Z, Gaede KI, Russell KA, *et al.* Different gender-associated genotype risks of Wegener's granulomatosis and microscopic polyangiitis. *Clin Immunol* 2003;109:330-7.
44. Wiczorek S, Holle JU, Muller S, *et al.* A functionally relevant IRF5 haplotype is associated with reduced risk to Wegener's granulomatosis. *J Mol Med (Berl)* 2010;88:413-21.
45. Kawasaki A, Inoue N, Ajimi C, *et al.* Association of IRF5 polymorphism with MPO-ANCA-positive vasculitis in a Japanese population. *Genes Immun* 2013;14:527-9.
46. Reynolds WF, Stegeman CA, Tervaert JW. -463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis. *Clin Immunol* 2002;103:154-60.
47. Fiebler A, Borgmann S, Woywodt A, *et al.* No association of G-463A myeloperoxidase gene polymorphism with MPO-ANCA-associated vasculitis. *Nephrol Dial Transplant* 2004;19:969-71.
48. Rajp A, Adu D, Savage CO. Meta-analysis of myeloperoxidase G-463/A polymorphism in anti-neutrophil cytoplasmic autoantibody-positive vasculitis. *Clin Exp Immunol* 2007;149:251-6.
49. Sakthivel P, Giscombe R, Ramanujam R, *et al.* Polymorphisms in PDCD1 gene are not associated with Wegener's granulomatosis. *Rheumatol Int* 2009;29:1247-50.
50. Jagiello P, Aries P, Arning L, *et al.* The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. *Arthritis Rheum* 2005;52:4039-43.
51. Martorana D, Maritati F, Malerba G, *et al.* PTPN22 R620W polymorphism in the ANCA-associated vasculitides. *Rheumatology (Oxford)* 2012;51:805-12.
52. Szyld P, Jagiello P, Csernok E, *et al.* On the Wegener granulomatosis associated region on chromosome 6p21.3. *BMC Med Genet* 2006;7:21.
53. Wiczorek S, Knaup S, Gross WL, *et al.* Genetic variability of RXRB, PPARG, and PPARG in Wegener's granulomatosis. *PPAR Res* 2009;2009:786781.
54. Lhotta K, Vogel W, Meisl T, *et al.* Alpha

- 1-antitrypsin phenotypes in patients with anti-neutrophil cytoplasmic antibody-positive vasculitis. *Clin Sci (Lond)* 1994;87:693-5.
55. Griffith ME, Lovegrove JU, Gaskin G, *et al.* C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele. *Nephrol Dial Transplant* 1996;11:438-43.
56. Mahr AD, Edberg JC, Stone JH, *et al.* Alpha(1)-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis. *Arthritis Rheum* 2010;62:3760-7.
57. Morris H, Morgan MD, Wood AM, *et al.* ANCA-associated vasculitis is linked to carriage of the Z allele of alpha(1) antitrypsin and its polymers. *Ann Rheum Dis* 2011;70:1851-6.
58. Chorostowska-Wynimko J, Gawryluk D, Struniawski R, *et al.* Incidence of alpha-1 antitrypsin Z and S alleles in patients with granulomatosis with polyangiitis - pilot study. *PneumonolAlergolPol* 2013;81:319-22.
59. Callea F, Gregorini G, Sinico A, *et al.* alpha 1-Antitrypsin (AAT) deficiency and ANCA-positive systemic vasculitis: genetic and clinical implications. *Eur J Clin Invest* 1997;27:696-702.
60. Borgmann S, Endisch G, Urban S, *et al.* A linkage disequilibrium between genes at the serine protease inhibitor gene cluster on chromosome 14q32.1 is associated with Wegener's granulomatosis. *Clin Immunol* 2001;98:244-8.
61. Mascher B, Schmitt W, Csernok E, *et al.* Polymorphisms in the tumor necrosis factor genes in Wegener's granulomatosis. *Exp Clin Immunogenet* 1997;14:226-33.

II. Supplementary data Chapter III

Renal function and ear, nose, throat involvement in ANCA associated vasculitis: prospective data from the European Vasculitis Society clinical trials

<i>Table S1. ENT manifestations</i>	<i>302</i>
<i>Table S2. ENT symptoms and ANCA-subtype</i>	<i>302</i>
<i>Table S3. ENT symptoms and baseline eGFR</i>	<i>303</i>
<i>Table S4. Clinical and histological parameters and baseline renal function</i>	<i>303</i>
<i>Table S5. Multivariable regression: ENT involvement and renal function</i>	<i>304</i>
<i>Table S6. Multivariable regression: ENT involvement and renal function in GPA</i>	<i>305</i>
<i>Table S7. Multivariable regression: ENT involvement and 5-year follow-up eGFR</i>	<i>305</i>
<i>Table S8. Multivariable regression: baseline eGFR and other disease manifestations</i>	<i>306</i>
<i>Table S9. Multivariable regression: 5-year follow-up eGFR and other disease manifestations</i>	<i>308</i>

Supplementary table 1. ENT manifestations

ENT symptom	Patients
Nasal obstruction	76 (43)
Bloody nasal discharge	70 (40)
Nasal crusting	60 (34)
Sinus involvement	45 (25)
Hearing loss	46 (26)
Hoarseness/stridor	12 (7)
Otorhinolaryngologist's opinion	
Granulomatous sinusitis	28 (16)
Conductive hearing loss	20 (11)
Sensorineural hearing loss	9 (5)
Significant subglottic inflammation	4 (2)

All data are presented as n (%). ENT symptoms scored using the Birmingham Vasculitis Activity Score are shown. Data were available for 177 of the 185 patients with ENT involvement. Percentages are expressed relative to the number of patients with ENT involvement. All items below 'otorhinolaryngologist's opinion' were only scored by the otorhinolaryngologist. ENT, ear-, nose-, and throat.

Supplementary table 2. Associations between ENT symptoms and ANCA-subtype in patients with ENT involvement

ENT symptom	PR3-ANCA patients (n=116)	MPO-ANCA patients (n=46)	P Value
Nasal obstruction	57 (49)	14 (30)	0.03
Bloody nasal discharge	45 (39)	19 (41)	0.77
Nasal crusting	43 (37)	13 (28)	0.29
Sinus involvement	30 (26)	13 (28)	0.76
Hearing loss	34 (29)	7 (15)	0.06
Hoarseness/stridor	7 (6)	5 (11)	0.30
Otorhinolaryngologist's opinion			
Granulomatous sinusitis	25 (22)	2 (4)	0.008
Conductive hearing loss	16 (14)	3 (7)	0.20
Sensorineural hearing loss	5 (4)	2 (4)	0.99
Significant subglottic inflammation	2 (2)	2 (4)	0.33

Data are presented as n (%). The distribution of ANCA-subtype in patients with ENT involvement is shown. Data regarding the specific ENT symptoms were available for 177 of the 185 patients with ENT involvement. All 8 patients with missing ENT symptoms data were PR3-ANCA positive. All items listed under 'otorhinolaryngologist's opinion' were scored by the otorhinolaryngologist alone. ENT, ear-, nose-, and throat; PR3-ANCA, anti-proteinase 3 anti-neutrophil cytoplasm antibody; MPO-ANCA, anti-myeloperoxidase anti-neutrophil cytoplasm antibody.

Supplementary table 3. Associations between ENT symptoms and baseline eGFR

ENT symptom	eGFR in symptom+ patients (mL/min/1.73 m ²)	eGFR in symptom- patients (mL/min/1.73 m ²)	95% CI	P Value
Nasal obstruction	43.09	26.59	9.91 – 23.10	<0.001
Bloody nasal discharge	37.81	28.05	2.82 – 16.71	0.006
Nasal crusting	43.25	27.36	8.60 – 23.19	<0.001
Sinus involvement	36.38	28.93	-0.95 – 15.84	0.08
Hearing loss	36.78	28.86	-0.40 – 16.23	0.06
Hoarseness/stridor	28.70	29.82	-16.72 – 14.47	0.89
Otorhinolaryngologist's opinion				
Granulomatous sinusitis	41.56	28.88	2.32 – 23.03	0.02
Conductive hearing loss	44.89	29.98	3.80 – 28.02	0.01
Sensorineural hearing loss	26.88	29.86	-20.91 – 14.96	0.74
Significant subglottic inflammation	45.53	29.63	-10.78 – 42.60	0.24

ENT symptoms were scored using the Birmingham Vasculitis Activity Score. Data regarding the specific ENT symptoms were available for 177 of the 185 patients with ENT involvement. All items listed under 'otorhinolaryngologist's opinion' were scored by the otorhinolaryngologist alone. ENT, ear-, nose-, and throat; eGFR, estimated glomerular filtration rate.

Supplementary table 4. Correlations of clinical and histological parameters with baseline and 5-year follow-up eGFR

	Baseline eGFR		5-year follow-up eGFR	
	r	p Value	r	P Value
ENT involvement	0,274	< 0.001	0,224	0.005
Age	-0,379	< 0.001	-0,395	< 0.001
PR3-ANCA	0,240	< 0.001	0,097	<0.24
Tubulitis	-0,445	< 0.001	-0,266	0.12
Interstitial infiltrate	-0,477	< 0.001	-0,396	< 0.001
IFTA	-0,436	< 0.001	-0,477	< 0.001
AAGN classification	-0,424	< 0.001	-0,511	< 0.001

ENT, ear-, nose-, and throat; PR3-ANCA, anti-proteinase 3 anti-neutrophil cytoplasm antibody; IFTA, interstitial fibrosis and tubular atrophy; AAGN, anti-neutrophil cytoplasm antibody associated glomerulonephritis; eGFR, estimated glomerular filtration rate.

Supplementary table 5. Three multivariable regression models investigating the association between ENT involvement and baseline eGFR

Model 1	β (95% CI)	P Value
ENT involvement	10.40 (5.24 – 15.55)	< 0.001
Age	-0.65 (-0.82 – -0.47)	< 0.001
PR3-ANCA	6.21 (1.03 – 11.38)	0.02
Model 2	β (95% CI)	P Value
ENT involvement	10.32 (4.05 – 16.59)	0.001
Age	-0.46 (-0.68 – -0.24)	< 0.001
PR3-ANCA	-1.43 (-7.73 – 4.88)	0.66
Tubulitis	-13.93 (-20.87 – -6.99)	< 0.001
Interstitial infiltrate	-8.56 (-12.64 – -4.47)	< 0.001
IFTA	-10.54 (-15.61 – -5.47)	< 0.001
Model 3	β (95% CI)	P Value
ENT involvement	9.14 (2.30 – 15.98)	0.009
Age	-0.60 (-0.83 – -0.36)	< 0.001
PR3-ANCA	-1.26 (-8.28 – 5.75)	0.71
Tubulitis	-17.82 (-25.78 – -9.86)	< 0.001
Interstitial infiltrate	-6.86 (-11.20 – -2.52)	0.002
IFTA	-8.72 (-14.67 – -2.77)	0.004
AAGN classification	-6.20 (-9.84 – -2.57)	0.001

Since renal biopsies were not available for all patients, including the histopathological parameters limited the number of patients included in the analysis. To be able to include all patients we therefore created three models. The first model included only clinical parameters (n=412). In the second model, we added tubulointerstitial parameters (n=195). The third model, we added the histopathological classification (n=149). In all models, age is included per year unit. ENT involvement was significantly associated with higher baseline eGFR. 95% CI, 95% confidence interval; ENT, ear-, nose-, and throat; eGFR, estimated glomerular filtration rate; PR3-ANCA, anti-proteinase 3 anti-neutrophil cytoplasm antibody; IFTA, interstitial fibrosis and tubular atrophy; AAGN, anti-neutrophil cytoplasm antibody associated glomerulonephritis.

Supplementary table 6. Multivariable regression analyses investigating the relationship between ENT involvement and eGFR in GPA patients

	β (95% CI)	P Value
ENT involvement	12.44 (0.08 – 24.80)	0.04
Age	-1.26 (-8.28 – 5.75)	0.02
PR3-ANCA	-5.17 (-17.02 – 6.68)	0.39
Tubulitis	-9.47 (-23.10 – 4.15)	0.17
Interstitial infiltrate	-16.29 (-24.93 – -7.64)	< 0.001
IFTA	-9.35 (-18.46 – -0.24)	0.01
AAGN classification	-9.79 (-15.58 – -4.00)	0.001

ENT involvement is associated with higher baseline eGFR in GPA patients. Age is included per year unit in the model. 95% CI, 95% confidence interval; ENT, ear-, nose-, and throat; eGFR, estimated glomerular filtration rate; PR3-ANCA, anti-proteinase 3 anti-neutrophil cytoplasm antibody; IFTA, interstitial fibrosis and tubular atrophy; AAGN, anti-neutrophil cytoplasm antibody associated glomerulonephritis.

Supplementary table 7. Multivariable regression analyses investigating the relationship between ENT involvement and 5-year follow-up eGFR

	Model investigating 5-year follow-up eGFR		Model investigating 5-year follow-up eGFR in PR3-ANCA positive patients	
	β (95% CI)	P Value	β (95% CI)	P Value
ENT involvement	2.12 (-4.90 – 9.14)	0.55	8.10 (-1.73 – 17.93)	0.10
Age	-0.27 (-0.52 – -0.03)	0.03	-0.03 (-0.37 – 0.30)	0.84
PR3-ANCA	-6.28 (-13.33 – 0.77)	0.08	N/A	N/A
Baseline eGFR	0.33 (0.17 – 0.48)	< 0.001	0.43 (0.24 – 0.61)	< 0.001
Tubulitis	4.25 (-4.43 – 12.92)	0.33	-1.92 (-13.49 – 9.64)	0.74
Interstitial infiltrate	-2.42 (-8.13 – 3.29)	0.40	-0.86 (-9.05 – 7.32)	0.83
IFTA	-1.65 (-8.23 – 4.92)	0.62	-2.73 (-11.14 – 5.69)	0.52
AAGN classification	-5.44 (-9.71 – -1.17)	0.01	N/A	N/A

ENT involvement is no longer associated with 5-year follow-up eGFR when baseline eGFR is included in the model. Both models are adjusted for within-trial therapy. Age is included per year unit in both models. 95% CI, 95% confidence interval; ENT, ear-, nose-, and throat; eGFR, estimated glomerular filtration rate; PR3-ANCA, anti-proteinase 3 anti-neutrophil cytoplasm antibody; IFTA, interstitial fibrosis and tubular atrophy; AAGN, anti-neutrophil cytoplasm antibody associated glomerulonephritis; N/A, not applicable.

Supplementary table 8. Three multivariable regression models investigating the association between baseline eGFR and other early disease manifestations

Model 1	Cutaneous model		Arthralgia/arthritis model		Lung model	
	β (95% CI)	P Value	β (95% CI)	P Value	β (95% CI)	P Value
Cutaneous involvement	5.61 (-0.27 – 11.49)	0.06	N/A	N/A	N/A	N/A
Arthralgia/arthritis	N/A	N/A	3.40 (-1.67 – 8.48)	0.19	N/A	N/A
Lung involvement	N/A	N/A	N/A	N/A	-2.63 (-7.56 – 2.30)	0.30
Age	-0.66 (-0.84 – -0.48)	< 0.001	-0.63 (-0.81 – -0.45)	< 0.001	-0.69 (-0.87 – -0.51)	< 0.001
PR3-ANCA	8.78 (3.74 – 13.82)	0.001	8.73 (3.65 – 13.80)	0.001	9.58 (4.56 – 14.60)	< 0.001

Model 2	Cutaneous model		Arthralgia/arthritis model		Lung model	
	β (95% CI)	P Value	β (95% CI)	P Value	β (95% CI)	P Value
Cutaneous involvement	-0.76 (-8.47 – 6.95)	0.85	N/A	N/A	N/A	N/A
Arthralgia/arthritis	N/A	N/A	-1.74 (-7.94 – 4.46)	0.58	N/A	N/A
Lung involvement	N/A	N/A	N/A	N/A	-5.46 (-11.46 – 0.53)	0.07
Age	-0.48 (-0.71 – -0.25)	< 0.001	-0.40 (-0.63 – -0.16)	0.001	-0.48 (-0.71 – -0.25)	< 0.001
PR3-ANCA	1.45 (-4.81 – 7.70)	0.65	0.67 (-5.65 – 6.99)	0.83	2.57 (-3.74 – 8.89)	0.42
Tubulitis	-13.12 (-20.27 – -5.97)	< 0.001	-11.02 (-18.30 – -3.74)	0.003	-13.20 (-20.25 – -6.14)	< 0.001
Interstitial infiltrate	-8.86 (-13.06 – -4.66)	< 0.001	-9.21 (-13.46 – -4.95)	< 0.001	-8.75 (-12.91 – -4.59)	< 0.001
IFTA	-11.97 (-17.11 – -6.84)	< 0.001	-11.89 (-17.16 – -6.62)	< 0.001	-12.07 (-17.16 – -6.98)	< 0.001

Model 3	Cutaneous model		Arthralgia/arthritis model		Lung model	
	β (95% CI)	P Value	β (95% CI)	P Value	β (95% CI)	P Value
Cutaneous involvement	-2.98 (-11.58 – 5.62)	0.49	N/A	N/A	N/A	N/A
Arthralgia/arthritis	N/A	N/A	-4.85 (-11.40 – 1.71)	0.15	N/A	N/A
Lung involvement	N/A	N/A	N/A	N/A	-4.74 (-11.19 – 1.70)	0.15
Age	-0.63 (-0.87 – -0.38)	< 0.001	-0.54 (-0.78 – -0.29)	< 0.001	-0.61 (-0.85 – -0.37)	< 0.001
PR3-ANCA	1.29 (-5.62 – 8.21)	0.71	0.41 (-6.52 – 7.33)	0.91	1.86 (-5.06 – 8.78)	0.60

Supplementary table 8. Three multivariable regression models investigating the association between baseline eGFR and other early disease manifestations (Continued)

Model 3	Cutaneous model		Arthralgia/arthritis model		Lung model	
	β (95% CI)	P Value	β (95% CI)	P Value	β (95% CI)	P Value
Tubulitis	-16.54 (-24.62 – -8.47)	<0.001	-14.71 (-22.91 – -6.50)	0.01	-16.83 (-24.87 – -8.79)	<0.001
Interstitial infiltrate	-7.48 (-11.96 – -3.00)	0.001	-7.38 (-11.83 – -2.93)	0.001	-7.12 (-11.53 – -2.71)	0.002
IFTA	-9.57 (-15.62 – -3.51)	0.002	-9.92 (-16.01 – -3.83)	0.002	-9.97 (-15.97 – -3.97)	0.001
AAGN classification	-6.82 (-10.61 – -3.03)	0.001	-6.98 (-10.79 – -3.17)	<0.001	-6.79 (-10.49 – -3.09)	<0.001

Since renal biopsies were not available for all patients, including the histopathological parameters limited the number of patients included in the analysis. To be able to include all patients we therefore created three models. The first model included only clinical parameters (n=412). In the second model, we added tubulointerstitial parameters (n=195). The third model, we added the histopathological classification (n=149). In all models, age is included per year unit. 95% CI, 95% confidence interval; eGFR, estimated glomerular filtration rate; PR3-ANCA, anti-proteinase 3 anti-neutrophil cytoplasm antibody; IFTA, interstitial fibrosis and tubular atrophy; AAGN, anti-neutrophil cytoplasm antibody associated glomerulonephritis.

Supplementary table 9. Multivariable regression analyses investigating the relationships between 5-year follow-up eGFR and other early disease manifestations

	Cutaneous model		Arthralgia/arthritis model		Lung model	
	β (95% CI)	P Value	β (95% CI)	P Value	β (95% CI)	P Value
Cutaneous involvement	0.78 (-8.80 – 10.35)	0.87	N/A	N/A	N/A	N/A
Arthralgia/arthritis	N/A	N/A	0.00 (-8.62 – 8.62)	0.99	N/A	N/A
Lung involvement	N/A	N/A	N/A	N/A	6.99 (-1.19 – 15.17)	0.09
Age	-0.37 (-0.67 – -0.07)	0.02	-0.32 (-0.63 – -0.01)	0.04	-0.32 (-0.61 – -0.03)	0.03
PR3-ANCA	-4.19 (-12.48 – -4.09)	0.32	-5.39 (-13.67 – 2.89)	0.20	-5.66 (-13.97 – 2.65)	0.18
Tubulitis	-3.68 (-12.87 – 5.50)	0.43	-0.96 (-10.45 – 8.53)	0.84	-2.70 (-11.76 – 6.36)	0.56
Interstitial infiltrate	-4.84 (-11.66 – 1.99)	0.16	-6.89 (-13.77 – -0.02)	0.05	-4.74 (-11.42 – 1.94)	0.16
IFTA	-10.07 (-16.84 – -3.29)	0.004	-10.74 (-17.91 – -3.57)	0.004	-10.12 (-16.75 – -3.48)	0.003

To investigate whether our associations are specific to ENT involvement, analyses between eGFR at 5-year follow-up and other early disease manifestations were performed. There are no associations between eGFR at 5-year follow-up and cutaneous involvement, arthralgia/arthritis, or lung involvement. All models are adjusted for within-trial therapy. In all models, age is included per year unit. 95% CI, 95% confidence interval; eGFR, estimated glomerular filtration rate; PR3-ANCA, anti-proteinase 3 anti-neutrophil cytoplasm antibody; IFTA, interstitial fibrosis and tubular atrophy; AAGN, anti-neutrophil cytoplasm antibody associated glomerulonephritis; N/A, not applicable

III. Supplementary data Chapter VI

Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis

<i>Table S1.</i>	<i>Subgroup analysis</i>	<i>312</i>
<i>Table S2.</i>	<i>Cyclophosphamide and rituximab treatment in the subgroups</i>	<i>313</i>
<i>Table S3.</i>	<i>SIR according to cumulative cyclophosphamide and rituximab dose</i>	<i>314</i>
<i>Table S4.</i>	<i>Treatment dose of each patient with a malignancy</i>	<i>314</i>

Supplementary table 1. Subgroup analysis

	N patients	N observed malignancies	SIR (95% CI)*	SIR p value*	RR (95% CI)*	RR p value*
Gender						
Male	149	20	1.58 (0.96–2.44)	0.07	1 (reference)	
Female	174	25	2.25 (1.45–3.32)	<0.001	1.43 (0.76–2.71)	0.30
Age at diagnosis						
≥59 years	159	29	1.60 (1.07–2.29)	0.02	1 (reference)	
<59 years	164	16	2.84 (1.62–4.61)	<0.001	1.78 (0.90–3.38)	0.10
Clinical diagnosis						
Microscopic polyangiitis	160	23	1.59 (1.01–2.38)	0.05	1 (reference)	
Granulomatosis with polyangiitis	109	14	2.20 (1.20–3.68)	0.01	1.39 (0.66–2.81)	0.43
Eosinophilic granulomatosis with polyangiitis	54	8	2.75 (1.19–5.41)	0.02	1.73 (0.67–4.02)	0.27
ANCA serotype†						
MPO-ANCA	110	15	1.56 (0.87–2.58)	0.13	1 (reference)	
PR3-ANCA	152	24	2.18 (1.40–3.25)	<0.001	1.40 (0.70–2.87)	0.39
Renal transplantation						
No	311	41	1.79 (1.29–2.43)	<0.001	1 (reference)	
Yes	12	4	4.31 (1.17–11.04)	0.03	2.40 (0.62–6.62)	0.20
Follow-up						
0–5 years	156	16	2.38 (1.36–3.86)	<0.001	1 (reference)	
5–10 years	135	23	1.81 (1.15–2.72)	0.01	0.76 (0.39–1.54)	0.50
>10 years	32	6	1.38 (0.51–3.00)	0.55	0.58 (0.19–1.56)	0.35

* The standard incidence ratio (SIR) is the ratio of observed to expected malignancies and represents the malignancy risk compared to the general population, and the relative risk (RR) represents the malignancy risk compared to the reference group. Calculated by exact Poisson regression analysis.

† Unknown for 61 patients.

MPO-ANCA, myeloperoxidase ANCA; PR3-ANCA, proteinase 3 ANCA.

Supplementary table 2. Cyclophosphamide and rituximab treatment in the subgroups

	N patients treated with cyclophosphamide	Duration of cyclophosphamide treatment, months (SD)	Mean cumulative cyclophosphamide dose, g (SD)	N patients treated with rituximab	Duration of rituximab treatment, months (SD)	Mean cumulative rituximab dose, g (SD)
Gender						
Male	107	5.5 (5.5)	9.9 (6.5)	68	22.1 (14.9)	5.8 (3.4)
Female	116	6.4 (14.4)	8.4 (10.8)	85	20.9 (14.4)	5.9 (3.4)
Age at diagnosis						
≥59 years	114	6.5 (13.8)	6.8 (3.9)	63	20.2 (14.2)	5.2 (2.9)
<59 years	109	5.1 (4.2)	11.5 (11.8)	90	22.5 (14.9)	6.3 (3.6)
Clinical diagnosis						
Microscopic polyangiitis	116	6.3 (12.6)	8.1 (10.5)	65	18.7 (13.3)	5.2 (2.6)
Granulomatosis with polyangiitis	88	5.4 (4.4)	10.7 (7.3)	66	27.7 (15.0)	6.7 (4.0)
Eosinophilic granulomatosis with polyangiitis	19	4.5 (2.8)	7.8 (4.2)	22	22.6 (15.7)	5.3 (2.9)
ANCA serotype*						
MPO-ANCA	72	7.4 (16.1)	7.2 (4.7)	43	20.7 (16.9)	5.1 (2.9)
PR3-ANCA	121	5.0 (4.2)	9.2 (6.5)	82	20.9 (13.0)	6.1 (3.3)
Renal transplantation						
No	213	5.2 (4.9)	9.1 (9.0)	149	21.6 (14.4)	5.9 (3.4)
Yes	10	15.6 (37.3)	8.5 (8.6)	4	16.7 (19.4)	4.5 (2.4)
Follow-up						
0–5 years	102	4.7 (3.5)	7.0 (4.6)	52	17.5 (10.9)	4.6 (2.8)
5–10 years	101	7.2 (15.5)	10.8 (11.9)	82	23.5 (15.2)	6.3 (3.6)
>10 years	20	5.4 (5.1)	10.9 (6.8)	19	24.6 (19.6)	7.4 (3.1)

* Unknown for 61 patients.

MPO-ANCA, myeloperoxidase ANCA; PR3-ANCA, proteinase 3 ANCA.

Supplementary table 3. SIR for non-melanoma skin cancer according to cumulative cyclophosphamide and rituximab dose*

Cumulative dose (g)	N patients	N observed non-melanoma skin cancer	SIR (95% CI)†	SIR p value†
Cyclophosphamide				
0	89	3	2.17 (0.45– 6.34)	0.16
0.1–20	207	18	4.89 (2.90 – 7.72)	<0.001
20–108	16	3	11.72 (2.42 – 34.25)	0.002
Rituximab				
0	167	23	8.47 (5.37 – 12.71)	<0.001
0.1–6	70	1	0.83 (0.02 – 4.64)	0.66
6–18	83	0	0 (0 – 2.47)	0.23

* SIR, standardised incidence ratio; the SIR is the ratio of the observed to expected malignancies adjusted for sex, age (per 5-year age group), and calendar time period (per 1-year calendar time period).

† Calculated by exact Poisson regression analysis.

Supplementary table 4. Cumulative cyclophosphamide and rituximab dose of each patient with a malignancy

Malignancy or malignancy site	N observed malignancies	Cumulative cyclophosphamide dose (g)*	Cumulative rituximab dose (g)*	Time to malignancy (years)†
Lung	4	36.0; 21.1; 4.9; 0.0	0.0; 7.0; 0.0; 5.0	3.7; 4.8; 0.5; 8.5
Breast	3	18.0; 6.0; 3.4	0; 4.0; 8.0	0.9; 1.1; 4.0
Colon or rectum	3	13.8; 9.5; 4.0	0.0; 0.0; 0.0	2.4; 4.5; 4.0
Prostate	2	10.0; 0.0	0.0; 0.0	7.4; 1.2
Bladder	1	0.0	1.0	2.4
Pancreas	1	0.0	0.0	1.4
Testis	1	7.0	5.0	4.6
Ovary	1	3.0	6.6	2.4
Melanoma	1	3.3	0.0	1.8
Tongue	1	0.0	0.0	4.5
Central nervous system	1	2.0	5.6	3.2
Kidney	1	7.0	4.0	2.4

* The cumulative doses of each patient with a malignancy is given. Patients with a cumulative dose of 0.0 did not receive the treatment. When more cases of the malignancy were observed, the first reported cumulative cyclophosphamide dose corresponds to the first reported cumulative rituximab dose, and to the first reported time to malignancy.

† This is the time between the date of diagnosis of ANCA-associated vasculitis and the date of diagnosis of the malignancy.

Authors and affiliations
Curriculum vitae
List of publications
Acknowledgements

Authors and affiliations

Aarhus University Hospital, Aarhus, Denmark

Olaf Dekkers

Cardiology Centers of the Netherlands, Amsterdam, the Netherlands

Herbert Hauer

Charles University and General University Hospital, Prague, Czech Republic

Zdenka Hrušková

Vladimir Tesař

Copenhagen University Hospital, Copenhagen, Denmark

Bo Baslund

Erasmus Medical Center, Rotterdam, the Netherlands

Arda Göçeroğlu

Antien Mooyaart

Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

Jochen Zwerina

Hammersmith Hospital, Imperial College London, London, United Kingdom

Gill Gaskin

Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, France

Loic Guillevin

Imperial College, London, United Kingdom

Charles Pusey

Alan Salama

Ipswich Hospital NHS Trust, Suffolk, United Kingdom

Richard Watts

Karolinska Institute, Stockholm, Sweden

Annette Bruchfeld

Iva Gunnarsson

Klinikum Bad Bramstedt, Bad Bramstedt, Germany

Wolfgang Gross

Julia Holle

Leiden University Medical Center, Leiden, the Netherlands

Ingeborg Bajema
Annelies Berden
Jan Anthonie Bruijn
Emma van Daalen
Olaf Dekkers
Daphne van Hooven
Chinar Rahmattulla
Marlies Reinders
Jan Schoones
Sophie-Charlotte Wakker
Robert de Lind van Wijngaarden
Ron Wolterbeek

Linköping University, Linköping, Sweden

Mårten Segelmark

Lund University, Lund, Sweden

Sophie Ohlsson
Mårten Segelmark

Maastricht University Medical Centre, Maastricht, the Netherlands

Benjamin Wilde

Meander Medical Center, Amersfoort, the Netherlands

Chris Hagen

Medical University of Innsbruck, Innsbruck, Austria

Andreas Kronbichler

Medical University of Vienna, Vienna, Austria

Andrew Rees

Norwich Medical School, Norwich, United Kingdom

Richard Watts

Paris V University, Hôpital Necker, Paris, France

Laure-Hélène Noël

Royal Berkshire Hospital, Reading, United Kingdom

Oliver Floßmann

Royal Free Hospital, London, United Kingdom

Mark Little

Alan Salama

Ruhr-University, Bochum, Germany

Stefan Wieczorek

San Gerardo Hospital, Monza, Italy

Franco Ferrario

Sant'Orsola-Malpighi University Hospital, Bologna, Italy

Raffaella Rizzo

Statens Seruminstitut, Copenhagen, Denmark

Niels Rasmussen

Trinity College Dublin, Dublin, Ireland

Conleth Feighery

University Hospital Jena, Jena, Germany

Thomas Neumann

University Hospital of Parma, Parma, Italy

Davide Martorana

Augusto Vaglio

University Hospital Schleswig-Holstein, Campus Luebeck, Luebeck, Germany

Wolfgang Gross

University Medical Center Groningen, Groningen, the Netherlands

Jan-Stephan Sanders

Coen Stegeman

University of Birmingham, Edgbaston, Birmingham, United Kingdom

Lorraine Harper

Caroline Savage

University of Cambridge, Cambridge, United Kingdom

Afzal Chaudhry

David Jayne

Paul Lyons

Tim Rayner

Kenneth Smith
Sapna Trivedi

University of Glasgow, Glasgow, United Kingdom
Sandosh Padmanabhan

University of Heidelberg, Mannheim, Germany
Rüdiger Waldherr

University of Manchester, Manchester, United Kingdom
Paul Brenchley

Curriculum vitae

Chinar Rahmattulla werd geboren op 16 oktober 1989 te Tuz, Kirkuk (Irak). Drie maanden later verhuisde haar gezin in het kader het promotieonderzoek van haar vader naar Frankrijk. Hierna was het gezin woonachtig in Libië en Irak voordat het in 1997 naar Nederland verhuisde.

In 2009 behaalde Chinar haar VWO-diploma *cum laude* (Natuur & Gezondheid en Natuur & Techniek). In datzelfde jaar begon zij met de opleiding Geneeskunde aan de Universiteit Leiden. Daarnaast begon zij in 2012 met de studie Biomedische Wetenschappen aan dezelfde universiteit. Nadat zij in 2011 werd toegelaten tot het MD/PhD traject van het Honours College (Universiteit Leiden) ontving zij in het kader van dit traject in 2013 een beurs voor een tweejarige promotieaanstelling. Onder begeleiding van prof. dr. J.A. Bruijn, dr. I.M. Bajema en dr. A.E. Berden startte zij op de afdeling Pathologie van het Leids Universitair Medisch Centrum (LUMC) met onderzoek naar ANCA-geassocieerde vasculitis. In het kader van haar promotieonderzoek deed zij in 2015 een half jaar onderzoek aan de Universiteit van Cambridge (Verenigd Koninkrijk) onder begeleiding van prof. dr. D.R. Jayne. Voor de publicatie die hieruit voortkwam – waarvan zij de laatste auteur was – won zij de KNMG Dick Held juniorprijs en de Stichting Hippocrates Studiefonds Prijs. Zij heeft tevens onderzoek verricht op de afdelingen Cardiologie (2010 – 2011; begeleider: dr. ir. C.A. Swenne) en Neonatologie (2017 – 2018; begeleider: prof. dr. E. Lopriore) van het LUMC. Sinds 2013 is zij vrijwilligster bij de Vasculitis Stichting (landelijke vereniging vasculitispatiënten) en redacteur van het tijdschrift Vascuzine.

Tijdens haar studie Geneeskunde volgde zij klinische verdiepingsstages aan het Neurenberg Ziekenhuis (Duitsland) en het Academisch Ziekenhuis Innsbruck (Oostenrijk). In 2017 behaalde zij – als eerste student aan de Universiteit Leiden – het masterdiploma Geneeskunde *summa cum laude* en in 2018 behaalde zij het masterdiploma Biomedische Wetenschappen *cum laude*.

Chinar Rahmattulla was born on the 16th of October in Tuz, Kirkuk (Iraq). Three months later she moved with her parents to France for her father to work on his PhD thesis. Hereafter, the family lived in Libya and Iraq before moving to the Netherlands in 1997.

In 2009, she graduated from secondary school *cum laude*. That same year she started studying Medicine at Leiden University. In addition, she started studying Biomedical Sciences at the same university in 2012. She was accepted to participate in the MD/PhD Honours Program of Leiden University in 2011. As part of this program she received a PhD grant for two years in 2013. Under the guidance of prof. dr. J.A. Bruijn, dr. I.M. Bajema and dr. A.E. Berden, she started research into the ANCA-associated vasculitides at the Department of Pathology of the Leiden University Medical Center (LUMC). She was a visiting PhD researcher at the University of Cambridge (United Kingdom) for six months in 2015 (supervisor: prof. dr. D.R. Jayne). For the publication that resulted from that research – of which she was the senior author – she won the KNMG Dick Held Junior Prize and the Hippocrates Scholarship Prize. In addition to the Department of Pathology, she conducted research at the Departments of Cardiology (2010 – 2011; supervisor: dr. C.A. Swenne) and Neonatology (2017-2018; supervisor: prof. dr. E. Lopriore) of the LUMC. From 2013 onwards she has been volunteering at the Vasculitis Foundation (the Dutch vasculitis patient foundation), and in the same year she became part of the editorial board of the *Vascuzine*.

During her medical studies, she followed clinical internships at the Nuremberg Hospital (Germany) and the Academic Hospital Innsbruck (Austria). In 2017, she became the first student to graduate *summa cum laude* from Leiden University with a Master of Sciences in Medicine, and in 2018 she graduated with a Master of Sciences in Biomedical Sciences *cum laude*.

List of publications

Van Daalen EE, Rafi R, Kronbichler A, Wolterbeek R, Bruin JA, Jayne DJ, Bajema IM, **Rahmattulla C**. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. *Ann Rheum Dis*. 2017;76:1064-1069.

Van Daalen EE, **Rahmattulla C**, Wolterbeek R, Bruin JA, Bajema IM. Incidence of Malignancy prior to ANCA-Associated Vasculitis Compared to the General Population. *J Rheumatol*. 2017;44:314-18.

Rahmattulla C, Mooyaart AL, Van Hooven D, Schoones JW, Bruijn JA, Dekkers OM, European Vasculitis Genetics Consortium, Bajema IM. Genetic variants in ANCA-associated vasculitis: a meta-analysis. *Ann Rheum Dis*. 2016;75:1687-92.

Göçeroğlu A, **Rahmattulla C**, Berden AE, Reinders ME, Wolterbeek R, Steenbergen EJ, Hilbrands LB, Noorlander I, Berger SP, Peutz-Kootstra CJ, Christiaans MH, van Dijk MC, de Joode AA, Goldschmeding R, van Zuilen AD, Harper L, Little MA, Hagen EC, Bruijn JA, Bajema IM. The Dutch Transplantation in Vasculitis (DUTRAVAS) Study: Outcome of Renal Transplantation in Antineutrophil Cytoplasmic Antibody-associated Glomerulonephritis. *Transplantation*. 2016;100:916-24.

Rahmattulla C, Berden AE, Wakker SC, Reinders ME, Hagen EC, Wolterbeek R, Bruijn JA, Bajema IM. Incidence of malignancies in patients diagnosed with ANCA-associated vasculitis between 1991 and 2013. *Arthritis Rheumatol*. 2015;67:3270-8.

Rahmattulla C, Bruijn JA, Bajema IM. Histopathological classification of antineutrophil cytoplasmic antibody-associated glomerulonephritis: an update. *Curr Opin Nephrol Hypertens* 2014;23:224-31.

Rahmattulla C, de Lind van Wijngaarden RA, Berden AE, Hauer HA, Floßmann O, Jayne DR, Gaskin G, Rasmussen N, Noël LH, Ferrario F, Waldherr R, Wolterbeek R, Göçeroğlu A, Pusey CD, Hagen EC, Bruijn JA, Bajema IM; the European Vasculitis Study Group (EUVAS). Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibody-associated vasculitis: prospective data from the European Vasculitis Society clinical trials. *Rheumatology (Oxford)* 2015;54:899-907.

Man S, **Rahmattulla C**, Maan AC, van der Putten NH, Dijk WA, van Zwet EW, van der Wall EE, Schalij MJ, Gorgels AP, Swenne CA. Acute coronary syndrome with a totally occluded culprit artery: relation of the ST injury vector with ST-elevation and non-ST elevation ECGs. *J Electrocardiol* 2014;47:183-90.

Rahmattulla C, Berden AE, Bajema IM. Kidneys in ANCA-associated vasculitis: What to learn from biopsies? *Presse Med* 2013;42:563-65.

Man S, **Rahmattulla C**, Maan AC, Holman E, Bax JJ, Van der Wall EE, Schalij MJ, Swenne CA. Role of the vectorcardiogram-derived spatial QRS-T angle and ventricular gradient in diagnosing left ventricular hypertrophy. *J Electrocardiol* 2012;45:154-160.

Maan AC, Dijk WA, Van der Putten NHJJ, Man S, **Rahmatulla C**, Van Zwet E, Swenne CA, Schalij MJ. A vector cardiographic based method to determine the culprit artery in acute coronary syndrome. *Comput Cardiol* 2011;38:409-412.

Woord van dank

De bijdragen van zo velen aan de totstandkoming van dit proefschrift worden zeer gewaardeerd. In het bijzonder wil ik de volgende personen bedanken:

Jan Anthonie Bruijn, dank voor alle kansen die jij mij hebt geboden en voor jouw bijdrage aan mijn wetenschappelijke en persoonlijke ontwikkeling.

Ingeborg Bajema, ik had me geen fijnere begeleiding kunnen wensen. Dank voor je tomeloze inzet, inspiratie en vertrouwen. Jij hebt mij als wetenschapper gevormd.

Annelies Berden, jouw enthousiasme voor vasculitis werkte aanstekelijk. Dank voor je steun en luisterend oor.

Arda Göçeroğlu, dank voor de introductie in de wereld van ANCA.

Ron Wolterbeek, jij stond op elk moment van de dag klaar om al mijn statistische vragen te beantwoorden.

Professor Van Es, Hans Baelde, Chris Hagen, Emile de Heer, dank voor jullie wijsheid en kritische inzichten.

De Nepa's, jullie hebben mij met raad en daad bijgestaan en een fantastische tijd bezorgd, met name tijdens de ASN-bezoeken.

David Jayne, I am grateful for the opportunity that you gave me to do research in Cambridge. Thank you for teaching me how to critically appraise science.

My colleagues and friends, *Andreas, Debby, Els, Federico, and Raffaella*, thank you for the great moments inside and outside Addenbrooke's that we shared together.

The members of the *European Vasculitis Society* I would like to thank for their efforts to the studies and this thesis.

De redactieleden van de Vascuzine, *Peter, Rina, Henk, Karen, Corné*, en *Sandra*, wil ik bedanken voor de leuke tijd die ik met jullie door heb mogen maken tijdens de redactievergaderingen. *Henk*, je wordt gemist.

Bram en Ada, jullie wil ik graag bedanken voor al jullie wijze adviezen en steun.

Mijn vrienden wil ik bedanken voor alle liefde en support. Speciale dank gaat uit naar mijn paranimfen, *Dilek en Mays*, voor het samen toelevens naar 'De Grote Dag'.

Lieve *Robert*, jou wil ik bedanken voor alle vreugde die jij in mijn leven brengt. Ik geniet intens van onze tijd samen en kijk uit naar al het moois wat de toekomst ons zal brengen.

Lieve *papa en mama*, aan jullie wijd ik de laatste woorden van dit proefschrift. Jullie hebben mij altijd overladen met liefde, onvoorwaardelijk gesteund en gestimuleerd het beste uit mijzelf te halen. Ik bewonder de wijze waarop jullie in het leven staan. Met alle liefde draag ik dit boekje op aan jullie.

